NO342105B1 - Karbonylerte (aza)cykloheksaner, fremgangsmåte for fremstilling av slike forbindelser, farmasøytiske preparater omfattende slike forbindelser samt anvendelse av slike forbindelser for behandling - Google Patents
Karbonylerte (aza)cykloheksaner, fremgangsmåte for fremstilling av slike forbindelser, farmasøytiske preparater omfattende slike forbindelser samt anvendelse av slike forbindelser for behandling Download PDFInfo
- Publication number
- NO342105B1 NO342105B1 NO20085288A NO20085288A NO342105B1 NO 342105 B1 NO342105 B1 NO 342105B1 NO 20085288 A NO20085288 A NO 20085288A NO 20085288 A NO20085288 A NO 20085288A NO 342105 B1 NO342105 B1 NO 342105B1
- Authority
- NO
- Norway
- Prior art keywords
- ethyl
- cyclohexyl
- piperazin
- cyano
- acetamide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 130
- 238000002360 preparation method Methods 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 44
- 230000008569 process Effects 0.000 title claims abstract description 4
- 150000001934 cyclohexanes Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 9
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 389
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 349
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 158
- -1 polyhalogenoalkyl Chemical group 0.000 claims description 146
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 118
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 105
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 79
- 125000000217 alkyl group Chemical group 0.000 claims description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- 125000003118 aryl group Chemical group 0.000 claims description 47
- 150000003839 salts Chemical class 0.000 claims description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 125000004432 carbon atom Chemical group C* 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 150000001408 amides Chemical class 0.000 claims description 22
- 150000002367 halogens Chemical class 0.000 claims description 21
- 125000002252 acyl group Chemical group 0.000 claims description 20
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 125000006684 polyhaloalkyl group Polymers 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 11
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 claims description 11
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 150000004677 hydrates Chemical class 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 230000003287 optical effect Effects 0.000 claims description 11
- 125000001931 aliphatic group Chemical group 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 10
- 239000000654 additive Substances 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 9
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 208000012661 Dyskinesia Diseases 0.000 claims description 8
- 125000004945 acylaminoalkyl group Chemical group 0.000 claims description 8
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 8
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 claims description 8
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 claims description 8
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 8
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 claims description 8
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000006682 monohaloalkyl group Chemical group 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 208000028017 Psychotic disease Diseases 0.000 claims description 7
- 125000004686 alkyl sulfanyl alkyl group Chemical group 0.000 claims description 7
- 125000005188 oxoalkyl group Chemical group 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 125000004687 alkyl sulfinyl alkyl group Chemical group 0.000 claims description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 6
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 6
- 230000003054 hormonal effect Effects 0.000 claims description 6
- 230000000642 iatrogenic effect Effects 0.000 claims description 6
- 201000001881 impotence Diseases 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 208000011117 substance-related disease Diseases 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 208000012639 Balance disease Diseases 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 5
- 125000004442 acylamino group Chemical group 0.000 claims description 5
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 5
- 150000008064 anhydrides Chemical class 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 125000005128 aryl amino alkyl group Chemical group 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 206010026749 Mania Diseases 0.000 claims description 4
- 208000017657 Menopausal disease Diseases 0.000 claims description 4
- 208000019430 Motor disease Diseases 0.000 claims description 4
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 208000037824 growth disorder Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 208000012201 sexual and gender identity disease Diseases 0.000 claims description 4
- 208000015891 sexual disease Diseases 0.000 claims description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
- 102000004073 Dopamine D3 Receptors Human genes 0.000 claims description 3
- 108090000525 Dopamine D3 Receptors Proteins 0.000 claims description 3
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
- 206010044565 Tremor Diseases 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 229960003920 cocaine Drugs 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 238000001784 detoxification Methods 0.000 claims description 3
- 229960002069 diamorphine Drugs 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 229960002715 nicotine Drugs 0.000 claims description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
- 229940005483 opioid analgesics Drugs 0.000 claims description 3
- CVKQMKGYSGMQRR-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2,5-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC1=CC=C(F)C(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 CVKQMKGYSGMQRR-UHFFFAOYSA-N 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 2
- 230000000561 anti-psychotic effect Effects 0.000 claims description 2
- 229940125682 antidementia agent Drugs 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 229940125708 antidiabetic agent Drugs 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 230000000949 anxiolytic effect Effects 0.000 claims description 2
- 239000000496 cardiotonic agent Substances 0.000 claims description 2
- 230000003177 cardiotonic effect Effects 0.000 claims description 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 2
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 claims description 2
- FAECMMMBNKZRIP-UHFFFAOYSA-N n-[4-[2-[4-[2-cyano-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]-2-ethoxyacetamide Chemical compound C1CC(NC(=O)COCC)CCC1CCN1CCN(C=2C(=C(C=CC=2)C(F)(F)F)C#N)CC1 FAECMMMBNKZRIP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002664 nootropic agent Substances 0.000 claims description 2
- 238000006268 reductive amination reaction Methods 0.000 claims description 2
- 208000005793 Restless legs syndrome Diseases 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 238000002483 medication Methods 0.000 claims 2
- 201000006152 substance dependence Diseases 0.000 claims 2
- NKAXSILKAOVGFZ-UHFFFAOYSA-N ClC=1C=C(C=C(C1)C)N1CCN(CC1)CCC1CCC(CC1)NC(CCCC#N)=O.ClC=1C=C(C=C(C1)C)N1CCN(CC1)CCC1CCC(CC1)NC(CC#N)=O.Cl Chemical compound ClC=1C=C(C=C(C1)C)N1CCN(CC1)CCC1CCC(CC1)NC(CCCC#N)=O.ClC=1C=C(C=C(C1)C)N1CCN(CC1)CCC1CCC(CC1)NC(CC#N)=O.Cl NKAXSILKAOVGFZ-UHFFFAOYSA-N 0.000 claims 1
- GJPVKGFPVLJIHG-UHFFFAOYSA-N ClC=1C=C(C=CC1C)N1CCN(CC1)CCC1CCC(CC1)NC(CC#N)=O.C(#N)CCCC(=O)NC1CCC(CC1)CCN1CCN(CC1)C1=CC(=C(C=C1)Cl)Cl.Cl Chemical compound ClC=1C=C(C=CC1C)N1CCN(CC1)CCC1CCC(CC1)NC(CC#N)=O.C(#N)CCCC(=O)NC1CCC(CC1)CCN1CCN(CC1)C1=CC(=C(C=C1)Cl)Cl.Cl GJPVKGFPVLJIHG-UHFFFAOYSA-N 0.000 claims 1
- DWVKWKKNLIGRGJ-UHFFFAOYSA-N FC(CC(=O)NC1CCC(CC1)CCN1CCN(CC1)C1=C(C=CC(=C1)C(F)(F)F)F)(F)F.Cl Chemical compound FC(CC(=O)NC1CCC(CC1)CCN1CCN(CC1)C1=C(C=CC(=C1)C(F)(F)F)F)(F)F.Cl DWVKWKKNLIGRGJ-UHFFFAOYSA-N 0.000 claims 1
- 125000005081 alkoxyalkoxyalkyl group Chemical group 0.000 claims 1
- 150000001805 chlorine compounds Chemical group 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- OJRCCOVAZKKXHQ-UHFFFAOYSA-N n-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-ethoxyacetamide Chemical compound C1CC(NC(=O)COCC)CCC1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 OJRCCOVAZKKXHQ-UHFFFAOYSA-N 0.000 claims 1
- NKQXAERTEJFEHM-UHFFFAOYSA-N n-[4-[2-[4-[3,5-bis(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]-4-cyanobutanamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 NKQXAERTEJFEHM-UHFFFAOYSA-N 0.000 claims 1
- 150000002926 oxygen Chemical class 0.000 claims 1
- 230000003414 procognitive effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 133
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 100
- 230000015572 biosynthetic process Effects 0.000 description 99
- 238000003786 synthesis reaction Methods 0.000 description 98
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 96
- 239000007858 starting material Substances 0.000 description 95
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- 239000000243 solution Substances 0.000 description 71
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 68
- 239000000203 mixture Substances 0.000 description 65
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 60
- 230000002829 reductive effect Effects 0.000 description 56
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 51
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 45
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 44
- 239000000460 chlorine Substances 0.000 description 42
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 42
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
- 238000005481 NMR spectroscopy Methods 0.000 description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- 238000005160 1H NMR spectroscopy Methods 0.000 description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 30
- 235000019341 magnesium sulphate Nutrition 0.000 description 30
- 239000007787 solid Substances 0.000 description 29
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 25
- 238000002844 melting Methods 0.000 description 24
- 230000008018 melting Effects 0.000 description 24
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 22
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 22
- 239000012074 organic phase Substances 0.000 description 22
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 239000003480 eluent Substances 0.000 description 19
- 239000000741 silica gel Substances 0.000 description 19
- 229910002027 silica gel Inorganic materials 0.000 description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000002253 acid Substances 0.000 description 12
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
- 239000000725 suspension Substances 0.000 description 11
- IVTZRJKKXSKXKO-UHFFFAOYSA-N 1-(2-fluorophenyl)piperazine Chemical compound FC1=CC=CC=C1N1CCNCC1 IVTZRJKKXSKXKO-UHFFFAOYSA-N 0.000 description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000003647 oxidation Effects 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- IIRXZLZIJHKUKX-UHFFFAOYSA-N 2-methoxybutanamide Chemical compound CCC(OC)C(N)=O IIRXZLZIJHKUKX-UHFFFAOYSA-N 0.000 description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 235000011181 potassium carbonates Nutrition 0.000 description 8
- 238000007792 addition Methods 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 7
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 description 7
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 7
- 125000004212 difluorophenyl group Chemical group 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 125000001207 fluorophenyl group Chemical group 0.000 description 7
- 239000012442 inert solvent Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 6
- QIWORMKRMYXXJC-UHFFFAOYSA-N 2-cyanobutanamide Chemical compound CCC(C#N)C(N)=O QIWORMKRMYXXJC-UHFFFAOYSA-N 0.000 description 6
- BCEXHABGXALHQU-UHFFFAOYSA-N 4-(2-hydroxyethyl)cyclohexan-1-one Chemical compound OCCC1CCC(=O)CC1 BCEXHABGXALHQU-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- QLSFMYCHPVOSCD-UHFFFAOYSA-N cleroindicin B Natural products OCCC1(O)CCC(=O)CC1 QLSFMYCHPVOSCD-UHFFFAOYSA-N 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 229960003638 dopamine Drugs 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- YYSORRIPXHMBPR-UHFFFAOYSA-N 1-[2-(1,4-dioxaspiro[4.5]decan-8-yl)ethyl]-4-[3-(trifluoromethyl)phenyl]piperazine Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC3CCC4(CC3)OCCO4)CC2)=C1 YYSORRIPXHMBPR-UHFFFAOYSA-N 0.000 description 5
- OAAKFAXUEYTMHF-UHFFFAOYSA-N 2-ethoxyacetamide Chemical compound CCOCC(N)=O OAAKFAXUEYTMHF-UHFFFAOYSA-N 0.000 description 5
- SZIBVWWQOOVXHS-UHFFFAOYSA-N 4-(2-hydroxyethyl)cyclohexan-1-ol Chemical compound OCCC1CCC(O)CC1 SZIBVWWQOOVXHS-UHFFFAOYSA-N 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- XVSYDLITVYBCBD-UHFFFAOYSA-N cyclopent-3-ene-1-carboxylic acid Chemical compound OC(=O)C1CC=CC1 XVSYDLITVYBCBD-UHFFFAOYSA-N 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- MFRAKCIFTVYASX-UHFFFAOYSA-N 1-(2-piperidin-4-ylethyl)-4-[3-(trifluoromethyl)phenyl]piperazine Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC3CCNCC3)CC2)=C1 MFRAKCIFTVYASX-UHFFFAOYSA-N 0.000 description 4
- RDZCSTLPRXANJV-UHFFFAOYSA-N 2-(1,4-dioxaspiro[4.5]decan-8-yl)acetic acid Chemical compound C1CC(CC(=O)O)CCC21OCCO2 RDZCSTLPRXANJV-UHFFFAOYSA-N 0.000 description 4
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 4
- MZBSJLAGBUNNLH-UHFFFAOYSA-N 3,3,3-trifluoropropanamide Chemical compound NC(=O)CC(F)(F)F MZBSJLAGBUNNLH-UHFFFAOYSA-N 0.000 description 4
- HBSJWBJWLGUCOP-UHFFFAOYSA-N 3-[4-[2-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]ethyl]piperazin-1-yl]benzoic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CCN1CCN(C=2C=C(C=CC=2)C(O)=O)CC1 HBSJWBJWLGUCOP-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 125000004350 aryl cycloalkyl group Chemical group 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 4
- 125000004188 dichlorophenyl group Chemical group 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 description 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- HXXUHEBFNJNMQF-UHFFFAOYSA-N tert-butyl 4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 HXXUHEBFNJNMQF-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QRIVJDGDHLGQAR-UHFFFAOYSA-N 1-(1,1-difluoroethyl)-3-nitrobenzene Chemical compound CC(F)(F)C1=CC=CC([N+]([O-])=O)=C1 QRIVJDGDHLGQAR-UHFFFAOYSA-N 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- ADHPWSZUKDJBES-UHFFFAOYSA-N 1-[3-(1,1-difluoroethyl)phenyl]piperazine hydrochloride Chemical compound Cl.CC(F)(F)c1cccc(c1)N1CCNCC1 ADHPWSZUKDJBES-UHFFFAOYSA-N 0.000 description 3
- OVYGOADATLWIIS-UHFFFAOYSA-N 1-[3-(difluoromethyl)phenyl]piperazine Chemical compound FC(F)C1=CC=CC(N2CCNCC2)=C1 OVYGOADATLWIIS-UHFFFAOYSA-N 0.000 description 3
- DGNLGWJZZZOYPT-UHFFFAOYSA-N 1-[3-(trifluoromethyl)phenyl]piperazin-1-ium;chloride Chemical compound [Cl-].FC(F)(F)C1=CC=CC(N2CC[NH2+]CC2)=C1 DGNLGWJZZZOYPT-UHFFFAOYSA-N 0.000 description 3
- ZBJNGJQYYVMSJZ-UHFFFAOYSA-N 1-[3-[4-[2-(1,4-dioxaspiro[4.5]decan-8-yl)ethyl]piperazin-1-yl]phenyl]-2-methylpropan-1-ol Chemical compound CC(C)C(O)C1=CC=CC(N2CCN(CCC3CCC4(CC3)OCCO4)CC2)=C1 ZBJNGJQYYVMSJZ-UHFFFAOYSA-N 0.000 description 3
- BBTRJHSNFLPLTE-UHFFFAOYSA-N 1-[3-[4-[2-(1,4-dioxaspiro[4.5]decan-8-yl)ethyl]piperazin-1-yl]phenyl]-2-methylpropan-1-one Chemical compound CC(C)C(=O)C1=CC=CC(N2CCN(CCC3CCC4(CC3)OCCO4)CC2)=C1 BBTRJHSNFLPLTE-UHFFFAOYSA-N 0.000 description 3
- POABXXXMIKQXGV-UHFFFAOYSA-N 1-[4-[2-[4-(3-aminophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(N)C=CC=2)CC1 POABXXXMIKQXGV-UHFFFAOYSA-N 0.000 description 3
- QAWIOIFGOSYCNE-UHFFFAOYSA-N 1-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]propane-1,2-dione Chemical compound C1CN(C(=O)C(=O)C)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 QAWIOIFGOSYCNE-UHFFFAOYSA-N 0.000 description 3
- UCDCWSBXWOGCKR-UHFFFAOYSA-N 2-(2-methylpropyl)aniline Chemical compound CC(C)CC1=CC=CC=C1N UCDCWSBXWOGCKR-UHFFFAOYSA-N 0.000 description 3
- DKLQJNUJPSHYQG-UHFFFAOYSA-N 2-cyclohexylacetamide Chemical compound NC(=O)CC1CCCCC1 DKLQJNUJPSHYQG-UHFFFAOYSA-N 0.000 description 3
- MTEZLAATISORQK-UHFFFAOYSA-N 2-methoxyacetamide Chemical compound COCC(N)=O MTEZLAATISORQK-UHFFFAOYSA-N 0.000 description 3
- XETWTCSIVIMDBU-UHFFFAOYSA-N 2-methyl-1-(3-nitrophenyl)propan-1-one Chemical compound CC(C)C(=O)C1=CC=CC([N+]([O-])=O)=C1 XETWTCSIVIMDBU-UHFFFAOYSA-N 0.000 description 3
- QDGJIBRTFXRYTH-UHFFFAOYSA-N 3-(1,1-difluoroethyl)aniline Chemical compound CC(F)(F)C1=CC=CC(N)=C1 QDGJIBRTFXRYTH-UHFFFAOYSA-N 0.000 description 3
- FSAGXSALOXJCGA-UHFFFAOYSA-N 4-(2-hydroxyethyl)cyclohexan-1-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.OCCC1CCC(=O)CC1 FSAGXSALOXJCGA-UHFFFAOYSA-N 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- NMJGRMMOHVYVAJ-UHFFFAOYSA-N N-[4-[2-[4-(2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C(C)(=O)NC1CCC(CC1)CCN1CCN(CC1)C1=C(C=CC=C1)F NMJGRMMOHVYVAJ-UHFFFAOYSA-N 0.000 description 3
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 125000006001 difluoroethyl group Chemical group 0.000 description 3
- YMTXKDPCOGEABQ-UHFFFAOYSA-N ethyl n-[3-[4-[2-(1,4-dioxaspiro[4.5]decan-8-yl)ethyl]piperazin-1-yl]phenyl]carbamate Chemical compound CCOC(=O)NC1=CC=CC(N2CCN(CCC3CCC4(CC3)OCCO4)CC2)=C1 YMTXKDPCOGEABQ-UHFFFAOYSA-N 0.000 description 3
- XCAFARBQBYRFBS-UHFFFAOYSA-N ethyl n-[3-[4-[2-[1-(2-oxopropyl)piperidin-4-yl]ethyl]piperazin-1-yl]phenyl]carbamate Chemical compound CCOC(=O)NC1=CC=CC(N2CCN(CCC3CCN(CC(C)=O)CC3)CC2)=C1 XCAFARBQBYRFBS-UHFFFAOYSA-N 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- LOFYLIRHOUPKFX-UHFFFAOYSA-N n-(methoxymethyl)acetamide Chemical compound COCNC(C)=O LOFYLIRHOUPKFX-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- ZWMCBMDSJYNDDQ-UHFFFAOYSA-N n-[4-[2-[4-(3-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C=C(C=CC=2)C#N)CC1 ZWMCBMDSJYNDDQ-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- WSNYPQZNUKSYBI-UHFFFAOYSA-N tert-butyl 4-(2-methylsulfonyloxyethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CCOS(C)(=O)=O)CC1 WSNYPQZNUKSYBI-UHFFFAOYSA-N 0.000 description 3
- JUJIUSHACBLNFB-UHFFFAOYSA-N tert-butyl 4-[2-[4-[3-(hydroxymethyl)phenyl]piperazin-1-yl]ethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CCN1CCN(C=2C=C(CO)C=CC=2)CC1 JUJIUSHACBLNFB-UHFFFAOYSA-N 0.000 description 3
- DYVSZHSFXFSITQ-UHFFFAOYSA-N tert-butyl 4-[2-[4-[3-[methoxy(methyl)carbamoyl]phenyl]piperazin-1-yl]ethyl]piperidine-1-carboxylate Chemical compound CON(C)C(=O)C1=CC=CC(N2CCN(CCC3CCN(CC3)C(=O)OC(C)(C)C)CC2)=C1 DYVSZHSFXFSITQ-UHFFFAOYSA-N 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- 125000004360 trifluorophenyl group Chemical group 0.000 description 3
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- QOGPXSPKXMNSLH-UHFFFAOYSA-N 1-(difluoromethyl)-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(C(F)F)=C1 QOGPXSPKXMNSLH-UHFFFAOYSA-N 0.000 description 2
- AOVOPFGNVDRXSC-UHFFFAOYSA-N 1-[2-(1,4-dioxaspiro[4.5]decan-8-yl)ethyl]-4-[3-(methoxymethyl)phenyl]piperazine Chemical compound COCC1=CC=CC(N2CCN(CCC3CCC4(CC3)OCCO4)CC2)=C1 AOVOPFGNVDRXSC-UHFFFAOYSA-N 0.000 description 2
- MONVIUZKFDTVGJ-UHFFFAOYSA-N 1-[3-[4-[2-(1,4-dioxaspiro[4.5]decan-8-yl)ethyl]piperazin-1-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC(N2CCN(CCC3CCC4(CC3)OCCO4)CC2)=C1 MONVIUZKFDTVGJ-UHFFFAOYSA-N 0.000 description 2
- GNPWEUOTUVLEPR-UHFFFAOYSA-N 1-[3-[4-[2-(1,4-dioxaspiro[4.5]decan-8-yl)ethyl]piperazin-1-yl]phenyl]propan-1-ol Chemical compound CCC(O)C1=CC=CC(N2CCN(CCC3CCC4(CC3)OCCO4)CC2)=C1 GNPWEUOTUVLEPR-UHFFFAOYSA-N 0.000 description 2
- AEJAMFBQYVPHGT-UHFFFAOYSA-N 1-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]butan-2-ol Chemical compound C1CN(CC(O)CC)CCC1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 AEJAMFBQYVPHGT-UHFFFAOYSA-N 0.000 description 2
- OREMDXOYHXVPKY-UHFFFAOYSA-N 1-[4-[2-[4-(2,3-dimethylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]-3-methylbutan-2-one Chemical compound C1CN(CC(=O)C(C)C)CCC1CCN1CCN(C=2C(=C(C)C=CC=2)C)CC1 OREMDXOYHXVPKY-UHFFFAOYSA-N 0.000 description 2
- UBQAHKUXQRAKGT-UHFFFAOYSA-N 1-[4-[2-[4-(2,3-dimethylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]butan-2-one Chemical compound C1CN(CC(=O)CC)CCC1CCN1CCN(C=2C(=C(C)C=CC=2)C)CC1 UBQAHKUXQRAKGT-UHFFFAOYSA-N 0.000 description 2
- NTVSDQBHXXONLY-UHFFFAOYSA-N 1-[4-[2-[4-(2,3-dimethylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]pentan-2-one Chemical compound C1CN(CC(=O)CCC)CCC1CCN1CCN(C=2C(=C(C)C=CC=2)C)CC1 NTVSDQBHXXONLY-UHFFFAOYSA-N 0.000 description 2
- SHXJDOOACNJSNA-UHFFFAOYSA-N 1-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]propan-2-one Chemical compound C1CC(CC(=O)C)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 SHXJDOOACNJSNA-UHFFFAOYSA-N 0.000 description 2
- HQPWLUGKEYMXHE-UHFFFAOYSA-N 1-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexylidene]propan-2-one Chemical compound C1CC(=CC(=O)C)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 HQPWLUGKEYMXHE-UHFFFAOYSA-N 0.000 description 2
- IJJLBPCYPBZONW-UHFFFAOYSA-N 2-(1,4-dioxaspiro[4.5]decan-8-yl)-1-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethanone Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CC2)C(=O)CC2CCC3(CC2)OCCO3)=C1 IJJLBPCYPBZONW-UHFFFAOYSA-N 0.000 description 2
- GNFHYUCEKATGLF-UHFFFAOYSA-N 2-[4-[2-[4-(2,3-dimethylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]acetic acid Chemical compound CC1=CC=CC(N2CCN(CCC3CCN(CC(O)=O)CC3)CC2)=C1C GNFHYUCEKATGLF-UHFFFAOYSA-N 0.000 description 2
- OZRFZDKFGNBSBW-UHFFFAOYSA-N 2-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexylidene]acetic acid hydrochloride Chemical compound Cl.OC(=O)C=C1CCC(CCN2CCN(CC2)c2cccc(c2)C(F)(F)F)CC1 OZRFZDKFGNBSBW-UHFFFAOYSA-N 0.000 description 2
- JOHFQENQNVRXGF-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3,5-dimethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CC1=CC(C)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 JOHFQENQNVRXGF-UHFFFAOYSA-N 0.000 description 2
- ZABQHRQPIFGPKZ-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3-ethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CCC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 ZABQHRQPIFGPKZ-UHFFFAOYSA-N 0.000 description 2
- BIJKLRIWSILMBF-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-[2-fluoro-5-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC1=CC=C(C(F)(F)F)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 BIJKLRIWSILMBF-UHFFFAOYSA-N 0.000 description 2
- VMSDQFGRYMGLML-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1=CC(C(F)(F)F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 VMSDQFGRYMGLML-UHFFFAOYSA-N 0.000 description 2
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 2
- KOUBNSYUFYPGJT-UHFFFAOYSA-N 2-methoxy-n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)COC)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 KOUBNSYUFYPGJT-UHFFFAOYSA-N 0.000 description 2
- WOGXHNJBKGZMHV-UHFFFAOYSA-N 2-methoxypropanamide Chemical compound COC(C)C(N)=O WOGXHNJBKGZMHV-UHFFFAOYSA-N 0.000 description 2
- URRIBGFCIOLNPD-UHFFFAOYSA-N 2-methyl-1-(2-nitrophenyl)propan-1-one Chemical compound CC(C)C(=O)C1=CC=CC=C1[N+]([O-])=O URRIBGFCIOLNPD-UHFFFAOYSA-N 0.000 description 2
- ZBLUAVADFAWYLL-UHFFFAOYSA-N 2-methylsulfonylacetamide Chemical compound CS(=O)(=O)CC(N)=O ZBLUAVADFAWYLL-UHFFFAOYSA-N 0.000 description 2
- WOMBHFDZBLZRLM-UHFFFAOYSA-N 2-propan-2-yloxyacetamide Chemical compound CC(C)OCC(N)=O WOMBHFDZBLZRLM-UHFFFAOYSA-N 0.000 description 2
- JSOMPMRZESLPSM-UHFFFAOYSA-N 3-(2-methylpropyl)aniline Chemical compound CC(C)CC1=CC=CC(N)=C1 JSOMPMRZESLPSM-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- JGLPHNOGTJJBCN-UHFFFAOYSA-N 3-[4-[2-(1,4-dioxaspiro[4.5]decan-8-yl)ethyl]piperazin-1-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(N2CCN(CCC3CCC4(CC3)OCCO4)CC2)=C1 JGLPHNOGTJJBCN-UHFFFAOYSA-N 0.000 description 2
- HRCNDZKXGUGZJF-UHFFFAOYSA-N 4-[2-[4-[2-fluoro-5-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexan-1-one Chemical compound FC1=CC=C(C(F)(F)F)C=C1N1CCN(CCC2CCC(=O)CC2)CC1 HRCNDZKXGUGZJF-UHFFFAOYSA-N 0.000 description 2
- PWSXXVMVPXYFDQ-UHFFFAOYSA-N 4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexan-1-amine Chemical compound C1CC(N)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 PWSXXVMVPXYFDQ-UHFFFAOYSA-N 0.000 description 2
- PTCLFIYGQRLDRQ-UHFFFAOYSA-N 4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexan-1-one Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC3CCC(=O)CC3)CC2)=C1 PTCLFIYGQRLDRQ-UHFFFAOYSA-N 0.000 description 2
- MMAIQMDEDONGOC-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-[2-fluoro-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1=CC=C(C(F)(F)F)C(F)=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 MMAIQMDEDONGOC-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010007979 Glycocholic Acid Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- BGKFUDCWQFPOPO-UHFFFAOYSA-N [3-[4-[2-(1,4-dioxaspiro[4.5]decan-8-yl)ethyl]piperazin-1-yl]phenyl]methanol Chemical compound OCC1=CC=CC(N2CCN(CCC3CCC4(CC3)OCCO4)CC2)=C1 BGKFUDCWQFPOPO-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003849 aromatic solvent Substances 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- WDOWMEJUVSRDBB-UHFFFAOYSA-N ethyl 2-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexylidene]acetate Chemical compound C1CC(=CC(=O)OCC)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 WDOWMEJUVSRDBB-UHFFFAOYSA-N 0.000 description 2
- RVXCLPDXTRPJBM-UHFFFAOYSA-N ethyl 2-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]acetate Chemical compound C1CN(CC(=O)OCC)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 RVXCLPDXTRPJBM-UHFFFAOYSA-N 0.000 description 2
- DGFOBDMWSSJXIW-UHFFFAOYSA-N ethyl 3-[4-[2-(1,4-dioxaspiro[4.5]decan-8-yl)ethyl]piperazin-1-yl]benzoate Chemical compound CCOC(=O)C1=CC=CC(N2CCN(CCC3CCC4(CC3)OCCO4)CC2)=C1 DGFOBDMWSSJXIW-UHFFFAOYSA-N 0.000 description 2
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 2
- LVKCSZQWLOVUGB-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].C[CH-]C LVKCSZQWLOVUGB-UHFFFAOYSA-M 0.000 description 2
- WRIRWRKPLXCTFD-UHFFFAOYSA-N malonamide Chemical compound NC(=O)CC(N)=O WRIRWRKPLXCTFD-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 2
- CLOSFWWFDCNXDA-UHFFFAOYSA-N n-[4-[2-[4-(2,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-(4-fluorophenoxy)acetamide Chemical compound C1=CC(F)=CC=C1OCC(=O)NC1CCC(CCN2CCN(CC2)C=2C(=CC(F)=CC=2)F)CC1 CLOSFWWFDCNXDA-UHFFFAOYSA-N 0.000 description 2
- OZGYLHKEQVGWFV-UHFFFAOYSA-N n-[4-[2-[4-(2-chloro-4-fluoro-5-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C(=CC(F)=C(C)C=2)Cl)CC1 OZGYLHKEQVGWFV-UHFFFAOYSA-N 0.000 description 2
- AVTGUPVMNFMKLZ-UHFFFAOYSA-N n-[4-[2-[4-(2-chloro-5-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound ClC1=CC=C(C#N)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 AVTGUPVMNFMKLZ-UHFFFAOYSA-N 0.000 description 2
- SWIRVSTZKIKEOX-UHFFFAOYSA-N n-[4-[2-[4-(2-fluoro-4-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C(=CC(C)=CC=2)F)CC1 SWIRVSTZKIKEOX-UHFFFAOYSA-N 0.000 description 2
- MKALMSHPCUBSMP-UHFFFAOYSA-N n-[4-[2-[4-(3,5-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C=C(Cl)C=C(Cl)C=2)CC1 MKALMSHPCUBSMP-UHFFFAOYSA-N 0.000 description 2
- ISNKARZRRHZCGR-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-2,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-cyanobutanamide Chemical compound FC1=C(Cl)C(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 ISNKARZRRHZCGR-UHFFFAOYSA-N 0.000 description 2
- LJLBJYUKEOQDRD-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-2-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-cyanobutanamide Chemical compound ClC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1C#N LJLBJYUKEOQDRD-UHFFFAOYSA-N 0.000 description 2
- OLOGSFMXXWWUJX-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-2-methoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-cyanobutanamide Chemical compound COC1=C(Cl)C=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 OLOGSFMXXWWUJX-UHFFFAOYSA-N 0.000 description 2
- MLJSDZSDUFSRKX-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-4-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound C1=C(Cl)C(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 MLJSDZSDUFSRKX-UHFFFAOYSA-N 0.000 description 2
- YJRWFLZESYIPGI-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-4-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-cyanobutanamide Chemical compound C1=C(Cl)C(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 YJRWFLZESYIPGI-UHFFFAOYSA-N 0.000 description 2
- VBSXQCLHIXXCOT-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-4-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound C1=C(Cl)C(C)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 VBSXQCLHIXXCOT-UHFFFAOYSA-N 0.000 description 2
- DEUMVUIPYIPHJQ-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-4-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-ethoxyacetamide Chemical compound C1CC(NC(=O)COCC)CCC1CCN1CCN(C=2C=C(Cl)C(C)=CC=2)CC1 DEUMVUIPYIPHJQ-UHFFFAOYSA-N 0.000 description 2
- BUGCIOGPAIOSIM-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-5-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-methoxyacetamide Chemical compound C1CC(NC(=O)COC)CCC1CCN1CCN(C=2C=C(Cl)C=C(F)C=2)CC1 BUGCIOGPAIOSIM-UHFFFAOYSA-N 0.000 description 2
- DXGIMIAAFAAVSV-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-5-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-3-cyanopropanamide Chemical compound FC1=CC(Cl)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCC#N)CC2)=C1 DXGIMIAAFAAVSV-UHFFFAOYSA-N 0.000 description 2
- LVJGZGKUDVXQAA-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-5-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound CC1=CC(Cl)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 LVJGZGKUDVXQAA-UHFFFAOYSA-N 0.000 description 2
- QSCRDENXRBHTOS-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-5-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-ethoxyacetamide Chemical compound C1CC(NC(=O)COCC)CCC1CCN1CCN(C=2C=C(Cl)C=C(C)C=2)CC1 QSCRDENXRBHTOS-UHFFFAOYSA-N 0.000 description 2
- FQVLVTULNWEQHH-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-5-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-cyanobutanamide Chemical compound CC1=CC(Cl)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 FQVLVTULNWEQHH-UHFFFAOYSA-N 0.000 description 2
- ULWJZXZLQPWNQO-UHFFFAOYSA-N n-[4-[2-[4-(3-cyano-2,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C(=C(C#N)C(F)=CC=2)F)CC1 ULWJZXZLQPWNQO-UHFFFAOYSA-N 0.000 description 2
- ULUGTCSQRVOGCZ-UHFFFAOYSA-N n-[4-[2-[4-(3-ethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound CCC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCOC)CC2)=C1 ULUGTCSQRVOGCZ-UHFFFAOYSA-N 0.000 description 2
- ZCIZMDSFPYKMKM-UHFFFAOYSA-N n-[4-[2-[4-(3-fluoro-2-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C(=C(F)C=CC=2)C)CC1 ZCIZMDSFPYKMKM-UHFFFAOYSA-N 0.000 description 2
- KKHSOIOAPFMXLQ-UHFFFAOYSA-N n-[4-[2-[4-(3-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C=C(F)C=CC=2)CC1 KKHSOIOAPFMXLQ-UHFFFAOYSA-N 0.000 description 2
- LHPYHJZZMNPQAN-UHFFFAOYSA-N n-[4-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-cyanobutanamide Chemical compound C1=CC(Cl)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 LHPYHJZZMNPQAN-UHFFFAOYSA-N 0.000 description 2
- LXRKHTGKHNZSCP-UHFFFAOYSA-N n-[4-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C=CC(Cl)=CC=2)CC1 LXRKHTGKHNZSCP-UHFFFAOYSA-N 0.000 description 2
- MYNHDXYQIOOAHP-UHFFFAOYSA-N n-[4-[2-[4-(5-chloro-2-methoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-cyanobutanamide Chemical compound COC1=CC=C(Cl)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 MYNHDXYQIOOAHP-UHFFFAOYSA-N 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 231100000989 no adverse effect Toxicity 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 150000003138 primary alcohols Chemical class 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- GLXXAJODWMPLKF-UHFFFAOYSA-N tert-butyl 4-[2-[4-[3-(methoxymethyl)phenyl]piperazin-1-yl]ethyl]piperidine-1-carboxylate Chemical compound COCC1=CC=CC(N2CCN(CCC3CCN(CC3)C(=O)OC(C)(C)C)CC2)=C1 GLXXAJODWMPLKF-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- MFCBCXRMDAOFOT-IUYQGCFVSA-N (1r,2r)-2-cyanocyclopropane-1-carboxylic acid Chemical compound OC(=O)[C@@H]1C[C@H]1C#N MFCBCXRMDAOFOT-IUYQGCFVSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- RKWNQODBLXZUES-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-6-carbonitrile Chemical compound C1NCCC2=CC(C#N)=CC=C21 RKWNQODBLXZUES-UHFFFAOYSA-N 0.000 description 1
- LJFNUFCUPDECPC-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-7-carbonitrile Chemical compound C1CNCC2=CC(C#N)=CC=C21 LJFNUFCUPDECPC-UHFFFAOYSA-N 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- RBACIKXCRWGCBB-UHFFFAOYSA-N 1,2-Epoxybutane Chemical compound CCC1CO1 RBACIKXCRWGCBB-UHFFFAOYSA-N 0.000 description 1
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- PLCMNTIYNKRHRJ-UHFFFAOYSA-N 1-(2,3-dichlorophenyl)-4-(2-piperidin-4-ylethyl)piperazine Chemical compound ClC1=CC=CC(N2CCN(CCC3CCNCC3)CC2)=C1Cl PLCMNTIYNKRHRJ-UHFFFAOYSA-N 0.000 description 1
- VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 description 1
- KKIMDKMETPPURN-UHFFFAOYSA-N 1-(3-(trifluoromethyl)phenyl)piperazine Chemical compound FC(F)(F)C1=CC=CC(N2CCNCC2)=C1 KKIMDKMETPPURN-UHFFFAOYSA-N 0.000 description 1
- ARKIFHPFTHVKDT-UHFFFAOYSA-N 1-(3-nitrophenyl)ethanone Chemical compound CC(=O)C1=CC=CC([N+]([O-])=O)=C1 ARKIFHPFTHVKDT-UHFFFAOYSA-N 0.000 description 1
- GUISDOUDDCHVAL-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]ethanone Chemical compound C1=CC(F)=CC=C1C(=O)CN1CCC(CCN2CCN(CC2)C=2C=C(C=CC=2)C(F)(F)F)CC1 GUISDOUDDCHVAL-UHFFFAOYSA-N 0.000 description 1
- AVJKDKWRVSSJPK-UHFFFAOYSA-N 1-(4-fluorophenyl)piperazine Chemical compound C1=CC(F)=CC=C1N1CCNCC1 AVJKDKWRVSSJPK-UHFFFAOYSA-N 0.000 description 1
- UMCLBQHPTDPNCS-UHFFFAOYSA-N 1-[2-(1,4-dioxaspiro[4.5]decan-8-yl)ethyl]-4-(3-nitrophenyl)piperazine Chemical compound [O-][N+](=O)C1=CC=CC(N2CCN(CCC3CCC4(CC3)OCCO4)CC2)=C1 UMCLBQHPTDPNCS-UHFFFAOYSA-N 0.000 description 1
- OLVOSPKOPKMMJX-UHFFFAOYSA-N 1-[2-fluoro-5-(trifluoromethyl)phenyl]piperazine Chemical compound FC1=CC=C(C(F)(F)F)C=C1N1CCNCC1 OLVOSPKOPKMMJX-UHFFFAOYSA-N 0.000 description 1
- MFVZOXRTIFMHQF-UHFFFAOYSA-N 1-[3-[4-[2-(1,4-dioxaspiro[4.5]decan-8-yl)ethyl]piperazin-1-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(N2CCN(CCC3CCC4(CC3)OCCO4)CC2)=C1 MFVZOXRTIFMHQF-UHFFFAOYSA-N 0.000 description 1
- UMRNLWJVGXYIOV-UHFFFAOYSA-N 1-[3-[4-[2-(1,4-dioxaspiro[4.5]decan-8-yl)ethyl]piperazin-1-yl]phenyl]propan-1-one Chemical compound CCC(=O)C1=CC=CC(N2CCN(CCC3CCC4(CC3)OCCO4)CC2)=C1 UMRNLWJVGXYIOV-UHFFFAOYSA-N 0.000 description 1
- QLNCIUORTLUIFA-UHFFFAOYSA-N 1-[4-[2-(4-naphthalen-1-ylpiperazin-1-yl)ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C3=CC=CC=C3C=CC=2)CC1 QLNCIUORTLUIFA-UHFFFAOYSA-N 0.000 description 1
- NSBYSZXKQLIWIP-UHFFFAOYSA-N 1-[4-[2-(4-quinolin-5-ylpiperazin-1-yl)ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C3=CC=CN=C3C=CC=2)CC1 NSBYSZXKQLIWIP-UHFFFAOYSA-N 0.000 description 1
- IFNHFFQDQVZIIE-UHFFFAOYSA-N 1-[4-[2-(4-quinolin-8-ylpiperazin-1-yl)ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C3=NC=CC=C3C=CC=2)CC1 IFNHFFQDQVZIIE-UHFFFAOYSA-N 0.000 description 1
- QQYUIMZRYQWFON-UHFFFAOYSA-N 1-[4-[2-[4-(1,3-benzodioxol-4-yl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=3OCOC=3C=CC=2)CC1 QQYUIMZRYQWFON-UHFFFAOYSA-N 0.000 description 1
- CVYSZQWGBBXIBC-UHFFFAOYSA-N 1-[4-[2-[4-(1,3-benzodioxol-5-yl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C3OCOC3=CC=2)CC1 CVYSZQWGBBXIBC-UHFFFAOYSA-N 0.000 description 1
- QPWHJSILGNHVBL-UHFFFAOYSA-N 1-[4-[2-[4-(1,3-benzothiazol-5-yl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C3N=CSC3=CC=2)CC1 QPWHJSILGNHVBL-UHFFFAOYSA-N 0.000 description 1
- ZPAHGWCCCWUSKV-UHFFFAOYSA-N 1-[4-[2-[4-(2,3,4,5-tetrafluorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=C(F)C(F)=C(F)C=2)F)CC1 ZPAHGWCCCWUSKV-UHFFFAOYSA-N 0.000 description 1
- HJAUWRNWQJUPPZ-UHFFFAOYSA-N 1-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 HJAUWRNWQJUPPZ-UHFFFAOYSA-N 0.000 description 1
- QPGYHXVYMBUNDO-UHFFFAOYSA-N 1-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propane-1,2-dione Chemical compound C1CN(C(=O)C(=O)C)CCC1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 QPGYHXVYMBUNDO-UHFFFAOYSA-N 0.000 description 1
- SGNLADNWWNFKBK-UHFFFAOYSA-N 1-[4-[2-[4-(2,3-difluorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=C(F)C=CC=2)F)CC1 SGNLADNWWNFKBK-UHFFFAOYSA-N 0.000 description 1
- WYPLSLFQPVULRX-UHFFFAOYSA-N 1-[4-[2-[4-(2,3-dihydro-1h-inden-4-yl)piperazin-1-yl]ethyl]piperidin-1-yl]-3,3,3-trifluoropropan-1-one Chemical compound C1CN(C(=O)CC(F)(F)F)CCC1CCN1CCN(C=2C=3CCCC=3C=CC=2)CC1 WYPLSLFQPVULRX-UHFFFAOYSA-N 0.000 description 1
- FKJCCUHHWXSNGT-UHFFFAOYSA-N 1-[4-[2-[4-(2,3-dihydro-1h-inden-4-yl)piperazin-1-yl]ethyl]piperidin-1-yl]-4,4,4-trifluorobutan-1-one Chemical compound C1CN(C(=O)CCC(F)(F)F)CCC1CCN1CCN(C=2C=3CCCC=3C=CC=2)CC1 FKJCCUHHWXSNGT-UHFFFAOYSA-N 0.000 description 1
- VOUOQHKUDSSQFE-UHFFFAOYSA-N 1-[4-[2-[4-(2,3-dimethylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=C(C)C=CC=2)C)CC1 VOUOQHKUDSSQFE-UHFFFAOYSA-N 0.000 description 1
- UFMOOGIZRBNODQ-UHFFFAOYSA-N 1-[4-[2-[4-(2,4,5-trifluorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC(F)=C(F)C=2)F)CC1 UFMOOGIZRBNODQ-UHFFFAOYSA-N 0.000 description 1
- PCIXGSULUDYSIV-UHFFFAOYSA-N 1-[4-[2-[4-(2,4-dichlorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC(Cl)=CC=2)Cl)CC1 PCIXGSULUDYSIV-UHFFFAOYSA-N 0.000 description 1
- IQNBNSVZNHKOQK-UHFFFAOYSA-N 1-[4-[2-[4-(2,4-difluorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC(F)=CC=2)F)CC1 IQNBNSVZNHKOQK-UHFFFAOYSA-N 0.000 description 1
- GWVYSDUNDZCWFT-UHFFFAOYSA-N 1-[4-[2-[4-(2,5-dichlorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC=C(Cl)C=2)Cl)CC1 GWVYSDUNDZCWFT-UHFFFAOYSA-N 0.000 description 1
- ODWBMPLEUZGQAU-UHFFFAOYSA-N 1-[4-[2-[4-(2,5-dimethoxyphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound COC1=CC=C(OC)C(N2CCN(CCC3CCN(CC(C)=O)CC3)CC2)=C1 ODWBMPLEUZGQAU-UHFFFAOYSA-N 0.000 description 1
- JFUMSDNDKPJKGU-UHFFFAOYSA-N 1-[4-[2-[4-(2,5-dimethylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC=C(C)C=2)C)CC1 JFUMSDNDKPJKGU-UHFFFAOYSA-N 0.000 description 1
- LGJAUQIZDMJMNG-UHFFFAOYSA-N 1-[4-[2-[4-(2,6-dimethylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC=CC=2C)C)CC1 LGJAUQIZDMJMNG-UHFFFAOYSA-N 0.000 description 1
- CYVBPAPDUIEZNA-UHFFFAOYSA-N 1-[4-[2-[4-(2,6-ditert-butylpyrimidin-4-yl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2N=C(N=C(C=2)C(C)(C)C)C(C)(C)C)CC1 CYVBPAPDUIEZNA-UHFFFAOYSA-N 0.000 description 1
- HCEBHPDGWMXCOP-UHFFFAOYSA-N 1-[4-[2-[4-(2-chloro-4-fluoro-5-methylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC(F)=C(C)C=2)Cl)CC1 HCEBHPDGWMXCOP-UHFFFAOYSA-N 0.000 description 1
- YUEAMDSZMZVJII-UHFFFAOYSA-N 1-[4-[2-[4-(2-chloro-5-methylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC=C(C)C=2)Cl)CC1 YUEAMDSZMZVJII-UHFFFAOYSA-N 0.000 description 1
- QEIKTIZBVAUDCZ-UHFFFAOYSA-N 1-[4-[2-[4-(2-chlorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC=CC=2)Cl)CC1 QEIKTIZBVAUDCZ-UHFFFAOYSA-N 0.000 description 1
- WWIWWZLAWYSWGF-UHFFFAOYSA-N 1-[4-[2-[4-(2-ethoxyphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound CCOC1=CC=CC=C1N1CCN(CCC2CCN(CC(C)=O)CC2)CC1 WWIWWZLAWYSWGF-UHFFFAOYSA-N 0.000 description 1
- OKEOZFHBPZAPBU-UHFFFAOYSA-N 1-[4-[2-[4-(2-ethylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound CCC1=CC=CC=C1N1CCN(CCC2CCN(CC(C)=O)CC2)CC1 OKEOZFHBPZAPBU-UHFFFAOYSA-N 0.000 description 1
- UFUXZXBPUANMMO-UHFFFAOYSA-N 1-[4-[2-[4-(2-fluoro-4-methylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC(C)=CC=2)F)CC1 UFUXZXBPUANMMO-UHFFFAOYSA-N 0.000 description 1
- FEMACHOXWIHKCK-UHFFFAOYSA-N 1-[4-[2-[4-(2-fluoro-5-methylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC=C(C)C=2)F)CC1 FEMACHOXWIHKCK-UHFFFAOYSA-N 0.000 description 1
- CHTSKGQEYGTEEQ-UHFFFAOYSA-N 1-[4-[2-[4-(2-fluorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC=CC=2)F)CC1 CHTSKGQEYGTEEQ-UHFFFAOYSA-N 0.000 description 1
- WVHRETFREQWSFY-UHFFFAOYSA-N 1-[4-[2-[4-(2-methoxy-5-methylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound COC1=CC=C(C)C=C1N1CCN(CCC2CCN(CC(C)=O)CC2)CC1 WVHRETFREQWSFY-UHFFFAOYSA-N 0.000 description 1
- CBPVLMMGBIUFQS-UHFFFAOYSA-N 1-[4-[2-[4-(2-methylsulfanylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound CSC1=CC=CC=C1N1CCN(CCC2CCN(CC(C)=O)CC2)CC1 CBPVLMMGBIUFQS-UHFFFAOYSA-N 0.000 description 1
- QZLDPPXODIVELC-UHFFFAOYSA-N 1-[4-[2-[4-(3,4,5-trifluorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(F)C(F)=C(F)C=2)CC1 QZLDPPXODIVELC-UHFFFAOYSA-N 0.000 description 1
- AUIRBUWOXLZLPK-UHFFFAOYSA-N 1-[4-[2-[4-(3,4-dichlorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(Cl)C(Cl)=CC=2)CC1 AUIRBUWOXLZLPK-UHFFFAOYSA-N 0.000 description 1
- OSXIPCITKVHZSP-UHFFFAOYSA-N 1-[4-[2-[4-(3,4-difluorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(F)C(F)=CC=2)CC1 OSXIPCITKVHZSP-UHFFFAOYSA-N 0.000 description 1
- XAIFMJMCQNZMRP-UHFFFAOYSA-N 1-[4-[2-[4-(3,4-dimethylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(C)C(C)=CC=2)CC1 XAIFMJMCQNZMRP-UHFFFAOYSA-N 0.000 description 1
- BGFLOOVBJZEQPJ-UHFFFAOYSA-N 1-[4-[2-[4-(3,5-dichlorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(Cl)C=C(Cl)C=2)CC1 BGFLOOVBJZEQPJ-UHFFFAOYSA-N 0.000 description 1
- BJQYTGVHKQANAV-UHFFFAOYSA-N 1-[4-[2-[4-(3,5-difluorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(F)C=C(F)C=2)CC1 BJQYTGVHKQANAV-UHFFFAOYSA-N 0.000 description 1
- KDYKPNQCYVOBJN-UHFFFAOYSA-N 1-[4-[2-[4-(3,5-dimethylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(C)C=C(C)C=2)CC1 KDYKPNQCYVOBJN-UHFFFAOYSA-N 0.000 description 1
- BGNJSQDPIKFESM-UHFFFAOYSA-N 1-[4-[2-[4-(3,5-ditert-butylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(C=C(C=2)C(C)(C)C)C(C)(C)C)CC1 BGNJSQDPIKFESM-UHFFFAOYSA-N 0.000 description 1
- IENXZJLHLQBRGY-UHFFFAOYSA-N 1-[4-[2-[4-(3-acetylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(C=CC=2)C(C)=O)CC1 IENXZJLHLQBRGY-UHFFFAOYSA-N 0.000 description 1
- DVFHTSIKLRGWCT-UHFFFAOYSA-N 1-[4-[2-[4-(3-benzylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(CC=3C=CC=CC=3)C=CC=2)CC1 DVFHTSIKLRGWCT-UHFFFAOYSA-N 0.000 description 1
- IIYSOYDUGROLCV-UHFFFAOYSA-N 1-[4-[2-[4-(3-chloro-2-fluorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=C(Cl)C=CC=2)F)CC1 IIYSOYDUGROLCV-UHFFFAOYSA-N 0.000 description 1
- OOMNLCSWRPMEAR-UHFFFAOYSA-N 1-[4-[2-[4-(3-chloro-2-methoxyphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound COC1=C(Cl)C=CC=C1N1CCN(CCC2CCN(CC(C)=O)CC2)CC1 OOMNLCSWRPMEAR-UHFFFAOYSA-N 0.000 description 1
- LDSZFKPWMBLUNP-UHFFFAOYSA-N 1-[4-[2-[4-(3-chloro-2-methylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=C(Cl)C=CC=2)C)CC1 LDSZFKPWMBLUNP-UHFFFAOYSA-N 0.000 description 1
- OGMOEPFCSZCLKE-UHFFFAOYSA-N 1-[4-[2-[4-(3-chloro-4-methylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(Cl)C(C)=CC=2)CC1 OGMOEPFCSZCLKE-UHFFFAOYSA-N 0.000 description 1
- QRQUYFKBOXMVKO-UHFFFAOYSA-N 1-[4-[2-[4-(3-chloro-5-methylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(Cl)C=C(C)C=2)CC1 QRQUYFKBOXMVKO-UHFFFAOYSA-N 0.000 description 1
- GATFEWNBUHFCAB-UHFFFAOYSA-N 1-[4-[2-[4-(3-chlorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(Cl)C=CC=2)CC1 GATFEWNBUHFCAB-UHFFFAOYSA-N 0.000 description 1
- NEXYWNURTAUSME-UHFFFAOYSA-N 1-[4-[2-[4-(3-ethoxyphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound CCOC1=CC=CC(N2CCN(CCC3CCN(CC(C)=O)CC3)CC2)=C1 NEXYWNURTAUSME-UHFFFAOYSA-N 0.000 description 1
- MKMHKYGWOCSWAF-UHFFFAOYSA-N 1-[4-[2-[4-(3-ethylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound CCC1=CC=CC(N2CCN(CCC3CCN(CC(C)=O)CC3)CC2)=C1 MKMHKYGWOCSWAF-UHFFFAOYSA-N 0.000 description 1
- WDHGSLIQCRRUOU-UHFFFAOYSA-N 1-[4-[2-[4-(3-fluoro-2-methylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=C(F)C=CC=2)C)CC1 WDHGSLIQCRRUOU-UHFFFAOYSA-N 0.000 description 1
- XCDTUCJCMUBMRU-UHFFFAOYSA-N 1-[4-[2-[4-(3-fluoro-4-methylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(F)C(C)=CC=2)CC1 XCDTUCJCMUBMRU-UHFFFAOYSA-N 0.000 description 1
- LJXPFLFLTOMGEI-UHFFFAOYSA-N 1-[4-[2-[4-(3-fluoro-5-methylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(F)C=C(C)C=2)CC1 LJXPFLFLTOMGEI-UHFFFAOYSA-N 0.000 description 1
- ZSVXEEYOQBKIEL-UHFFFAOYSA-N 1-[4-[2-[4-(3-fluorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(F)C=CC=2)CC1 ZSVXEEYOQBKIEL-UHFFFAOYSA-N 0.000 description 1
- ADZSSOQPGRJWCF-UHFFFAOYSA-N 1-[4-[2-[4-(3-methoxyphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound COC1=CC=CC(N2CCN(CCC3CCN(CC(C)=O)CC3)CC2)=C1 ADZSSOQPGRJWCF-UHFFFAOYSA-N 0.000 description 1
- HBCQFMFTRAPMQR-UHFFFAOYSA-N 1-[4-[2-[4-(3-methylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(C)C=CC=2)CC1 HBCQFMFTRAPMQR-UHFFFAOYSA-N 0.000 description 1
- BKWMURHLKWEWCR-UHFFFAOYSA-N 1-[4-[2-[4-(3-methylsulfanylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound CSC1=CC=CC(N2CCN(CCC3CCN(CC(C)=O)CC3)CC2)=C1 BKWMURHLKWEWCR-UHFFFAOYSA-N 0.000 description 1
- SBMSQZBDGUTEEU-UHFFFAOYSA-N 1-[4-[2-[4-(3-methylsulfonylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(C=CC=2)S(C)(=O)=O)CC1 SBMSQZBDGUTEEU-UHFFFAOYSA-N 0.000 description 1
- RUGXTACVZLUECQ-UHFFFAOYSA-N 1-[4-[2-[4-(3-nitrophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(C=CC=2)[N+]([O-])=O)CC1 RUGXTACVZLUECQ-UHFFFAOYSA-N 0.000 description 1
- GWFKSVQRWXJJPU-UHFFFAOYSA-N 1-[4-[2-[4-(3-phenoxyphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(OC=3C=CC=CC=3)C=CC=2)CC1 GWFKSVQRWXJJPU-UHFFFAOYSA-N 0.000 description 1
- SEELDPZHOCNCBZ-UHFFFAOYSA-N 1-[4-[2-[4-(3-phenylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(C=CC=2)C=2C=CC=CC=2)CC1 SEELDPZHOCNCBZ-UHFFFAOYSA-N 0.000 description 1
- YHGJXBQYHJTAJM-UHFFFAOYSA-N 1-[4-[2-[4-(3-propan-2-yloxyphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound CC(C)OC1=CC=CC(N2CCN(CCC3CCN(CC(C)=O)CC3)CC2)=C1 YHGJXBQYHJTAJM-UHFFFAOYSA-N 0.000 description 1
- TUEIJOAUVSNMNU-UHFFFAOYSA-N 1-[4-[2-[4-(3-propan-2-ylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound CC(C)C1=CC=CC(N2CCN(CCC3CCN(CC(C)=O)CC3)CC2)=C1 TUEIJOAUVSNMNU-UHFFFAOYSA-N 0.000 description 1
- ZTPRQLFGGDYUMA-UHFFFAOYSA-N 1-[4-[2-[4-(3-propylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound CCCC1=CC=CC(N2CCN(CCC3CCN(CC(C)=O)CC3)CC2)=C1 ZTPRQLFGGDYUMA-UHFFFAOYSA-N 0.000 description 1
- GJGXNTKRZGPSHR-UHFFFAOYSA-N 1-[4-[2-[4-(3-tert-butylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(C=CC=2)C(C)(C)C)CC1 GJGXNTKRZGPSHR-UHFFFAOYSA-N 0.000 description 1
- FPSGZALZPDHXPT-UHFFFAOYSA-N 1-[4-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=CC(Cl)=CC=2)CC1 FPSGZALZPDHXPT-UHFFFAOYSA-N 0.000 description 1
- ICXJSNUZMOXNAN-UHFFFAOYSA-N 1-[4-[2-[4-(4-fluoro-2-methylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC(F)=CC=2)C)CC1 ICXJSNUZMOXNAN-UHFFFAOYSA-N 0.000 description 1
- WCCGOKNLRNWEEG-UHFFFAOYSA-N 1-[4-[2-[4-(4-fluoro-3-methylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(C)C(F)=CC=2)CC1 WCCGOKNLRNWEEG-UHFFFAOYSA-N 0.000 description 1
- VNCMXLQFPUIDFC-UHFFFAOYSA-N 1-[4-[2-[4-(4-fluorophenyl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CC=C(C=2C=CC(F)=CC=2)CC1 VNCMXLQFPUIDFC-UHFFFAOYSA-N 0.000 description 1
- LKHPRKXQFIYOIW-UHFFFAOYSA-N 1-[4-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=CC(C)=CC=2)CC1 LKHPRKXQFIYOIW-UHFFFAOYSA-N 0.000 description 1
- SLZXJXNNOQDSKA-UHFFFAOYSA-N 1-[4-[2-[4-(5,6,7,8-tetrahydronaphthalen-2-yl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C3CCCCC3=CC=2)CC1 SLZXJXNNOQDSKA-UHFFFAOYSA-N 0.000 description 1
- ARDPKTHLULCTRE-UHFFFAOYSA-N 1-[4-[2-[4-(5-chloro-2-fluorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC=C(Cl)C=2)F)CC1 ARDPKTHLULCTRE-UHFFFAOYSA-N 0.000 description 1
- LRKKEKDFMPFFOG-UHFFFAOYSA-N 1-[4-[2-[4-(5-chloro-2-methoxyphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound COC1=CC=C(Cl)C=C1N1CCN(CCC2CCN(CC(C)=O)CC2)CC1 LRKKEKDFMPFFOG-UHFFFAOYSA-N 0.000 description 1
- QYMJHZUJBSZASQ-UHFFFAOYSA-N 1-[4-[2-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC=C(Cl)C=2)C)CC1 QYMJHZUJBSZASQ-UHFFFAOYSA-N 0.000 description 1
- XMICILITIPEUAS-UHFFFAOYSA-N 1-[4-[2-[4-(5-fluoro-2-methylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC=C(F)C=2)C)CC1 XMICILITIPEUAS-UHFFFAOYSA-N 0.000 description 1
- QHUINAQGJLUVER-UHFFFAOYSA-N 1-[4-[2-[4-(5-methoxy-2-methylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound COC1=CC=C(C)C(N2CCN(CCC3CCN(CC(C)=O)CC3)CC2)=C1 QHUINAQGJLUVER-UHFFFAOYSA-N 0.000 description 1
- OZXJBEWQOIDJTJ-UHFFFAOYSA-N 1-[4-[2-[4-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-3-yl)piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C3CCCCCC3=CC=2)CC1 OZXJBEWQOIDJTJ-UHFFFAOYSA-N 0.000 description 1
- AUHOJSDEHPNLOX-UHFFFAOYSA-N 1-[4-[2-[4-[2-(2-methylpropyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound CC(C)CC1=CC=CC=C1N1CCN(CCC2CCN(CC(C)=O)CC2)CC1 AUHOJSDEHPNLOX-UHFFFAOYSA-N 0.000 description 1
- BPTWEDOQMRCARB-UHFFFAOYSA-N 1-[4-[2-[4-[2-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC=CC=2)C(F)(F)F)CC1 BPTWEDOQMRCARB-UHFFFAOYSA-N 0.000 description 1
- VTFSZLRDDQODMY-UHFFFAOYSA-N 1-[4-[2-[4-[2-chloro-5-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC=C(C=2)C(F)(F)F)Cl)CC1 VTFSZLRDDQODMY-UHFFFAOYSA-N 0.000 description 1
- JYGOZXSKDVWOSW-UHFFFAOYSA-N 1-[4-[2-[4-[2-fluoro-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=C(C=CC=2)C(F)(F)F)F)CC1 JYGOZXSKDVWOSW-UHFFFAOYSA-N 0.000 description 1
- PPZDCKYQUPRSBX-UHFFFAOYSA-N 1-[4-[2-[4-[2-fluoro-5-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=CC=C(C=2)C(F)(F)F)F)CC1 PPZDCKYQUPRSBX-UHFFFAOYSA-N 0.000 description 1
- FCQNIBONNIAFTO-UHFFFAOYSA-N 1-[4-[2-[4-[2-methoxy-5-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound COC1=CC=C(C(F)(F)F)C=C1N1CCN(CCC2CCN(CC(C)=O)CC2)CC1 FCQNIBONNIAFTO-UHFFFAOYSA-N 0.000 description 1
- AAYASOQXJHPPNV-UHFFFAOYSA-N 1-[4-[2-[4-[2-methyl-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=C(C=CC=2)C(F)(F)F)C)CC1 AAYASOQXJHPPNV-UHFFFAOYSA-N 0.000 description 1
- BVVKPCKFKIYYBZ-UHFFFAOYSA-N 1-[4-[2-[4-[3,5-bis(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 BVVKPCKFKIYYBZ-UHFFFAOYSA-N 0.000 description 1
- BCELAYLKKZYEQU-UHFFFAOYSA-N 1-[4-[2-[4-[3-(1-hydroxy-2-methylpropyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound CC(C)C(O)C1=CC=CC(N2CCN(CCC3CCN(CC(C)=O)CC3)CC2)=C1 BCELAYLKKZYEQU-UHFFFAOYSA-N 0.000 description 1
- HAPLJXLHFLTOBN-UHFFFAOYSA-N 1-[4-[2-[4-[3-(1-hydroxyethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound CC(O)C1=CC=CC(N2CCN(CCC3CCN(CC(C)=O)CC3)CC2)=C1 HAPLJXLHFLTOBN-UHFFFAOYSA-N 0.000 description 1
- GPCOKLTZEAZWFS-UHFFFAOYSA-N 1-[4-[2-[4-[3-(methoxymethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound COCC1=CC=CC(N2CCN(CCC3CCN(CC(C)=O)CC3)CC2)=C1 GPCOKLTZEAZWFS-UHFFFAOYSA-N 0.000 description 1
- SZUXZHQEHMTZEK-UHFFFAOYSA-N 1-[4-[2-[4-[3-(trifluoromethoxy)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(OC(F)(F)F)C=CC=2)CC1 SZUXZHQEHMTZEK-UHFFFAOYSA-N 0.000 description 1
- WZYPTTZMPFTJJW-UHFFFAOYSA-N 1-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]butane-1,2-dione Chemical compound C1CN(C(=O)C(=O)CC)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 WZYPTTZMPFTJJW-UHFFFAOYSA-N 0.000 description 1
- LKSUFXOUMOTXKS-UHFFFAOYSA-N 1-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 LKSUFXOUMOTXKS-UHFFFAOYSA-N 0.000 description 1
- WQTNATFHZFQSTH-UHFFFAOYSA-N 1-[4-[2-[4-[3-methoxy-5-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound FC(F)(F)C1=CC(OC)=CC(N2CCN(CCC3CCN(CC(C)=O)CC3)CC2)=C1 WQTNATFHZFQSTH-UHFFFAOYSA-N 0.000 description 1
- YMBKDQKIWFSLSQ-UHFFFAOYSA-N 1-[4-[2-[4-[4-chloro-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(C(Cl)=CC=2)C(F)(F)F)CC1 YMBKDQKIWFSLSQ-UHFFFAOYSA-N 0.000 description 1
- UQJPZUIIJLFWEP-UHFFFAOYSA-N 1-[4-[2-[4-[4-fluoro-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]propan-2-one Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C=C(C(F)=CC=2)C(F)(F)F)CC1 UQJPZUIIJLFWEP-UHFFFAOYSA-N 0.000 description 1
- VKEGOEYINSYJPL-UHFFFAOYSA-N 1-[6-(trifluoromethyl)-1-benzothiophen-3-yl]piperazine Chemical compound C=1SC2=CC(C(F)(F)F)=CC=C2C=1N1CCNCC1 VKEGOEYINSYJPL-UHFFFAOYSA-N 0.000 description 1
- IBYHOPWUQSQSIV-UHFFFAOYSA-N 1-acetyl-n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]piperidine-4-carboxamide Chemical compound C1CN(C(=O)C)CCC1C(=O)NC1CCC(CCN2CCN(CC2)C=2C=C(C=CC=2)C(F)(F)F)CC1 IBYHOPWUQSQSIV-UHFFFAOYSA-N 0.000 description 1
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 1
- VPKXUXYEZAEYOU-UHFFFAOYSA-N 1-phenyl-2-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]ethanone Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC3CCN(CC(=O)C=4C=CC=CC=4)CC3)CC2)=C1 VPKXUXYEZAEYOU-UHFFFAOYSA-N 0.000 description 1
- CHLFINZCIMNMHA-UHFFFAOYSA-N 1-piperidin-1-ylbutane-1,2-dione Chemical compound CCC(=O)C(=O)N1CCCCC1 CHLFINZCIMNMHA-UHFFFAOYSA-N 0.000 description 1
- GRCCNIGKBAGOHL-UHFFFAOYSA-N 1-pyrrolidin-1-yl-2-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]ethanone Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC3CCC(CC(=O)N4CCCC4)CC3)CC2)=C1 GRCCNIGKBAGOHL-UHFFFAOYSA-N 0.000 description 1
- IQIRPRGROHAMEX-UHFFFAOYSA-N 1-pyrrolidin-1-yl-2-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexylidene]ethanone Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC3CCC(CC3)=CC(=O)N3CCCC3)CC2)=C1 IQIRPRGROHAMEX-UHFFFAOYSA-N 0.000 description 1
- QEUQHGVOYBPSDE-UHFFFAOYSA-N 2,2,2-trifluoro-n-[4-[2-[4-(3-methylsulfonylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CS(=O)(=O)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)C(F)(F)F)CC2)=C1 QEUQHGVOYBPSDE-UHFFFAOYSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- XKWMSKXDFJSKJO-UHFFFAOYSA-N 2,3-dihydrofuran-4-carboxylic acid Chemical compound OC(=O)C1=COCC1 XKWMSKXDFJSKJO-UHFFFAOYSA-N 0.000 description 1
- BXAUDGINNUGUHE-UHFFFAOYSA-N 2,4-ditert-butyl-6-piperazin-1-ylpyrimidine Chemical compound CC(C)(C)C1=NC(C(C)(C)C)=CC(N2CCNCC2)=N1 BXAUDGINNUGUHE-UHFFFAOYSA-N 0.000 description 1
- LAHHAGKSSDDUGW-UHFFFAOYSA-N 2,6-difluoro-3-[4-[2-[1-(2-oxopropyl)piperidin-4-yl]ethyl]piperazin-1-yl]benzonitrile Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=C(C#N)C(F)=CC=2)F)CC1 LAHHAGKSSDDUGW-UHFFFAOYSA-N 0.000 description 1
- JNFVSQBROPLFRH-UHFFFAOYSA-N 2-(1,4-dioxaspiro[4.5]decan-8-yl)ethyl methanesulfonate Chemical compound C1CC(CCOS(=O)(=O)C)CCC21OCCO2 JNFVSQBROPLFRH-UHFFFAOYSA-N 0.000 description 1
- XLOJPFNIAXIWBY-UHFFFAOYSA-N 2-(2-cyanoethoxy)acetic acid Chemical compound OC(=O)COCCC#N XLOJPFNIAXIWBY-UHFFFAOYSA-N 0.000 description 1
- ORSWMWGFHKDTRW-UHFFFAOYSA-N 2-(dimethylamino)-n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)CN(C)C)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 ORSWMWGFHKDTRW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- UTZVSIXTYYWUOB-USJZOSNVSA-N 2-[(1s,2s,4as,8as)-2-hydroxy-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]-n-methoxy-n-methylacetamide Chemical compound CC1(C)CCC[C@]2(C)[C@H](CC(=O)N(C)OC)[C@@](C)(O)CC[C@H]21 UTZVSIXTYYWUOB-USJZOSNVSA-N 0.000 description 1
- IWKQQHPNTBDHBH-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxy]-n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)COC(C)(C)C)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 IWKQQHPNTBDHBH-UHFFFAOYSA-N 0.000 description 1
- HQLILHPGWSURBT-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)OCC(O)=O HQLILHPGWSURBT-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- KFPNFLWKVXZHAL-UHFFFAOYSA-N 2-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]acetamide Chemical compound C1CN(CC(=O)N)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 KFPNFLWKVXZHAL-UHFFFAOYSA-N 0.000 description 1
- ZICKGWQYRXAKEQ-UHFFFAOYSA-N 2-acetamido-n-[4-[2-[4-(2,3-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)CNC(=O)C)CCC1CCN1CCN(C=2C(=C(F)C=CC=2)F)CC1 ZICKGWQYRXAKEQ-UHFFFAOYSA-N 0.000 description 1
- REQUPGRKOWEMEL-UHFFFAOYSA-N 2-acetamido-n-[4-[2-[4-(2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)CNC(=O)C)CCC1CCN1CCN(C=2C(=CC=CC=2)F)CC1 REQUPGRKOWEMEL-UHFFFAOYSA-N 0.000 description 1
- KONRTSBWPZNVSZ-UHFFFAOYSA-N 2-acetamido-n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)CNC(=O)C)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 KONRTSBWPZNVSZ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- HJBXYTPCBPSRRD-UHFFFAOYSA-N 2-cyano-2-methyl-n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]propanamide Chemical compound C1CC(NC(=O)C(C)(C#N)C)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 HJBXYTPCBPSRRD-UHFFFAOYSA-N 0.000 description 1
- DZDVNAVPCCNJRK-UHFFFAOYSA-N 2-cyano-2-methylpropanoic acid Chemical compound N#CC(C)(C)C(O)=O DZDVNAVPCCNJRK-UHFFFAOYSA-N 0.000 description 1
- CBUJIZMPBGIUAL-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2,3,4,5-tetrafluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC1=C(F)C(F)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1F CBUJIZMPBGIUAL-UHFFFAOYSA-N 0.000 description 1
- PJEUMXHQKODEMP-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2,3,4-trichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound ClC1=C(Cl)C(Cl)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 PJEUMXHQKODEMP-UHFFFAOYSA-N 0.000 description 1
- YWEGLEZPXWTBNW-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2,3,4-trifluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC1=C(F)C(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 YWEGLEZPXWTBNW-UHFFFAOYSA-N 0.000 description 1
- KUWRCXGWEKBPFS-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound ClC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1Cl KUWRCXGWEKBPFS-UHFFFAOYSA-N 0.000 description 1
- LOPYTQPFDLCHNY-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2,3-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1F LOPYTQPFDLCHNY-UHFFFAOYSA-N 0.000 description 1
- OZQQSQUXSBTLSR-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2,3-dimethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1C OZQQSQUXSBTLSR-UHFFFAOYSA-N 0.000 description 1
- FOVPJMNHZNZCOA-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2,4,5-trichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1=C(Cl)C(Cl)=CC(Cl)=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 FOVPJMNHZNZCOA-UHFFFAOYSA-N 0.000 description 1
- BBWRMGARQNXOME-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2,4,5-trifluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1=C(F)C(F)=CC(F)=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 BBWRMGARQNXOME-UHFFFAOYSA-N 0.000 description 1
- QMLBDNBGPHOUGU-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2,4-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound ClC1=CC(Cl)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 QMLBDNBGPHOUGU-UHFFFAOYSA-N 0.000 description 1
- SNRCTTGSXMQLBP-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2,4-diethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CCC1=CC(CC)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 SNRCTTGSXMQLBP-UHFFFAOYSA-N 0.000 description 1
- CNSZRUVXYHMZCK-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC1=CC(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 CNSZRUVXYHMZCK-UHFFFAOYSA-N 0.000 description 1
- LWBAWSUDFBYTPN-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2,5-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound ClC1=CC=C(Cl)C(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 LWBAWSUDFBYTPN-UHFFFAOYSA-N 0.000 description 1
- WHFFHDLCDYSSKN-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2,5-dimethoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound COC1=CC=C(OC)C(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 WHFFHDLCDYSSKN-UHFFFAOYSA-N 0.000 description 1
- HQUMVALEGRDPBP-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2,5-dimethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CC1=CC=C(C)C(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 HQUMVALEGRDPBP-UHFFFAOYSA-N 0.000 description 1
- ZLQOSJWJWYVNJC-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2,6-dimethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CC1=CC=CC(C)=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 ZLQOSJWJWYVNJC-UHFFFAOYSA-N 0.000 description 1
- PPODEGPVBPDULI-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2,6-ditert-butylpyrimidin-4-yl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CC(C)(C)C1=NC(C(C)(C)C)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=N1 PPODEGPVBPDULI-UHFFFAOYSA-N 0.000 description 1
- YQEZMJGBNNSLHH-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2-cyano-3-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1C#N YQEZMJGBNNSLHH-UHFFFAOYSA-N 0.000 description 1
- IKKXXDRWPIVHQE-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(CC#N)=O)CCC1CCN1CCN(C=2C(=CC=CC=2)C#N)CC1 IKKXXDRWPIVHQE-UHFFFAOYSA-N 0.000 description 1
- PFWSKOBIYDKMFO-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2-ethoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CCOC1=CC=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 PFWSKOBIYDKMFO-UHFFFAOYSA-N 0.000 description 1
- QPNQFTFCEIMUKA-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2-ethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CCC1=CC=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 QPNQFTFCEIMUKA-UHFFFAOYSA-N 0.000 description 1
- GDSRTNXAVAPEDU-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2-fluoro-4-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC1=CC(C)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 GDSRTNXAVAPEDU-UHFFFAOYSA-N 0.000 description 1
- QZMACCTUOIYYKZ-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2-fluoro-5-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CC1=CC=C(F)C(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 QZMACCTUOIYYKZ-UHFFFAOYSA-N 0.000 description 1
- XGRURCZWGIJSKM-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC1=CC=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 XGRURCZWGIJSKM-UHFFFAOYSA-N 0.000 description 1
- ADXHJOVUPKLZBL-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2-methoxy-5-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound COC1=CC=C(C)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 ADXHJOVUPKLZBL-UHFFFAOYSA-N 0.000 description 1
- UNIPUCBNBHWLMM-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound COC1=CC=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 UNIPUCBNBHWLMM-UHFFFAOYSA-N 0.000 description 1
- LEUDSLKYHCHQEV-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2-methylsulfanylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CSC1=CC=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 LEUDSLKYHCHQEV-UHFFFAOYSA-N 0.000 description 1
- ZMACLDNHBJYCKU-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(2-phenoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(CC#N)=O)CCC1CCN1CCN(C=2C(=CC=CC=2)OC=2C=CC=CC=2)CC1 ZMACLDNHBJYCKU-UHFFFAOYSA-N 0.000 description 1
- UKBJGFREXVRSTC-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3,4,5-trifluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC1=C(F)C(F)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 UKBJGFREXVRSTC-UHFFFAOYSA-N 0.000 description 1
- MTLIPYVKWRYTOI-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3,4-dichloro-2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC1=C(Cl)C(Cl)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 MTLIPYVKWRYTOI-UHFFFAOYSA-N 0.000 description 1
- GMQRKEUXSDIROY-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3,4-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 GMQRKEUXSDIROY-UHFFFAOYSA-N 0.000 description 1
- MBHWUPHLJLVWTJ-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1=C(F)C(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 MBHWUPHLJLVWTJ-UHFFFAOYSA-N 0.000 description 1
- MJHULJPGGWGKSW-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3,4-dimethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1=C(C)C(C)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 MJHULJPGGWGKSW-UHFFFAOYSA-N 0.000 description 1
- JRPQMUQZBKVVEN-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3,5-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound ClC1=CC(Cl)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 JRPQMUQZBKVVEN-UHFFFAOYSA-N 0.000 description 1
- FPVJJBSBYSWQAH-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3,5-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC1=CC(F)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 FPVJJBSBYSWQAH-UHFFFAOYSA-N 0.000 description 1
- PMJXAZGTSAGMQM-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound COC1=CC(OC)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 PMJXAZGTSAGMQM-UHFFFAOYSA-N 0.000 description 1
- NCFJCFSYOBXSSW-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3,5-ditert-butylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 NCFJCFSYOBXSSW-UHFFFAOYSA-N 0.000 description 1
- QCOVLBSGAHYOGJ-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3-cyano-2,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC1=C(C#N)C(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 QCOVLBSGAHYOGJ-UHFFFAOYSA-N 0.000 description 1
- JOFPNQPYBUSTOC-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3-cyano-4-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1=C(C#N)C(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 JOFPNQPYBUSTOC-UHFFFAOYSA-N 0.000 description 1
- JMHSGMHQDMJUSI-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(CC#N)=O)CCC1CCN1CCN(C=2C=C(C=CC=2)C#N)CC1 JMHSGMHQDMJUSI-UHFFFAOYSA-N 0.000 description 1
- PIIKIVYOAVMHJA-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3-ethoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CCOC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 PIIKIVYOAVMHJA-UHFFFAOYSA-N 0.000 description 1
- BWMODWIZNZSLCM-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3-fluoro-2-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CC1=C(F)C=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 BWMODWIZNZSLCM-UHFFFAOYSA-N 0.000 description 1
- BVQCHTFMRHCOMD-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3-fluoro-4-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1=C(F)C(C)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 BVQCHTFMRHCOMD-UHFFFAOYSA-N 0.000 description 1
- CVRGSPCMCGEQST-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3-fluoro-5-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CC1=CC(F)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 CVRGSPCMCGEQST-UHFFFAOYSA-N 0.000 description 1
- FWEWBWBHKMXICC-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3-hydroxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound OC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 FWEWBWBHKMXICC-UHFFFAOYSA-N 0.000 description 1
- SOGHCXRTUQINSV-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3-methylsulfanylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CSC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 SOGHCXRTUQINSV-UHFFFAOYSA-N 0.000 description 1
- YNZACZZPYYGGDV-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3-methylsulfonylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CS(=O)(=O)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 YNZACZZPYYGGDV-UHFFFAOYSA-N 0.000 description 1
- FVWTXZPMWYCMRC-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3-propan-2-ylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CC(C)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 FVWTXZPMWYCMRC-UHFFFAOYSA-N 0.000 description 1
- CNSRYCPKOIXZII-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3-propanoylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CCC(=O)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 CNSRYCPKOIXZII-UHFFFAOYSA-N 0.000 description 1
- ROYNUPKROUCRBD-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(3-propylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CCCC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 ROYNUPKROUCRBD-UHFFFAOYSA-N 0.000 description 1
- YBHRRUZTXKBHLH-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(4-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(CC#N)=O)CCC1CCN1CCN(C=2C=CC(=CC=2)C#N)CC1 YBHRRUZTXKBHLH-UHFFFAOYSA-N 0.000 description 1
- ZMYPGNJLXQSLPM-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(4-ethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1=CC(CC)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 ZMYPGNJLXQSLPM-UHFFFAOYSA-N 0.000 description 1
- UGAZGWMDUGIRCY-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(4-fluoro-3-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1=C(F)C(C)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 UGAZGWMDUGIRCY-UHFFFAOYSA-N 0.000 description 1
- NCZRVLXGPAFSLS-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(4-methoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1=CC(OC)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 NCZRVLXGPAFSLS-UHFFFAOYSA-N 0.000 description 1
- GRUXIJSFOFJOCV-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(5,6,7,8-tetrahydronaphthalen-1-yl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(CC#N)=O)CCC1CCN1CCN(C=2C=3CCCCC=3C=CC=2)CC1 GRUXIJSFOFJOCV-UHFFFAOYSA-N 0.000 description 1
- LMMRMLQLKOVBOI-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(5,6,7,8-tetrahydronaphthalen-2-yl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(CC#N)=O)CCC1CCN1CCN(C=2C=C3CCCCC3=CC=2)CC1 LMMRMLQLKOVBOI-UHFFFAOYSA-N 0.000 description 1
- VXWQXEHQSILTRT-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(5-ethyl-2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CCC1=CC=C(F)C(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 VXWQXEHQSILTRT-UHFFFAOYSA-N 0.000 description 1
- DFAYLNFMOVYXKV-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(5-fluoro-2-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CC1=CC=C(F)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 DFAYLNFMOVYXKV-UHFFFAOYSA-N 0.000 description 1
- SHHWBVQGTOXNQS-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-(5-methoxy-2-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound COC1=CC=C(C)C(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 SHHWBVQGTOXNQS-UHFFFAOYSA-N 0.000 description 1
- NFZMIJIXZSFHGR-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-[2,4-dichloro-5-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1Cl NFZMIJIXZSFHGR-UHFFFAOYSA-N 0.000 description 1
- ZQNHTUGBOKOHPL-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-[2-cyano-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1C#N ZQNHTUGBOKOHPL-UHFFFAOYSA-N 0.000 description 1
- PJESJFVPFCBLGX-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-[2-fluoro-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1=CC=C(C(F)(F)F)C(F)=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 PJESJFVPFCBLGX-UHFFFAOYSA-N 0.000 description 1
- LESIHCKYUYDFSC-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-[2-fluoro-4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC1=CC(C(F)(F)F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 LESIHCKYUYDFSC-UHFFFAOYSA-N 0.000 description 1
- XIPXIKBYMGPQMM-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-[2-methoxy-5-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound COC1=CC=C(C(F)(F)F)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 XIPXIKBYMGPQMM-UHFFFAOYSA-N 0.000 description 1
- HZGWQTNWRJKHCI-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-[2-methyl-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 HZGWQTNWRJKHCI-UHFFFAOYSA-N 0.000 description 1
- OKGXLRJVYKMRIS-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-[2-methyl-5-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CC1=CC=C(C(F)(F)F)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 OKGXLRJVYKMRIS-UHFFFAOYSA-N 0.000 description 1
- PTOWBWVPJZSCLI-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-[3,5-difluoro-4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC1=C(C(F)(F)F)C(F)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 PTOWBWVPJZSCLI-UHFFFAOYSA-N 0.000 description 1
- ASKNMKGYCRBHDP-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-[3-(2-methylpropyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CC(C)CC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 ASKNMKGYCRBHDP-UHFFFAOYSA-N 0.000 description 1
- PQTNAAKDIFBABW-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-[3-(dimethylamino)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound CN(C)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 PQTNAAKDIFBABW-UHFFFAOYSA-N 0.000 description 1
- OGHRFZPKAQFRDI-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-[3-(hydroxymethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound OCC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 OGHRFZPKAQFRDI-UHFFFAOYSA-N 0.000 description 1
- BUBWJGLZNOWNPP-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-[3-(methoxymethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound COCC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 BUBWJGLZNOWNPP-UHFFFAOYSA-N 0.000 description 1
- GPABUMYCQBJUKK-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 GPABUMYCQBJUKK-UHFFFAOYSA-N 0.000 description 1
- XTYMJUBREOCMAG-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-[3-fluoro-5-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC(F)(F)C1=CC(F)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 XTYMJUBREOCMAG-UHFFFAOYSA-N 0.000 description 1
- GCRZJLSOEKZSED-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-[3-methoxy-5-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC(F)(F)C1=CC(OC)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 GCRZJLSOEKZSED-UHFFFAOYSA-N 0.000 description 1
- WFHRPYRGVMXLMD-UHFFFAOYSA-N 2-cyano-n-[4-[2-[4-[4-fluoro-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 WFHRPYRGVMXLMD-UHFFFAOYSA-N 0.000 description 1
- DASYJICSSLWYAG-UHFFFAOYSA-N 2-cyanopropanamide Chemical compound N#CC(C)C(N)=O DASYJICSSLWYAG-UHFFFAOYSA-N 0.000 description 1
- PANIWTMABIGSBR-UHFFFAOYSA-N 2-cyclopent-2-en-1-yl-n-[4-[2-[4-(3-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC3C=CCC3)CC2)=C1 PANIWTMABIGSBR-UHFFFAOYSA-N 0.000 description 1
- LRSQATWPOSWXPK-UHFFFAOYSA-N 2-cyclopent-2-en-1-yl-n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC3C=CCC3)CC2)=C1 LRSQATWPOSWXPK-UHFFFAOYSA-N 0.000 description 1
- DVQMPWOLBFKUMM-UHFFFAOYSA-N 2-diethoxyphosphorylacetic acid Chemical compound CCOP(=O)(CC(O)=O)OCC DVQMPWOLBFKUMM-UHFFFAOYSA-N 0.000 description 1
- UUOZDXZQFIZVOF-UHFFFAOYSA-N 2-ethoxy-1-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)COCC)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 UUOZDXZQFIZVOF-UHFFFAOYSA-N 0.000 description 1
- YFIYILWMQPPQDA-UHFFFAOYSA-N 2-ethoxy-n-[4-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)COCC)CCC1CCN1CCN(C=2C(=CC=CC=2)OC)CC1 YFIYILWMQPPQDA-UHFFFAOYSA-N 0.000 description 1
- BJXCKFPGSSKGKX-UHFFFAOYSA-N 2-ethoxy-n-[4-[2-[4-(3,4,5-trifluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)COCC)CCC1CCN1CCN(C=2C=C(F)C(F)=C(F)C=2)CC1 BJXCKFPGSSKGKX-UHFFFAOYSA-N 0.000 description 1
- LJNXSPVJIZWGHQ-UHFFFAOYSA-N 2-ethoxy-n-[4-[2-[4-(3-ethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)COCC)CCC1CCN1CCN(C=2C=C(CC)C=CC=2)CC1 LJNXSPVJIZWGHQ-UHFFFAOYSA-N 0.000 description 1
- SIIUNWXVSMJMCO-UHFFFAOYSA-N 2-ethoxy-n-[4-[2-[4-(4-methoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)COCC)CCC1CCN1CCN(C=2C=CC(OC)=CC=2)CC1 SIIUNWXVSMJMCO-UHFFFAOYSA-N 0.000 description 1
- QOZWDOAUJGXYDE-UHFFFAOYSA-N 2-ethoxy-n-[4-[2-[4-(5,6,7,8-tetrahydronaphthalen-1-yl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)COCC)CCC1CCN1CCN(C=2C=3CCCCC=3C=CC=2)CC1 QOZWDOAUJGXYDE-UHFFFAOYSA-N 0.000 description 1
- FHANKIRTJOXPJH-UHFFFAOYSA-N 2-methoxy-1-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)COC)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 FHANKIRTJOXPJH-UHFFFAOYSA-N 0.000 description 1
- BKBZFJRHYSCZQA-UHFFFAOYSA-N 2-methoxy-2-methylpropanoic acid Chemical compound COC(C)(C)C(O)=O BKBZFJRHYSCZQA-UHFFFAOYSA-N 0.000 description 1
- KGLARZXGAGTKQV-UHFFFAOYSA-N 2-methoxy-n-[4-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)COC)CCC1CCN1CCN(C=2C(=CC=CC=2)OC)CC1 KGLARZXGAGTKQV-UHFFFAOYSA-N 0.000 description 1
- LGPJRMFQRPYYJQ-UHFFFAOYSA-N 2-methoxy-n-[4-[2-[4-(3,4,5-trifluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)COC)CCC1CCN1CCN(C=2C=C(F)C(F)=C(F)C=2)CC1 LGPJRMFQRPYYJQ-UHFFFAOYSA-N 0.000 description 1
- LGXZFTMBDBRMRA-UHFFFAOYSA-N 2-methoxy-n-[4-[2-[4-(5,6,7,8-tetrahydronaphthalen-1-yl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)COC)CCC1CCN1CCN(C=2C=3CCCCC=3C=CC=2)CC1 LGXZFTMBDBRMRA-UHFFFAOYSA-N 0.000 description 1
- SPAXWMOZKXMBHM-UHFFFAOYSA-N 2-methoxy-n-[4-[2-[4-[2-methyl-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)COC)CCC1CCN1CCN(C=2C(=C(C=CC=2)C(F)(F)F)C)CC1 SPAXWMOZKXMBHM-UHFFFAOYSA-N 0.000 description 1
- BMFBAVYDAFBESV-UHFFFAOYSA-N 2-methyl-1-[3-[4-[2-[1-(2-oxopropyl)piperidin-4-yl]ethyl]piperazin-1-yl]phenyl]propan-1-one Chemical compound CC(C)C(=O)C1=CC=CC(N2CCN(CCC3CCN(CC(C)=O)CC3)CC2)=C1 BMFBAVYDAFBESV-UHFFFAOYSA-N 0.000 description 1
- BSMGLVDZZMBWQB-UHFFFAOYSA-N 2-methyl-1-phenylpropan-1-one Chemical compound CC(C)C(=O)C1=CC=CC=C1 BSMGLVDZZMBWQB-UHFFFAOYSA-N 0.000 description 1
- JWTGHOGWAWZFHK-UHFFFAOYSA-N 2-methyl-6-[4-[2-[1-(2-oxopropyl)piperidin-4-yl]ethyl]piperazin-1-yl]benzonitrile Chemical compound C1CN(CC(=O)C)CCC1CCN1CCN(C=2C(=C(C)C=CC=2)C#N)CC1 JWTGHOGWAWZFHK-UHFFFAOYSA-N 0.000 description 1
- XXHRNHGYJGAUGR-UHFFFAOYSA-N 2-methylsulfinyl-n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)CS(=O)C)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 XXHRNHGYJGAUGR-UHFFFAOYSA-N 0.000 description 1
- KXAOBAOEETVRBD-UHFFFAOYSA-N 2-methylsulfonyl-n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)CS(=O)(=O)C)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 KXAOBAOEETVRBD-UHFFFAOYSA-N 0.000 description 1
- NYEHUAQIJXERLP-UHFFFAOYSA-N 2-methylsulfonylacetic acid Chemical compound CS(=O)(=O)CC(O)=O NYEHUAQIJXERLP-UHFFFAOYSA-N 0.000 description 1
- 125000005979 2-naphthyloxy group Chemical group 0.000 description 1
- XUOKHKDFJNDJGN-UHFFFAOYSA-N 2-phenoxy-n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)COC=3C=CC=CC=3)CC2)=C1 XUOKHKDFJNDJGN-UHFFFAOYSA-N 0.000 description 1
- OAIRTVZAAFZBMR-UHFFFAOYSA-N 2-propan-2-yloxyacetic acid Chemical compound CC(C)OCC(O)=O OAIRTVZAAFZBMR-UHFFFAOYSA-N 0.000 description 1
- FGEUSDSCBAJZFP-UHFFFAOYSA-N 3,3,3-trifluoro-n-[4-[2-[4-(3-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]propanamide Chemical compound FC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC(F)(F)F)CC2)=C1 FGEUSDSCBAJZFP-UHFFFAOYSA-N 0.000 description 1
- LGOLCLNLZDQMMH-UHFFFAOYSA-N 3,3,3-trifluoro-n-[4-[2-[4-(4-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]propanamide Chemical compound C1=CC(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC(F)(F)F)CC1 LGOLCLNLZDQMMH-UHFFFAOYSA-N 0.000 description 1
- JRTKQWJYNIXCCL-UHFFFAOYSA-N 3,3,3-trifluoro-n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]propanamide Chemical compound C1CC(NC(=O)CC(F)(F)F)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 JRTKQWJYNIXCCL-UHFFFAOYSA-N 0.000 description 1
- PMLOUCFXSMIGQI-UHFFFAOYSA-N 3-(1,3-oxazol-2-yl)aniline Chemical compound NC1=CC=CC(C=2OC=CN=2)=C1 PMLOUCFXSMIGQI-UHFFFAOYSA-N 0.000 description 1
- ZBDJEMCJCJVEQI-UHFFFAOYSA-N 3-(diethylamino)-n-[4-[2-[4-(3-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]propanamide Chemical compound C1CC(NC(=O)CCN(CC)CC)CCC1CCN1CCN(C=2C=C(F)C=CC=2)CC1 ZBDJEMCJCJVEQI-UHFFFAOYSA-N 0.000 description 1
- FCAZYJYGHMOPMH-UHFFFAOYSA-N 3-(diethylamino)-n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]propanamide Chemical compound C1CC(NC(=O)CCN(CC)CC)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 FCAZYJYGHMOPMH-UHFFFAOYSA-N 0.000 description 1
- NOGGJCJYUQSIEB-UHFFFAOYSA-N 3-[4-[2-(1,4-dioxaspiro[4.5]decan-8-yl)ethyl]piperazin-1-yl]aniline Chemical compound NC1=CC=CC(N2CCN(CCC3CCC4(CC3)OCCO4)CC2)=C1 NOGGJCJYUQSIEB-UHFFFAOYSA-N 0.000 description 1
- NDGQDWAVLQYRAZ-UHFFFAOYSA-N 3-[4-[2-[4-(4-methoxybutylamino)cyclohexyl]ethyl]piperazin-1-yl]benzamide Chemical compound C1CC(NCCCCOC)CCC1CCN1CCN(C=2C=C(C=CC=2)C(N)=O)CC1 NDGQDWAVLQYRAZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SNLFWJPLLZJANY-UHFFFAOYSA-N 3-cyano-n-[4-[2-[4-(2,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]propanamide Chemical compound FC1=CC(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCC#N)CC1 SNLFWJPLLZJANY-UHFFFAOYSA-N 0.000 description 1
- HMCRKAUFPLQJHF-UHFFFAOYSA-N 3-cyano-n-[4-[2-[4-(2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]propanamide Chemical compound FC1=CC=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCC#N)CC1 HMCRKAUFPLQJHF-UHFFFAOYSA-N 0.000 description 1
- JGXZYRIKLYEPAZ-UHFFFAOYSA-N 3-cyano-n-[4-[2-[4-(3,4-dichloro-2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]propanamide Chemical compound FC1=C(Cl)C(Cl)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCC#N)CC1 JGXZYRIKLYEPAZ-UHFFFAOYSA-N 0.000 description 1
- VKONDQGCZVPNAL-UHFFFAOYSA-N 3-cyano-n-[4-[2-[4-(3,5-dimethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]propanamide Chemical compound CC1=CC(C)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCC#N)CC2)=C1 VKONDQGCZVPNAL-UHFFFAOYSA-N 0.000 description 1
- NGLQVTNDIXSKOL-UHFFFAOYSA-N 3-cyano-n-[4-[2-[4-(3-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]propanamide Chemical compound C1CC(NC(CCC#N)=O)CCC1CCN1CCN(C=2C=C(C=CC=2)C#N)CC1 NGLQVTNDIXSKOL-UHFFFAOYSA-N 0.000 description 1
- ISMBFCSZZRMQEM-UHFFFAOYSA-N 3-cyano-n-[4-[2-[4-(3-ethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]propanamide Chemical compound CCC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCC#N)CC2)=C1 ISMBFCSZZRMQEM-UHFFFAOYSA-N 0.000 description 1
- WECFDFJDLHQHCV-UHFFFAOYSA-N 3-cyano-n-[4-[2-[4-(3-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]propanamide Chemical compound FC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCC#N)CC2)=C1 WECFDFJDLHQHCV-UHFFFAOYSA-N 0.000 description 1
- PPHGDSUUIOANEM-UHFFFAOYSA-N 3-cyano-n-[4-[2-[4-(3-methoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]propanamide Chemical compound COC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCC#N)CC2)=C1 PPHGDSUUIOANEM-UHFFFAOYSA-N 0.000 description 1
- CAQHAJXEZRTUFS-UHFFFAOYSA-N 3-cyano-n-[4-[2-[4-(3-methylsulfanylphenyl)piperazin-1-yl]ethyl]cyclohexyl]propanamide Chemical compound CSC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCC#N)CC2)=C1 CAQHAJXEZRTUFS-UHFFFAOYSA-N 0.000 description 1
- KNDMLXSLXUGFNS-UHFFFAOYSA-N 3-cyano-n-[4-[2-[4-(5-fluoro-2-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]propanamide Chemical compound CC1=CC=C(F)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CCC#N)CC1 KNDMLXSLXUGFNS-UHFFFAOYSA-N 0.000 description 1
- DDPUMCDCXHRVSU-UHFFFAOYSA-N 3-cyano-n-[4-[2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]propanamide Chemical compound C1=CC(C(F)(F)F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCC#N)CC1 DDPUMCDCXHRVSU-UHFFFAOYSA-N 0.000 description 1
- BXYQHDXDCJQOFD-UHFFFAOYSA-N 3-cyanopropanoic acid Chemical compound OC(=O)CCC#N BXYQHDXDCJQOFD-UHFFFAOYSA-N 0.000 description 1
- DSBOZJZAFSDXCB-UHFFFAOYSA-N 3-methoxy-n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]propanamide Chemical compound C1CC(NC(=O)CCOC)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 DSBOZJZAFSDXCB-UHFFFAOYSA-N 0.000 description 1
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 description 1
- CMEVXBVATZPZAN-UHFFFAOYSA-N 3-oxo-3-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]propanenitrile Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC3CCN(CC3)C(=O)CC#N)CC2)=C1 CMEVXBVATZPZAN-UHFFFAOYSA-N 0.000 description 1
- BRIPRCPBGSEVQM-UHFFFAOYSA-N 3-oxo-4-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]butanenitrile Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC3CCN(CC(=O)CC#N)CC3)CC2)=C1 BRIPRCPBGSEVQM-UHFFFAOYSA-N 0.000 description 1
- QMQBHJLTPOHACS-UHFFFAOYSA-N 4,4,4-trifluoro-n-[4-[2-[4-(3-methylsulfonylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound CS(=O)(=O)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCC(F)(F)F)CC2)=C1 QMQBHJLTPOHACS-UHFFFAOYSA-N 0.000 description 1
- RRIHBAAFBONJDL-UHFFFAOYSA-N 4,4,4-trifluorobutanamide Chemical compound NC(=O)CCC(F)(F)F RRIHBAAFBONJDL-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- JLGCJURMIVLPJV-UHFFFAOYSA-N 4-(dimethylamino)-n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1CC(NC(=O)CCCN(C)C)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 JLGCJURMIVLPJV-UHFFFAOYSA-N 0.000 description 1
- MUPXUWIXOLBLEV-UHFFFAOYSA-N 4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexan-1-amine;dihydrochloride Chemical compound Cl.Cl.C1CC(N)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 MUPXUWIXOLBLEV-UHFFFAOYSA-N 0.000 description 1
- MOLNBHBNQYSQQQ-UHFFFAOYSA-N 4-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]piperidin-1-yl]-4-oxobutanenitrile Chemical compound ClC1=CC=CC(N2CCN(CCC3CCN(CC3)C(=O)CCC#N)CC2)=C1Cl MOLNBHBNQYSQQQ-UHFFFAOYSA-N 0.000 description 1
- BWUANIDZTKUMKT-UHFFFAOYSA-N 4-[4-[2-[4-[3-chloro-5-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]-4-oxobutanenitrile Chemical compound FC(F)(F)C1=CC(Cl)=CC(N2CCN(CCC3CCN(CC3)C(=O)CCC#N)CC2)=C1 BWUANIDZTKUMKT-UHFFFAOYSA-N 0.000 description 1
- OKIHKUDYXPZXQG-UHFFFAOYSA-N 4-[4-[2-[4-[3-fluoro-5-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]-4-oxobutanenitrile Chemical compound FC(F)(F)C1=CC(F)=CC(N2CCN(CCC3CCN(CC3)C(=O)CCC#N)CC2)=C1 OKIHKUDYXPZXQG-UHFFFAOYSA-N 0.000 description 1
- OPWINJFJCBZVTA-UHFFFAOYSA-N 4-cyano-n-[4-[2-(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)ethyl]cyclohexyl]butanamide Chemical compound C1CC(NC(CCCC#N)=O)CCC1CCN1CC=C(C=2C=CC=CC=2)CC1 OPWINJFJCBZVTA-UHFFFAOYSA-N 0.000 description 1
- ZWJXVXWJPIGCCC-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2,3,4,5-tetrafluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound FC1=C(F)C(F)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1F ZWJXVXWJPIGCCC-UHFFFAOYSA-N 0.000 description 1
- HBQIJGBIBHZLFF-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2,3,4-trifluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound FC1=C(F)C(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 HBQIJGBIBHZLFF-UHFFFAOYSA-N 0.000 description 1
- XLIWTLRRDQXEDF-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound ClC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1Cl XLIWTLRRDQXEDF-UHFFFAOYSA-N 0.000 description 1
- OSDGOLRTELEDRI-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2,3-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound FC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1F OSDGOLRTELEDRI-UHFFFAOYSA-N 0.000 description 1
- XQQMQYNHEFIPLZ-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2,3-dimethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound CC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1C XQQMQYNHEFIPLZ-UHFFFAOYSA-N 0.000 description 1
- UJZFYTCYPIONCX-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2,4,5-trichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1=C(Cl)C(Cl)=CC(Cl)=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 UJZFYTCYPIONCX-UHFFFAOYSA-N 0.000 description 1
- BMQDKPXDFPLQLK-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2,4,5-trifluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1=C(F)C(F)=CC(F)=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 BMQDKPXDFPLQLK-UHFFFAOYSA-N 0.000 description 1
- RWSSPKIYWZMBIA-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2,4-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound ClC1=CC(Cl)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 RWSSPKIYWZMBIA-UHFFFAOYSA-N 0.000 description 1
- XNIWMGAKFFDVCQ-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound FC1=CC(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 XNIWMGAKFFDVCQ-UHFFFAOYSA-N 0.000 description 1
- WJSKOGNSQSLMPM-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2,5-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound ClC1=CC=C(Cl)C(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 WJSKOGNSQSLMPM-UHFFFAOYSA-N 0.000 description 1
- NSKIPBCYTCOHCC-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2,5-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound FC1=CC=C(F)C(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 NSKIPBCYTCOHCC-UHFFFAOYSA-N 0.000 description 1
- POQQIYDQZWQNSH-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2,5-dimethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound CC1=CC=C(C)C(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 POQQIYDQZWQNSH-UHFFFAOYSA-N 0.000 description 1
- URDZIINZOJRSOX-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2-cyano-3-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound FC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1C#N URDZIINZOJRSOX-UHFFFAOYSA-N 0.000 description 1
- GFCSQHGHVNQLJC-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1CC(NC(CCCC#N)=O)CCC1CCN1CCN(C=2C(=CC=CC=2)C#N)CC1 GFCSQHGHVNQLJC-UHFFFAOYSA-N 0.000 description 1
- JUYCZJQPZIXTDE-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2-ethoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound CCOC1=CC=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 JUYCZJQPZIXTDE-UHFFFAOYSA-N 0.000 description 1
- IFPKGLAOFZVNHG-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2-ethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound CCC1=CC=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 IFPKGLAOFZVNHG-UHFFFAOYSA-N 0.000 description 1
- FLFKYVQJVMRISV-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2-fluoro-4-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound FC1=CC(C)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 FLFKYVQJVMRISV-UHFFFAOYSA-N 0.000 description 1
- ADGFOFMZMCNVTF-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2-fluoro-5-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound CC1=CC=C(F)C(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 ADGFOFMZMCNVTF-UHFFFAOYSA-N 0.000 description 1
- QNOUFYOWRTYTOZ-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound FC1=CC=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 QNOUFYOWRTYTOZ-UHFFFAOYSA-N 0.000 description 1
- BPASZPBEYHHKFL-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2-methoxy-5-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound COC1=CC=C(C)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 BPASZPBEYHHKFL-UHFFFAOYSA-N 0.000 description 1
- RDNVMCHYXOBJII-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound COC1=CC=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 RDNVMCHYXOBJII-UHFFFAOYSA-N 0.000 description 1
- FAQBOERFRQNCEA-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(2-methylsulfanylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound CSC1=CC=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 FAQBOERFRQNCEA-UHFFFAOYSA-N 0.000 description 1
- HTCPERUKMKIQOP-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3,4,5-trifluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound FC1=C(F)C(F)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 HTCPERUKMKIQOP-UHFFFAOYSA-N 0.000 description 1
- QPUKKICXALEYMM-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3,4-dichloro-2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound FC1=C(Cl)C(Cl)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 QPUKKICXALEYMM-UHFFFAOYSA-N 0.000 description 1
- PIYCTRQIMWELQG-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3,4-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1=C(Cl)C(Cl)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 PIYCTRQIMWELQG-UHFFFAOYSA-N 0.000 description 1
- ISLKVLXYTWNKSO-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1=C(F)C(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 ISLKVLXYTWNKSO-UHFFFAOYSA-N 0.000 description 1
- LECDQMCSUYQBBZ-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3,4-dimethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1=C(C)C(C)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 LECDQMCSUYQBBZ-UHFFFAOYSA-N 0.000 description 1
- VULXJQZMFZPHAT-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3,5-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound ClC1=CC(Cl)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 VULXJQZMFZPHAT-UHFFFAOYSA-N 0.000 description 1
- MCOSLMAIVWAUKX-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3,5-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound FC1=CC(F)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 MCOSLMAIVWAUKX-UHFFFAOYSA-N 0.000 description 1
- HDQGVRVTUIRWDH-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound COC1=CC(OC)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 HDQGVRVTUIRWDH-UHFFFAOYSA-N 0.000 description 1
- BLZYGOYRNDBSRO-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3,5-dimethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound CC1=CC(C)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 BLZYGOYRNDBSRO-UHFFFAOYSA-N 0.000 description 1
- ZNBAWHLLDSKAQB-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3-cyano-2,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound FC1=C(C#N)C(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 ZNBAWHLLDSKAQB-UHFFFAOYSA-N 0.000 description 1
- IPSXVOWMONCWQZ-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3-cyano-4-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1=C(C#N)C(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 IPSXVOWMONCWQZ-UHFFFAOYSA-N 0.000 description 1
- KHPQBXHECCDFDZ-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1CC(NC(CCCC#N)=O)CCC1CCN1CCN(C=2C=C(C=CC=2)C#N)CC1 KHPQBXHECCDFDZ-UHFFFAOYSA-N 0.000 description 1
- NAOYQLUPYRBGGP-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3-ethoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound CCOC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 NAOYQLUPYRBGGP-UHFFFAOYSA-N 0.000 description 1
- ZPTVLFQKBWGYCM-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3-ethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound CCC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 ZPTVLFQKBWGYCM-UHFFFAOYSA-N 0.000 description 1
- SPCZQHZJGJKXNW-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3-fluoro-2-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound CC1=C(F)C=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 SPCZQHZJGJKXNW-UHFFFAOYSA-N 0.000 description 1
- TXASSPMTJIETEB-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3-fluoro-4-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1=C(F)C(C)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 TXASSPMTJIETEB-UHFFFAOYSA-N 0.000 description 1
- NEQAJBQMHYZXDW-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3-fluoro-5-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound CC1=CC(F)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 NEQAJBQMHYZXDW-UHFFFAOYSA-N 0.000 description 1
- KPBHAGUWQJOYLF-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound FC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 KPBHAGUWQJOYLF-UHFFFAOYSA-N 0.000 description 1
- LHFSSMLKAILUBR-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3-methoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound COC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 LHFSSMLKAILUBR-UHFFFAOYSA-N 0.000 description 1
- VGCHNYOKPSCPOP-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3-methylsulfanylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound CSC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 VGCHNYOKPSCPOP-UHFFFAOYSA-N 0.000 description 1
- XXCHUZPLJJEGRG-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3-propanoylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound CCC(=O)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 XXCHUZPLJJEGRG-UHFFFAOYSA-N 0.000 description 1
- UGSKEQCXKCXYSA-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(3-propylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound CCCC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 UGSKEQCXKCXYSA-UHFFFAOYSA-N 0.000 description 1
- LJUDNSZBSJRZBG-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(4-fluoro-3-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1=C(F)C(C)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 LJUDNSZBSJRZBG-UHFFFAOYSA-N 0.000 description 1
- PETZBNRSFQROOG-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(4-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1=CC(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 PETZBNRSFQROOG-UHFFFAOYSA-N 0.000 description 1
- LXUODMGXQJBGOT-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(4-methoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1=CC(OC)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 LXUODMGXQJBGOT-UHFFFAOYSA-N 0.000 description 1
- ZRALKQJMLXMUGQ-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(5,6,7,8-tetrahydronaphthalen-1-yl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1CC(NC(CCCC#N)=O)CCC1CCN1CCN(C=2C=3CCCCC=3C=CC=2)CC1 ZRALKQJMLXMUGQ-UHFFFAOYSA-N 0.000 description 1
- LLWAFJWYAQLGAV-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(5,6,7,8-tetrahydronaphthalen-2-yl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1CC(NC(CCCC#N)=O)CCC1CCN1CCN(C=2C=C3CCCCC3=CC=2)CC1 LLWAFJWYAQLGAV-UHFFFAOYSA-N 0.000 description 1
- NIJCDIVZFSSABY-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(5-ethyl-2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound CCC1=CC=C(F)C(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 NIJCDIVZFSSABY-UHFFFAOYSA-N 0.000 description 1
- JYJYMMFCGQGHLV-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(5-fluoro-2-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound CC1=CC=C(F)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 JYJYMMFCGQGHLV-UHFFFAOYSA-N 0.000 description 1
- MLLIBEDSIOMCGB-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-(5-methoxy-2-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound COC1=CC=C(C)C(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 MLLIBEDSIOMCGB-UHFFFAOYSA-N 0.000 description 1
- JYLYZKJMFASEDJ-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-[2-fluoro-4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound FC1=CC(C(F)(F)F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 JYLYZKJMFASEDJ-UHFFFAOYSA-N 0.000 description 1
- GVDAXIZDIUZWCG-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-[2-fluoro-5-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound FC1=CC=C(C(F)(F)F)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 GVDAXIZDIUZWCG-UHFFFAOYSA-N 0.000 description 1
- LENGBTASRPQAIJ-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-[2-methyl-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 LENGBTASRPQAIJ-UHFFFAOYSA-N 0.000 description 1
- ZJRMUIHDGAGJLA-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-[2-methyl-5-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound CC1=CC=C(C(F)(F)F)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 ZJRMUIHDGAGJLA-UHFFFAOYSA-N 0.000 description 1
- MYIMPIFUUSUFKS-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-[3-fluoro-5-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound FC(F)(F)C1=CC(F)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 MYIMPIFUUSUFKS-UHFFFAOYSA-N 0.000 description 1
- CUUXTTIAWUPRPB-UHFFFAOYSA-N 4-cyano-n-[4-[2-[4-[4-fluoro-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 CUUXTTIAWUPRPB-UHFFFAOYSA-N 0.000 description 1
- NHMAWNBVHVQDPU-UHFFFAOYSA-N 4-cyanobutanamide Chemical compound NC(=O)CCCC#N NHMAWNBVHVQDPU-UHFFFAOYSA-N 0.000 description 1
- YXBVMSQDRLXPQV-UHFFFAOYSA-N 4-cyanobutanoic acid Chemical compound OC(=O)CCCC#N YXBVMSQDRLXPQV-UHFFFAOYSA-N 0.000 description 1
- TWTQODGEVCEFTK-UHFFFAOYSA-N 4-methoxy-n-[4-[2-[4-(2,3,4,5-tetrafluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C(=C(F)C(F)=C(F)C=2)F)CC1 TWTQODGEVCEFTK-UHFFFAOYSA-N 0.000 description 1
- HCFYWLRAAQMZRC-UHFFFAOYSA-N 4-methoxy-n-[4-[2-[4-(2,3,4-trifluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C(=C(F)C(F)=CC=2)F)CC1 HCFYWLRAAQMZRC-UHFFFAOYSA-N 0.000 description 1
- SPNZOXLJUUBGOI-UHFFFAOYSA-N 4-methoxy-n-[4-[2-[4-(3,4,5-trifluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C=C(F)C(F)=C(F)C=2)CC1 SPNZOXLJUUBGOI-UHFFFAOYSA-N 0.000 description 1
- IKQYGLNRLYQCGT-UHFFFAOYSA-N 4-methoxy-n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 IKQYGLNRLYQCGT-UHFFFAOYSA-N 0.000 description 1
- IHMJYZVDCJMDBV-UHFFFAOYSA-N 4-methoxy-n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]ethyl]cyclohexyl]butanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCC(C=2C=C(C=CC=2)C(F)(F)F)CC1 IHMJYZVDCJMDBV-UHFFFAOYSA-N 0.000 description 1
- XJXBWJFUCWOLSY-UHFFFAOYSA-N 4-methoxybutanamide Chemical compound COCCCC(N)=O XJXBWJFUCWOLSY-UHFFFAOYSA-N 0.000 description 1
- VLYLRNMYMYKULP-UHFFFAOYSA-N 4-oxo-n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]pentanamide Chemical compound C1CC(NC(=O)CCC(=O)C)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 VLYLRNMYMYKULP-UHFFFAOYSA-N 0.000 description 1
- ICQFDXDCVSHUGY-UHFFFAOYSA-N 5-cyano-2,2-difluoropentanoic acid Chemical compound OC(=O)C(F)(F)CCCC#N ICQFDXDCVSHUGY-UHFFFAOYSA-N 0.000 description 1
- SKUPALMUTWEAPI-UHFFFAOYSA-N 5-cyanopentanoic acid Chemical compound OC(=O)CCCCC#N SKUPALMUTWEAPI-UHFFFAOYSA-N 0.000 description 1
- FHIPNZFCABBJRK-UHFFFAOYSA-N 5-oxo-5-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]pentanenitrile Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC3CCN(CC3)C(=O)CCCC#N)CC2)=C1 FHIPNZFCABBJRK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- NMEZJSDUZQOPFE-UHFFFAOYSA-N Cyclohex-1-enecarboxylic acid Chemical compound OC(=O)C1=CCCCC1 NMEZJSDUZQOPFE-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- FVIGODVHAVLZOO-UHFFFAOYSA-N Dixanthogen Chemical compound CCOC(=S)SSC(=S)OCC FVIGODVHAVLZOO-UHFFFAOYSA-N 0.000 description 1
- 108091007265 Dopamine D2-Like Receptors Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000011514 Familial renal glucosuria Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- FJQPENBMUDNMJW-UHFFFAOYSA-N N-[4-[2-[4-(2,3-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C(C)(=O)NC1CCC(CC1)CCN1CCN(CC1)C1=C(C(=CC=C1)F)F FJQPENBMUDNMJW-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N Sec-butyl alcohol Natural products CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- TXFLGZOGNOOEFZ-UHFFFAOYSA-N bis(2-chloroethyl)amine Chemical compound ClCCNCCCl TXFLGZOGNOOEFZ-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- ZICDXDPVQDNYTC-UHFFFAOYSA-N butan-2-ol Chemical compound CCC([CH2+])O ZICDXDPVQDNYTC-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical class NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005072 dihydrothiopyranyl group Chemical group S1C(CCC=C1)* 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- CDMADVZSLOHIFP-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane;decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 CDMADVZSLOHIFP-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- 229950008932 epolamine Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LBAQSKZHMLAFHH-UHFFFAOYSA-N ethoxyethane;hydron;chloride Chemical compound Cl.CCOCC LBAQSKZHMLAFHH-UHFFFAOYSA-N 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- ABSAAQSCUQHJOC-NTSWFWBYSA-N ethyl (1r,2r)-2-cyanocyclopropane-1-carboxylate Chemical compound CCOC(=O)[C@@H]1C[C@H]1C#N ABSAAQSCUQHJOC-NTSWFWBYSA-N 0.000 description 1
- MFGQIZPUMIISPR-UHFFFAOYSA-N ethyl 2-(1,4-dioxaspiro[4.5]decan-8-yl)acetate Chemical compound C1CC(CC(=O)OCC)CCC21OCCO2 MFGQIZPUMIISPR-UHFFFAOYSA-N 0.000 description 1
- NFZCMVKZCUDCMG-UHFFFAOYSA-N ethyl 2-[4-[2-[4-(2,3-dimethylphenyl)piperazin-1-yl]ethyl]piperidin-1-yl]acetate Chemical compound C1CN(CC(=O)OCC)CCC1CCN1CCN(C=2C(=C(C)C=CC=2)C)CC1 NFZCMVKZCUDCMG-UHFFFAOYSA-N 0.000 description 1
- WSQORLAUCBRAJH-UHFFFAOYSA-N ethyl 5-cyano-2,2-difluoropentanoate Chemical compound CCOC(=O)C(F)(F)CCCC#N WSQORLAUCBRAJH-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000374 eutectic mixture Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- JISVIRFOSOKJIU-UHFFFAOYSA-N hexylidene Chemical group [CH2+]CCCC[CH-] JISVIRFOSOKJIU-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical class ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- UGVPKMAWLOMPRS-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].CC[CH2-] UGVPKMAWLOMPRS-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- AMWRITDGCCNYAT-UHFFFAOYSA-L manganese oxide Inorganic materials [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 1
- PPNAOCWZXJOHFK-UHFFFAOYSA-N manganese(2+);oxygen(2-) Chemical class [O-2].[Mn+2] PPNAOCWZXJOHFK-UHFFFAOYSA-N 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- KNWQLFOXPQZGPX-UHFFFAOYSA-N methanesulfonyl fluoride Chemical compound CS(F)(=O)=O KNWQLFOXPQZGPX-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- XFLBZKFCELTANC-UHFFFAOYSA-N n-(3-piperazin-1-ylphenyl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(N2CCNCC2)=C1 XFLBZKFCELTANC-UHFFFAOYSA-N 0.000 description 1
- BBWIUCFANQAUFL-UHFFFAOYSA-N n-(cyanomethyl)-2-[4-[2-[4-(2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound FC1=CC=CC=C1N1CCN(CCC2CCC(CC(=O)NCC#N)CC2)CC1 BBWIUCFANQAUFL-UHFFFAOYSA-N 0.000 description 1
- BBAGJAAYYYVDRH-UHFFFAOYSA-N n-(cyanomethyl)-2-[4-[2-[4-(2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexylidene]acetamide Chemical compound FC1=CC=CC=C1N1CCN(CCC2CCC(CC2)=CC(=O)NCC#N)CC1 BBAGJAAYYYVDRH-UHFFFAOYSA-N 0.000 description 1
- CNRGJVJGYLAZNS-UHFFFAOYSA-N n-[3-[4-[2-(1,4-dioxaspiro[4.5]decan-8-yl)ethyl]piperazin-1-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(N2CCN(CCC3CCC4(CC3)OCCO4)CC2)=C1 CNRGJVJGYLAZNS-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- DTZBEGLRIXWOBA-UHFFFAOYSA-N n-[4-[2-(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound C=1CCCC=1C(=O)NC(CC1)CCC1CCN(CC=1)CCC=1C1=CC=CC=C1 DTZBEGLRIXWOBA-UHFFFAOYSA-N 0.000 description 1
- WDHYFDZSQKSUCX-UHFFFAOYSA-N n-[4-[2-(4-phenylpiperazin-1-yl)ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)C)CCC1CCN1CCN(C=2C=CC=CC=2)CC1 WDHYFDZSQKSUCX-UHFFFAOYSA-N 0.000 description 1
- XEEKXRDMWZXEEI-UHFFFAOYSA-N n-[4-[2-(4-phenylpiperazin-1-yl)ethyl]cyclohexyl]cyclohexene-1-carboxamide Chemical compound C=1CCCCC=1C(=O)NC(CC1)CCC1CCN(CC1)CCN1C1=CC=CC=C1 XEEKXRDMWZXEEI-UHFFFAOYSA-N 0.000 description 1
- NQDZZNOEUXTYLN-UHFFFAOYSA-N n-[4-[2-(4-pyridin-2-ylpiperazin-1-yl)ethyl]cyclohexyl]cyclopent-3-ene-1-carboxamide Chemical compound C1C=CCC1C(=O)NC(CC1)CCC1CCN(CC1)CCN1C1=CC=CC=N1 NQDZZNOEUXTYLN-UHFFFAOYSA-N 0.000 description 1
- DIRKDNYXNPECEK-UHFFFAOYSA-N n-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)C)CCC1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 DIRKDNYXNPECEK-UHFFFAOYSA-N 0.000 description 1
- WBCUKZPMGSHJLY-UHFFFAOYSA-N n-[4-[2-[4-(2,3-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound FC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)C=3CCCC=3)CC2)=C1F WBCUKZPMGSHJLY-UHFFFAOYSA-N 0.000 description 1
- RDWHQMKFSRFJMK-UHFFFAOYSA-N n-[4-[2-[4-(2,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2,3-dihydrofuran-4-carboxamide Chemical compound FC1=CC(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C=2CCOC=2)CC1 RDWHQMKFSRFJMK-UHFFFAOYSA-N 0.000 description 1
- HAQPUSLDTNUWPY-UHFFFAOYSA-N n-[4-[2-[4-(2,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-ethoxyacetamide Chemical compound C1CC(NC(=O)COCC)CCC1CCN1CCN(C=2C(=CC(F)=CC=2)F)CC1 HAQPUSLDTNUWPY-UHFFFAOYSA-N 0.000 description 1
- IETSVRZPNCQJSG-UHFFFAOYSA-N n-[4-[2-[4-(2,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-3,3,3-trifluoropropanamide Chemical compound FC1=CC(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC(F)(F)F)CC1 IETSVRZPNCQJSG-UHFFFAOYSA-N 0.000 description 1
- ASLYIKSWBLDYDF-UHFFFAOYSA-N n-[4-[2-[4-(2,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-3,4-dihydro-2h-pyran-6-carboxamide Chemical compound FC1=CC(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C=2OCCCC=2)CC1 ASLYIKSWBLDYDF-UHFFFAOYSA-N 0.000 description 1
- NFHDJYHKMOKVJC-UHFFFAOYSA-N n-[4-[2-[4-(2,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C(=CC(F)=CC=2)F)CC1 NFHDJYHKMOKVJC-UHFFFAOYSA-N 0.000 description 1
- ILQQIYFUMVLQDG-UHFFFAOYSA-N n-[4-[2-[4-(2,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclohexene-1-carboxamide Chemical compound FC1=CC(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C=2CCCCC=2)CC1 ILQQIYFUMVLQDG-UHFFFAOYSA-N 0.000 description 1
- GNXLCQCLZFRUDY-UHFFFAOYSA-N n-[4-[2-[4-(2,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopent-3-ene-1-carboxamide Chemical compound FC1=CC(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C2CC=CC2)CC1 GNXLCQCLZFRUDY-UHFFFAOYSA-N 0.000 description 1
- XFOKPZLSNQVLDM-UHFFFAOYSA-N n-[4-[2-[4-(2,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound FC1=CC(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C=2CCCC=2)CC1 XFOKPZLSNQVLDM-UHFFFAOYSA-N 0.000 description 1
- YXEGXWFMDBVLSE-UHFFFAOYSA-N n-[4-[2-[4-(2,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]pyrrolidine-2-carboxamide Chemical compound FC1=CC(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C2NCCC2)CC1 YXEGXWFMDBVLSE-UHFFFAOYSA-N 0.000 description 1
- BSWJELRVLAPBOW-UHFFFAOYSA-N n-[4-[2-[4-(2,5-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound FC1=CC=C(F)C(N2CCN(CCC3CCC(CC3)NC(=O)C=3CCCC=3)CC2)=C1 BSWJELRVLAPBOW-UHFFFAOYSA-N 0.000 description 1
- CNNAPBLCCLYWRM-UHFFFAOYSA-N n-[4-[2-[4-(2,6-ditert-butylpyrimidin-4-yl)piperazin-1-yl]ethyl]cyclohexyl]-2-ethoxyacetamide Chemical compound C1CC(NC(=O)COCC)CCC1CCN1CCN(C=2N=C(N=C(C=2)C(C)(C)C)C(C)(C)C)CC1 CNNAPBLCCLYWRM-UHFFFAOYSA-N 0.000 description 1
- BGLBMIMPQPCOJS-UHFFFAOYSA-N n-[4-[2-[4-(2,6-ditert-butylpyrimidin-4-yl)piperazin-1-yl]ethyl]cyclohexyl]-2-methoxyacetamide Chemical compound C1CC(NC(=O)COC)CCC1CCN1CCN(C=2N=C(N=C(C=2)C(C)(C)C)C(C)(C)C)CC1 BGLBMIMPQPCOJS-UHFFFAOYSA-N 0.000 description 1
- SXKPTMCDWPLVJS-UHFFFAOYSA-N n-[4-[2-[4-(2-chloro-4-fluoro-5-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound C1=C(F)C(C)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1Cl SXKPTMCDWPLVJS-UHFFFAOYSA-N 0.000 description 1
- GBAFBRAPPVWMFH-UHFFFAOYSA-N n-[4-[2-[4-(2-chloro-5-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-cyanobutanamide Chemical compound ClC1=CC=C(C#N)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 GBAFBRAPPVWMFH-UHFFFAOYSA-N 0.000 description 1
- VMCDOISZVDJRRX-UHFFFAOYSA-N n-[4-[2-[4-(2-chloro-5-methoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound COC1=CC=C(Cl)C(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 VMCDOISZVDJRRX-UHFFFAOYSA-N 0.000 description 1
- KEQDLVZEIFKIPC-UHFFFAOYSA-N n-[4-[2-[4-(2-chloro-5-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound CC1=CC=C(Cl)C(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 KEQDLVZEIFKIPC-UHFFFAOYSA-N 0.000 description 1
- VMGMFGKEEIEIHI-UHFFFAOYSA-N n-[4-[2-[4-(2-chlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound ClC1=CC=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 VMGMFGKEEIEIHI-UHFFFAOYSA-N 0.000 description 1
- MLJXEOLMLJWYEO-UHFFFAOYSA-N n-[4-[2-[4-(2-chlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-ethoxyacetamide Chemical compound C1CC(NC(=O)COCC)CCC1CCN1CCN(C=2C(=CC=CC=2)Cl)CC1 MLJXEOLMLJWYEO-UHFFFAOYSA-N 0.000 description 1
- YVUURKUOOBLAPN-UHFFFAOYSA-N n-[4-[2-[4-(2-chlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-methoxyacetamide Chemical compound C1CC(NC(=O)COC)CCC1CCN1CCN(C=2C(=CC=CC=2)Cl)CC1 YVUURKUOOBLAPN-UHFFFAOYSA-N 0.000 description 1
- RKTMPIMOMSTGID-UHFFFAOYSA-N n-[4-[2-[4-(2-chlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-cyanobutanamide Chemical compound ClC1=CC=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 RKTMPIMOMSTGID-UHFFFAOYSA-N 0.000 description 1
- XENMWIJJKSWKQN-UHFFFAOYSA-N n-[4-[2-[4-(2-cyano-3-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-methoxyacetamide Chemical compound C1CC(NC(=O)COC)CCC1CCN1CCN(C=2C(=C(C)C=CC=2)C#N)CC1 XENMWIJJKSWKQN-UHFFFAOYSA-N 0.000 description 1
- GBWSGOCCQNWIAP-UHFFFAOYSA-N n-[4-[2-[4-(2-cyano-3-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-3,3,3-trifluoropropanamide Chemical compound CC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC(F)(F)F)CC2)=C1C#N GBWSGOCCQNWIAP-UHFFFAOYSA-N 0.000 description 1
- KUPKVEAQEKFQQA-UHFFFAOYSA-N n-[4-[2-[4-(2-cyano-3-methylphenyl)piperidin-1-yl]ethyl]cyclohexyl]-2-methoxyacetamide Chemical compound C1CC(NC(=O)COC)CCC1CCN1CCC(C=2C(=C(C)C=CC=2)C#N)CC1 KUPKVEAQEKFQQA-UHFFFAOYSA-N 0.000 description 1
- CZQOOWLYMFEYJO-UHFFFAOYSA-N n-[4-[2-[4-(2-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound C=1CCCC=1C(=O)NC(CC1)CCC1CCN(CC1)CCN1C1=CC=CC=C1C#N CZQOOWLYMFEYJO-UHFFFAOYSA-N 0.000 description 1
- LJHMIDLLAJSVIH-UHFFFAOYSA-N n-[4-[2-[4-(2-ethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-3,3,3-trifluoropropanamide Chemical compound CCC1=CC=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC(F)(F)F)CC1 LJHMIDLLAJSVIH-UHFFFAOYSA-N 0.000 description 1
- BABCZLDGNCQAGK-UHFFFAOYSA-N n-[4-[2-[4-(2-fluoro-4-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound FC1=CC(C)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C=2CCCC=2)CC1 BABCZLDGNCQAGK-UHFFFAOYSA-N 0.000 description 1
- AKSVRNHLFNIFDI-UHFFFAOYSA-N n-[4-[2-[4-(2-fluoro-5-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound CC1=CC=C(F)C(N2CCN(CCC3CCC(CC3)NC(=O)C=3CCCC=3)CC2)=C1 AKSVRNHLFNIFDI-UHFFFAOYSA-N 0.000 description 1
- LUXGSZZKLMHGOR-UHFFFAOYSA-N n-[4-[2-[4-(2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopent-3-ene-1-carboxamide Chemical compound FC1=CC=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C2CC=CC2)CC1 LUXGSZZKLMHGOR-UHFFFAOYSA-N 0.000 description 1
- VJIDLBLXVTVWFK-UHFFFAOYSA-N n-[4-[2-[4-(2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound FC1=CC=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C=2CCCC=2)CC1 VJIDLBLXVTVWFK-UHFFFAOYSA-N 0.000 description 1
- DPVOOKONQQKHQE-UHFFFAOYSA-N n-[4-[2-[4-(2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]oxolane-2-carboxamide Chemical compound FC1=CC=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C2OCCC2)CC1 DPVOOKONQQKHQE-UHFFFAOYSA-N 0.000 description 1
- UNZHSMSZZXQJFO-UHFFFAOYSA-N n-[4-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound CC1=CC=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C=2CCCC=2)CC1 UNZHSMSZZXQJFO-UHFFFAOYSA-N 0.000 description 1
- QPDOOYIGPXUVDT-UHFFFAOYSA-N n-[4-[2-[4-(3,4,5-trifluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound FC1=C(F)C(F)=CC(N2CCN(CCC3CCC(CC3)NC(=O)C=3CCCC=3)CC2)=C1 QPDOOYIGPXUVDT-UHFFFAOYSA-N 0.000 description 1
- OIQNGABJCWVYDJ-UHFFFAOYSA-N n-[4-[2-[4-(3,4-dichloro-2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-methoxyacetamide Chemical compound C1CC(NC(=O)COC)CCC1CCN1CCN(C=2C(=C(Cl)C(Cl)=CC=2)F)CC1 OIQNGABJCWVYDJ-UHFFFAOYSA-N 0.000 description 1
- GNRQSJXIMZBACU-UHFFFAOYSA-N n-[4-[2-[4-(3,4-dichloro-2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C(=C(Cl)C(Cl)=CC=2)F)CC1 GNRQSJXIMZBACU-UHFFFAOYSA-N 0.000 description 1
- MNAYLXIJGBBWFL-UHFFFAOYSA-N n-[4-[2-[4-(3,4-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-ethoxyacetamide Chemical compound C1CC(NC(=O)COCC)CCC1CCN1CCN(C=2C=C(Cl)C(Cl)=CC=2)CC1 MNAYLXIJGBBWFL-UHFFFAOYSA-N 0.000 description 1
- XQOJFSVCPIZTPX-UHFFFAOYSA-N n-[4-[2-[4-(3,4-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C=2CCCC=2)CC1 XQOJFSVCPIZTPX-UHFFFAOYSA-N 0.000 description 1
- ILTGATCNWYFGML-UHFFFAOYSA-N n-[4-[2-[4-(3,4-dimethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-ethoxyacetamide Chemical compound C1CC(NC(=O)COCC)CCC1CCN1CCN(C=2C=C(C)C(C)=CC=2)CC1 ILTGATCNWYFGML-UHFFFAOYSA-N 0.000 description 1
- RXXIMBLQJSTZKU-UHFFFAOYSA-N n-[4-[2-[4-(3,4-dimethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C=C(C)C(C)=CC=2)CC1 RXXIMBLQJSTZKU-UHFFFAOYSA-N 0.000 description 1
- YXIKUUNCEUUJBC-UHFFFAOYSA-N n-[4-[2-[4-(3,4-dimethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound C1=C(C)C(C)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C=2CCCC=2)CC1 YXIKUUNCEUUJBC-UHFFFAOYSA-N 0.000 description 1
- WRUFPHDNUFDPRO-UHFFFAOYSA-N n-[4-[2-[4-(3,5-dimethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C=C(C)C=C(C)C=2)CC1 WRUFPHDNUFDPRO-UHFFFAOYSA-N 0.000 description 1
- FAPZKMBMBMZPBK-UHFFFAOYSA-N n-[4-[2-[4-(3-acetylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound CC(=O)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 FAPZKMBMBMZPBK-UHFFFAOYSA-N 0.000 description 1
- DGDLFLQARWKZGI-UHFFFAOYSA-N n-[4-[2-[4-(3-acetylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-3,3,3-trifluoropropanamide Chemical compound CC(=O)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC(F)(F)F)CC2)=C1 DGDLFLQARWKZGI-UHFFFAOYSA-N 0.000 description 1
- VLRBFDGBQQQFLF-UHFFFAOYSA-N n-[4-[2-[4-(3-bromophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound BrC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 VLRBFDGBQQQFLF-UHFFFAOYSA-N 0.000 description 1
- FDCSNGBJHJRXCX-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-2,4-difluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound FC1=C(Cl)C(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 FDCSNGBJHJRXCX-UHFFFAOYSA-N 0.000 description 1
- NVDFEBOGKFRHGK-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-2-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound ClC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1C#N NVDFEBOGKFRHGK-UHFFFAOYSA-N 0.000 description 1
- POJWKZRAUVAMFA-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound FC1=C(Cl)C=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 POJWKZRAUVAMFA-UHFFFAOYSA-N 0.000 description 1
- ISHXLNCZYALWNS-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-cyanobutanamide Chemical compound FC1=C(Cl)C=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 ISHXLNCZYALWNS-UHFFFAOYSA-N 0.000 description 1
- CHTZADWKSFIJGP-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-2-methoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound COC1=C(Cl)C=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 CHTZADWKSFIJGP-UHFFFAOYSA-N 0.000 description 1
- MUSNQUAXBRDHDF-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-2-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-ethoxyacetamide Chemical compound C1CC(NC(=O)COCC)CCC1CCN1CCN(C=2C(=C(Cl)C=CC=2)C)CC1 MUSNQUAXBRDHDF-UHFFFAOYSA-N 0.000 description 1
- HTKWJRHNHGYQPU-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-2-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C(=C(Cl)C=CC=2)C)CC1 HTKWJRHNHGYQPU-UHFFFAOYSA-N 0.000 description 1
- RHUGNNXQGJFNDX-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-4-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-3,3,3-trifluoropropanamide Chemical compound C1=C(Cl)C(C)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC(F)(F)F)CC1 RHUGNNXQGJFNDX-UHFFFAOYSA-N 0.000 description 1
- QVEVRHPBBVTNFN-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-4-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-cyanobutanamide Chemical compound C1=C(Cl)C(C)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 QVEVRHPBBVTNFN-UHFFFAOYSA-N 0.000 description 1
- UKNGXQMYJLBLOD-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-5-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound FC1=CC(Cl)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 UKNGXQMYJLBLOD-UHFFFAOYSA-N 0.000 description 1
- TUFXTKIWGGQVPE-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-5-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C=C(Cl)C=C(F)C=2)CC1 TUFXTKIWGGQVPE-UHFFFAOYSA-N 0.000 description 1
- XATBQTWJQKYDNN-UHFFFAOYSA-N n-[4-[2-[4-(3-chloro-5-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C=C(Cl)C=C(C)C=2)CC1 XATBQTWJQKYDNN-UHFFFAOYSA-N 0.000 description 1
- WJRRQMJWMKBCJA-UHFFFAOYSA-N n-[4-[2-[4-(3-chlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound ClC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 WJRRQMJWMKBCJA-UHFFFAOYSA-N 0.000 description 1
- YDKPENFIZBMXBG-UHFFFAOYSA-N n-[4-[2-[4-(3-chlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-cyanobutanamide Chemical compound ClC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCCC#N)CC2)=C1 YDKPENFIZBMXBG-UHFFFAOYSA-N 0.000 description 1
- QDPBFRUYVRCIEN-UHFFFAOYSA-N n-[4-[2-[4-(3-cyanophenyl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CC=C(C=2C=C(C=CC=2)C#N)CC1 QDPBFRUYVRCIEN-UHFFFAOYSA-N 0.000 description 1
- ULIIRPUVALTKJK-UHFFFAOYSA-N n-[4-[2-[4-(3-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2,3-dihydrofuran-4-carboxamide Chemical compound C=1OCCC=1C(=O)NC(CC1)CCC1CCN(CC1)CCN1C1=CC=CC(C#N)=C1 ULIIRPUVALTKJK-UHFFFAOYSA-N 0.000 description 1
- FCVQUMYRGGFSER-UHFFFAOYSA-N n-[4-[2-[4-(3-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-methoxyacetamide Chemical compound C1CC(NC(=O)COC)CCC1CCN1CCN(C=2C=C(C=CC=2)C#N)CC1 FCVQUMYRGGFSER-UHFFFAOYSA-N 0.000 description 1
- KWFBBHHNUCIPJT-UHFFFAOYSA-N n-[4-[2-[4-(3-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]-3,3,3-trifluoropropanamide Chemical compound C1CC(NC(=O)CC(F)(F)F)CCC1CCN1CCN(C=2C=C(C=CC=2)C#N)CC1 KWFBBHHNUCIPJT-UHFFFAOYSA-N 0.000 description 1
- PLMAPPWZOQMTBI-UHFFFAOYSA-N n-[4-[2-[4-(3-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]-3-methoxypropanamide Chemical compound C1CC(NC(=O)CCOC)CCC1CCN1CCN(C=2C=C(C=CC=2)C#N)CC1 PLMAPPWZOQMTBI-UHFFFAOYSA-N 0.000 description 1
- GKEHXZRTIIYKEA-UHFFFAOYSA-N n-[4-[2-[4-(3-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound C=1CCCC=1C(=O)NC(CC1)CCC1CCN(CC1)CCN1C1=CC=CC(C#N)=C1 GKEHXZRTIIYKEA-UHFFFAOYSA-N 0.000 description 1
- YWGYFTLYEXKZSG-UHFFFAOYSA-N n-[4-[2-[4-(3-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]pyrrolidine-2-carboxamide Chemical compound C1CCNC1C(=O)NC(CC1)CCC1CCN(CC1)CCN1C1=CC=CC(C#N)=C1 YWGYFTLYEXKZSG-UHFFFAOYSA-N 0.000 description 1
- OWECJIYLRYVJNH-UHFFFAOYSA-N n-[4-[2-[4-(3-ethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-3,3,3-trifluoropropanamide Chemical compound CCC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC(F)(F)F)CC2)=C1 OWECJIYLRYVJNH-UHFFFAOYSA-N 0.000 description 1
- ISBFMIQKHVYHKJ-UHFFFAOYSA-N n-[4-[2-[4-(3-ethylphenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopent-3-ene-1-carboxamide Chemical compound CCC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3CC=CC3)CC2)=C1 ISBFMIQKHVYHKJ-UHFFFAOYSA-N 0.000 description 1
- QJMLSRAKIASKCQ-UHFFFAOYSA-N n-[4-[2-[4-(3-fluoro-4-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound C1=C(F)C(C)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C=2CCCC=2)CC1 QJMLSRAKIASKCQ-UHFFFAOYSA-N 0.000 description 1
- OCJUSORUIQIETF-UHFFFAOYSA-N n-[4-[2-[4-(3-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-phenoxyacetamide Chemical compound FC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)COC=3C=CC=CC=3)CC2)=C1 OCJUSORUIQIETF-UHFFFAOYSA-N 0.000 description 1
- FTAQYZXSPCDIFP-UHFFFAOYSA-N n-[4-[2-[4-(3-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound FC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)C=3CCCC=3)CC2)=C1 FTAQYZXSPCDIFP-UHFFFAOYSA-N 0.000 description 1
- XWNNDWPHIPOCFR-UHFFFAOYSA-N n-[4-[2-[4-(3-methoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound COC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)C=3CCCC=3)CC2)=C1 XWNNDWPHIPOCFR-UHFFFAOYSA-N 0.000 description 1
- YXMMONNVJVZPTJ-UHFFFAOYSA-N n-[4-[2-[4-(3-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound CC1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)C=3CCCC=3)CC2)=C1 YXMMONNVJVZPTJ-UHFFFAOYSA-N 0.000 description 1
- PJUYUGQIZQLSDM-UHFFFAOYSA-N n-[4-[2-[4-(3-tert-butylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound CC(C)(C)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 PJUYUGQIZQLSDM-UHFFFAOYSA-N 0.000 description 1
- YYEJRZOOGFLVII-UHFFFAOYSA-N n-[4-[2-[4-(4-chloro-2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound FC1=CC(Cl)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 YYEJRZOOGFLVII-UHFFFAOYSA-N 0.000 description 1
- ZNDNTDFJGSNXSQ-UHFFFAOYSA-N n-[4-[2-[4-(4-chloro-2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-cyanobutanamide Chemical compound FC1=CC(Cl)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 ZNDNTDFJGSNXSQ-UHFFFAOYSA-N 0.000 description 1
- FCAINKUZFUBGII-UHFFFAOYSA-N n-[4-[2-[4-(4-chloro-2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound FC1=CC(Cl)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C=2CCCC=2)CC1 FCAINKUZFUBGII-UHFFFAOYSA-N 0.000 description 1
- CDWRPVUUMYXXBP-UHFFFAOYSA-N n-[4-[2-[4-(4-chlorophenyl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound C1=CC(Cl)=CC=C1C(CC1)=CCN1CCC1CCC(NC(=O)CC#N)CC1 CDWRPVUUMYXXBP-UHFFFAOYSA-N 0.000 description 1
- GDVPQIUSKDKOCZ-UHFFFAOYSA-N n-[4-[2-[4-(4-chlorophenyl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]cyclohexyl]-2-ethoxyacetamide Chemical compound C1CC(NC(=O)COCC)CCC1CCN1CC=C(C=2C=CC(Cl)=CC=2)CC1 GDVPQIUSKDKOCZ-UHFFFAOYSA-N 0.000 description 1
- IECILCJWQXSVAN-UHFFFAOYSA-N n-[4-[2-[4-(4-chlorophenyl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]cyclohexyl]-4-cyanobutanamide Chemical compound C1=CC(Cl)=CC=C1C(CC1)=CCN1CCC1CCC(NC(=O)CCCC#N)CC1 IECILCJWQXSVAN-UHFFFAOYSA-N 0.000 description 1
- WMFJXPKMFDYWTK-UHFFFAOYSA-N n-[4-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound C1=CC(Cl)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 WMFJXPKMFDYWTK-UHFFFAOYSA-N 0.000 description 1
- UUOSWTHWMGKRSB-UHFFFAOYSA-N n-[4-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-methylsulfonylacetamide Chemical compound C1CC(NC(=O)CS(=O)(=O)C)CCC1CCN1CCN(C=2C=CC(Cl)=CC=2)CC1 UUOSWTHWMGKRSB-UHFFFAOYSA-N 0.000 description 1
- OEIVXINWHIAOMR-UHFFFAOYSA-N n-[4-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-3,3,3-trifluoropropanamide Chemical compound C1CC(NC(=O)CC(F)(F)F)CCC1CCN1CCN(C=2C=CC(Cl)=CC=2)CC1 OEIVXINWHIAOMR-UHFFFAOYSA-N 0.000 description 1
- RLRSHPDNYLZJKO-UHFFFAOYSA-N n-[4-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C=2CCCC=2)CC1 RLRSHPDNYLZJKO-UHFFFAOYSA-N 0.000 description 1
- CFOYPZUGUOGNQT-UHFFFAOYSA-N n-[4-[2-[4-(4-fluorophenyl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CC=C(C=2C=CC(F)=CC=2)CC1 CFOYPZUGUOGNQT-UHFFFAOYSA-N 0.000 description 1
- AZGIMFDOAWEPKI-UHFFFAOYSA-N n-[4-[2-[4-(4-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound C1=CC(F)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C=2CCCC=2)CC1 AZGIMFDOAWEPKI-UHFFFAOYSA-N 0.000 description 1
- FWEQQTFSWQXYJS-UHFFFAOYSA-N n-[4-[2-[4-(4-methoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound C1=CC(OC)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C=2CCCC=2)CC1 FWEQQTFSWQXYJS-UHFFFAOYSA-N 0.000 description 1
- PMSNXOOVJVCYGC-UHFFFAOYSA-N n-[4-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound C1=CC(C)=CC=C1N1CCN(CCC2CCC(CC2)NC(=O)C=2CCCC=2)CC1 PMSNXOOVJVCYGC-UHFFFAOYSA-N 0.000 description 1
- CCJNLECCKFAVLT-UHFFFAOYSA-N n-[4-[2-[4-(5-chloro-2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound FC1=CC=C(Cl)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 CCJNLECCKFAVLT-UHFFFAOYSA-N 0.000 description 1
- FNSGZCUQAXZPBV-UHFFFAOYSA-N n-[4-[2-[4-(5-chloro-2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-cyanobutanamide Chemical compound FC1=CC=C(Cl)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 FNSGZCUQAXZPBV-UHFFFAOYSA-N 0.000 description 1
- ITIGTQDXGUYDTI-UHFFFAOYSA-N n-[4-[2-[4-(5-chloro-2-fluorophenyl)piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound FC1=CC=C(Cl)C=C1N1CCN(CCC2CCC(CC2)NC(=O)C=2CCCC=2)CC1 ITIGTQDXGUYDTI-UHFFFAOYSA-N 0.000 description 1
- NTCWTAGBHRUKFA-UHFFFAOYSA-N n-[4-[2-[4-(5-chloro-2-methoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound COC1=CC=C(Cl)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 NTCWTAGBHRUKFA-UHFFFAOYSA-N 0.000 description 1
- DJKNANBJYJJTBE-UHFFFAOYSA-N n-[4-[2-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound CC1=CC=C(Cl)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 DJKNANBJYJJTBE-UHFFFAOYSA-N 0.000 description 1
- VDTAPDGCQQEUPO-UHFFFAOYSA-N n-[4-[2-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-3,3,3-trifluoropropanamide Chemical compound CC1=CC=C(Cl)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CC(F)(F)F)CC1 VDTAPDGCQQEUPO-UHFFFAOYSA-N 0.000 description 1
- ZWDVLWBZDDHVFF-UHFFFAOYSA-N n-[4-[2-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-3-cyanopropanamide Chemical compound CC1=CC=C(Cl)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CCC#N)CC1 ZWDVLWBZDDHVFF-UHFFFAOYSA-N 0.000 description 1
- FOBNDSLDDCCVDQ-UHFFFAOYSA-N n-[4-[2-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]ethyl]cyclohexyl]-4-cyanobutanamide Chemical compound CC1=CC=C(Cl)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CCCC#N)CC1 FOBNDSLDDCCVDQ-UHFFFAOYSA-N 0.000 description 1
- LCTWBHFDUYCUSW-UHFFFAOYSA-N n-[4-[2-[4-(5-tert-butyl-2-methoxyphenyl)piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound COC1=CC=C(C(C)(C)C)C=C1N1CCN(CCC2CCC(CC2)NC(=O)CC#N)CC1 LCTWBHFDUYCUSW-UHFFFAOYSA-N 0.000 description 1
- IKXAUEPWBFIHAL-UHFFFAOYSA-N n-[4-[2-[4-[2-cyano-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]-2-methoxyacetamide Chemical compound C1CC(NC(=O)COC)CCC1CCN1CCN(C=2C(=C(C=CC=2)C(F)(F)F)C#N)CC1 IKXAUEPWBFIHAL-UHFFFAOYSA-N 0.000 description 1
- YCQDWBVEXXUGMT-UHFFFAOYSA-N n-[4-[2-[4-[2-cyano-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]-2-propan-2-yloxyacetamide Chemical compound C1CC(NC(=O)COC(C)C)CCC1CCN1CCN(C=2C(=C(C=CC=2)C(F)(F)F)C#N)CC1 YCQDWBVEXXUGMT-UHFFFAOYSA-N 0.000 description 1
- NRUNIWMDVYHGHQ-UHFFFAOYSA-N n-[4-[2-[4-[2-fluoro-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]-2,3-dihydrofuran-4-carboxamide Chemical compound C1=CC=C(C(F)(F)F)C(F)=C1N1CCN(CCC2CCC(CC2)NC(=O)C=2CCOC=2)CC1 NRUNIWMDVYHGHQ-UHFFFAOYSA-N 0.000 description 1
- OHQHIMUZKYWRIM-UHFFFAOYSA-N n-[4-[2-[4-[2-fluoro-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound C1=CC=C(C(F)(F)F)C(F)=C1N1CCN(CCC2CCC(CC2)NC(=O)C=2CCCC=2)CC1 OHQHIMUZKYWRIM-UHFFFAOYSA-N 0.000 description 1
- VPPOUXZUILEANL-UHFFFAOYSA-N n-[4-[2-[4-[2-fluoro-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]pyrrolidine-2-carboxamide Chemical compound C1=CC=C(C(F)(F)F)C(F)=C1N1CCN(CCC2CCC(CC2)NC(=O)C2NCCC2)CC1 VPPOUXZUILEANL-UHFFFAOYSA-N 0.000 description 1
- HCMVVJBAEDABLI-UHFFFAOYSA-N n-[4-[2-[4-[2-fluoro-5-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]pyrrolidine-2-carboxamide Chemical compound FC1=CC=C(C(F)(F)F)C=C1N1CCN(CCC2CCC(CC2)NC(=O)C2NCCC2)CC1 HCMVVJBAEDABLI-UHFFFAOYSA-N 0.000 description 1
- ZCLRYCKLJFKUCO-UHFFFAOYSA-N n-[4-[2-[4-[3,5-bis(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]-2-cyanoacetamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CC#N)CC2)=C1 ZCLRYCKLJFKUCO-UHFFFAOYSA-N 0.000 description 1
- AUOZVVFDGBRDIA-UHFFFAOYSA-N n-[4-[2-[4-[3,5-bis(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]-2-methoxyacetamide Chemical compound C1CC(NC(=O)COC)CCC1CCN1CCN(C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 AUOZVVFDGBRDIA-UHFFFAOYSA-N 0.000 description 1
- GJXARLFHQHKHJD-UHFFFAOYSA-N n-[4-[2-[4-[3,5-bis(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]-3-cyanopropanamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(N2CCN(CCC3CCC(CC3)NC(=O)CCC#N)CC2)=C1 GJXARLFHQHKHJD-UHFFFAOYSA-N 0.000 description 1
- ROQPIQXORWFGIJ-UHFFFAOYSA-N n-[4-[2-[4-[3,5-bis(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]-4-methoxybutanamide Chemical compound C1CC(NC(=O)CCCOC)CCC1CCN1CCN(C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 ROQPIQXORWFGIJ-UHFFFAOYSA-N 0.000 description 1
- HBGRTKFHTLZPJE-UHFFFAOYSA-N n-[4-[2-[4-[3,5-bis(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]-4-oxopentanamide Chemical compound C1CC(NC(=O)CCC(=O)C)CCC1CCN1CCN(C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 HBGRTKFHTLZPJE-UHFFFAOYSA-N 0.000 description 1
- YZSPBAKIHSHCRY-UHFFFAOYSA-N n-[4-[2-[4-[3-(1,3-oxazol-2-yl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]-2,3-dihydrofuran-4-carboxamide Chemical compound C=1OCCC=1C(=O)NC(CC1)CCC1CCN(CC1)CCN1C(C=1)=CC=CC=1C1=NC=CO1 YZSPBAKIHSHCRY-UHFFFAOYSA-N 0.000 description 1
- QBIZWWMFYPEXMW-UHFFFAOYSA-N n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]-2,3-dihydrofuran-4-carboxamide Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)C=3CCOC=3)CC2)=C1 QBIZWWMFYPEXMW-UHFFFAOYSA-N 0.000 description 1
- CFKXFTLMWBTWOQ-UHFFFAOYSA-N n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]-3,4-dihydro-2h-pyran-6-carboxamide Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)C=3OCCCC=3)CC2)=C1 CFKXFTLMWBTWOQ-UHFFFAOYSA-N 0.000 description 1
- RKJSVNSECGMGKH-UHFFFAOYSA-N n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]cyclohexene-1-carboxamide Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)C=3CCCCC=3)CC2)=C1 RKJSVNSECGMGKH-UHFFFAOYSA-N 0.000 description 1
- QYKXWUSZQCZPCN-UHFFFAOYSA-N n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]cyclopentene-1-carboxamide Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)C=3CCCC=3)CC2)=C1 QYKXWUSZQCZPCN-UHFFFAOYSA-N 0.000 description 1
- PNFBQFGHNTXHPZ-UHFFFAOYSA-N n-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]oxolane-2-carboxamide Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCC3CCC(CC3)NC(=O)C3OCCC3)CC2)=C1 PNFBQFGHNTXHPZ-UHFFFAOYSA-N 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SHFVOHDCBRAIKK-UHFFFAOYSA-N n-methoxy-n-methyl-2-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexylidene]acetamide Chemical compound C1CC(=CC(=O)N(C)OC)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 SHFVOHDCBRAIKK-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IHPHPGLJYCDONF-UHFFFAOYSA-N n-propylacetamide Chemical compound CCCNC(C)=O IHPHPGLJYCDONF-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- UNEIHNMKASENIG-UHFFFAOYSA-N para-chlorophenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1CCNCC1 UNEIHNMKASENIG-UHFFFAOYSA-N 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000004885 piperazines Chemical group 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- ZRLVQFQTCMUIRM-UHFFFAOYSA-N potassium;2-methylbutan-2-olate Chemical compound [K+].CCC(C)(C)[O-] ZRLVQFQTCMUIRM-UHFFFAOYSA-N 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000002105 relative biological effectiveness Effects 0.000 description 1
- 208000007278 renal glycosuria Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 108010092215 spiroperidol receptor Proteins 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- ZYIREACDDXYOJI-UHFFFAOYSA-N tert-butyl 2-[4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]piperidin-1-yl]acetate Chemical compound C1CN(CC(=O)OC(C)(C)C)CCC1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 ZYIREACDDXYOJI-UHFFFAOYSA-N 0.000 description 1
- NCXSQUIHKGNROI-UHFFFAOYSA-N tert-butyl 4-[2-[4-(3-acetylphenyl)piperazin-1-yl]ethyl]piperidine-1-carboxylate Chemical compound CC(=O)C1=CC=CC(N2CCN(CCC3CCN(CC3)C(=O)OC(C)(C)C)CC2)=C1 NCXSQUIHKGNROI-UHFFFAOYSA-N 0.000 description 1
- YWDUSCJLBKPRFN-UHFFFAOYSA-N tert-butyl 4-[2-[4-(3-ethoxycarbonylphenyl)piperazin-1-yl]ethyl]piperidine-1-carboxylate Chemical compound CCOC(=O)C1=CC=CC(N2CCN(CCC3CCN(CC3)C(=O)OC(C)(C)C)CC2)=C1 YWDUSCJLBKPRFN-UHFFFAOYSA-N 0.000 description 1
- UMRIHTZZZNXXHL-UHFFFAOYSA-N tert-butyl 4-[2-[4-(3-propanoylphenyl)piperazin-1-yl]ethyl]piperidine-1-carboxylate Chemical compound CCC(=O)C1=CC=CC(N2CCN(CCC3CCN(CC3)C(=O)OC(C)(C)C)CC2)=C1 UMRIHTZZZNXXHL-UHFFFAOYSA-N 0.000 description 1
- KAVKKDHBVQRAOE-UHFFFAOYSA-N tert-butyl 4-[2-[4-[3-(1-hydroxy-2-methylpropyl)phenyl]piperazin-1-yl]ethyl]piperidine-1-carboxylate Chemical compound CC(C)C(O)C1=CC=CC(N2CCN(CCC3CCN(CC3)C(=O)OC(C)(C)C)CC2)=C1 KAVKKDHBVQRAOE-UHFFFAOYSA-N 0.000 description 1
- BALBTSCWTJPZRW-UHFFFAOYSA-N tert-butyl 4-[2-[4-[3-(1-hydroxyethyl)phenyl]piperazin-1-yl]ethyl]piperidine-1-carboxylate Chemical compound CC(O)C1=CC=CC(N2CCN(CCC3CCN(CC3)C(=O)OC(C)(C)C)CC2)=C1 BALBTSCWTJPZRW-UHFFFAOYSA-N 0.000 description 1
- RLKXJDNWLXGHGB-UHFFFAOYSA-N tert-butyl 4-[2-[4-[3-(1-hydroxypropyl)phenyl]piperazin-1-yl]ethyl]piperidine-1-carboxylate Chemical compound CCC(O)C1=CC=CC(N2CCN(CCC3CCN(CC3)C(=O)OC(C)(C)C)CC2)=C1 RLKXJDNWLXGHGB-UHFFFAOYSA-N 0.000 description 1
- UISZZBCTCGEWNE-UHFFFAOYSA-N tert-butyl 4-[2-[4-[3-(2-methylpropyl)phenyl]piperazin-1-yl]ethyl]piperidine-1-carboxylate Chemical compound CC(C)CC1=CC=CC(N2CCN(CCC3CCN(CC3)C(=O)OC(C)(C)C)CC2)=C1 UISZZBCTCGEWNE-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- PTMFUWGXPRYYMC-UHFFFAOYSA-N triethylazanium;formate Chemical compound OC=O.CCN(CC)CC PTMFUWGXPRYYMC-UHFFFAOYSA-N 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Oppfinnelsen angår forbindelser med den generelle formel (I), fremgangsmåte for fremstilling av dem og anvendelse av dem som et terapeutisk middel.
Description
Foreliggende patentsøknad angår nye liganderfor Ds-reseptoren,fremgangsmåter for fremstilling derav og terapeutisk anvendelse derav.
Disse ligander for den humane Ds-reseptor oppfører seg som antagonistereller inverse agonister eller partielle agonister eller fullstendige agonister.
BAKGRUNN
Oppfinnelsen angår nye karbonylerte (aza)cykloheksan-derivater somsterkt binder til dopamin Ds-reseptoren som partielle, fullstendige eller inverseagonister og antagonister. Denne reseptor, en D2-lignende reseptor, er diskretuttrykt bare i noen få hjerne-projeksjonsområder av dopamin-neuroner, innendopamin-neuroner selv (auto-reseptorer) og i adskilte perifere organer, f.eks.nyrene (Schwartz et al. Clinical NeuroPharmacol, 1993,16, 295). Det har vært foreslått eller også demonstrert at slik hjerne-lokalisering innebærer en rolle fordenne reseptorundertype ved flere fysiologiske eller patologiske prosesser så som kognisjon, demens, psykose, stoffmisbruk og -avhengighet, stemningsleieregulering og -forstyrrelser (f.eks. depresjon eller angst), motorisk regulering og-lidelser (f.eks. Parkinsons sykdom, dyskinesier eller balanse-forstyrrelser).
I tillegg synes perifere Ds-reseptorer, dvs. i nyre, involvert i kontroll avhormon-sekresjon, diabetiske lidelser eller blodtrykk (Jose et al., Curr. Opin.Nephrol. Hypertens., 2002, 11,87; Gross et al Lab. Invest., 2006, 86, 862). Disse betraktninger indikerer at modulering (via partiell, fullstendig eller invers agonisme eller antagonisme) av dopamin Ds-reseptorer representerer enpotensielt ny metode for behandling av sykdommer i sentralnervesystemet innen nevrologi og psykiatri så vel som sykdommer i de kardiovaskulære eller hormonelle systemer.
Internasjonal patentsøknad WO 01/49679 beskriver arylpiperazin-derivatersom oppviser dopamin-antagonist-egenskaper på dens reseptorer Ds og D4;imidlertid har disse forbindelser en fenylgruppe i stilling 4 av piperazinet substituert med et halogenatom og, på den annen side, i stilling 1 av piperazinet, en alkylengruppe eventuelt substituert med en karbonylgruppe og deretter en 5eller 6-leddet aza-heterocyklisk gruppe kondensert med en fenylgruppe, så somindolin eller isokinolein.
Internasjonal patentsøknad PCT/FR05/02964 beskriver arylpiperazinderivater som har en alkylengruppe og en indolinring. Disse forbindelser er selektive liganderfor Ds-reseptor.
WO 98/50364 beskriver tetrahydroisokinolinderivater som modulatorer av dopamin D3 reseptorer mens WO 2005/012266 beskriver karbamoylcykloheksanderivater som D3/D2 reseptoragonister.
Uventet er det nå oppdaget at forbindelsene ifølge oppfinnelsen, som representerer en ny familie av arylpiperazin-derivater, oppviser høy affinitet forDs-reseptoren av dopamin. I motsetning til forbindelsene beskrevet i WO01/49769 og i PCT/FR05/02964, har forbindelsene ifølge oppfinnelsen en azaheterocyklisk gruppe, så som en arylpiperazin- og en alkylengruppe substituertmed en (aza)cykloheksylgruppe. Videre er de selektive liganderfor Ds-reseptor.
Disse forbindelser er anvendelige som medikamenter, spesielt innen nevrologi og psykiatri, spesielt ved Parkinson's sykdom, schizofreni, demens, depresjon, mani, angst, dyskinesier, balanse-forstyrrelser, Gilles de la Tourette'ssykdom. Videre er disse forbindelser anvendelige for behandling av medikament- og tobakk-avhengighet.
De er også anvendelige for forhindring eller behandling av kardiovaskulære lidelser som impliserer de perifere dopamin-reseptorer, spesielt i nyrer, så somhypertensjon, hjertesvikt og andre lidelser så som nyreinsuffisiens eller diabetes.
Disse forbindelser er også anvendelige for forhindring eller behandling av hormonelle lidelser som impliserer dopamin-reseptorer i hypothalamushypofyse-komplekset, så som menopausale lidelser eller vekstlidelser.
I henhold til et første aspekt angår foreliggende oppfinnelse nye forbidelser med formel (I):
R '—' ^NR1R2
(I)
hvor NR1R2 er
—\|—Ar
l)
Z er
—N-Ca) H H
R representerer cyanoalkyl; monohalogenocyanoalkyl; polyhalogenocyanoalkyl; hydroksyalkyl; monohalogenoalkyl (hvor halogen er Cl, Br eller I); polyhalogenoalkyl; alkoksyalkyl; monohalogeno-alkoksyalkyl;polyhalogenoalkoksyalkyl; alkoksyalkoksyalkyl; monohalogenoalkoksyalkoksyalkyl; polyhalogenoalkoksyalkoksyalkyl; aryloksyalkyl; mono- ellerpolyhalogenoaryloksyalkyl; cykloalkenylalkyl; dialkylaminoalkyl; halogendialkylaminoalkyl; polyhalogenodialkylaminoalkyl;
—(CH2)m-C u . \ r >
v Het ) Hetj
'hvor s er en ikke-aromatisk heterocyklisk gruppeeventuelt kondensert med aryl eller eventuelt substituert med én eller flere acyl, alkyl eller halogen; arylaminoalkyl; alkylkarbonylalkyl; acylaminoalkyl; aminokarbonylalkyl; alkylsulfanylalkyl; alkylsulfinylalkyl; alkylsulfonylalkyl;
m er 2 eller 4;
Ar representerer en aryl; en heteroaryl eller en aryl kondensert med en cykloalkyl eller en heterocyklisk gruppe; Ar er eventuelt substituert med én eller flere alkyl; alkenyl; alkynyl; cyano; halogen; alkoksy; monohalogenoalkoksy; polyhalogenoalkoksy; alkoksyalkyl; dialkylamino; ikke-aromatisk heterocyklyltilknyttet gjennom et nitrogen; alkylsulfanyl; alkylsulfinyl; alkylsulfonyl; monohalogenoalkylsulfanyl; monohalogenoalkylsulfinyl;
monohalogenoalkylsulfonyl; polyhalogenoalkylsulfanyl; polyhalogenoalkylsulfinyl; polyhalogenoalkylsulfonyl; heteroaryl; aryl; aralkyl; aryloksy; alkoksy-karbonylamino; acyl; acylamino; aminokarbonyl;
monoalkylaminokarbonyl; dialkylaminokarbonyl; alkylsulfonylamino; monohalogenoalkyl; polyhalogenoalkyl; hydroksyl; hydroksyalkyl; oksoalkyl; eller deres farmasøytisk akseptable salter, hydrater eller hydratiserte salter eller polymorfe, krystallinske strukturer av disse forbindelser eller deres optiske
isomerer, racemater, diastereomerene eller enantiomerer; hvor:
"Alkyl" betyr en alifatisk hydrokarbongruppe som kan være lineær eller forgrenet og som har 1 til 12 karbonatomer i kjeden;
"Alkenyl" betyr en alifatisk hydrokarbongruppe inneholdende en karbon-karbondobbeltbinding og som kan være lineær eller forgrenet og som har 2 til 4 karbonatomer i kjeden;
"Alkynyl" betyr en alifatisk hydrokarbongruppe inneholdende en karbon-karbontrippelbinding og som kan være lineær eller forgrenet og som har 2 til 4 karbonatomer i kjeden;
"Aryl" betyr et aromatisk monocyklisk eller multicyklisk hydrokarbon-ringsystemmed 6 til 10 karbonatomer;
"Cykloalkyl" betyr et ikke-aromatisk mono- eller multicyklisk hydrokarbonringsystem med 5 til 6 karbonatomer;
"Cykloalkenyl" betyr et ikke-aromatisk mono- eller multicyklisk ringsystem medca. 5 til ca. 10 karbonatomer og som inneholder minst én karbon-karbondobbeltbinding;
"Heteroaryl" eller aromatisk heterocykliske grupper angir en 5 til 10 leddet aromatisk hetero, mono-, bi- eller multicyklisk ring;
"Heterocyklisk gruppe" eller "Heterocyklisk" refererer til en mettet, delvis umettet eller umettet, ikke-aromatisk med 5 til 10 leddet mono, bi eller multicykliskeringer hvor minst ett medlem av ringen er et heteroatom.
Fortrinnsvis er R er cyanoalkyl; polyhalogenocyanoalkyl; hydroksyalkyl; polyhalogenoalkyl; alkoksyalkyl; alkoksyalkoksyalkyl; aryloksyalkyl; mono- ellerpolyhalogenoaryloksyalkyl; ikke-aromatisk heterocyklyl(CH2)m hvor den ikkearomatiske heterocykliske gruppe eventuelt er kondensert med aryl eller eventuelt substituert med én eller flere acyl, alkyl eller halogen;
alkylkarbonylalkyl; acylaminoalkyl; aminokarbonylalkyl; alkylsulfanylalkyl; alkylsulfonylalkyl;
m er 2 eller 4,
Fortrinnsvis representerer Ar aryl, mer foretrukket fenyl.
Fortrinnsvis er Ar substituert med én eller flere flere alkyl, cyano, halogen, alkoksy, polyhalogenoalkoksy, alcanediyl, dialkylamino, alkylsulfanyl, aryl, aralkyl, aryloksy, alkoksykarbonylamino, acyl, alkylsulfonylamino, polyhalogenoalkyl, hydroksy, hydroksyalkyl, oksoalkyl.Fortrinnsvis er Ar usubstituert eller substituert med én eller flere av alkyl, polyhalogenalkyl, halogen eller cyano, mer foretrukket med alkyl eller polyhalogenalkyl.
Fortrinnsvis er forbindelsene ifølge oppfinnelsen de med formel (A):
r N-CHH
N N—Ar
(A)
hvor:
R er valgt fra cyanoalkyl; monohalogenoalkyl (hvor halogen er Cl, Br eller I); polyhalogenoalkyl; alkoksyalkyl; monohalogenoalkoksyalkyl;
polyhalogenoalkoksyalkyl; alkoksyalkoksyalkyl;
monohalogenoalkoksyalkoksyalkyl; polyhalogenoalkoksyalkoksyalkyl;
monohalogenocyanoalkyl; polyhalogenocyanoalkyl; aryloksyalkyl; cykloalkenylalkyl; dialkylaminoalkyl; hydroksyalkyl;
Het
Het
polyhalogenodialkylaminoalkyl;
er en ikke-aromatisk heterocyklisk gruppe eventuelt kondensert med aryl ellereventuelt substituert med én eller flere acyl, alkyl eller halogen; arylaminoalkyl;
alkylkarbonylalkyl; acylaminoalkyl; aminokarbonylalkyl; alkylsulfanylalkyl;
alkylsulfinylalkyl; alkylsulfonylalkyl; mono- eller polyhalogenoaryloksyalkyl;
m er 2 eller 4,
Ar representerer en aryl; en heteroaryl eller en aryl kondensert med en
cykloalkyl eller en heterocyklisk gruppe; Ar er eventuelt substituert med én eller flere alkyl; alkenyl; alkynyl; cyano; halogen; alkoksy; monohalogenoalkoksy; polyhalogenoalkoksy; alkoksyalkyl; dialkylamino; ikke-aromatisk heterocyklyltilknyttet gjennom et nitrogen; alkylsulfanyl; alkylsulfinyl; alkylsulfonyl;
monohalogenoalkylsulfanyl; monohalogenoalkylsulfinyl;
monohalogenoalkylsulfonyl; polyhalogenoalkylsulfanyl;
polyhalogenoalkylsulfinyl; polyhalogenoalkylsulfonyl; heteroaryl; aryl; aralkyl; aryloksy; alkoksy-karbonylamino; acyl; acylamino; aminokarbonyl;
monoalkylaminokarbonyl; dialkylaminokarbonyl; alkylsulfonylamino;
monohalogenoalkyl; polyhalogenoalkyl; hydroksyl; hydroksyalkyl; oksoalkyl;
eller deres farmasøytisk akseptable salter, hydrater eller hydratiserte salter eller polymorfe krystallinske strukturer av disse forbindelser eller deres optiske isomerer, racemater, diastereomerene eller enantiomerer.Fortrinnsvis, i formel (A):
R er valgt fra cyanoalkyl; polyhalogenalkyl; alkoksy; alkoksyalkyl; polyhalogencyanoalkyl; cyanocykloalkyl; aryloksyalkyl; arylalkoksy; cykloalkenyl; cykloalkenylalkyl; cykloalkenyl kondensert med benzen; dialkylaminoalkyl; hydroksyalkyl; alkylkarbonylalkyl; acylaminoalkyl; aminokarbonylalkyl; alkylsulfinylalkyl; alkyl-sulfonylalkyl; alkylkarbonyl;
—(CH9)m-C L, A r A
v 27 Het ) HetJ
hvor xer en ikke-aromatisk heterocykliskgruppe eventuelt kondensert med aryl eller eventuelt substituert med én eller flere av acyl, alkyl eller halogen;
Ar representerer aryl eventuelt kondensert med en cykloalkyl- eller enheterocyklisk gruppe og/eller Ar er eventuelt substituert med én eller flere av alkyl; cyano; halogen; alkoksy; polyhalogenalkoksy; alkoksyalkyl; dialkylamino; alkylsulfanyl; alkylsulfonyl; polyhalogenalkylsulfanyl; heteroaryl; aryloksy; alkoksy-karbonylamino; acyl; aminokarbonyl; alkylsulfonylamino;polyhalogenalkyl; hydroksyl; hydroksyalkyl;
eller deres farmasøytisk akseptable salter, hydrater eller hydratiserte salter eller polymorfe, krystallinske strukturer av disse forbindelser eller deres optiske isomerer, racemater, diastereomerer eller enantiomerer.
Foretrukne forbindelser med formel (I) kan være valgt fra:
- 2-cyano-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- A/-(4-{2-[4-(3-acetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-cyanoacetamid,
- 2,2,2-trifluor-A/-(4-{2-[4-(3-trifluormetylfenyI)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- 2-metoksy-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- 2-metoksy-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid, hydroklorid,
- 2,2-difluor-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- 2-hydroksy-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid, hydroklorid,
- 3-metoksy-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid,
- A/-(4-{2-[4-(2,4-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-metoksyacetamid,
- A/-(4-{2-[4-(2-cyano-3-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2metoksyacetamid,
- A/-(4-{2-[4-(2-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-metoksyacetamid,
- 2-etoksy-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid, hydroklorid,
- 2-etoksy-/V-(4-{2-[4-(2-fluorfenyl)piperazin-1 -yl]etyl}cyklo-heksyl)acetamid,
- /V-(4-{2-[4-(2-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-2-metoksyacetamid,
- 2-metoksy-/V-{4-[2-(4-fenylpiperazin-1-yl)etyl]cykloheksyl}acetamid,
- 2-fenoksy-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- 3,3,3-trifluor-A/-(4-{2-[4-(3-trifluormetylfenyI)piperazin-1 yl]etyl}cykloheksyl)propanamid,
- 4-metoksy-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid,
- /V-(4-{2-[4-(2-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-metoksypropanamid,
- /V-(4-{2-[4-(2-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-2-etoksyacetamid,
- /V-(4-{2-[4-(2-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-metoksypropanamid,
- A/-(4-{2-[4-(2-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-4-metoksybutanamid,
- 2-metoksy-2-metyl-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)propanamid,
- /V-(4-{2-[4-(3-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-2-etoksyacetamid,
- 2-cyano-/V-(4-{2-[4-(2-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 2-metylsulfanyl-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- 2-(2-metoksyetoksy)-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid, hydroklorid,
- /V-(4-{2-[4-(3-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-2-metoksyacetamid,
- 3,3,3-trifluor-/V-(4-{2-[4-(2-fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid,
- /V-(4-{2-[4-(2-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-fenoksyacetamid,
- 2-cyano-/V-(4-{2-[4-(3-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(2,3-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-metoksyacetamid,
- 2-dimetylamino-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(2-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-isopropoksyacetamid,
- 4-metoksy-/V-{4-[2-(4-fenylpiperazin-1-yl)etyl]cykloheksyl}butanamid,
- 2-isopropoksy-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- A/-(4-{2-[4-(2-cyano-3-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2isopropoksyacetam id,
- A/-(4-{2-[4-(2-cyano-3-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2etoksyacetamid,
- 2-cyano-/V-(4-{2-[4-(2-cyano-3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-{4-[2-(4-fenylpiperazin-1 -yl)etyl]cykloheksyl}acetamid, hydroklorid,
- 2-acetylamino-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- A/-(4-{2-[4-(3,5-bistrifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid,
- /V-(4-{2-[4-(3,5-bistrifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2etoksyacetamid,
- 3-okso-A/-(4-{2-[4-(3-trifluormetyIfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid,
- 2-cyano-/V-(4-{2-[4-(2,6-di-tert-butylpyrimidin-4-yl)piperazin-1yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(2,3-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-etoksyacetamid,
- 2-cyano-/V-(4-{2-[4-(2,3-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(2-cyano-3-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(2-cyano-3-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-3,3,3trifluorpropanamid,
- 2-cyano-/V-(4-{2-[4-(5,6,7,8-tetrahydronaftalen-1 -yl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- 2-etoksy-/V-(4-{2-[4-(5,6,7,8-tetrahydronaftalen-1 -yl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(3,5-bistrifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2metoksyacetamid,
- /V-(4-{2-[4-(2-cyano-3-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2metoksyacetamid,
- 2-cyano-/V-{4-[2-(4-pyridin-4-ylpiperazin-1-yl)etyl]cykloheksyl}acetamid,
- /V-(4-{2-[4-(2,6-di-terf-butylpyrimidin-4-yl)piperazin-1 -yl]etyl}cykloheksyl)-2etoksyacetamid,
- /V-(4-{2-[4-(2,6-di-terf-butylpyrimidin-4-yl)piperazin-1 -yl]etyl}cykloheksyl)-2
metoksyacetamid,
- 2-etoksy-/V-(4-{2-[4-(2-metoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(2-metoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 2-metoksy-/V-(4-{2-[4-(2-metoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(2-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,hydroklorid,
- 2-acetylamino-/V-{4-[2-(4-fenylpiperazin-1-yl)etyl]cykloheksyl}acetamid,
- A/-(4-{2-[4-(2-klorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-metoksyacetamid,
- 2-metoksy-/V-(4-{2-[4-(5,6,7,8-tetrahydronaftalen-1 -yl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(2-klorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-cyanoacetamid,
- A/-(4-{2-[4-(2-klorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-etoksyacetamid,
- 2-cyano-/V-(4-{2-[4-(3-fluorfenyl-piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 2-acetylamino-/V-(4-{2-[4-(2-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 2-tert-butoksy-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(3-klor-2-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid,
- /V-(4-{2-[4-(3-klor-2-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2etoksyacetamid,
- 2-cyano-/V-(4-{2-[4-(3-cyano-5-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- A/-(4-{2-[4-(3-cyano-5-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2
metoksyacetamid,
- A/-(4-{2-[4-(3-cyano-5-trifluormetylfenyl)piperazin-1 -yl]etyl}cykloheksyl)-2etoksyacetamid,
- /V-(4-{2-[4-(2,3-diklorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-metoksyacetamid,
- 2-cyano-/V-(4-{2-[4-(2,3-diklorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(2,3-diklorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-etoksyacetamid,
- 2-acetylamino-/V-(4-{2-[4-(2,3-difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- A/-(4-{2-[4-(2,3-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)2isopropoksyacetamid, hydroklorid,
- 2-cyano-/V-(4-{2-[4-(3,5-dimetylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(3-etylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(3-dimetylaminofenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(3,5-diklorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(2,5-dimetylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1-yl]etyl}cyklo-heksyl)succinamid,
- /V-(4-{2-[4-(5-klor-2-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid,
- /V-(4-{2-[4-(3-klorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-cyanoacetamid,
- 2-cyano-/V-(4-12-[4-(3-trifluormetoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(2-fluor-3-trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(3,5-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(3-metoksy-5-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid,
- 4-cyano-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid,
- 2-cyano-/V-(4-{2-[4-(2,4-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-12-[4-(3-isopropoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid, hydroklorid,
- 2-cyano-/V-(4-{2-[4-(3-metoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,hydroklorid,
- 2-cyano-/V-(4-{2-[4-(2-metoksy-5-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-{4-[2-(4-m-tolylpiperazin-1-yl)etyl]cykloheksyl}acetamid,
- 3-dietylamino-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid,
- 3-cyano-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid, hydroklorid,
- /V-(4-{2-[4-(3-terf-butylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-cyanoacetamid,
- 2-cyano-/V-(4-{2-[4-(3-etoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- A/-(4-{2-[4-(5-klor-2-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-cyanoacetamid,
- 4-cyano-/V-(4-{2-[4-(2-fluor-3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)butanamid,
- 2-cyano-/V-(4-{2-[4-(6-trifluormetylbenzo[b]tiofen-3-yl)piperazin-1yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(2-fluor-5-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(3-hydroksyfenyl)piperazin-1-yl]etyl}cyklo-heksyl)acetamid,hydroklorid,
- /V-(4-{2-[4-(5-klor-2-metoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid,
- /V-(4-{2-[4-(2-terf Butyl-6-trifluormetylpyrimidin-4-yl)piperazin-1 yl]etyl}cykloheksyl)-2-cyanoacetamid,
- 2-cyano-/V-(4-{2-[4-(2-metyl-3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(5-klor-2-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-3,3,3trifluorpropanamid,
- 2-cyano-/V-(4-{2-[4-(3,5-dimetoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(3-klor-5-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-cyanoacetamid,
- 2-cyano-/V-(4-{2-[4-(3-metylsulfanylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-{4-[2-(4-naftalen-1 -ylpiperazin-1 -yl)etyl]cykloheksyl}acetamid,
- A/-(4-{2-[4-(3,5-bistrifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4cyanobutanamid,
- /V-(4-{2-[4-(3-klor-2-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-cyanoacetamid,
- A/-(4-{2-[4-(2-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)succinamid,
- /V-{4-[2-(4-fenylpiperazin-1 -yl)etyl]cykloheksyl}succinamid,
- 3,3,3-trifluor-/V-{4-[2-(4-fenylpiperazin-1-yl)etyl]cykloheksyl}propanamid,
- A/-(4-{2-[4-(2-klor-5-trifluormetylfenyl)piperazin-1 -yl]etyl}cykloheksyl)-2cyanoacetamid,
- /V-(4-{2-[4-(5-klor-2-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)succinamid,
- 4-oksopentansyre (4-{2-[4-(3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)amid,
- 2-cyano-/V-(4-{2-[4-(2-fluor-5-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(2-klor-5-metoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid,
- 2-cyano-/V-(4-{2-[4-(2-metylsulfanylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(2-metoksy-5-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(5-fluor-2-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(5-terf-butyl-2-metoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid,
- 2-cyano-/V-(4-{2-[4-(5-metoksy-2-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- 5-oksoheksansyre (4-{2-[4-(3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)amid,
- 4-cyano-/V-(4-{2-[4-(3-etylfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid,hydroklorid,
- 4-cyano-/V-(4-{2-[4-(2-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid,
- A/-(4-{2-[4-(3-klor-2-fluorfenyl)piperazin-1 -yl]etyl}cykloheksyl)-4cyanobutanamid,
- 4-cyano-/V-(4-{2-[4-(3-trifluormetoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid,
- 4-cyano-/V-(4-{2-[4-(2-fluor-5-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)butanamid,
- 2-cyano-/V-(4-{2-[4-(2-cyano-3-fluorfenyl-piperazin-1 yl]etyl}cykloheksyl)acetamid,
- 4-cyano-/V-(4-{2-[4-(5,6,7,8-tetrahydronaftalen-1 -yl)piperazin-1 yl]etyl}cykloheksyl)butanamid,
- 4-cyano-/V-(4-{2-[4-(2,3-diklorfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid,
- 2-cyano-/V-(4-{2-[4-(5,6,7,8-tetrahydronaftalen-2-yl)piperazin-1yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-{4-[2-(4-indan-5-ylpiperazin-1-yl)etyl]cykloheksyl}acetamid,
- /V-(4-{2-[4-(3,5-bistrifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-3cyanopropanamid,
- 3-cyano-/V-(4-{2-[4-(2-fluor-3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)propanamid,
- /V-(4-{2-[4-(3-klor-2-metoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid,
- /V-(4-{2-[4-(3-benzylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-cyanoacetamid,
- [3-(4-{2-[4-(2-cyanoacetylamino)cykloheksyl]etyl}piperazin-1yl)fenyl]karbaminsyre-etylester,
- 2-cyano-/V-(4-{2-[4-(2,3-dimetylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-{4-[2-(4-o-tolylpiperazin-1 -yl)etyl]cykloheksyl}acetamid,
- 2-cyano-/V-(4-{2-[4-(2,5-dimetoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- 4-oksopentansyre (4-{2-[4-(3,5-bis-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)amid,
- 4-dimetylamino-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid,
- 2-(4-fluorfenoksy)-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(2-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid, hydroklorid,
- 2-cyano-/V-(4-{2-[4-(2,5-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(2-klor-5-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid,
- 2-cyano-/V-(4-{2-[4-(2,5-diklorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(3-klorfenyl)piperazin-1-yl]etyl}cykloheksyl)-4-cyanobutanamid,
- 4-cyano-/V-(4-{2-[4-(2-metyl-3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid,
- 4-oksopentansyre (4-{2-[4-(2-fluor-3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)amid,
- 2-cyano-/V-(4-{2-[4-(3,5-di-terf-butylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- A/-(4-{2-[4-(2-klorfenyl)piperazin-1-yl]etyl}cykloheksyl)-4-cyanobutanamid,
- 4-cyano-/V-{4-[2-(4-m-tolylpiperazin-1-yl)etyl]cykloheksyl}butanamid,
- 3,3,3-trifluor-/V-{4-[2-(4-m-tolylpiperazin-1-yl)etyl]cykloheksyl}propanamid,
- 4-cyano-/V-(4-{2-[4-(2-metylsulfanylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid,
- 2-cyano-/V-{4-[2-(4-kinolin-8-ylpiperazin-1-yl)etyl]cykloheksyl}acetamid,
- 4-cyano-/V-(4-{2-[4-(3-metylsulfanylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid,
- 2-cyano-/V-{4-[2-(4-kinolin-5-ylpiperazin-1-yl)etyl]cykloheksyl}acetamid,
- 2-cyano-/V-(4-{2-[4-(3-metansulfonylaminofenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(4-fluor-fenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-{4-[2-(4-p-tolylpiperazin-1-yl)etyl]cykloheksyl}acetamid,
- 2-cyano-/V-(4-{2-[4-(2-etoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(2-tert-butyl-6-trifluormetylpyrimidin-4-yl)piperazin-1yl]etyl}cykloheksyl)-3-cyanopropanamid,
- 2-cyano-/V-(4-{2-[4-(2-fenoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(3-klor-2-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid,
- 2-cyano-/V-(4-{2-[4-(2-etylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(5-klor-2-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4cyanobutanamid,
- 4-cyano-/V-(4-{2-[4-(3,5-dimetylfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid,
- /V-(4-{2-[4-(3-etylfenyl)piperazin-1-yl]etyl}cykloheksyl)-3,3,3-trifluorpropanamid,
- 3-cyano-/V-(4-{2-[4-(3-etylfenyl)piperazin-1 -yl]etyl}cykloheksyl)propanamid,
- 4-cyano-/V-(4-{2-[4-(6-trifluormetylbenzo[b]tiofen-3-yl)piperazin-1yl]etyl}cykloheksyl)butanamid,
- 4-cyano-/V-(4-{2-[4-(3,5-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid,
- 2-cyano-/V-(4-{2-[4-(2,4-dietylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 3,3,3-trifluor-/V-(4-{2-[4-(2-fluor-3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)propanamid,
- /V-(4-{2-[4-(5-klor-2-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-3cyanopropanamid,
- /V-(4-{2-[4-(3-klor-2-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4cyanobutanamid,
- /V-(4-{2-[4-(3-klor-5-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-4cyanobutanamid,
- A/-(4-{2-[4-(2-fluor-3-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2metoksyacetamid,
- 4-cyano-/V-(4-{2-[4-(3,5-diklorfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid,
- 4-cyano-/V-{4-[2-(4-kinolin-8-ylpiperazin-1-yl)etyl]cykloheksyl}butanamid,
- 4,4,4-trifluor-A/-(4-{2-[4-(3-trifluormetyIfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid,
- 3-cyano-/V-(4-{2-[4-(2-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)propanamid,
- 2-cyano-/V-(4-{2-[4-(2,6-dimetylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(3-hydroksymetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- 3-cyano-/V-(4-{2-[4-(3-metylsulfanylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid,
- 2-cyano-/V-(4-{2-[4-(3-metoksymetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(3-propylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-(4-{2-[4-(3,4-diklorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 2-cyano-/V-[4-(2-{4-[3-(1 -hydroksyetyl)fenyl]piperazin-1 yl}etyl)cykloheksyl]acetamid,
- 2-cyano-/V-(4-{2-[4-(4-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,
- /V-(4-{2-[4-(4-klorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-cyanoacetamid,
- /V-{4-[2-(4-bifenyl-3-yl-piperazin-1-yl)etyl]cykloheksyl}-2-cyanoacetamid,
- 2-cyano-/V-(4-{2-[4-(4-fluor-3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid,
- 3-cyano-/V-(4-{2-[4-(5-fluor-2-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid,
- 4-cyano-/V-(4-{2-[4-(5-fluor-2-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid,
- /V-(4-{2-[4-(3-bromfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-cyanoacetamid,
- 2-cyano-/V-[4-(2-{4-[3-(1,1 -difluoretyl)fenyl]piperazin-1 yl}etyl)cykloheksyl]acetamid,
- 2-cyano-2,2-dimetyl-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)acetamid,
- 4-cyano-/V-(4-{2-[4-(4-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid,
- 3,3,3-trifluor-/V-(4-{2-[4-(4-fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid,
- 2-cyano-/V-(4-{2-[4-(4-etylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,
- 4-cyano-/V-(4-{2-[4-(2-etylfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid,
- 4-cyano-/V-(4-{2-[4-(3-propylfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- 2-cyano-/V-(4-{2-[4-(3-fluor-2-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-[4-(2-{4-[3-(1,1 -difluoretyl)fenyl]piperazin-1 yl}etyl)cykloheksyl]butanamid
- /V-{4-[2-(4-benzo[1,3]dioksol-5-ylpiperazin-1 -yl)etyl]cykloheksyl}-2cyanoacetamid
- 2-cyano-N-(4-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 3,3,3-trifluor-/V-{4-[2-(4-kinolin-5-ylpiperazin-1-yl)etyl]cykloheksyl}propanamid
- 4-cyano-/V-{4-[2-(4-kinolin-5-ylpiperazin-1-yl)etyl]cykloheksyl}butanamid
- 2-cyano-/V-(4-{2-[4-(4-fluor-3-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-(4-{2-[4-(3,4-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-(4-{2-[4-(3-etylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 2-metansulfinyl-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-(4-{2-[4-(3-isopropylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-(4-{2-[4-(3,5-dimetylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 2-metansulfonyl-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-(4-{2-[4-(3-fluor-4-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-(4-{2-[4-(3,4-dimetylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-(4-{2-[4-(3,4,5-trifluorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-(4-{2-[4-(3-trifluormetylsulfanylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-(4-{2-[4-(3-metansulfonylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-(4-{2-[4-(3-difluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(3-fluor-2-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- 4-cyano-/V-(4-{2-[4-(3,4-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- 4-cyano-/V-(4-{2-[4-(4-fluor-3-metylfenyl)piperazin-1 yl]etyl}cykloheksylbutanamid
- /V-(4-{2-[4-(4-klor-2-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-cyanoacetamid
- /V-(4-{2-[4-(4-klor-3-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid
- 4-cyano-/V-(4-{2-[4-(3-trifluormetylsulfanylfenyl)piperazin-1yl]etyl}cykloheksyl)butanamid
- 4-cyano-/V-(4-{2-[4-(3-difluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- /V-{4-[2-(4-benzo[1,3]dioksol-5-ylpiperazin-1 -yl)etyl]cykloheksyl}-4cyanobutanamid
- 4-cyano-/V-(4-{2-[4-(2-fluor-3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)butanamid
- 4-cyano-/V-(4-{2-[4-(4-fluor-3-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid, hydroklorid
- 4-cyano-/V-(4-{2-[4-(3,4-diklorfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- /V-(4-{2-[4-(3-klor-4-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid
- 2-cyano-/V-(4-{2-[4-(4-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(2,5-diklorfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- 2-cyklopent-2-enyl-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(3,4,5-trifluorfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- /V-(4-{2-[4-(3-acetylfenyl)piperazin-1-yl]etylcykloheksyl)-4-cyanobutanamid
- 2-cyano-/V-(4-{2-[4-(2-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(2-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- /V-(4-{2-[4-(3-klor-4-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4cyanobutanamid
- 4-cyano-/V-(4-{2-[4-(2-metoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- /V-(4-{2-[4-(2,4-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-(4fluorfenoksy)acetamid
- /V-(4-{2-[4-(2,4-difluorfenyl)piperazin-1 -yl]etyl}cykloheksyl)-3,3,3trifluorpropanamid
- 2-cyklopent-3-enyl-/V-(4-{2-[4-(2-fluorfenylpiperazin-1 yl]etyl}cykloheksyl)acetamid
- /V-(4-{2-[4-(2-klor-4-fluor-5-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid
- /V-(4-{2-[4-(2-klor-4-fluor-5-metylfenylpiperazin-1-yl]etyl}cykloheksyl)-4cyanobutanamid
- 4-cyano-/V-(4-{2-[4-(5-metoksy-2-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- 4-cyano-/V-(4-{2-[4-(3,5-dimetoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- /V-(4-{2-[4-(3-klor-2-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-4cyanobutanamid
- 4-cyano-/V-(4-{2-[4-(3-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- /V-(4-{2-[4-(3-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-fenoksyacetamid
- A/-(4-{2-[4-(3-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)succinamid
- A/-(4-{2-[4-(3-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)succinamid
- 4-cyano-/V-(4-{2-[4-(2,4-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- 3-cyano-/V-(4-{2-[4-(2,4-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)propanamid
- /V-(4-{2-[4-(2-klor-5-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4cyanobutanamid
- 4-cyano-/V-(4-{2-[4-(2-metoksy-5-trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)butanamid
- 3,3,3-trifluor-/V-(4-{2-[4-(3-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)propanamid
- 3-dietylamino-/V-(4-{2-[4-(3-fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
- 3-cyano-/V-(4-{2-[4-(3-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)propanamid
- 4-cyano-/V-(4-{2-[4-(2,5-dimetylfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- /V-(4-{2-[4-(5-klor-2-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-4cyanobutanamid
- /V-(4-{2-[4-(5-klor-2-metoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)-4cyanobutanamid
- 4-cyano-/V-(4-{2-[4-(3-metoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- 3-cyano-/V-(4-{2-[4-(3-metoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)propanamid
- /V-(4-{2-[4-(3-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-4-metoksybutanamid
- 2-cyklopent-2-enyl-/V-(4-12-[4-(3-fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(3-metoksy-5-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)butanamid
- /V-(4-{2-[4-(2-etylfenyl)piperazin-1-yl]etyl}cykloheksyl)-3,3,3-trifluorpropanamid
- 2-cyano-/V-(4-{2-[4-(2,4-diklor-5-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(2,4-diklor-5-trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)butanamid
- /V-(4-{2-[4-(3-etylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-metansulfonylacetamid
- /V-(4-{2-[4-(2,3-difluorfenyl)piperazin-1 -yl]etyl}cykloheksyl)-2metansulfonylacetamid
- A/-(4-{2-[4-(4-klorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-metansulfonylacetamid
- 4-cyano-/V-{4-[2-(4-o-tolylpiperazin-1-yl)etyl]cykloheksyl}butanamid
- 4-cyano-/V-(4-{2-[4-(2,3-dimetylfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- 4-cyano-/V-(4-{2-[4-(4-fluor-3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)butanamid
- 4-cyano-/V-(4-{2-[4-(3-cyano-5-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- 4-cyano-/V-(4-{2-[4-(2-trifluormetylfenyl)piperazin-1 yl]etylcykloheksyl)butanamid, hydroklorid
- /V-(4-{2-[4-(3-klor-5-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid
- /V-(4-{2-[4-(3-klor-5-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4cyanobutanamid
- 4-cyano-/V-(4-{2-[4-(2-etoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- 4-cyano-/V-(4-12-[4-(2-fluor-5-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- 4-cyano-/V-(4-{2-[4-(2,5-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- 2,2-difluor-/V-(4-{2-[4-(2-fluor-3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(2,3-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- A/-(4-{2-[4-(2,3-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-3,3,3
trifluorpropanamid
- 4-cyano-/V-(4-{2-[4-(3-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- /V-(4-{2-[4-(3-klor-2-metoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)-4cyanobutanamid
- 2-cyano-/V-(4-{2-[4-(2,3,4-trifluorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(2,3,4-trifluorfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- 3,3,3-trifluor-/V-(4-{2-[4-(3-metansulfonylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
- 2-cyano-/V-{4-[2-(4-indan-4-ylpiperazin-1-yl)etyl]cykloheksyl}acetamid
- 4-cyano-/V-{4-[2-(4-indan-4-ylpiperazin-1-yl)etyl]cykloheksyl}butanamid
- A/-(4-{2-[4-(2-fluor-3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)succinamid
- 4-cyano-2,2-difluor-/V-(4-{2-[4-(2-fluor-3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)butanamid
- 2,2,2-trifluor-/V-(4-{2-[4-(3-metansulfonylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- /V-{4-[2-(4-bifenyl-3-ylpiperazin-1-yl)etyl]cykloheksyl}-4-cyanobutanamid
- 2-etoksy-/V-(4-{2-[4-(3,4,5-trifluorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-{4-[2-(4-p-tolylpiperazin-1-yl)etyl]cykloheksyl}butanamid
- 4,4,4-trifluor-/\/-(4-{2-[4-(3-metansulfonylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- A/-(4-{2-[4-(2-fluor-3-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4
metoksybutanamid
- A/-(4-{2-[4-(4-klor-2-fluorfenyl)piperazin-1 -yl]etyl}cykloheksyl)-4cyanobutanamid
- 2-cyano-/V-(4-{2-[4-(2,4,5-trifluorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(2,4,5-trifluorfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- 2-etoksy-/V-{4-[2-(4-p-tolylpiperazin-1-yl)etyl]cykloheksyl}acetamid
- 3,3,3-trifluor-A/-[4-(2-{4-[3-( 1 -hydroksyetyl)fenyl]piperazin-1 yl}etyl)cykloheksyl]propanamid
- 2-etoksy-/V-(4-{2-[4-(2-fluor-3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid
- /V-(4-{2-[4-(4-klorfenyl)piperazin-1-yl]etyl}cykloheksyl)-4-cyanobutanamid
- /V-(4-{2-[4-(4-klorfenyl)piperazin-1-yl]etyl}cykloheksyl)-3,3,3-trifluorpropanamid
- 4-cyano-/V-(4-{2-[4-(2-metoksy-5-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- 2-cyano-/V-(4-{2-[4-(2-fluor-4-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(2-fluor-4-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- /V-(4-{2-[4-(3,4-diklorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-etoksyacetamid
- /V-(4-{2-[4-(3-klor-4-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2etoksyacetamid
- /V-(4-{2-[4-(3-klor-4-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-3,3,3
trifluorpropanamid
- 3,3,3-trifluor-/V-{4-[2-(4-p-tolylpiperazin-1-yl)etyl]cykloheksyl}propanamid
- /V-(4-{2-[4-(3,4-diklorfenyl)piperazin-1-yl]etyl}cykloheksyl)-4-metoksybutanamid
- /V-(4-{2-[4-(2,4-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-etoksyacetamid
- /V-(4-{2-[4-(2,4-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-4metoksybutanamid
- 4-cyano-/V-(4-{2-[4-(3,4-dimetylfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- /V-(4-{2-[4-(3,4-dimetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4metoksybutanamid
- /V-(4-{2-[4-(3,4-dimetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-etoksyacetamid
- /V-(4-{2-[4-(3,4-dimetylfenyl) piperazin-1 -yIJetyl}cykloheksyI)-3,3,3trifluorpropanamid
- 4-cyano-/V-(4-{2-[4-(5,6,7,8-tetrahydronaftalen-2-yl)piperazin-1yl]etyl}cykloheksyl)butanamid
- /V-(4-{2-[4-(3-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-3,3,3trifluorpropanamid
- /V-(4-{2-[4-(3-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-4-metoksybutanamid
- 2-etoksy-/V-(4-{2-[4-(2-fluor-5-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid
- /V-(4-{2-[4-(4-klor-fenyl)piperazin-1-yl]etyl}-cykloheksyl)-2-etoksyacetamid
- A/-(4-{2-[4-(2-fluor-3-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2propoksyacetamid
- 2-cyano-/V-(4-{2-[4-(3,4-diklor-2-fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(3,4-diklor-2-fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- /V-(4-{2-[4-(2,5-diklorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-etoksyacetamid
- 4-cyano-/V-(4-{2-[4-(2-cyano-3-fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- 4-cyano-/V-(4-{2-[4-(3-oksazol-2-ylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- /V-(4-{2-[4-(3-klor-5-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid
- /V-(4-{2-[4-(3-klor-5-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4cyanobutanamid
- 2-cyano-/V-(4-{2-[4-(3-oksazol-2-ylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(3-etoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- 4-cyano-/V-(4-{2-[4-(3-fluor-4-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- 2-etoksy-/V-(4-{2-[4-(3-fluor-4-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-[4-(2-{4-[3-(1 -hydroksypropyl)fenyl]piperazin-1 yl}etyl)cykloheksyl]butanamid
- 2-metoksy-/V-(4-{2-[4-(3,4,5-trifluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(4-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- /V-(4-{2-[4-(2,5-diklorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-etoksyacetamid
- A/-(4-{2-[4-(3-klor-2-metylfenyl)piperazin-1 -yl]etyl}cykloheksyl)-4metoksybutanamid
- A/-(4-{2-[4-(3-klor-2,4-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid
- A/-(4-{2-[4-(3-klor-2,4-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-4cyanobutanamid
- 2-etoksy-/V-{4-[2-(4-o-tolylpiperazin-1-yletyl]cykloheksyl}acetamid
- /V-(4-{2-[4-(3-etylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4-metoksybutanamid
- 2-etoksy-/V-(4-{2-[4-(3-etylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-[4-(2-{4-[3-(1 -hydroksypropyl)fenyl]piperazin-1 yl}etyl)cykloheksyl]acetamid
- 4-metoksy-/V-(4-{2-[4-(3,4,5-trifluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- 2-etoksy-/V-(4-{2-[4-(4-metoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-(4-{2-[4-(4-metoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-(4-{2-[4-(3,5-difluor-4-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-[4-(2-{4-[3-(1 -hydroksy-2-metylpropyl)fenyl]piperazin-1 yl}etyl)cykloheksyl]acetamid
- /V-(4-{2-[4-(3-klor-5-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2etoksyacetamid
- /V-(4-{2-[4-(3-klor-5-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4
metoksybutanamid
- A/-(4-{2-[4-(2-klor-4-fluor-5-metylfenyl)piperazin-1 -yl]etyl}cykloheksyl)-2etoksyacetamid
- /V-(4-{2-[4-(2-klor-4-fluor-5-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4metoksybutanamid
- 4-cyano-/V-(4-{2-[4-(4-metoksyfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- 2-cyano-/V-(4-{2-[4-(2-fluor-5-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid
- /V-(4-{2-[4-(3-klor-4-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-cyanoacetamid
- /V-(4-{2-[4-(3-klor-4-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-4cyanobutanamid
- /V-(4-{2-[4-(2-klor-5-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid
- /V-(4-{2-[4-(2-klor-5-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-4cyanobutanamid
- A/-(4-{2-[4-(3-klor-2,4-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)succinamid
- 2-cyano-/V-(4-{2-[4-(4-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- A/-(4-{2-[4-(2-fluor-5-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4metoksybutanamid
- A/-(4-{2-[4-(2-fluor-5-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)succinamid
- 3-cyano-/V-(4-{2-[4-(4-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
- 3-cyano-/V-(4-{2-[4-(3-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)propanamid
- 2-cyano-/V-(4-{2-[4-(2-fluor-4-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(2-fluor-4-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- 4-metoksy-/V-(4-{2-[4-(2,3,4-trifluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- /V-(4-{2-[4-(3-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-4,4,4-trifluorbutanamid
- /V-(4-{2-[4-(3-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-3-metoksypropanamid
- 2-cyano-/V-(4-{2-[4-(3-cyano-4-fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- /V-(4-{2-[4-(3-cyano-4-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-4metoksybutanamid
- 4-cyano-/V-(4-12-[4-(3-cyano-4-fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- 2-cyano-/V-(4-{2-[4-(3-fluor-5-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(3-fluor-5-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)butanamid
- 3-cyano-/V-(4-{2-[4-(2-fluor-5-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)propanamid
- A/-(4-{2-[4-(2-fluor-5-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2propoksyacetamid, hydroklorid
- 3,3,3-trifluor-/V-(4-{2-[4-(2-fluor-5-trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)propanamid
- A/-(4-{2-[4-(2-fluor-5-trifluormetylfenyl)piperazin-1 -yl]etyl}cykloheksyl)malonamid
- 2-cyano-/V-(4-{2-[4-(5-etyl-2-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(5-etyl-2-fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- 4-metoksy-/V-{4-[2-(4-m-tolylpiperazin-1-yl)etyl]cykloheksyl}butanamid
- /V-(4-{2-[4-(3,4-diklor-2-fluor-fenyl)piperazin-1-yl]etyl}cykloheksyl)-4metoksybutanamid
- 2-cyano-/V-(4-12-[4-(3-cyano-2,4-difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(3-cyano-2,4-difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- /V-(4-{2-[4-(3-fluor-2-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4metoksybutanamid
- /V-(4-{2-[4-(3,5-diklorfenyl)piperazin-1-yl]etyl}cykloheksyl)-4-metoksybutanamid
- /V-(4-{2-[4-(3-cyano-2,4-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-4metoksybutanamid
- /V-(4-{2-[4-(4-klorfenyl)piperazin-1-yl]etyl}cykloheksyl)-4-metoksybutanamid
- A/-(4-{2-[4-(2-fluor-5-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2metoksyacetamid
- A/-(4-{2-[4-(2-fluor-5-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2metansulfonylacetamid
- /V-(4-{2-[4-(2-fluor-4-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4metoksybutanamid
- 2-cyano-/V-(4-{2-[4-(2,3,4,5-tetrafluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-(4-{2-[4-(2,4-diklorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- /V-(4-{2-[4-(3,5-dimetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4metoksybutanamid
- 3-cyano-/V-(4-{2-[4-(3,5-dimetylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
- 2-cyano-/V-(4-{2-[4-(2,4,5-triklorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- A/-(4-{2-[4-(3,4-diklor-2-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2metoksyacetamid
- 3-cyano-/V-(4-{2-[4-(3,4-diklor-2-fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
- 2-cyano-/V-(4-{2-[4-(3-fluor-5-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(3-fluor-5-metylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- 2-cyano-/V-(4-{2-[4-(2,3,4-triklorfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 5-cyano-pentansyre (4-{2-[4-(2-fluor-5-trifluormetylfenyl)piperazin-1 yletyl}cykloheksyl)amid
- A/-(4-{2-[4-(3-klor-2,4-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-3cyanopropanamid
- 2-metoksy-/V-(4-{2-[4-(2-metyl-3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid
- 4-metoksy-/V-(4-{2-[4-(2-metyl-3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)butanamid
- 4,4,4-trifluor-/\/-(4-{2-[4-(2-fluor-5-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)butanamid
- A/-(4-{2-[4-(3,5-bistrifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)malonamid
- /V-(4-{2-[4-(3-klor-5-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-4metoksybutanamid
- /V-(4-{2-[4-(3,5-bistrifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4metoksybutanamid
- /V-(4-{2-[4-(3-klor-5-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2metoksyacetamid
- /V-(4-{2-[4-(3-klor-5-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-3cyanopropanamid
- 5-cyano-pentansyre (4-{2-[4-(3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl) amid
- 2-cyano-/V-{4-[2-(4-pentafluorfenylpiperazin-1-yl)etyl]cykloheksyl}acetamid
- A/-(4-{2-[4-(4-fluor-3-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4metoksybutanamid
- /V-(4-{2-[4-(4-klor-3-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4metoksybutanamid
- /V-(4-{2-[4-(4-klor-3-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4cyanobutanamid
- A/-(4-{2-[4-(3-fluor-5-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4
metoksybutanamid
- A/-(4-{2-[4-(4-fluor-3-trifluormetylfenyl)piperazin-1 -yl]etyl}cykloheksyl)-2metoksyacetamid
- A/-(4-{2-[4-(2,4-diklorfenyl)piperazin-1-yl]etyl}cykloheksyl)-4-metoksybutanamid
- 4-cyano-/V-(4-{2-[4-(2,4-diklorfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- 4-cyano-/V-(4-{2-[4-(2,4,5-triklorfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- 4-cyano-/V-(4-{2-[4-(2,3,4-triklorfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- 3-(4-{2-[4-(4-metoksybutanoylamino)cykloheksyl]etyl}piperazin-1-yl)benzamid
- /V-(4-{2-[4-(3-acetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-3,3,3trifluorpropanamid
- 2-cyano-/V-(4-{2-[4-(3-propanoylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(3-propanoylfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamid
- 2-cyano-/V-(4-{2-[4-(3-isobutanylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid,dihydroklorid
- 4-metoksy-/V-(4-{2-[4-(2,3,4,5-tetrafluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butyramid
- 4-cyano-/V-(4-12-[4-(2,3,4,5-tetrafluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butyramid
- 2-cyano-/V-(4-{2-[4-(2-metyl-5-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(2-metyl-5-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butyramid
eller deres farmasøytisk akseptable salter, hydrater eller hydratiserte salter eller polymorfe, krystallinske strukturer av disse forbindelser eller deres optiske
isomerer, racemater, diastereomerene eller enantiomerer.
Mer spesielt:
- 4-metoksy-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- A/-(4-{2-[4-(3-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-2-etoksyacetamid
- A/-(4-{2-[4-(3-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-2-metoksyacetamid
- A/-(4-{2-[4-(3,5-bistrifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid
- A/-(4-{2-[4-(3-cyano-5-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2metoksyacetamid
- A/-(4-{2-[4-(3-cyano-5-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2etoksyacetamid
- 2-cyano-/V-(4-{2-[4-(3,5-dimetylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-(4-{2-[4-(3-etylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- 2-cyano-/V-(4-{2-[4-(2-fluor-5-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid
- A/-(4-{2-[4-(3-klor-5-fluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-2-cyanoacetamid
- 4-cyano-/V-(4-{2-[4-(2-fluor-5-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)butanamid
- A/-(4-{2-[4-(5-klor-2-metylfenyl)piperazin-1-yl]etyl}cykloheksyl)-3cyanopropanamid
- 2-cyano-A/-(4-{2-[4-(4-trifluormetyIfenyI)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-(4-{2-[4-(4-fluor-3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid
- 4-cyano-/V-[4-(2-{4-[3-(1,1 -difluoretyl)fenyl]piperazin-1 yl}etyl)cykloheksyl]butanamid
- 2-cyano-/V-(4-{2-[4-(3-metansulfonylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-(4-{2-[4-(3-difluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
- /V-(4-{2-[4-(3-acetylfenyl)piperazin-1-yl]etylcykloheksyl)-4-cyanobutanamid
- 4-cyano-/V-(4-{2-[4-(3,5-dimetoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
- 3,3,3-trifluor-/V-(4-{2-[4-(3-metansulfonylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
- /V-(4-{2-[4-(3-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-4-metoksybutanamid
- 4-cyano-/V-[4-(2-{4-[3-(1 -hydroksypropyl)fenyl]piperazin-1 yl}etyl)cykloheksyl]butanamid
- /V-(4-{2-[4-(3-klor-2,4-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)-4cyanobutanamid
- 2-cyano-/V-[4-(2-{4-[3-(1 -hydroksypropyl)fenyl]piperazin-1 yl}etyl)cykloheksyl]acetamid
- A/-(4-{2-[4-(3-klor-2,4-difluorfenyl)piperazin-1-yl]etyl}cykloheksyl)succinamid
- A/-(4-{2-[4-(2-fluor-5-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-4
metoksybutanamid
- A/-(4-{2-[4-(3-cyanofenyl)piperazin-1 -yl]etyl}cykloheksyl)-4,4,4-trifluorbutanamid
- /V-(4-{2-[4-(3-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-3-metoksypropanamid
eller deres farmasøytisk akseptable salter, hydrater eller hydratiserte salter eller polymorfe, krystallinske strukturer av disse forbindelser eller deres optiske isomerer, racemater, diastereomerene eller enantiomerer.|
Ytterligere foretrukket:
- A/-(4-{2-[4-(3-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-2-metoksyacetamid
- A/-(4-{2-[4-(3,5-bistrifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid
- 2-cyano-/V-(4-{2-[4-(3-metansulfonylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
- 2-cyano-/V-[4-(2-{4-[3-(1 -hydroksypropyl)fenyl]piperazin-1 yl}etyl)cykloheksyl]acetamid
- A/-(4-{2-[4-(3-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-4,4,4-trifluorbutanamid
- A/-(4-{2-[4-(3-cyanofenyl)piperazin-1-yl]etyl}cykloheksyl)-3-metoksypropanamid
eller deres farmasøytisk akseptable salter, hydrater eller hydratiserte salter eller polymorfe, krystallinske strukturer av disse forbindelser eller deres optiske isomerer, racemater, diastereomerene eller enantiomerer.
Som anvendt ovenfor eller i det følgende, om ikke på annen måte definert i kravene:
"Acyl" betyr en H-CO- eller alkyl-CO-gruppe hvor alkylgruppen er som herbeskrevet. Foretrukne acylgrupper inneholder lavere alkyl. Eksempler på acylgrupper omfatter formyl, acetyl, propanoyl, 2-metylpropanoyl, butanoyl ogpalmitoyl.
"Acylamino" er en acyl-NH-gruppe hvor acyl er som definert her.
"Acylaminoalkyl" betyr acyl-NH-alkyl hvor acyl og alkyl er som definert her.
"Alkandiyl" betyr -(CH2)q- hvor q er et helt tall fra 3 til 6, fortrinnsvis fra 3 til5.
"Alkenyl" betyr en alifatisk hydrokarbongruppe som inneholder en karbonkarbon dobbeltbinding og som kan være lineær eller forgrenet og som har 2 til 15 karbonatomer i kjeden. Foretrukne alkenylgrupper har 2 til 12 karbonatomer i kjeden; og mer foretrukket ca. 2 til 4 karbonatomer i kjeden. Eksempler på alkenylgrupper omfatter etenyl, propenyl, n-butenyl, /-butenyl, 3-metylbut-2-enyl,n-pentenyl, heptenyl, oktenyl, nonenyl, decenyl.
"Alkoksy" betyr en alkyl-O-gruppe hvor alkylgruppen er som beskrevet her.Eksempler på alkoksygrupper omfatter metoksy, etoksy, n-propoksy, /-propoksy,n-butoksy og heptoksy.
"Alkoksyalkyl" betyr en alkyl-O-alkyl-gruppe hvor alkylgruppene uavhengiger som beskrevet her. Eksempler på alkoksygrupper omfatter metoksyetyl, etoksymetyl, n-butoksymetyl og cyklopentylmetyloksyetyl.
"Alkoksyalkoksyalkyl" betyr en alkyl-O-alkyl-O-alkyl-gruppe hvoralkylgruppene uavhengig er som definert ovenfor.
"Alkoksyalkylamino" betyr alkyl-O-alkyl-NH- hvor alkyl er som definert her."Alkoksy(alkyl)amino" betyr alkyl-O-N(alkyl)- hvor alkyl er som definert her."Alkoksykarbonylamino" betyr alkyl-O-CO-NH- hvor alkyl er som definerther.
"Alkyl" betyr en alifatisk hydrokarbongruppe som kan være lineær eller forgrenet som har 1 til 20 karbonatomer i kjeden. Foretrukne alkylgrupper har 1 til 12 karbonatomer i kjeden. Forgrenet betyr at én eller flere lavere alkylgrupper så som metyl, etyl eller propyl er bundet til en lineær alkylkjede. Eksempler på alkylgrupper omfatter metyl, etyl, n-propyl, /-propyl, n-butyl, f-butyl, n-pentyl, 3pentyl, oktyl, nonyl, decyl.
Alkylgrupper kan være substituert med en cyanogruppe ("cyanoalkyl"), en hydroksylgruppe ("hydroksyalkyl"), en halogen-gruppe ("monohalogenalkyl")eller flere ("polyhalogenalkyl").
"Alkylamino" betyr en alkyl-NH-gruppe hvor alkylgruppen er som herbeskrevet.
"Alkylkarbonylalkyl" betyr alkyl-CO-alkyl- hvor alkyl uavhengig er somdefinert her.
"Alkylsulfanyl" betyr en alkyl-S-gruppe hvor alkylgruppen er som herbeskrevet.
"Alkylsulfanylalkyl" betyr en alkyl-S-alkyl-gruppe hvor alkylgruppeneuavhengig er som her beskrevet.
"Alkylsulfinyl" betyr en alkyl-SO-gruppe hvor alkylgruppen er som definerther. Foretrukne grupper er de hvor alkylgruppen er lavere alkyl.
"Alkylsulfinylalkyl" betyr en alkyl-SO-alkyl-gruppe hvor alkylgruppeneuavhengig er som definert ovenfor. Foretrukne grupper er de hvor alkylgruppen er lavere alkyl.
"Alkylsulfonyl" betyr en alkyl-SCte-gruppe hvor alkylgruppen er som definerther. Foretrukne grupper er de hvor alkylgruppen er lavere alkyl.
"Alkylsulfonylalkyl" betyr en alkyl-SCte-alkyl-gruppe hvor alkylgruppeneuavhengig er som definert her. Foretrukne grupper er de hvor alkylgruppen er lavere alkyl.
"Alkylsulfonylamino" betyr alkyl-SCte-NH- hvor alkyl er som definert her.
"Alkynyl" betyr en alifatisk hydrokarbongruppe som inneholder en karbonkarbon trippelbinding og som kan være lineær eller forgrenet som har 2 til 15 karbonatomer i kjeden. Foretrukne alkynylgrupper har 2 til 12 karbonatomer i kjeden; og mer foretrukket 2 til 4 karbonatomer i kjeden. Eksempler på alkynylgrupper omfatter etynyl, propynyl, n-butynyl, 2-butynyl, 3-metylbutynyl, npentynyl, heptynyl, oktynyl og decynyl.
"Aminokarbonylalkyl" betyr NFh-CO-alkyl- hvor alkyl er som definert her.
"Aralkyl" betyr en aryl-alkyl-gruppe hvor aryl og alkyl er som beskrevet her.Foretrukne aralkylgrupper inneholder en lavere alkylgruppe. Eksempler på aralkylgrupper omfatter benzyl, 2-fenetyl og naftylmetyl.
"Aryl" betyr et aromatisk monocyklisk eller multicyklisk hydrokarbonringsystem med 6 til 14 karbonatomer, fortrinnsvis med 6 til 10 karbonatomer. Eksempler på arylgrupper omfatter fenyl eller naftyl.
"Arylaminoalkyl" betyr aryl-NH-alkyl- hvor aryl og alkyl er som definert her.
"Arylalkoksy" betyr en aryl-alkyl-O-gruppe hvor aryl- eller alkylgrupper ersom beskrevet her.
"Aryloksy" betyr en aryl-O-gruppe hvor arylgruppen er som definert her.Eksempler på grupper omfatter fenoksy og 2-naftyloksy.
"Aryloksyalkyl" betyr en aryl-O-alkyl-gruppe hvor aryl- eller alkylgruppeneer som beskrevet her. Et eksempel på aryloksyalkylgrupper er fenoksypropyl.
"Cykloalkenyl" betyr et ikke-aromatisk mono- eller multicyklisk ringsystemmed ca. 3 til ca. 10 karbonatomer, fortrinnsvis med ca. 5 til ca. 10 karbonatomer og som inneholder minst én karbon-karbon dobbeltbinding. Foretrukneringstørrelser på ringer i ringsystemet omfatter ca. 5 til ca. 6 ringatomer. Eksempler på monocyklisk cykloalkenyl omfatter cyklopentenyl, cykloheksenyl, cykloheptenyl. Et eksempel på multicyklisk cykloalkenyl er norbornenyl.
"Cykloalkyl" betyr et ikke-aromatisk mono- eller multicyklisk hydrokarbonringsystem med 3 til 10 karbonatomer, fortrinnsvis med 5 til 10 karbonatomer. Foretrukne ringstørrelser på ringer i ringsystemet omfatter 5 til 6 ringatomer. Eksempler på monocyklisk cykloalkyl omfatter cyklopentyl, cykloheksyl, cykloheptyl. Eksempler på multicyklisk cykloalkyl omfatter 1 -dekalin, norbornyl,adamant-(1 - eller 2-)yl.
"Dialkylamino" betyr en (alkyl)2N- gruppe hvor alkylgruppene uavhengig ersom her beskrevet.
"Dialkylaminoalkyl" betyr en (alkyl)2N-alkyl- gruppe hvor alkylgruppeneuavhengig er som her beskrevet.
"Halogen" angir et fluor-, klor-, brom- eller jodatom; fortrinnsvis fluor- ogkloratom.
Som anvendt her angir betegnelsen "heteroaryl" eller aromatiske heterocykliske grupper en 5- til 14-, fortrinnsvis 5- til 10-leddet aromatisk hetero-,mono-, bi- eller multicyklisk ring. Eksempler omfatter pyrrolyl, pyridyl, pyrazolyl,tienyl, pyrimidinyl, pyrazinyl, tetrazolyl, indolyl, kinolinyl, purinyl, imidazolyl, tiazolyl, benzotiazolyl, furanyl, benzofuranyl, 1,2,4-tiadiazolyl, isotiazolyl, triazoyl, isokinolyl,benzotienyl, isobenzofuryl, karbazolyl, benzimidazolyl, isoksazolyl, pyridyl-N-oksid,så vel som de kondenserte systemer som er et resultat av kondensering med en fenylgruppe.
Som anvendt her refererer betegnelsene "heterocyklisk gruppe" eller "heterocyklyl" til mettede, delvis umettede eller umettede, ikke-aromatiske stabile 3til 14-, fortrinnsvis 5- til 10-leddede mono-, bi- eller multicykliske ringer hvor minst
ett element i ringen er et heteroatom. Typisk omfatter heteroatomer, men er ikke begrenset til, oksygen-, nitrogen-, svovel-, selen- og fosfor-atomer. Foretrukneheteroatomer er oksygen, nitrogen og svovel.
Egnede heterocykliske grupper er også beskrevet i The Handbook of Chemistry and Physics, 76. utgave, CRC Press, Inc., 1995-1996, sider 2-25 til 2-26.
Foretrukne ikke-aromatiske heterocykliske grupper omfatter pyrrolidinyl,pyrazolidinyl, imidazolidinyl, oksiranyl, tetrahydrofuranyl, dioksolanyl, dioksanyl, piperidyl, piperazinyl, morfolinyl, pyranyl, imidazolinyl, pyrrolinyl, pyrazolinyl, tiazolidinyl, tetrahydrotiopyranyl, ditianyl, tiomorfolinyl, dihydropyranyl, tetrahydropyranyl, dihydropyranyl, tetrahydro-pyridyl, dihydropyridyl,tetrahydropyrimidinyl, dihydrotiopyranyl, azepanyl, så vel som de kondenserte systemer som er et resultat av kondensering med en fenylgruppe.
"Oksoalkyl" betyr alkyl hvor en CH2 er erstattet med en CO hvor alkyl er som definert her.
"Polymetylendioksy" betyr -O-(CH2)P-O- hvor p er et helt tall fra 1 til 4.
"Kondensert arylheterocyklyl" betyr kondensert aryl og heterocyklyl som definert her. Foretrukne kondenserte arylheterocyklyl-grupper er de hvorarylgruppen derav erfenyl og heterocyklyl består av ca. 5 til ca. 6 ringatomer. En kondensert arylheterocyklylgruppe som en variabel kan være bundet gjennom hvilket som helst atom i ringsystemet derav som er i stand til dette. Betegnelsen aza, oksa eller tia som prefiks før heterocyklyl-delen avkondensert arylheterocyklyl definerer at henholdsvis minst ett nitrogen-,oksygen- eller svovel-atom er til stede som et ringatom. Nitrogenatomet ikondensert arylheterocyklyl kan være et basisk nitrogenatom. Nitrogen- ellersvovelatomet i heterocyklyl-delen av kondensert arylheterocyklyl kan ogsåeventuelt være oksidert til det tilsvarende N-oksid, S-oksid eller S,S-dioksid.Eksempler på foretrukne kondenserte arylheterocyklyl-ringsystemer omfatterindolinyl, 1,2,3,4-tetrahydroisokinolin, 1,2,3,4-tetrahydrokinolin, 1H-2,3-dihydroisoindol-2-yl, 2,3-dihydrobenz[f]isoindol-2-yl, 1,2,3,4-tetrahydrobenz[g]isokinolin2-yl.
"Kondensert arylcykloalkyl" betyr kondensert aryl og cykloalkyl som definert her. Foretrukne kondenserte arylcykloalkylgrupper er de hvor arylgruppen derav er fenyl og cykloalkylgruppen består av ca. 5 til ca. 6 ringatomer. Kondensert
arylcykloalkyl som en variabel kan være bundet gjennom hvilket som helst atom i ringsystemet derav som er i stand til dette. Eksempler på kondensert arylcykloalkyl omfatter 1,2,3,4-tetrahydronaftyl.
Som anvendt her refererer "farmasøytisk akseptable salter" til derivater av de beskrevne forbindelser hvor stamforbindelsen er modifisert ved fremstilling av syreeller basesalter derav. De farmasøytisk akseptable salter omfatter de konvensjonelle ikke-toksiske salter eller de kvaternære ammoniumsalter avstamforbindelsen dannet, for eksempel fra ikke-toksiske uorganiske eller organiskesyrer. For eksempel omfatter slike konvensjonelle ikke-toksiske salter de avledet frauorganiske syrer så som saltsyre, bromhydrogensyre, svovelsyre, sulfaminsyre, fosforsyre, salpetersyre; og saltene fremstilt fra organiske syrer så som eddiksyre, propansyre, ravsyre, vinsyre, sitronsyre, metansulfonsyre, benzensulfonsyre, glukuronsyre, glutaminsyre, benzosyre, salicylsyre, toluensulfonsyre, oksalsyre, fumarsyre, maleinsyre. Ytterligere addisjonssalter omfatter ammoniumsalter så som trometamin, meglumin, epolamin, etc., metallsalter så som natrium, kalium, kalsium, sink eller magnesium. Hydroklorid- og oksalat-salter er foretrukket.
De farmasøytisk akseptable salter ifølge foreliggende oppfinnelse kan syntetiseres fra stamforbindelsen som inneholder en basisk eller sur gruppe ved konvensjonelle kjemiske metoder. Generelt kan slike salter fremstilles ved omsetning av de frie syre- eller baseformer av disse forbindelser med enstøkiometrisk mengde av den passende base eller syre i vann eller i et organisk løsningsmiddel eller i en blanding av de to. Generelt er ikke-vandige medier så someter, etylacetat, etanol, isopropanol eller acetonitril foretrukket. Lister over egnede salter finnes i Remington's Pharmaceutical Sciences, 17. ed., Mack Publishing Company, Easton, PA, 1985, s. 1418.
Forbindelsene med den generelle formel (I) som har geometriske og stereomerer er også en del av oppfinnelsen.
I henhold til et ytterligere aspekt angår foreliggende oppfinnelse også fremgangsmåter for fremstilling av forbindelsene med formel (I).
Forbindelsene og prosessene ifølge foreliggende oppfinnelse kan fremstilles på flere måter velkjent for fagfolk på området. Forbindelsene kan syntetiseres, for eksempel ved anvendelse eller tilpasning av metodene beskrevet nedenfor eller
variasjoner derav som forstått av fagfolk. De passende modifikasjoner og substitusjoner vil lett være klare og velkjente eller kan lett oppnås fra vitenskapelig litteratur av fagfolk på området.
Spesielt kan slike metoder finnes i R.C. Larock, Comprehensive Organic Transformations, VCH publishers, 1989.
Det vil forstås at forbindelsene ifølge foreliggende oppfinnelse kan inneholde ett eller flere asymmetrisk substituerte karbonatomer og kan isoleres i optisk aktive eller racemiske former. Således er alle chirale, diastereomere, racemiske former og alle geometriske isomere former av en struktur omfattet, hvis ikke den spesifikke stereokjemi eller isomere form er spesifikt angitt. Det er velkjent på området hvorledes fremstille og isolere slike optisk aktive former. For eksempel kan blandinger av stereomerer separeres ved standard teknikker omfattende spaltning av racemiske former, normal, revers-fase og chiral kromatografi, preferensiellsaltdannelse, omkrystallisering eller ved chiral syntese enten fra chirale utgangsmaterialer eller ved tilsiktet syntese av målrettede chirale sentere.
Forbindelser ifølge foreliggende oppfinnelse kan fremstilles ved en rekke synteseveier. Reagensene og utgangsmaterialene er kommersielt tilgjengelige eller kan lett syntetiseres ved velkjente teknikker av en fagmann på området. Alle substituenter, hvis ikke annet er angitt, er som tidligere definert.
I reaksjonene beskrevet nedenfor, kan det være nødvendig å beskytte reaktive funksjonelle grupper, for eksempel hydroksy-, amino-, imino-, tio- ellerkarboksygrupper, hvor disse er ønsket i sluttproduktet, for å unngå deres uønskede deltagelse i reaksjonene. Konvensjonelle beskyttelsesgrupper kan anvendes i henhold til standard praksis, se for eksempler T.W. Greene og R. G. M. Wuts i Protective Groups in Organic Chemistry, John Wiley and Sons, 1991; J. F. W. McOmie i Protective Groups in Organic Chemistry, Plenum Press, 1973.
Noen reaksjoner kan utføres i nærvær av en base. Det er ingen spesiell restriksjon på typen av basen som skal anvendes i denne reaksjonen og hvilken som helst base konvensjonelt anvendt i reaksjoner av denne typen kan like gjerne anvendes her, forutsatt at den ikke har noen ugunstig effekt på andre deler av molekylet. Eksempler på egnede baser omfatter: natriumhydroksid, kaliumkarbonat, trietylamin, alkalimetallhydrider, så som natriumhydrid og
kaliumhydrid; alkyllitium-forbindelser, så som metyllitium og butyllitium; ogalkalimetallalkoksider, så som natriummetoksid og natriumetoksid.
Vanligvis blir reaksjoner utført i et egnet løsningsmiddel. En rekke løsningsmidler kan anvendes, forutsatt at de ikke har noen ugunstig effekt på reaksjonen eller på reagensene involvert. Eksempler på egnede løsningsmidler omfatter: hydrokarboner, som kan være aromatiske, alifatiske eller cykloalifatiske hydrokarboner, så som heksan, cykloheksan, metylcykloheksan, toluen og xylen; am ider, så som /V,/V-dimetylformamid; alkoholer så som etanol og metanol ogetere, så som dietyleter, metyl-terf-butyleter, metyl-cyklopentyleter ogtetrahydrofuran.
Reaksjonene kan skje over et bredt område av temperaturer. Generelt finner vi det hensiktsmessig å utføre reaksjonen ved en temperatur på fra 0°C til 150°C (mer foretrukket fra ca. romtemperatur til 100°C). Tiden som er nødvendig for reaksjonen kan også variere sterkt, avhengig av mange faktorer, spesielt reaksjonstemperaturen og typen av reagensene. Imidlertid, forutsatt at reaksjonen blir utført under de foretrukne betingelser beskrevet ovenfor, vil en periode på fra 3 timer til 20 timer vanligvis være tilstrekkelig.
Forbindelsen således fremstilt kan gjenvinnes fra reaksjonsblandingen ved konvensjonelle metoder. For eksempel kan forbindelsene gjenvinnes ved avdestillering av løsningsmidletfra reaksjonsblandingen eller, hvis nødvendig, etter avdestillering av løsningsmidletfra reaksjonsblandingen, helling av residuet i vann fulgt av ekstraksjon med et vann-ublandbart organisk løsningsmiddel ogavdestillering av løsningsmidletfra ekstrakten. I tillegg kan produktet, om ønsket, være ytterligere renset ved forskjellige velkjente teknikker, så som omkrystallisering, represipitering eller de forskjellige kromatografi-teknikker, spesieltkolonnekromatografi eller preparativ tynnskiktskromatografi.
Fremgangsmåten for fremstilling av en forbindelse med formel (I) ifølge oppfinnelsen er et annet aspekt ved foreliggende oppfinnelse.
I henhold til beskrivelsen kan forbindelser med formel (I) oppnås fra tilsvarende forbindelser med formel (II)
hvor R', R'i og R'2 representerer henholdsvis R, Ri og R2 eller en forløpergruppe for henholdsvis R, Ri og R2.
Ifølge beskrivelsen kan forbindelser med formel (I) oppnås ved en metode omfattende trinnene:
a) omdannelse av forbindelsen med formel (II) til en forbindelse med formel (I); og eventuelt
b) isolering av den oppnådde forbindelse med formel (I).
Ifølge foreliggende oppfinnelse angir en "forløper-gruppe" av enfunksjonell gruppe hvilken som helst gruppe som kan, ved én eller flere reaksjoner, føre til den ønskede funksjon, ved hjelp av én eller flere egnede reagenser. Reaksjonene omfatter avbeskyttelse av funksjonelle grupper, så vel som vanlig addisjon, substitusjon, reduksjon, oksidasjon eller funksjonaliseringsreaksjon.
Fortrinnsvis kan en forbindelse med formel (I) hvor Ar i NR1R2 er substituert med en acylgruppe fremstilles fra en tilsvarende forbindelse med formel (II) hvor Ar i NR1R2 er substituert med en hydroksylert kjede. Denne reaksjonen kan utføres ved Swern eller Swern Moffatt oksidasjon så vel som virkning av metallisk oksid så som krom- eller mangan-oksider.
Fortrinnsvis kan en forbindelse med formel (I) hvor Z er e) fremstilles fra en tilsvarende forbindelse med formel (II) hvor Z er f) ved reduksjon. Denne reaksjonen kan utføres med hydrogen og en overgangsmetall-katalysator såsom palladium eller nikkel.
Fortrinnsvis kan en forbindelse med formel (I) hvor R er alkyl fremstilles fra en tilsvarende forbindelse med formelen hvor R er alkoksy ved hydrolysering av denne ester til den tilsvarende syre (R=OH), omdannelse av syren til Weinreb's amid (R=N(Me)OMe) og til slutt omsetning med et Grignard's reagens.
Fortrinnsvis kan en forbindelse med formel (I) hvor Z er e) eller f) og R er et amin fremstilles fra den tilsvarende syre (R=OH) ved en peptidisk koblingsreaksjon. Denne reaksjonen blir utført ved anvendelse av reagenser så som et karbodiimid, karbonyldiimidazol eller et klorformiat i nærvær av
katalysatorer så som DMAP, HOBt i et inert løsningsmiddel så som diklormetan, /V,/V-dimetylformamid, tetrahydrofuran eller etylacetat ved en temperaturomfattet mellom 0°C og 40°C.
Forbindelser ifølge oppfinnelsen med formel (I) hvor Z er
—N-cCf
a) H H "
kan fremstilles ved kobling av forbindelser med formel (III) med syre eller syrederivater R'COX eller R'COCOX
(III)
hvor R' og NR'iR'2 representeret henholdsvis Ri og NR1R2 som tidligere definert og Z er:
—N-cCf
a) H
Mer presist, når reaksjonen kan være en peptidisk kobling med R'COOH eller R'COCOOH og blir utført ved anvendelse av reagenser så som et karbodiimid, karbonyldiimidazol eller et klorformiat i nærvær av katalysatorer så som DMAP, HOBt i et inert løsningsmiddel så som diklormetan, N,Ndimetylformamid, tetrahydrofuran eller etylacetat ved en temperatur omfattet mellom 0°C og 40°C.
Forbindelse R'COX eller R'COCOX kan også være en aktivert form av et karboksylat så som et syreklorid (X=CI), et imidazolid (X=imidazol-1-yl), ethydroksysuccinimidoyl (X= OSu), en paranitrofenylester (X= 4-nitrofenoksy), etblandet anhydrid eller et symmetrisk anhydrid. Reaksjonen blir utført i et inert løsningsmiddel så som diklormetan, /V,/V-dimetylformamid, tetrahydrofuran elleretylacetat ved en temperatur omfattet mellom 0°C og 40°C, eventuelt i nærvær av en katalysator så som DMAP eller HOBt og en base så som trietylamin eller et karbonat.
Forbindelser med formel (III) kan oppnås ved avbeskyttelse av forbindelser med formel (IV)
p—z
NR^R^
(IV)
hvor P representerer en nitrogen-beskyttelsesgruppe så sombenzyloksykarbonyl eller terf-butoksykarbonyl.
Når P er benzyloksykarbonyl kan avbeskyttelse utføres ved anvendelse av dihydrogen, cykloheksen eller et formiat i nærvær av en katalysator så som palladium på trekull i en alkohol så som metanol eller etanol ved en temperatur omfattet mellom romtemperatur og 80°C eller med aluminiumtriklorid i nærvær av anisol.
Når P er terf-butoksykarbonyl kan avbeskyttelse utføres ved anvendelse avtrimetylsilyljodid eller en Brdnsted-syre så som trifluoreddiksyre eller saltsyreeller en Lewis-syre så som tinntetraklorid i et egnet løsningsmiddel ved entemperatur omfattet mellom 0 og 40°C.
Forbindelser med formel (IV) kan fremstilles ved nukleofil substitusjon av forbindelser med formel (V)
(V)
hvor L representerer en utgående gruppe så som et halogen eller et sulfonat (mesylat eller arylsulfonat).
Denne substitusjon kan utføres ved blanding av forbindelse (V) og aminet HNR'iR'2 i et egnet løsningsmiddel så som acetonitril, aceton, N,Ndimetylformamid, diklormetan eller en alkohol, i nærvær av en base så som et karbonat, et bikarbonat eller et tertiært amin, ved en temperatur omfattet mellom romtemperatur og tilbakeløpstemperatur.
Forbindelser med formel (V) kan fremstilles fra den tilsvarende alkohol med formel (VI)
OH
(VI)
Denne reaksjonen kan utføres ved anvendelse av tionylklorid med eller uten imidazol eller et fosfin og tetrahalogenmetan eller heksahalogenetan eller et sulfonylklorid eller anhydrid i et egnet løsningsmiddel ved en temperatur omfattet mellom 0° og 40°C.
Alternativt kan forbindelser med formel (I) hvor Z representerer
a) —N-CH
H \
fremstilles fra forbindelser med formel (VII) ved reduktiv aminering
0=\ /—\
(VII)
Denne reaksjonen kan utføres med ammonium så som ammoniumacetat eller -klorid i nærvær av et reduksjonsmiddel så som natriumtriacetoksyborhydrid, natrium-borhydrid eller natriumcyanoborhydrid i en alkoholså som metanol eller etanol og eventuelt vann ved en temperatur omfattet mellom -20°C og tilbakeløp.
Forbindelser med formel (VII) kan fremstilles ved avbeskyttelse av spiroketal med formel (VIII)
C°>O^
O >—f ^NR'^
(VIII)
Denne avbeskyttelse kan utføres med en syre så som saltsyre, svovelsyre eller en sulfonsyre i en alkohol så som metanol eller etanol og vann ved en temperatur omfattet mellom romtemperatur og tilbakeløp.
Forbindelser med formel (VIII) kan fremstilles fra det tilsvarende mesylat
o..,P s/ -o
Denne substitusjon kan utføres ved blanding av mesylatet og aminet HNR'iR'2 i et egnet løsningsmiddel så som acetonitril, aceton, A/,A/dimetylformamid, diklormetan eller en alkohol, i nærvær av en base så som et karbonat, et bikarbonat eller et tertiært amin, ved en temperatur omfattet mellom romtemperatur og tilbakeløpstemperaturen.
Forbindelser med formel (VIII) kan også fremstilles ved reduksjon av amider med formel (IX)
NR^R^
(IX) 0
Denne reduksjonen kan utføres med litiumaluminiumhydrid i en eter så som dietyleter, metyl-terf-butyleter, metyl-cyklopentyleter eller tetrahydrofuranved en temperatur omfattet mellom 0°C og tilbakeløp.
Forbindelser med formel (VIII) kan også fremstilles fra det tilsvarende ytterligere mesylat med formelen:
Denne substitusjon kan utføres ved blanding av mesylatet og aminet HNR'iR'2 i et egnet løsningsmiddel så som acetonitril, aceton, N,Ndimetylformamid, diklormetan eller en alkohol, i nærvær av en base så som et karbonat, et bikarbonat eller et tertiært amin, ved en temperatur omfattet mellom romtemperatur og tilbakeløpstemperaturen.
Dette ytterligere mesylat kan fremstilles fra det tilsvarende 4-(2hydroksyetyl)cykloheksanon
OH
Denne reaksjonen kan utføres ved omsetning av 4-(2hydroksyetyl)cykloheksanon med metansulfonylklorid, metansulfonylfluorid eller metansulfonsyreanhydrid i nærvær av en organisk eller uorganisk base så som pyridin, trietylamin, 1,4-diazabicyklo[2,2,2]oktan, 1,5-diazabicyklo[4,3,0]non-5en, 1,8-diazabicyklo[5,4,0]undec-7-en, et karbonat eller et bikarbonat i et inertløsningsmiddel så som diklormetan, dikloretan, et aromatisk løsningsmiddel, en eter eller en blanding derav, ved en temperatur omfattet mellom -20°C ogtilbakeløpstemperaturen.
4-(2-hydroksyetyl)cykloheksanon er et kjent mellomprodukt på forskjelligeindustrielle områder så som farmasøytisk syntese og flytende krystall
opparbeiding, det kan fremstilles fra 4-(2-hydroksyetyl)cykloheksanol vedselektiv oksidasjon
OH
HO
Denne oksidasjon kan utføres med en oksidant som er i stand til å omdanne en sekundær alkohol til et keton i nærvær av en primær alkohol. En slik oksidant kan være et hypokloritt-salt så som natrium- eller kalsiumhypokloritt i et egnet løsningsmiddel så som en karboksylsyre, vann eller en blanding derav.
Alternativt kan ikke-selektiv oksidant anvendes med tidligere beskyttelse avden primære alkohol før oksidasjonstrinnet.
4-(2-hydroksyetyl)cykloheksanol er et kjent mellomprodukt på forskjelligeindustrielle områder så som farmasøytisk syntese og flytende krystall opparbeiding, det kan fremstilles ved reduksjon av 4-(2-hydroksyetyl)fenol
OH
HO
Denne reduksjonen kan utføres med hydrogen eller en hydrogen-donor (såsom cykloheksen, maursyre, maursyre-trietylamin eutektisk blanding) i nærværav en metall-katalysator (så som palladium, platina, nikkel eller ruthenium båretpå trekull, silika eller alumina), endelig i nærvær av et additiv (så som boraks, natriumacetat, kaliumacetat, litiumacetat, natriumhydroksid, litium-hydroksid,kaliumkarbonat, natriumkarbonat, kaliumhydrogenkarbonat eller natriumhydrogenkarbonat i et egnet løsningsmiddel så som en alkohol (metanol, etanol, isopropanol), vann, en karboksylsyre (eddiksyre, propansyre), en eter (dietyleter, metyl-terf-butyleter, tetrahydrofuran, dioksan, cyklopentylmetyleter), et aromatisk løsningsmiddel (toluen, xylen) eller en blanding derav
Amider med formel (IX) kan fremstilles ved kondensering av aminet HNR'iR'2 med (1,4-dioksaspiro[4,5]dec-8-yl)eddiksyre.
OH
O
Denne reaksjonen kan utføres ved anvendelse av reagenser så som et karbodiimid, karbonyldiimidazol eller et klorformiat i nærvær av katalysatorer så som DMAP, HOBt i et inert løsningsmiddel så som diklormetan, N,Ndimetylformamid, tetrahydrofuran eller etylacetat ved en temperatur omfattet mellom 0°C og 40°C.
I henhold til et tredje aspekt kan forbindelser ifølge oppfinnelsen med formel (II) hvor Z er
x /
C) —(CH2)—N
fremstilles ved alkylering av forbindelser med formel (III) med halogenketoner R'CO(CH2)nBr eller R'CO(CH2)nCI
(III) hvor NR'iR'2 er som definert i formel (II) og Z er
/
b) —N
\
Denne alkyleringen kan utføres ved omsetning av aminet med formel (III) og halogenketonet R'CO(CH2)nBr eller R'CO(CH2)nCI i nærvær av base så som et karbonat eller et bikarbonat i et inert løsningsmiddel så som acetonitril eller et keton (aceton, metylisobutylketon, metyletylketon) eller en alkohol (metanol, etanol eller isopropanol) ved en temperatur omfattet mellom romtemperatur og tilbakeløp.
I henhold til et fjerde aspekt kan forbindelser ifølge oppfinnelsen med formel (II) hvor Z er
f) -CH=C\
fremstilles ved kondensering av en forbindelse med formel (VII) med en (trifenylÅ5-fosfanyliden)eddiksyreester ved tilbakeløpsbehandling i et inertløsningsmiddel så som toluen eller en (dietoksyfosforyl)eddiksyreester i nærvær av en base så som natriumhydroksid eller natriumhydrid ved en temperatur
omfattet mellom 0°C og 40°C i et løsningsmiddel så som en eter (tetrahydrofuran, metyl-terf-butyleter, metyl cyklopentyleter).
o
NR^ (VII)
5 Disse generelle metoder kan oppsummeres i det følgende skjema:
Rute III Rute I
Rute II Rute IV
OH
OH
^NR'^
(VII)
^NR'^
(IV)
PPtlg or O.
Rute C
(I)
(II)
I henhold til et ytterligere aspekt angår foreliggende oppfinnelse også farmasøytiske preparater omfattende en forbindelse med formel (I) sammen med et farmasøytisk akseptabelt tilsetningsmiddel eller bærer.
I henhold til et annet aspekt angår foreliggende oppfinnelse også anvendelse av forbindelser med den generelle formel (I) for fremstilling av farmasøytiske preparater ment for å forhindre og/eller behandle en nevropsykiatrisk sykdom eller hvilken som helst sykdom som involverer dopamin Ds reseptor. Nevnte nevropsykiatriske sykdommer er fortrinnsvis valgt fra Parkinson's sykdom, schizofreni, demens, psykose eller psykotiske tilstander, depresjon, manier, angst, dyskinesier, balanse-forstyrrelser, Gilles de laTourette's sykdom.
Ifølge oppfinnelsen er nevnte forebygging og/eller behandling av Parkinson's sykdom fortrinnsvis en supplementsterapi for Parkinson's sykdom.
Andre sykdommer omfatter stoff-avhengighet, seksuelle lidelser, motoriskelidelser, kardiovaskulære lidelser, hormonelle lidelser, nyreinsuffisiens eller diabetes.
Ifølge oppfinnelsen skal stoff-avhengighet bety hvilken som helst tilstandforbundet med avvenning, abstinens og/eller detoksifisering av et individ som er avhengig av hvilket som helst middel, spesielt terapeutisk aktive midler, så som opioider og/eller medikamenter så som kokain, heroin eller alternativt alkohol og/eller nikotin.
Ifølge oppfinnelsen skal seksuelle lidelser spesielt bety impotens, spesielt mannlig impotens.
Ifølge oppfinnelsen skal motoriske lidelser spesielt bety essensiell eller iatrogen dyskinesi og/eller essensiell eller iatrogen tremor.
Ifølge oppfinnelsen omfatter kardiovaskulære lidelser hypertensjon, hjertesvikt.
Ifølge oppfinnelsen omfatter hormonelle lidelser menopausale lidelser eller vekstlidelser.
I henhold til et annet aspekt angår foreliggende oppfinnelse også ovennevnte terapeutiske behandlingsmetoder omfattende administrering av en
forbindelse ifølge oppfinnelsen sammen med en farmasøytisk akseptabel bærer eller tilsetningsmiddel til en pasient med behov for dette.
I henhold til et ytterligere aspekt angår foreliggende oppfinnelse også kombinasjoner omfattende en forbindelse ifølge oppfinnelsen og én eller flere ytterligere aktiv(e) bestanddel(er).
Spesielt for behandling av nevropsykiatriske lidelser kan forbindelser ifølge oppfinnelsen fordelaktig administreres med ett eller flere andre nevropsykiatriske midler så som anxiolytiske, antipsykotiske, antidepressive, prekognitive eller antidemens midler.
For behandling av kardiovaskulære eller metabolske lidelser kan forbindelser ifølge oppfinnelsen også fordelaktig administreres med ett eller flere antihypertensive, kardiotoniske eller antidiabetiske midler.
Identifikasjon av de individer som har behov for behandling av de her beskrevne sykdommer og lidelser er vel innenfor evnen og kunnskapen til fagfolk på området. En erfaren kliniker på området kan lett identifisere, ved anvendelse av kliniske tester, fysisk undersøkelse, genetiske tester og medisinsk/familie-historie,de individer som har behov for slik behandling.
En terapeutisk effektiv mengde kan lett bestemmes av behandlende diagnostiker, som fagmann på området, ved å anvende konvensjonelle teknikker og ved å observere resultater oppnådd under analoge omstendigheter. For bestemmelse av den terapeutisk effektive mengden, er flere faktorer tatt i betraktning av den behandlende diagnostiker, omfattende, men ikke begrenset til: arten av individet; dets størrelse, alder og generelle helse; den spesifikke sykdom involvert; graden av involvering eller alvorlighetsgraden av sykdommen; responsen til det individuelle individ; den spesielle forbindelse administrert; administreringsmetoden; biotilgjengeligheten karakteristisk for preparatet administrert; doseregimet valgt; anvendelse av ledsagende medisinering; og andre relevante omstendigheter.
Mengden av en forbindelse med formel (I) som er nødvendig for å oppnå den ønskede biologiske effekt, vil variere avhengig av flere faktorer, omfattende dosen av medikamentet som skal administreres, de kjemiske karakteristika (f.eks.
hydrofobisitet) av forbindelsene anvendt, styrken av forbindelsene, typen sykdom, sykdomstilstanden til pasienten og administreringsveien.
"Farmasøytiske" eller "farmasøytisk akseptable" refererer til molekylære enheter og preparater som ikke gir en ugunstig, allergisk eller annen uheldig reaksjon når administrert til et dyr eller et menneske, som det passer.
Som anvendt her omfatter "farmasøytisk akseptabel bærer" hvilke som helst fortynningsmidler, adjuvantia, tilsetningsmidler eller konstituenter, så som konserveringsmidler, fyllmidler, desintegreringsmidler, fuktemidler, emulgeringsmidler, suspenderingsmidler, løsningsmidler, dispersjonsmedier, belegg, antibakterielle og antifungale midler, isotoniske og absorpsjonsforsinkende midler. Anvendelse av slike medier og midler for farmasøytisk aktive substanser er velkjent på området. Bortsett fra hvis hvilket som helst konvensjonelt medium eller middel er inkompatibelt med den aktive bestanddel, er dens anvendelse i de terapeutiske preparater omfattet. Supplerende aktive bestanddeler kan også innføres i preparatene.
I sammenheng med oppfinnelsen betyr betegnelsen "behandling av" eller "behandling", som anvendt her, reversering, lindring, hemning av utvikling av eller forhindring av lidelsen eller tilstanden for hvilken en slik betegnelse anvendes eller ett eller flere symptomer på en slik lidelse eller tilstand.
"Terapeutisk effektiv mengde" betyr en mengde av en forbindelse/ medikament ifølge foreliggende oppfinnelse effektiv til å produsere den ønskede terapeutiske effekt.
Ifølge oppfinnelsen er betegnelsen "pasient" eller "pasient med behov for dette", ment for et humant eller ikke-humant pattedyr rammet av eller sannsynligå bli rammet av en neuropsykologisk lidelse. Fortrinnsvis er pasienten et menneske.
Generelt kan forbindelsene ifølge foreliggende oppfinnelse gis i en vandig fysiologisk bufferløsning inneholdende 0,1 til 10% vekt/volum forbindelse for parenteral administrering. Typiske doseområder er fra 1 pig/kg til 0,1 g/kg kroppsvekt pr. dag; et foretrukket doseområde er fra 0,01 mg/kg til 10 mg/kg kroppsvekt pr. dag. En foretrukket daglig dose for voksne mennesker omfatter 5, 50,100 og 200 mg og en ekvivalent dose for et menneskebarn. Den foretrukne dose av medikament som skal administreres er sannsynlig å avhenge av slike
variabler som typen og graden av progresjon av sykdommen eller lidelsen, den totale helsestatus til den spesielle pasienten, den relative biologiske effektivitet av forbindelsen valgt og formulering av forbindelse-tilsetningsmiddel ogadministreringsveien.
Forbindelsene ifølge foreliggende oppfinnelse kan administreres i enhetsdoseformer, hvor betegnelsen "enhetsdose" betyr en enkel dose som kan administreres til en pasient og som lett kan håndteres og pakkes, som forblir som en fysisk og kjemisk stabil enhetsdose omfattende enten den aktive forbindelse selv eller som et farmasøytisk akseptabelt preparat, som beskrevet nedenfor. Som sådanne er typiske daglige doseområder fra 0,01 til 10 mg/kg kroppsvekt. Som generell rettledning er enhetsdoserfor mennesker i området fra 0,1 mg til 1000 mg pr. dag. Fortrinnsvis er enhetsdoseområdet fra 1 til 500 mg administrert én til fire ganger pr. dag og enda mer foretrukket fra 10 mg til 300 mg, to ganger pr. dag. Forbindelser gitt her kan formuleres til farmasøytiske preparater ved blanding med én eller flere farmasøytisk akseptable tilsetningsmidler. Slike preparater kan fremstilles for anvendelse for oral administrering, spesielt i form av tabletter eller kapsler; eller parenteral administrering, spesielt i form av flytende løsninger, suspensjoner eller emulsjoner; eller intranasalt, spesielt i form av pulvere, nesedråper eller aerosol-preparater; eller dermalt, for eksempel topisk eller viatransdermale plastere.
Preparatene kan hensiktsmessig administreres i enhetsdoseform og kan fremstilles ved hvilken som helst av metodene velkjent på det farmasøytiske området, for eksempel som beskrevet i Remington: The Science and Practice of Pharmacy, 20. ed.; Gennaro, A. R., Ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2000. Farmasøytisk kompatible bindemidlerog/eller adjuvans-materialer kaninkluderes som del av preparatet. Orale preparater vil generelt omfatte en inert fortynningsmiddel-bærer eller en spiselig bærer.
Tabletter, piller, pulvere, kapsler og trocher kan inneholde én eller flere av hvilke som helst av de følgende bestanddeler eller forbindelser av en lignende natur: et bindemiddel så som mikrokrystallinsk cellulose eller gummi tragant; et fortynningsmiddel så som stivelse eller laktose; et desintegreringsmiddel så som stivelse og cellulosederivater; et glattemiddel så som magnesiumstearat; et glidemiddel så som kolloidal silisiumdioksid; et søtningsmiddel så som sukrose eller
sakkarin; eller et smaksgivende middel så som peppermynte eller metyl-salicylat.Kapsler kan være i form av en hard kapsel eller myk kapsel, som generelt er fremstilt fra gelatinblandinger eventuelt blandet med myknere, så vel som en stivelsekapsel. I tillegg kan doseenhetsformer inneholde forskjellige andre materialer som modifiserer den fysiske form av doseenheten, for eksempel belegg av sukker, skjellakk eller enteriske midler. Andre orale doseformer som sirup eller eliksir kan inneholde søtningsmidler, konserveringsmidler, fargemidler, farger og smaksmidler. I tillegg kan de aktive forbindelser innføres i preparater og formuleringer med rask oppløsning, modifisert frigjøring eller forlenget frigjøring og hvor slike formuleringer med forlenget frigjøring fortrinnsvis er bi-modale.
Foretrukne formuleringer omfatter farmasøytiske preparater hvor en forbindelse ifølge foreliggende oppfinnelse er formulert for oral eller parenteral administrering eller mer foretrukket de hvor en forbindelse ifølge foreliggende oppfinnelse er formulert som en tablett. Foretrukne tabletter inneholder laktose, maisstivelse, magnesiumsilikat, croscarmellose-natrium, povidon,magnesiumstearat eller talk i hvilken som helst kombinasjon. Det er også et aspekt ved foreliggende beskrivelse at en forbindelse ifølge foreliggende oppfinnelse kan innføres i et matprodukt eller væske.
Flytende preparater for administrering omfatter sterile vandige eller ikkevandige løsninger, suspensjoner og emulsjoner. Flytende preparater kan også omfatte bindemidler, buffere, konserveringsmidler, chelaterende midler, søtnings-,smaks- og farge-midler. Ikke-vandige løsningsmidler omfatter alkoholer,propylenglykol, polyetylenglykol, vegetabilske oljer så som olivenolje og organiske estere så som etyloleat. Vandige bærere omfatter blandinger av alkoholer og vann, bufrede medier og saltløsning. Spesielt kan biokompatibel, bionedbrytbar laktidpolymer, laktid/glykolid-kopolymer eller polyoksyetylen-polyoksypropylenkopolymerer være anvendelige tilsetningsmidler for å kontrollere frigjøring av de aktive forbindelser. Intravenøse konstituenter kan omfatte væske- ognæringsmiddel-påfyllere, elektrolytt-påfyllere, så som de basert på Ringer'sdekstrose. Andre potensielt anvendelige parenterale leveringssystemer for disse aktive forbindelser omfatter etylen-vinylacetat- kopolymer-partikler, osmotiskepumper, implanterbare infusjonssystemer og liposomer.
Alternative administreringsmetoder omfatter formuleringer for inhalering, som omfatter slike midler som tørt pulver, aerosol eller dråper. De kan være vandige løsninger inneholdende for eksempel polyoksyetylen-9-lauryleter, glykocholat ogdeoksycholat eller oljeaktige løsninger for administrering i form av nesedråper eller som en gel som skal anvendes intranasalt. Formuleringer for buckal administrering omfatter for eksempel sugetabletter eller pastiller og kan også omfatte en smaksbase, så som sukrose eller akasie og andre tilsetningsmidler så som glykocholat. Formuleringer egnet for rektal administrering er fortrinnsvis presentert som enhetsdose-suppositorier, med en faststoff-basert bærer, så som kakaosmør ogkan omfatte et salicylat. Formuleringer for topisk påføring på huden er fortrinnsvis i form av en salve, krem, losjon, pasta, gel, spray, aerosol eller olje. Bærere som kan anvendes omfatter petroleumgelé, lanolin, polyetylenglykoler, alkoholer eller kombinasjoner derav. Formuleringer egnet for transdermal administrering kan presenteres som adskilte plastere og kan være lipofile emulsjoner eller bufrede, vandige løsninger, oppløst og/eller dispergert i en polymer eller et adhesiv.
De følgende eksempler og referanseforbindelser illustrerer oppfinnelsen. Utgangsmaterialene anvendt er produkter som er kjent eller fremstilt ved anvendelse av kjente metoder.
Hvis ikke annet er angitt er prosentdeler vektprosentdeler.
EKSEMPLER
Smeltepunkter er bestemt på Buchi kapillar smeltepunkt-apparat.
Proton NMR-spektra er registrert på et Bruker 250 MHz NMR instrument.Deuterokloroform er anvendt som løsningsmiddel hvis ikke annet er angitt. Kjemiske skift 5 er uttrykt i ppm. De følgende forkortelser er anvendt for å bety signal-mønstere: s = singlett, d = dublett, t = triplett, q = kvartett, m = multiplett,ms = massiv. Koblingsinnhold er uttrykt i Hz. Spektra registrert er i overensstemmelse med de foreslåtte strukturer.
TLC er utført på 0,25 mm silikagel F254 plater.
Arylpiperaziner er kommersielt tilgjengelige eller kan fremstilles i henhold til metoder beskrevet i franske patentsøknader FR 04 11303 og FR 04 12763. 2,4di-ferf-butyl-6-piperazin-1 -ylpyrimidin og 2-terf-butyl-6-trifluormetyl-4-piperazin-1 ylpyrimidin kan fremstilles i henhold til US 2004/0259882 A1, 1-(6trifluormetylbenzo[b]tiofen-3yl)piperazin (WO 02/066469); /V-(3-piperazin-1ylfenyl)metansulfonamid (Pharmazie, 57, (8), 515-518, (2002)).
4-aryl-3,6-dihydro-2/-/-pyridin og 4-arylpiperidin er kommersielt tilgjengeligeeller kan fremstilles i henhold til metoder beskrevet i fransk søknad FR 04 12763.
1,2,3,4-tetrahydroisokinolin-7-karbonitril kan fremstilles i henhold til Synth.Commun., 25, (20), 3255-3261, (2001).
3-oksazol-2-ylanilin kan fremstilles i henhold til J. Org. Chem. 42, (19),3208-3209, (1977).
Karboksylsyrederivatene er kommersielt tilgjengelige eller fremstilt. 3cyanopropansyre kan fremstilles fra [3-propanlakton i henhold til J. Am. Chem.Soc., 74, 1323, (1952); 4-cyanobutansyre (J. Org. Chem., 61, (19), 6486-6487,(1996); 2-metoksy-2-metylpropansyre (Tetrahedron, 53, (42), 14286, (1997)); 2isopropoksyeddiksyre (Tetrahedron, 59, 7915-7920, (2003); 2-tertbutoksyeddiksyre (Bioorg. Med. Chem. 11,4287-4293, (2003);cyanodimetyleddiksyre (J. Org. Chem., 46, (24), 4907-4911, (1981);metansulfonyleddiksyre, (Arch. Pharm. Med. Chem. 333, 293-298, (2000)); 5,6dihydro-4/-/-pyran-3-karboksylsyre og 4,5-dihydrofuran-3-karboksylsyre(Synthesis, 12, 1016-1017, (1986)); 5-cyanopentansyre, (Tetrahedron, 48, 43,9531-9536, (1992)); (2-cyanoetoksy)eddiksyre, US 4,105,687.
Noen syrer er fremstilt ved vanlig forsåpning av den tilsvarende etylester med vandig natriumhydroksid-løsning: trans-2-cyanocyklopropankarboksylsyrefra trans-2-cyanocyklopropankarboksylsyre-etylester (Synthesis, 301-303,(1982)); 5-cyano-2,2-difluorpentansyre fra 5-cyano-2,2-difluor-pentansyreetylester (J. Fluorine Chem. 121, 105-107, (2003)).
Fremstilling A: 1 -[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]-4-(3-hydroksymetylfenyl)piperazin
Til en avkjølt løsning av 2,5 g (6,25 mmol) 1-[2-(1,4-dioksaspiro[4,5]dec-8yl)etyl]-4-(3-etoksykarbonylfenyl)piperazin (fremstilt ved rute II), blir satt, underargon, 0,36 g (9,36 mmol) litiumaluminiumhydrid. Suspensjonen bliromrørt natten over ved romtemperatur. Hydrolyse blir utført ved 0°C ved langsom tilsetning av 0,35 ml vann, 0,35 ml 15% vandig natriumhydroksid-løsning og1,0 ml vann. Oppslemningen bliromrørt i 15 minutter ved romtemperatur, deretter blir magnesiumsulfat tilsatt. Blandingen blir filtrert og saltene blir vasket med etylacetat. Filtratet blir konsentrert under redusert trykk, hvilket gir 2,0 g (89%) av 1-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]-4-(3-hydroksymetylfenyl)piperazin som et fast stoff.
1H NMR: 7,25 (t, 1H, J = 7,5); 6,95 (s, 1H); 6,9 til 6,8 (ms, 2H); 4,65 (s, 2H); 3,95 (s, 4H); 3,2 (m, 4H); 2,6 (m, 4H); 2,4 (m, 2H); 2,0 (bred s, 1H); 1,85 til 1,65 (ms, 4H); 1,65 til 1,4 (ms, 3H); 1,4 til 1,2 (ms, 4H)
Fremstilling B: 1 -[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]-4-(3-metoksymetylfenyl)piperazin
N I
Til en løsning av 1,2 g (3,42 mmol) 1-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etylj4-(3-hydroksymetylfenyl)piperazin (fremstilling A) i 15 ml dimetylsulfoksid blirved romtemperatur, satt 1,0 g (17,2 mmol) kaliumfluorid, 0,52 g (3,66 mmol) jodmetan og 0,68 g (10,3 mmol) kaliumhydroksid. Blandingen bliromrørt natten over ved romtemperatur, fordelt mellom med etylacetat og vann. Den vandige fasen blir separert og den organiske fasen blir vasket med vann, tørket over magnesiumsulfat, filtrert og konsentrert. Det oljeaktige residuet blir renset ved kromatografi over silikagel (elueringsmiddel hetan/etylacetat 1/1), hvilket gir 0,3
g 1-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]-4-(3-metoksymetylfenyl)piperazin somen olje.
1H NMR: 7,25 (t, 1H, J = 7,5); 6,9 (s, 1H); 6,9 til 6,75 (ms, 2H); 4,4 (s, 2H); 3,95 (s, 4H); 3,35 (s, 3H); 3,2 (m, 4H); 2,6 (m, 4H); 2,45 (m, 2H); 1,85 til 1,65 (ms, 4H); 1,65 til 1,4 (ms, 3H); 1,4 til 1,2 (ms, 4H)
Fremstilling C: 1 -[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]-4-(3-(1 hydroksyetyl)fenyl)-piperazin
OH
M
Til en avkjølt løsning av 1,6 g (4,3 mmol) 1-[2-(1,4-dioksaspiro[4,5]dec-8yl)etyl]-4-(3-acetylfenyl)piperazin (fremstilt ved rute II) i 15 ml metanol blir sattporsjonsvis, 0,18 g (4,7 mmol) natrium-borhydrid. Blandingen bliromrørt i 3timer ved romtemperatur. Metanol blir inndampet under redusert trykk og residuet tatt opp med vann og ekstrahert to ganger med etylacetat. De organiske fasene blir samlet, vasket med vann, deretter saltvann, tørket over magnesiumsulfat, filtrert og konsentrert, hvilket gir 1,61 g (100%) av 1 -[2-(1,4dioksaspiro[4,5]dec-8-yl)etyl]-4-(3-(1-hydroksyetyl)fenyl)piperazin som en olje.
1H NMR: 7,25 (t, 1H, J = 7,5); 7,0 (s, 1H); 6,9 til 6,75 (ms, 2H); 4,85 (q, 1H, J = 7,5); 3,95 (s, 4H); 3,2 (m, 4H); 2,6 (m, 4H); 2,4 (m, 2H); 2,0 (bred s, 1H); 1,8 til 1,65 (ms, 4H); 1,6 til 1,4 (ms, 7H); 1,4 til 1,2 (ms, 3H)
Fremstilling D: 1 -[3-(1,1 -difluoretyl)fenyl]piperazin, hydroklorid
Trinn 1: 1-(1,1-difluoretyl)-3-nitrobenzen
N
En blanding av 2,0 g (12 mmol) 1-(3-nitrofenyl)etanon og 7,4 g (16,7 mmol)50% bis(2-metoksyetyl)aminosvoveltrifluorid-løsning i toluen blir oppvarmet til80°C natten over. Blandingen blir langsomt hellet i avkjølt vann og ekstrahert to ganger med etylacetat. De organiske fasene blir samlet, vasket med en vandig mettet natriumhydrogenkarbonat-løsning, deretter med saltvann, tørket overmagnesiumsulfat, filtrert og konsentrert under redusert trykk. Residuet (2,5 g) blir renset over 160 g silikagel (elueringsmiddel heptan/etylacetat 85/15), hvilket gir 1,6 g (71%) av 1-(1,1-difluoretyl)-3-nitrobenzen som en olje.
1H NMR: 8,4 (s, 1H); 8,3 (d, 1H, J = 7,5); 7,9 (d, 1H, J = 7,5); 7,65 (t, 1H, J = 7,5); 2,0 (t, 3H, J = 17,5)
Trinn 2: 3-(1,1 -difluoretyl)anilin
,N
En blanding av 3,0 g (16 mmol) 1-(1,1-difluoretyl)-3-nitrobenzen, 18,0 g(80 mmol) tinnklorid-dihydrat og 50 ml etanol blir tilbakeløpskokt i én time.Blandingen blir langsomt hellet på avkjølt vann. pH blir regulert til 7 ved tilsetning av en vandig 10N løsning av natriumhydroksid, deretter regulert til 9 ved tilsetning av en vandig mettet løsning av natriumhydrogenkarbonat. Produktet blir ekstrahert 4 ganger med etylacetat. De organiske fasene blir samlet, tørket over magnesiumsulfat, filtrert og konsentrert under redusert trykk. Det oljeaktige residuet (2,2 g) blir renset over 100 g silikagel (elueringsmiddel heptan/etylacetat 2/1), hvilket gir 1,7 g (68%) av 3-(1,1 -difluoretyl)anilin som enolje.
1H NMR: 7,2 (t, 1H, J = 7,5); 6,9 (d, 1H, J = 7,5); 6,8 (s, 1H); 6,9 (d, 1H, J = 7,5); 3,8 (bred s, 2H); 1,9 (t, 3H, J = 17,5)
Trinn 3: 1-[3-(1,1 -difluoretyl)fenyl]piperazin, hydroklorid
En blanding av 2,5 g (15,9 mmol) 3-(1,1 -difluoretyl)anilin og 2,8 g(15,9 mmol) bis(2-kloretyl)amin i 20 ml klorbenzen blir tilbakeløpskokt nattenover. Etter avkjøling til romtemperatur blir dietyleter tilsatt og utfelling skjer. Det faste stoffet blir filtrert, vasket med dietyleter og tørket under redusert trykk, hvilket gir 3,8 g (90%) av 1 -[3-(1,1 -difluor-etyl)fenyl]piperazin, hydroklorid som ethvitt, fast stoff.
1H NMR (DMSO De): 9,2 (bred s, 2H); 7,3 (t, 1H, J = 7,5); 7,15 til 6,95 (ms, 2H); 7,0 (d, 1H, J = 7,5); 3,4 (m, 4H); 3,2 (m, 4H); 1,9 (t, 3H, J = 14,5)
Fremstilling E: 1-(3-difluormetylfenyl)piperazin, hydroklorid
HN^J F . HCI
Trinn 1: 1-difluormetyl-3-nitrobenzen
F
Til en løsning av 2,6 g (17 mmol) 3-nitrobenzaldehyd i 5 ml diklormetan blirsatt 11,4 ml 50% bis(2-metoksyetyl)aminosvoveltrifluorid-løsning i toluen.Blandingen blir omrørt natten over ved romtemperatur, vasket to ganger med en mettet vandig natriumhydrogenkarbonat-løsning deretter med saltvann, tørketover magnesiumsulfat, filtrert og konsentrert under redusert trykk. Residuet blir renset over 150 g silikagel (elueringsmiddel heptan/etylacetat 85/15), hvilket gir 2,3 g (78%) av 1-difluormetyl-3-nitrobenzen som en olje.
1H NMR: 8,4 (s, 1H); 8,35 (d, 1H, J = 7,5); 7,9 (d, 1H, J = 7,5); 7,7 (t, 1H, J = 7,5); 7,0 (t, 1H, J = 55)
Trinn 2: 1-(3-difluormetylfenyl)piperazin, hydroklorid
I N
HN^ J
F , HCI
1-(3-difluormetylfenyl)piperazin, hydrokloridet blir oppnådd fra 1difluormetyl-3-nitrobenzen ved anvendelse av metoden beskrevet i fremstillingD, trinn 2 og 3.
1H NMR (DMSO De): 9,25 (bred s, 2H); 7,35 (m, 1H); 7,2 (m, 2H); 7,0 (d, 1H, J = 7,5); 6,9 (t, 1H, J = 55); 3,4 (m, 4H); 3,2 (m, 4H)
Fremstilling F: 1 -(3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1 yl}fenyl)propan-1-ol
Jl
■hk J
OH
Trinn 1: 3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1-yl}benzosyre
OH
f N
Til en løsning av 3,75 g (9,3 mmol) 3-{4-[2-(1,4-dioksaspiro[4,5]dec-8yl)etyl]piperazin-1-yl}benzosyre-etylester i 20 ml etanol blir satt 10,2 ml av envandig 1N natriumhydroksid-løsning. Omrøring blir holdt natten over. Blandingenblir avkjølt og 2,55 ml (10,2 mmol) 4N saltsyreløsning blir tilsatt. Etter inndampning under redusert trykk blir det faste stoffet tatt opp med etylacetat, filtrert og tørket ved 50°C under vakuum, hvilket gir 3,7 g rå 3-{4-[2-(1,4dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1-yl}benzosyre.
Trinn 2: 3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1 -yl}-/Vmetoksy-/V-metylbenzamid
I rN'° o
f N
3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1-yl}-/V-metoksy-/Vmetyl-benzamidet blir oppnådd fra 3-{4-[2-(1,4-dioksa-spiro[4,5]dec-8
yl)etyl]piperazin-1 -yljbenzosyre ved anvendelse av metoden beskrevet ieksempel 4, trinn c hvilket gir tittelforbindelsen i 85% utbytte.
1H NMR: 7,25 (m, 1H); 7,2 (m, 1H); 7,15 (m, 1H); 7,0 (m, 1H); 3,95 (s, 4H);
3,6 (s, 3H); 3,35 (s, 3H); 3,3 (m, 4H); 2,65 (m, 4H); 2,45 (m, 2H); 1,75 (m, 4H);
1,65 til 1,4 (ms, 4H); 1,4 til 1,2 (ms, 3H)
Trinn 3: 1 -(3-{4-[2-( 1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1
yl}fenyl)propan-1-on
II
Til en løsning av 1,6 g (3,8 mmol) 3-{4-[2-(1,4-dioksaspiro[4,5]dec-8yl)etyl]piperazin-1-yl}-/V-metoksy-/V-metylbenzamid i 25 ml tørr tetrahydrofuranavkjølt til 0°C blir satt 8 ml 1M etylmagnesiumbromid-løsning i tetrahydrofuran.Blandingen blir omrørt i 90 minutter og deretter hellet i 100 ml av en vandig mettet natriumhydrogenkarbonat-løsning. Produktet blir ekstrahert to gangermed etylacetat. De organiske fasene blir samlet, tørket over magnesiumsulfat, filtrert og konsentrert under redusert trykk. Residuet (1,4 g) blir renset over 50 g silikagel (elueringsmiddel heptan/etylacetat 1/1), hvilket gir 1,06 g (72%) av 1-(3{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1-yl}fenyl)propan-1-on som enolje.
1H NMR: 7,55 (s, 1H); 7,45 (m, 1H); 7,35 (t, 1H, J = 7,5); 7,15 (m, 1H); 3,95 (s, 4H); 3,3 (m, 4H); 3,0 (q, 2H, J = 7,5); 2,65 (m, 4H); 2,5 (m, 2H); 1,8 (m, 4H);
1,7 til 1,35 (ms, 4H); 1,35 til 1,25 (ms, 3H); 1,2 (t, 3H, J = 7,5)
Trinn 4: 1 -(3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1 yl}fenyl)propan-1-ol
p N
OH
1 -(3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1 -yl}fenyl)propan-1 olen blir fremstilt fra 1 -(3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1 yl}fenyl)-propan-1-on ved anvendelse av metoden beskrevet i fremstilling C.
1H NMR: 7,25 (t, 1H, J = 7,5); 6,95 (s, 1H); 6,9 til 6,75 (ms, 2H); 4,55 (m, 1H); 3,95 (s, 4H); 3,25 (m, 4H); 2,65 (m, 4H); 2,5 (m, 2H); 2,0 (m, 1H); 1,9 til 1,75 (ms, 6H); 1,65 til 1,4 (ms, 5H); 1,4 til 1,2 (ms, 5H)
Fremstilling G: 1 -(3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1 yl}fenyl)-2-metylpropan-1 -ol
f N .N. J
OH
Trinn 1: 1 -(3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1 -yl}fenyl)-2metylpropan-1-on
f N
1 -(3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1 -yl}fenyl)-2-metylpropan-1-onet blir fremstilt ved tilsetning av isopropylmagnesiumbromid på 3-{4[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1-yl}-/V-metoksy-/V-metylbenzamidved anvendelse av metoden beskrevet i fremstilling F, trinn 3, hvilket gir tittelforbindelsen i 27% utbytte.
1H NMR: 7,5 (s, 1H); 7,4 til 7,25 (ms, 2H); 7,1 (d, 1H, J = 7,5); 3,95 (s, 4H); 3,55 (m, 1H); 3,35 (m, 4H); 2,7 (m, 4H); 2,55 (m, 2H); 1,75 (m, 4H); 1,65 til 1,45 (ms, 5H); 1,45 til 1,2 (ms, 8H)
Trinn 2: 1 -(3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1 -yl}fenyl)-2metylpropan-1-ol
1 -(3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1 -yl}fenyl)-2-metylpropan-1 -olen blir fremstilt fra 1 -(3-{4-[2-(1,4-dioksaspiro[4,5]dec-8yl)etyl]piperazin-1-yl}fenyl)-2-metylpropan-1-on ved anvendelse av metodenbeskrevet i fremstilling C.
1H NMR: 7,25 (t, 1H, J = 7,5); 6,9 (s, H); 6,9 til 6,75 (m, 2H); 4,3 (m, 1H); 3,95 (s, 4H); 3,35 (m, 4H); 2,8 (m, 4H); 2,65 (m, 2H); 1,95 (m, 1H); 1,85 (m, 1H);
1,8 til 1,2 (ms, 11H); 1,0 (d, 3H, J = 7,5); 0,8 (d, 3H, J = 7,5)
Fremstilling H: 4-(2-{4-[3-(metoksymetylkarbamoyl)fenyl]piperazin-1 -yljetyl)piperidin-1-karboksylsyre-terf-butylester
p N
Trinn 1 :4-{2-[4-(3-karboksyfenyl)piperazin-1-yl]etyl}piperidin-1karboksylsyre-terf-butylester
Til en løsning av 2,8 g (12,8 mmol) 4-{2-[4-(3-etoksykarbonylfenyl)piperazin-1-yl]etyl}piperidin-1-karboksylsyre-ferf-butylester blir satt 12,8 ml 1Nvandig natriumhydroksid-løsning. Blandingen bliromrørt natten over vedromtemperatur og deretter konsentrert under redusert trykk. Residuet blir surgjort med 12,8 ml 1N vandig saltsyreløsning. Produktet blir ekstrahert med etylacetat, vasket med vann, tørket over magnesiumsulfat, filtrert og konsentrert under redusert trykk, hvilket gir 2,5 g (47%) av 4-{2-[4-(3karboksyfenyl)piperazin-1-yl]etyl}piperidin-1-karboksylsyre-terf-butylester.
1H NMR: 8,5 (bred s, 1H); 7,7 til 7,5 (ms, 2H); 7,3 (t, 1H, J = 7,5); 7,1 (d, 1H, J = 7,5); 4,1 (m, 2H); 3,45 (m, 4H); 3,1 (m, 4H); 2,85 (m, 2H); 2,7 (m, 2H); 1,7 (m, 2H); 1,65 til 1,35 (ms, 12H); 1,3 til 1,0 (ms, 2H)
Trinn 2: 4-[2-(4-{3-[metoksy(metyl)karbamoyl]fenyl}piperazin-1yl)etyl]piperidin-1-karboksylsyre-terf-butylester
p N
4-[2-(4-{3-[metoksy(metyl)karbamoyl]fenyl}piperazin-1-yl)etyl]piperidin-1karboksylsyre-terf-butylesteren blir fremstilt fra 4-{2-[4-(3karboksyfenyl)piperazin-1 -yl]etyl}piperid in-1 -karboksylsyre-terf-butylester vedanvendelse av metoden beskrevet i fremstilling F, trinn 2.
1H NMR: 7,25 (t, 1H, J = 7,5); 7,2 (s, 1H); 7,1 (d, 1H, J = 7,5), 7,0 (d, 1H, J = 7,5); 4,1 (m, 2H); 3,6 (s, 3H); 3,3 (s, 3H); 3,2 (m, 4H); 2,8 til 2,5 (m, 6H); 2,4 (m, 2H); 1,7 (m, 2H); 1,65 til 1,2 (ms, 12H); 1,3 til 1,0 (ms, 2H)
Fremstillinger I, J og K:
Ved å starte fra 4-[2-(4-{3-[metoksy(metyl)karbamoyl]fenyl}piperazin-1yl)etyl]-piperidin-1-karboksylsyre-terf-butylester og ved anvendelse av metodenbeskrevet i fremstilling F, trinn 3, blir de følgende forbindelser oppnådd:
Fremstilling I: 4-{2-[4-(3-acetylfenyl)piperazin-1 -yl]etyl}piperidin-1 karboksylsyre-terf-butylester
I N
•ISk )
En løsning av metylmagnesiumklorid blir anvendt.
Utbytte : 88%
1H NMR: 7,5 (s, 1H); 7,4 (d, 1H, J = 7,5); 7,35 (t, 1H, J = 7,5); 7,15 (d, 1H, J = 7,5); 4,1 (m, 2H); 3,3 (m, 4H); 1,7 (m, 2H); 1,65 til 1,55 (ms, 7H); 2,45 (m, 2H); 1,7 (m, 2H); 1,6 til 1,35 (ms, 12H); 1,25 til 1,0 (ms, 2H)
Fremstilling J: 4-{2-[4-(3-propanoylfenyl)piperazin-1 -yl]etyl}piperidin-1 karboksylsyre-terf-butylester
f N
n.
En løsning av etylmagnesiumbromid blir anvendt.
Utbytte : 80%
1H NMR: 7,55 (s, 1H); 7,4 (d, 1H, J = 7,5); 7,3 (t, 1H, J = 7,5); 7,1 (d, 1H, J = 7,5); 4,1 (m, 2H); 3,3 (m, 4H); 3,0 (q, 2H, J = 7,5); 3,7 (m, 2H); 2,6 (m, 4H); 2,45 (m, 2H); 1,65 (m, 2H); 1,6 til 1,35 (ms, 12H); 1,3 til 1,0 (ms, 5H)
Fremstilling K: 4-{2-[4-(3-isobutanylfenyl)piperazin-1 -yl]etyl}piperidin-1 karboksylsyre-terf-butylester
En løsning av isopropylmagnesiumbromid blir anvendt.
Utbytte : 60%
1H NMR: 7,5 (s, 1H); 7,5 til 7,25 (ms, 2H); 7,1 (d, 1H, J = 7,5); 4,1 (m, 2H); 3,55 (m, 1H); 3,3 (m, 4H); 2,7 (m, 2H); 2,6 (m, 4H); 2,45 (m, 2H); 1,7 (m, 2H);
1,6 til 1,35 (ms, 12H); 1,3 til 1,0 (ms, 8H)
Fremstillinger L, M og N:
Ved å starte fra fremstillinger I, J og K og ved anvendelse av reduksjonsprosedyren beskrevet i fremstilling C, blir de følgende forbindelser oppnådd:
Fremstilling L: 4-(2-{4-[3-(1 -hydroksyetyl)fenyl]piperazin-1 -yl}etyl)piperidin-1 karboksylsyre-terf-butylester
\ N
OH
Utbytte : kvantitativt
1H NMR: 7,3 (t, 1H, J = 7,5); 6,95 (s, 1H); 6,9 til 6,8 (ms, 2H); 4,85 (q, 1H, J = 6,5); 4,1 (m, 2H); 3,25 (m, 4H); 2,7 (m, 2H); 2,6 (m, 4H); 2,55 (m, 2H); 1,85 (bred s, 1H); 1,7 (m, 2H); 1,55 til 1,4 (ms, 15H); 1,25 til 1,0 (ms, 2H)
Fremstilling M: 4-(2-{4-[3-(1 -hydroksypropyl)fenyl]piperazin-1 -yl}etyl)piperidin-1 karboksylsyre-terf-butylester
{ N
OH
N.
Utbytte : kvantitativt
1H NMR: 7,25 (t, 1H, J = 7,5); 6,9 (s, 1H); 6,9 til 6,75 (ms, 2H); 4,55 (t, 1H, J = 7,5); 4,1 (m, 2H); 3,2 (m, 4H); 1,7 (m, 2H); 2,6 (m, 2H); 2,45 (m, 4H); 1,95 til 1,6 (ms, 5H); 1,6 til 1,4 (ms, 12H); 1,3 til 1,05 (ms, 2H); 0,9 (t, 3H, J = 7,5)
Fremstilling N: 4-(2-{4-[3-(1 -hydroksy-2-metylpropyl)fenyl]piperazin-1 yl}etyl)piperidin-1-karboksylsyre-terf-butylester
f N
OH
Utbytte : 78%
1H NMR: 7,25 (t, 1H, J = 7,5); 6,9 (s, 1H); 6,85 (d, 1H, J = 7,5); 6,8 (d, 1H,
J = 7,5); 4,3 (d, 1H); 4,2 (m, 2H); 3,25 (m, 4H); 1,7 (m, 2H); 2,6 (m, 4H); 2,45 (m,
2H); 1,95 (m, 1H); 1,85 (bred s, 1H); 1,7 (m, 2H); 1,65 til 1,35 (ms, 12H); 1,3 til 1,05 (ms, 2H); 1,0 (d, 3H, J = 7,5); 0,8 (d, 3H, J = 7,5)
Fremstilling O: 4-{2-[4-(3-hydroksymetylfenyl)piperazin-1 -yl]etyl}piperidin-1 karboksylsyre-terf-butylester
II
.N. J
n.
En løsning av 1,5 g (3,59 mmol) 4-{2-[4-(3-karboksyfenyl)piperazin-1yl]etyl}piperidin-1 -karboksylsyre-ferf-butylester i 20 ml tørr tetrahydrofuran bliravkjølt til -10°C under argon. En tilsetning av 11 ml av en 1M løsning av borantetrahydrofuran-kompleks i tetrahydrofuran blir utført ved -10°C. Omrøring blirholdt natten over ved romtemperatur. Blandingen blir avkjølt til 0°C og 12 ml 1N vandig natriumhydroksid-løsning blir tilsatt. Produktet blir ekstrahert medetylacetat, vasket med vann, tørket over magnesiumsulfat, filtrert og konsentrert under redusert trykk. Residuet blir omrørt med diisopropyleter, filtrert og tørket under redusert trykk, hvilket gir 1,0 g (69%) av 4-{2-[4-(3-hydroksymetylfenyl)piperazin-1 -yl]etyl}piperid in-1 -karboksylsyre-terf-butylester.
1H NMR: 7,25 (m, 1H); 6,95 (s, 1H); 6,9 til 6,75 (ms, 2H); 4,7 (s, 2H); 4,1 (m, 2H); 3,6 (m, 2H); 3,4 til 3,1 (ms, 4H); 3,0 til 2,8 (ms, 4H); 2,7 (m, 2H); 1,85 (m, 2H); 1,75 til 1,55 (ms, 3H); 1,55 til 1,3 (ms, 10H); 1,2 (m, 2H)
Fremstilling P: 4-{2-[4-(3-metoksymetylfenyl)piperazin-1 -yl]etyl}piperidin-1 karboksylsyre-terf-butylester
f N
En løsning av 0,4 g (1 mmol) av 4-{2-[4-(3-hydroksymetylfenyl)piperazin-1yl]etyl}piperidin-1 -karboksylsyre-terf-butylester i 10 ml tørr dimetylsulfoksid bliravkjølt ved en temperatur nær 5°C og 40 mg (1 mmol) natriumhydrid (60%
suspensjon) blir tilsatt. Blandingen bliromrørt i 30 minutter ved romtemperatur deretter blir 140 mg (1 mmol) jodmetan tilsatt og omrøring blir holdt natten over ved romtemperatur. Blandingen blir konsentrert under redusert trykk. Residuet blir oppløst i etylacetat, vasket med vann, tørket over magnesiumsulfat, filtrert og konsentrert under redusert trykk, hvilket gir 0,3 g (73%) av rå 4-{2-[4-(3metoksymetylfenyl)piperazin-1-yl]etyl}piperidin-1-karboksylsyre-terf-butylestersom blir anvendt uten rensning i neste trinn.
TLC (elueringsmiddel diklormetan/metanol/ammoniakk-løsning 90/10/1):Rf: 0,6
Fremstilling Q: 2-isobutylanilin
Trinn 1: 2-metyl-1-(2-nitrofenyl)propan-1-on og 2-metyl-1-(3nitrofenyl)propan-1 -on
O„N
Til en avkjølt løsning av 14,8 g (100 mmol) 2-metyl-1-fenylpropan-1-on i 2ml iseddik blir over en periode på én time, satt 90 g rykende salpetersyre. Blandingen blir omrørt ved 5°C i 90 minutter deretter hellet på knust is. Produktet blir ekstrahert 3 ganger med dietyleter. De organiske fasene blir samlet, vasket med en vandig mettet natriumhydrogenkarbonat-løsning, tørketover magnesiumsulfat, filtrert og konsentrert under redusert trykk. Det oljeaktige residuet (20 g) blir renset over 350 g silikagel (elueringsmiddel heptan/etylacetat 4/1), hvilket gir en første porsjon på 7,1 g inneholdende hovedsakelig 2-metyl-1(2-nitrofenyl)propan-1-on og en andre porsjon på 10,2 g inneholdendehovedsakelig 2-metyl-1-(3-nitrofenyl)propan-1-on. Disse to fraksjoner blir
anvendt uten ytterligere rensning i neste trinn.
Trinn 2: 2-isobutylanilin
h2n
Til en avkjølt løsning av 5,7 g (29,5 mmol) 2-metyl-1-(2-nitrofenyl)propan-1on i 35 ml etanol og 7 ml konsentrert saltsyre blir under inert atmosfære, satt 0,7 g 10% palladium på aktivert karbon. Blandingen blir hydrogener! ved 50°C under 4 bar i 2 timer. Suspensjonen blir filtrert over celite og filtratet blir konsentrert under redusert trykk. Residuet blir oppløst i vann, alkalisert til pH 9 med en konsentrert løsning av natriumhydroksid og ekstrahert 3 ganger med etylacetat. De organiske fasene blir samlet, vasket med vann deretter med saltvann, tørket over magnesiumsulfat, filtrert og konsentrert under redusert trykk. Det oljeaktige gule residuet (5 g) blir renset over 150 g silikagel (elueringsmiddel heptan/etylacetat 2/1), hvilket gir 1,2 g (27%) av 2-isobutylanilin som en olje.
1H NMR: 7,1 til 6,95 (ms, 2H); 6,8 til 6,65 (ms, 2H); 3,6 (bred s, 2H); 2,4 (d, 2H, J = 7,5); 1,95 (m, 1H, J = 7,5); 1,0 (d, 6H, J = 7,5)
Fremstilling R: 3-isobutylanilin
3-isobutylanilinet blir fremstilt ved katalytisk hydrogenering av 2-metyl-1-(3nitrofenyl)propan-1-on ved anvendelse av metoden beskrevet for fremstilling O,hvilket gir tittelforbindelsen i 46% utbytte.
1H NMR: 7,05 (t, 1H, J = 7,5); 6,65 til 6,55 (m, 2H); 6,5 (s, 1H); 3,6 (bred s, 2H); 2,4 (d, 2H, J = 7,5); 1,85 (m, 1H, J = 7,5); 0,9 (d, 6H, J = 7,5)
Fremstilling S: (3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1 yl}fenyl)karbaminsyre-etylester
O nA H
p N N. J
Trinn 1 : 3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1-yl}anilin
NH
I N
Til en avkjølt løsning av 2,6 g (7,1 mmol) 1-[2-(1,4-dioksaspiro[4,5]dec-8yl)etyl]-4-(3-nitrofenyl)piperazin i 50 ml metanol blir under inert atmosfære, satt0,5 g 10% palladium på aktivert karbon. Blandingen blir hydrogener! ved 40°C under 4 bar i 17 timer. Suspensjonen blir filtrert over celite og filtratet blir konsentrert under redusert trykk, hvilket gir 2,3 g (97%) av 3-{4-[2-(1,4dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1 -yljanilin.
1H NMR: 7,1 (t, 1H, J = 7,5); 6,35 (d, 1H, J = 7,5=; 6,3 (s, 1H); 6,2 (d, 1H, J = 7,5); 3,95 (s, 4H); 3,2 (m, 4H); 3,6 (bred s, 2H); 2,6 (m, 4H); 2,4 (m, 2H); 1,75 (m, 2H); 1,65 til 1,4 (ms, 4H); 1,4 til 1,2 (ms, 3H)
Trinn 2 : (3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1yl}fenyl)karbaminsyre-etylester
o ZoH
f N
Til en avkjølt løsning av 1 g (3 mmol) av 3-{4-[2-(1,4-dioksaspiro[4,5]dec-8yl)etyl]piperazin-1 -yljanilin i 30 ml diklormetan og 0,3 g (3 mmol) trietylamin, blirlangsomt satt 0,32 g (3 mmol) etylklorformiat. Blandingen blir omrørt natten over ved romtemperatur og deretter konsentrert under redusert trykk. Produktet blir oppløst i etylacetat, vasket to ganger med vann, tørket over magnesiumsulfat, filtrert og konsentrert under redusert trykk. Det oljeaktige residuet blir renset
over 10 g silikagel (elueringsmiddel diklormetan/metanol 95/5), hvilket gir 0,35 g (29%) av (3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1yl}fenyl)karbaminsyre-etylester.
1H NMR: 7,25 til 7,1 (ms, 2H); 6,7 (d, 1H, J = 7,5); 6,6 (d, 1H, J = 7,5); 6,5 (s, 1H); 4,2 (q, 2H, J = 7,5); 3,95 (s, 4H); 3,2 (m, 4H); 2,6 (m, 4H); 2,45 (m, 2H); 1,85 til 1,4 (ms, 8H); 1,4 til 1,15 (ms, 6H)
Fremstilling T: A/-(3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1 yl}fenyl)metansulfonamid
o. ,o N;SH
f N
/V-(3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin-1-yl}fenyl)metansulfonamidet blir fremstilt fra 3-{4-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]piperazin1 -yljanilin og metansulfonylklorid ved anvendelse av metoden beskrevet forfremstilling S, trinn 2 hvilket gir tittelforbindelsen i 89% utbytte.
1H NMR: 7,2 (t, 1H, J = 7,5); 8,3 (bred s, 1H); 7,05 (s, 1H); 6,95 (d, 1H, J = 7,5); 6,65 (d, 1H, J = 7,5); 3,95 (s, 4H); 3,6 (m, 4H); 3,15 (m, 4H); 3,0 (s, 3H);
1,9 til 1,65 (ms, 6H); 1,6 til 1,2 (ms, 7H)
Fremstilling U: 4-(2-hydroksyetyl)cykloheksanon
OH
Trinn 1: 4-(2-hydroksyetyl)cykloheksanol
OH
HO
I en 1L reaktor blir suksessivt innført: 50 g (362 mmol) 4-(2hydroksyetyl)fenol, 5 g (13,6 mmol) natriumtetraborat-dekahydrat, 500 mlisopropanol, 5 g palladium (10% på trekull vasket med isopropanol). Karet blir lukket, spylt tre ganger med nitrogen og tre ganger med hydrogen. Blandingen
blir omrørt i 22 timer under 10 bar trykk av hydrogen ved 80°C, avkjølt tilbake til romtemperatur, filtrert over et celite-sjikt og skyllet med isopropanol. Filtratet blirkonsentrert under redusert trykk, toluen (100 ml) blir tilsatt og inndampet under redusert trykk. Denne siste prosedyre blir gjentatt for å fjerne spormengde av isopropanol og gir 52 g (99% utbytte) av 4-(2-hydroksyetyl)cykloheksanol somen klar viskøs olje.
TLC (etylacetat/heptan 75/25): Rf = 0,2
Trinn 2: 4-(2-hydroksyetyl)cykloheksanon
OH
Til en løsning av 10 g (69 mmol) 4-(2-hydroksyetyl)cykloheksanol i 50 mleddiksyre holdt ved en temperatur mellom 18 og 21 °C blir over 35 min satt 35,9 ml (79 mmol) av en vandig natriumhypokloritt-løsning. Blandingen blir videreomrørt i 45 min, TLC-analyse indikerer forsvinning av utgangsmateriale.Isopropanol (0,8 ml) blir tilsatt, fulgt 10 min senere av vann (75 ml) og diklormetan (100 ml). De to faser blir separert ved dekantering og den vandige fasen blir ekstrahert med diklormetan (50 ml). Kombinerte organiske faser blir vasket med en vandig 3N natriumhydroksid-løsning (70 ml). Denne alkaliskevandige fasen blir ekstrahert tilbake med diklormetan (30 ml). Kombinerte organiske faser blir tørket over magnesiumsulfat og konsentrert under redusert trykk, hvilket gir 9,42 g (95%) av tittelforbindelsen.
TLC (etylacetat/heptan 75/25): Rf = 0,29
Fremstilling V: 4-(2-fluor-5-trifluormetylfenyl)-1 -[2-(4-oksocykloheksyl)etyljpiperazin
.F r-fF
p N
Trinn 1: 4-(2-hydroksyetyl)cykloheksanon mesylat
V
o o
Til en løsning av 15,25 g (107,24 mmol) 4-(2-hydroksyetyl)cykloheksanon i115 ml diklormetan avkjølt ved en temperatur nær 0°C, blir satt 18 ml (129,5 mmol) trietylamin, deretter 9,25 ml (119,50 mmol) mesylklorid. Blandingen blir omrørt i to timer ved romtemperatur. Vann (120 ml) blir tilsatt. Den organiske fasen blir separert ved dekantering, vasket med en mettet, vandig løsning av natriumhydrogenkarbonat (100 ml), tørket over magnesiumsulfat og konsentrert under redusert trykk, hvilket gir 28 g 4-(2-hydroksyetyl)-cykloheksanon-mesylatanvendt uten ytterligere rensning i neste trinn.
1H NMR: 4,30 (t, 2H, J = 7,5); 3,05 (s, 3H); 2,40 (m, 4H); 2,20 til 2,05 (m, 2H); 2,00 (m, 1H); 1,8 (q, 2H, J = 6,5); 1,60 til 1,85 (m, 2H)
Trinn 2: 4-(2-fluor-5-trifluormetylfenyl)-1 -[2-(4-oksocykloheksyl)etyl]piperazin
N
Rute IV
En blanding av 11,6 g (52,66 mmol) 4-(2-hydroksyetyl)cykloheksanonmesylat, av 13,72 g (55,27 mmol) 1-(2-fluor-5-trifluormetylfenyl)piperazin og8,37 g (60,65 mmol) kaliumkarbonat i 220 ml acetonitril blir tilbakeløpskokt natten over og deretter avkjølt tilbake til romtemperatur. Vann (80 ml) blir tilsatt. Organiske lag blir ekstrahert med etylacetat (100 ml). Den organiske fasen blir vasket med vann (20 ml), tørket over magnesiumsulfat og konsentrert under redusert trykk, hvilket gir et råprodukt. Rensning ved kolonnekromatografi over 320 g silikagel (elueringsmiddel diklormetan/metanol 98/2 til 96/4) gir 15,86 g 4(2-fluor-5-trifluormetylfenyl)-1 -[2-(4-oksocykloheksyl)etyl]piperazin som smelterved 75-76°C.
1H NMR: 7,30 til 7,00 (m, 3H); 3,20 (m, 4H); 2,65 (m, 4H); 2,50 (t, 2H, J = 7,5); 2,40 (m, 4H); 2,10 (m, 2H); 1,80 (m, 1H); 1,70 til 1,35 (m, 4H)
Eksempel 1: 2-cyano-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid (trans-isomer)
PF F
( N
N
N‘ H
Rute I
Trinn a: (1,4-dioksaspiro[4,5]dec-8-yl)eddiksyre
O
O
OH
Til en løsning av 4 g (17,5 mmol av (1,4-dioksaspiro[4,5]dec-8-yl)eddiksyreetylester (Tetrahedron, 51,37, 10259-10280, (1995)) i 35 ml etanol blir satt22 ml (22 mmol) av en vandig N natriumhydroksid-løsning. Blandingen bliromrørt natten over ved romtemperatur.
Etter konsentrasjon blir residuet tatt opp i avkjølt vann, nøytralisert med 22 ml av en vandig N saltsyreløsning og ekstrahert 4 ganger med dietyleter. De organiske fasene blir samlet, tørket over magnesiumsulfat, filtrert og konsentrert under redusert trykk, hvilket gir 3,0 g (85%) av (1,4-dioksaspiro[4,5]dec-8yl)eddiksyre som en olje som krystalliserer ved henstand.
1H NMR: 3,95 (s, 4H); 2,3 (d, 2H, J = 7,5); 2,0 til 1,7 (ms, 5H); 1,6 (m, 2H); 1,5 til 1,2 (ms, 2H)
Trinn b: 2-(1,4-dioksaspiro[4,5]dec-8-yl)-1-[4-(3-trifluormetylfenyl)
piperazin-lyljetanon
N
L ,N.
\ F F
Til en løsning av 1,5 g (7,5 mmol) (1,4-dioksaspiro[4,5]dec-8-yl)eddiksyre i50 ml diklormetan stabilisert på amylen blir suksessivt tilsatt ved romtemperatur, 1,0 g (7,5 mmol) 1-hydroksybenzotriazol og 1,43 g (7,5 mmol) 3-etyl-1-(3
dimetylaminopropyl)karbodiimid-hydroklorid. Blandingen bliromrørt i 10 minutterog deretter blir 2,0 g (7,5 mmol) 1-(3-trifluormetylfenyl)piperazin-hydroklorid og2,3 ml (16,5 mmol) trietylamin tilsatt. Blandingen bliromrørt natten over ved romtemperatur.
Etter konsentrasjon under redusert trykk blir residuet oppløst i etylacetat og vasket med vann. Den organiske fasen blir tørket over magnesiumsulfat, filtrert og konsentrert under redusert trykk. Det faste stoffet (3,6 g) blir renset ved kromatografi over 150 g silikagel (elueringsmiddel diklormetan/metanol 97,5/2,5), hvilket gir 2,5 g (81 %) av 2-(1,4-dioksaspiro[4,5]dec-8-yl)-1 -[4-(3trifluormetylfenyl)-piperazin-1yl]etanon som en olje.
1H NMR: 7,4 (t, 1H, J = 7,5); 7,2 til 7,0 (ms, 3H); 3,95 (s, 4H); 3,8 (m, 2H);
2.7 (m, 2H); 3,2 (m, 4H); 2,4 (d, 2H, J = 7,5); 1,95 (m, 1H); 1,9 til 1,7 (ms, 4H);
1.7 til 1,5 (ms, 2H); 1,45 til 1,2 (ms, 2H)
Trinn c: 1 -[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]-4-(3-trifluormetylfenyl)piperazin
N
F
A F F
I en trehalset rundbunnet kolbe blir 30 ml dietyleter avkjølt til -10°C.Systemet blir spylt med argon og 0,48 g (12,75 mmol) litiumaluminiumhydrid blir tilsatt. Suspensjonen blir omrørt og en løsning av 3,5 g (8,5 mmol) 2-(1,4dioksaspiro[4,5]dec-8-yl)-1-[4-(3-trifluormetylfenyl)-piperazin-1yl]etanon i 20 mldietyleter blir tilsatt slik at den indre temperatur ikke overstiger 10°C. Blandingen blir tilbakeløpskokt i 4 timer og deretter omrørt natten over ved romtemperatur.
Hydrolyse blir utført ved 0°C ved langsom tilsetning av 0,5 ml vann, 0,5 ml 15% vandig natriumhydroksid-løsning og 1,5 ml vann. Oppslemningen bliromrørt i 15 minutter ved romtemperatur og deretter blir magnesiumsulfat tilsatt. Blandingen blir filtrert og saltene blir vasket med en stor mengde av dietyleter. Filtratet blir konsentrert under redusert trykk, hvilket gir 2,5 g (74%) av 1 -[2-(1,4dioksaspiro[4,5]dec-8-yl)etyl]-4-(3-trifluormetylfenyl)piperazin som en olje.
1H NMR: 7,35 (t, 1H, J = 7,5); 7,15 (ms, 3H); 3,95 (s, 4H); 3,25 (m, 4H); 2,6 (m, 4H); 2,45 (m, 2H); 1,85 til 1,65 (ms, 4H); 1,65 til 1,45 (ms, 4H); 1,45 til 1,2 (ms, 3H)
Rute II
Trinn a: 1 -[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]-4-(3-trifluormetylfenyl)piperazin
F
En blanding av 10 g (37,8 mmol) 2-(1,4-dioksaspiro[4,5]dec-8-yl)etylmetansulfonat (Tetrahedron, 51,37, 10259-10280, (1995)), 10,05 g (37,8 mmol)1-(3-trifluormetylfenyl)piperazin-hydroklorid, 10,97 g (79,38 mmol)kaliumkarbonat og 100 ml acetonitril blir tilbakeløpskokt natten over.
Etter konsentrasjon av løsningsmidlet blir residuet er tatt opp med 100 ml etylacetat og vasket med vann (to ganger 50 ml). Organisk fase blir tørket over magnesiumsulfat, filtrert og konsentrert under redusert trykk. Oljen således oppnådd blir renset ved kromatografi over 250 g silikagel (elueringsmiddel heptan/etylacetat 50/50), hvilket gir 14,4 g (95%) av 1-[2-(1,4dioksaspiro[4,5]dec-8-yl)etyl]-4-(3-trifluormetyl-fenyl)piperazin som en fargeløsolje.
1H NMR: 7,35 (t, 1H, J = 7,5); 7,15 (ms, 3H); 3,95 (s, 4H); 3,25 (m, 4H); 2,6 (m, 4H); 2,45 (m, 2H); 1,85 til 1,65 (ms, 4H); 1,65 til 1,45 (ms, 4H); 1,45 til 1,2 (ms, 3H)
Trinn b: 4-{2-[4-(3-trifluormetylfenyl)piperazin-1 -yljetyljcykloheksanon
F
En løsning av 14,4 g (36,1 mmol) 1-[2-(1,4-dioksaspiro[4,5]dec-8-yl)etyl]-4(3-trifluormetylfenyl)piperazin, 70 ml metanol, 59 ml vann og 11 ml av en 2Nvandig saltsyreløsning bliromrørt natten over ved romtemperatur.
En vandig mettet løsning av natriumhydrogenkarbonat blir tilsatt inntil pH 10. Etanol blir inndampet under redusert trykk og det oljeaktige residuet blir oppløst i 100 ml etylacetat. Den organiske fasen blir vasket med vann (4 ganger 30 ml), tørket over magnesiumsulfat, filtrert og konsentrert, hvilket gir 11,62 g (91%) av 4-{2-[4-(3-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksanon som enfargeløs olje.
1H NMR: 7,35 (t, 1H, J = 7,5); 7,2 til 7,0 (ms, 3H); 3,3 (m, 4H); 2,6 (m, 4H); 2,5 (t, 2H, J = 7,5); 2,4 (m, 4H); 2,1 (m, 2H); 1,8 (m, 1H); 1,7 til 1,35 (ms, 4H)
Trinn c: 4-{2-[4-(3-trifluormetylfenyl)piperazin-1 -yljetyljcykloheksylamin,dihydroklorid
M
F
A F F
2 HCI
En blanding av 5,75 g (16,2 mmol) 4-{2-[4-(3-trifluor-metylfenyl)piperazin-1yljetyljcykloheksanon, 12,51 g (162,3 mmol) ammoniumacetat, 200 ml metanol og 4,07 g (64,8 mmol) natriumcyanoborhydrid blir tilbakeløpskokt i 3 timer.
Metanol blir konsentrert under redusert trykk og residuet blir tatt opp i 20 ml vann. En konsentrert vandig saltsyreløsning blir tilsatt under avkjøling inntil slutt av gassutvikling. Blandingen blir gjort basisk med 35% natriumhydroksid og ekstrahert med diklormetan (3 ganger 50 ml). De organiske fasene blir samlet, tørket over magnesiumsulfat, filtrert og konsentrert under redusert trykk, hvilket gir en olje som består av en ca. 65%/35% blanding (1H NMR bestemmelse) av trans og cis 4-{2-[4-(3-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksylamin.
Isomerene blir delvis separert ved oppløsning i en saltsyre-etylacetatløsning. Etter avdampning av løsningsmidlet blir det faste stoffet blandet med 10 ml acetonitril og oppvarmet til 50°C. Suspensjonen blir filtrert, det faste stoffet blir vasket med acetonitril (5 ml) og med dietyleter (15 ml). Det hygroskopiske faste stoff blir tørket ved 50°C under redusert trykk, hvilket gir 4,3 g (62%) av ca.
80%/20% (1H NMR bestemmelse) av trans og cis 4-{2-[4-(3trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksylamin, dihydroklorid som et hvitt,fast stoff.
Smeltepunkt 300-305°C (dekomponering)
1H NMR spektra blir utført på den frie basen.
1H NMR: 7,35 (t, 1H, J = 7); 7,15 til 7,0 (ms, 3H); 3,25 (m, 4H); 3,0 (m, 0,2H ekvatorial); 2,7 til 2,35 (ms, 4,8H); 2,0 til 1,35 (ms, 11H); 1,35 til 0,9 (ms, 4H)
Rute A
2-cyano-/V-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
.F
F
{ N
Til en løsning av 43 mg (0,5 mmol) cyanoeddiksyre i 5 ml diklormetan stabilisert på amylen blir suksessivt satt 68 mg (0,5 mmol) 1-hydroksybenzotriazol, 96 mg (0,5 mmol) 3-etyl-1-(3-dimetylaminopropyl)-karbodiimidhydroklorid og 0,21 ml (1,5 mmol) trietylamin. Blandingen bliromrørt i 15 minutter og deretter blir 214 mg (0,5 mmol) av 80% / 20% trans/cis 4-{2-[4-(3trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksylamin-dihydrokloridet tilsatt.Blandingen blir omrørt natten over ved romtemperatur.
Flyktige stoffer blir inndampet under redusert trykk, residuet blir oppløst i etylacetat og vasket med en vandig mettet natriumhydrogenkarbonat-løsning,deretter med vann. Den organiske fasen blir tørket over magnesiumsulfat, filtrert og konsentrert under redusert trykk. Det gjenværende faste stoff blir omkrystallisert i en blanding av diisopropyleter/etanol 9/1. Etter filtrering blir det faste stoffet vasket med diisopropyleter og tørket under redusert trykk, hvilket gir 62 mg (29%) av trans 2-cyano-/V-(4-{2-[4-(3-trifluor-metylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid som et kremfarget fast stoff.
Smeltepunkt: 185°C
1H NMR: 7,35 (t, 1H, J = 7,5); 7,15 til 7,0 (ms, 3H); 5,85 (d, 1H, J = 7,5); 3,75 (m, 1H); 3,35 (s, 2H); 3,25 (m, 4H); 2,6 (m, 4H); 2,45 (m, 2H); 2,05 (m, 2H);
1,85 (m, 2H); 1,45 (m, 2H); 1,4 til 1,0 (ms, 5H)
Eksempel 2: 1 -(4-{2-[4-(3-trifluomnetylfenyl)piperazin-1 -yl]etyl}-piperidin-1 yl)propan-1,2-dion, hydroklorid
V PF F
f N
CIH
Rute III
Trinn a: 4-(2-metansulfonyloksyetyl)piperidin-1 -karboksylsyre-terfbutylester
N
Til en avkjølt løsning av 3 g (13 mmol) 4-(2-hydroksyetyl)piperidin-1karboksylsyre-terf-butylester (kommersielt tilgjengelig) i 20 ml diklormetan og1,45 g (14,5 mmol) trietylamin blir satt en løsning av 1,5 g (13 mmol) metansulfonylklorid i 4 ml diklormetan. Blandingen bliromrørt i 2 timer ved romtemperatur.
Etter vasking med vann blir den organiske fasen tørket over magnesiumsulfat, filtrert og konsentrert, hvilket gir 4 g (100%) av 4-(2metansulfonyloksyetyl)piperidin-1-karboksylsyre-terf-butylester som et hvitt, faststoff.
TLC: 0,53 (heptan/etylacetat 1/1)
1H NMR: 4,3 (t, 2H, J = 7,5); 4,1 (m, 2H); 3,0 (s, 3H); 2,7(m, 2H); 1,8 til 1,6 (ms, 5H); 1,45 (s, 9H); 1,25 til 1,0 (ms, 2H)
Trinn b: 4-{2[4-(3-trifluormetylfenyl)piperazin-1 -yl]-etyl}piperidin-1 karboksylsyre-terf-butylester, hydroklorid
En blanding av 1 g (3,25 mmol) 4-(2-metansulfonyloksyetyl)-piperidin-1karboksylsyre-terf-butylester, 0,87 g (3,25 mmol) 1 -(3-trifluormetylfenyl)piperazin-hydroklorid, 0,95 g (6,9 mmol) kaliumkarbonat og 20 mlacetonitril blir tilbakeløpskokt natten over.
Etter konsentrasjon av løsningsmiddel, blir residuet tatt opp med etylacetat og vann. Organisk fase blir separert, vasket med en 0,5N vandig løsning av saltsyre, tørket over magnesiumsulfat, filtrert og delvis konsentrert. Det faste stoffet blir filtrert, vasket med dietyleter og tørket under redusert trykk, hvilket gir 1,1 g (71%) av 4-{2[4-(3-trifluormetyl-fenyl)piperazin-1 -yl]-etyl}piperidin-1 karboksylsyre-terf-butylester, hydroklorid som et hvitt, fast stoff.
Smeltepunkt 188°C
1H NMR : 13,1 (bred s, 1H); 7,4 (t, 1H, J = 7,5); 7,25 (d, 1H, J = 7,5); 7,2 til 7,0 (ms, 2H); 4,1 (m, 2H); 3,9 til 3,5 (ms, 6H); 3,15 til 2,8 (ms, 4H); 2,7 (m, 2H);
1,95 (m, 2H); 1,8 til 1,5 (ms, 3H); 1,45 (s, 9H); 1,3 (m, 2H)
Trinn c: 1 -(2-piperidin-4-yletyl)-4-(3-trifluormetylfenyl)piperazin,dihydroklorid
N
2 HCI
Til en løsning av 0,5 g (1,0 mmol) 4-{2[4-(3-trifluor-metylfenyl)piperazin-1yl]etyl}piperidin-1 -karboksylsyre-ferf-butylester, hydroklorid i 5 ml etylacetat og2,5 ml metanol blir satt 2,5 ml av en mettet hydrogenklorid-løsning i dietyleter.Blandingen blir omrørt i 2 timer ved romtemperatur (utfelling skjer raskt).
Det faste stoffet blir filtrert, vasket med dietyleter og tørket under redusert trykk, hvilket gir 0,41 g (100%) av 1-(2-piperidin-4-yletyl)-4-(3-trifluormetylfenyl)piperazin, dihydroklorid som et hvitt, fast stoff.
Smeltepunkt: 260°C
1H NMR (DMSO De): 11,2 (bred s, 1H); 8,95 (bred s, 1H); 8,8 (bred s, 1H); 7,45 (t, 1H, J = 7,5); 7,35 (d, 1H, J = 7,5); 7,3 (s, 1H); 7,1 (d, 1H, J = 7,5); 3,95 (m, 2H); 3,6 (m, 2H); 3,4 til 2,95 (ms, 8H); 2,8 (m, 2H); 1,9 til 1,5 (ms, 5H); 1,5 til 1,2 (ms, 2H)
Rute A
1 -(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 -yl]etyl}piperid in-1 -yl)propan-1,2dion, hydroklorid
F
I N
CIH
1-(2-piperidin-4-yletyl)-4-(3-trifluormetylfenyl)piperazin, dihydroklorid150 mg (0,36 mmol) og 38 mg (0,43 mmol) pyrodruesyre blir koblet i henhold til fremgangsmåten beskrevet i eksempel 1, rute A.
Etter opparbeidelse blir residuet renset over 5 g silikagel (elueringsmiddel diklormetan/metanol 99/1). Det oljeaktige produkt blir oppløst i 1 ml etylacetat og surgjort med en mettet hydrogenklorid-løsning i dietyleter. Det faste stoffetblir filtrert, vasket med dietyleter og tørket under redusert trykk, hvilket gir 55 mg (35%) av 1 -(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 -yl]etyl}piperidin-1 -yl)propan1,2-dion, hydroklorid som et hvitt, fast stoff.
Smeltepunkt: 200°C
1H NMR (DMSO De): 10,8 (bred s, 1H); 7,45 (t, 1H, J = 7,5); 7,3 (d, 1H, J = 7,5); 7,25 (s, 1H); 7,15 (d, 1H, J = 7,5); 4,2 (m, 1H); 3,95 (m, 2H); 3,55 (m, 2H);
3,3 til 2,95 (ms, 8H); 2,75 (m, 1H); 2,3 (s, 3H); 1,85 til 1,55 (ms, 5H); 1,25 til 0,95 (ms, 2H)
Eksempel 3: 1 -(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 -yl]etyl}-piperidin-1 yl)propan-2-on
V r^F F
I N hk
Rute B
En blanding av 0,35 g (0,84 mmol) 1-(2-piperidin-4-yletyl)-4-(3trifluormetylfenyl)piperazin, dihydroklorid, 0,41 g (2,97 mmol) kaliumkarbonat, 10 ml acetonitril og 0,1 g (1,08 mmol) kloraceton bliromrørt ved romtemperatur natten over.
Etter konsentrasjon av løsningsmiddel blir residuet fordelt med etylacetat og vann. Den vandige fasen blir separert. Den organiske fasen blir vasket 3 ganger med vann, tørket over magnesiumsulfat, filtrert og konsentrert under redusert trykk, hvilket gir 0,24 g (72%) av 1-(4-{2-[4-(3-trifluormetylfenyl)piperazin-1-yl]etyl}piperidin-1-yl)propan-2-on som et hvitt, fast stoff.
Smeltepunkt: 82°C
1H NMR: 7,35 (t, 1H, J = 7,5); 7,2 til 7,0 (ms, 3H); 3,25 (m, 4H); 3,15 (s, 2H); 2,85 (m, 2H); 2,6 (m, 4H); 2,4 (t, 2H, J = 7,5); 2,15 (s, 3H); 2,05 (m, 2H); 1,8 (m, 2H); 1,6 til 1,2 (ms, 5H)
Eksempel 4: /V-metoksy-/V-metyl-2-(4-{2-[4-(3-trifluormetylfenyl)-piperazin1-yl]etyl}cykloheksyliden)acetamid
f N hk J
%
I
Rute C
Trinn a: (4-{2-[4-(3-trifluormetylfeny)piperazin-1 -yl]etyl}cykloheksyliden)eddiksyre-etylester
I N
F
En blanding av 2,77 g (7,8 mmol) 4-{2-[4-(3-trifluormetyl-fenyl)piperazin-1yl]etyl}cykloheksanon (eksempel 1, rute II, trinn b) og 3,13 g (9,0 mmol) (trifenylÅ5-fosfanyliden)eddiksyre-etylester i 40 ml toluen blir tilbakeløpskokt natten over.Etter konsentrasjon av toluen, blir residuet tatt opp i dietyleter og det faste stoffet blir filtrert. Filtratet blir konsentrert og renset over 150 g silikagel (elueringsmiddel diklor-metan/heptan 98/2), hvilket gir 1,48 g (45%) av (4-{2-[4(3-trifluormetyl-feny)piperazin-1-yl]etyl}cykloheksyliden)eddiksyre-etylester somen olje.
1H NMR: 7,35 (t, 1H); 7,2 til 7,0 (m, 3H); 5,6 (s, 1H); 4,15 (q, 2H, J = 7,5); 3,75 (m, 1H); 3,25 (m, 4H); 2,6 (m, 4H); 2,45 (t, 2H, J = 7,5); 2,4 til 1,85 (ms, 5H); 1,85 til 1,4 (ms, 4H); 1,3 (t, 3H, J = 7,5); 1,25 til 1,05 (m, 2H)
Trinn b: (4-{2-[4-(3-trifluormetylfeny)piperazin-1 -yl]etyl}cykloheksyliden)eddiksyre, hydroklorid
V
PF F
f N
1 MCI
HO
Til en løsning av 0,88 g (2,1 mmol) (4-{2-[4-(3-trifluormetylfeny)piperazin-1yl]etyl}cykloheksyliden)eddiksyre-etylester i 8 ml metanol blir satt 2,2 ml av envandig N natriumhydroksid-løsning. Omrøring blir holdt natten over vedromtemperatur. Metanol blir inndampet under redusert trykk og residuet blir fortynnet i 20 ml vann og vasket med dietyleter. Den vandige fasen blir avkjølt, surgjort til pH 1 med en vandig 1N løsning av saltsyre. Det faste stoffet blir filtrert, vasket med vann og tørket under redusert trykk, hvilket gir 0,36 g (44%) av (4-{2-[4-(3-trifluormetylfeny)piperazin-1-yl]etyl}cykloheksyliden)eddiksyre,hydroklorid som et hvitt, fast stoff.
1H NMR (DMSO De): 11,95 (bred s, 1H); 10,7 (bred s, 1H); 7,45 (t, 1H, J = 7,5); 7,3 (d, 1H, J =7,5); 7,25 (s, 1H); 7,15 (d, 1H, J = 7,5); 5,5 (s, 1H); 3,9 (m, 2H); 3,7 til 3,4 (ms, 3H); 3,3 til 2,9 (ms, 7H); 2,45 til 1,45 (ms, 7H); 1,05 (m, 2H)
Trinn c: /V-metoksy-/V-metyl-2-(4-{2-[4-(3-trifluormetylfeny)piperazin-1 yl]etyl}cykloheksyliden)acetamid
V
PF F
f N rt J
N
Til en løsning av 200 mg (0,46 mmol) (4-{2-[4-(3-trifluormetylfeny)piperazin1-yl]etyl}cykloheksyliden)eddiksyre, hydroklorid i 5 ml diklormetan stabilisert påamylen blir suksessivt satt 63 mg (0,46 mmol) 1-hydroksy-benzotriazol, 88 mg(0,46 mmol) 3-etyl-1-(3-dimetylaminopropyl)karbodiimid-hydroklorid og 140 mg(1,4 mmol) trietylamin. Blandingen blir omrørt i 15 minutter og deretter blir 45 mg (0,46 mmol) A/,O-dimetylhydroksylamin-hydroklorid tilsatt. Blandingen blir omrørtnatten over ved romtemperatur, deretter inndampet under redusert trykk. Residuet blir oppløst i etylacetat og vasket to ganger med vann. Den organiske fasen blir tørket over magnesiumsulfat, filtrert og konsentrert under redusert trykk. Residuet blir renset over 10 g silikagel (elueringsmiddel diklormetan/metanol 98/2), hvilket gir 143 mg (71%) av /V-metoksy-/V-metyl-2-(4{2-[4-(3-trifluormetylfeny)piperazin-1 -yl]etyl}cykloheksyliden)acetamid som enolje.
1H NMR: 7,35 (t, 1H, J = 7,5); 7,15 til 7,0 (ms, 3H); 6,05 (s, 1H); 3,7 (s, 3H); 3,6 (m, 1H); 3,25 (m, 4H); 3,2 (s, 4H); 2,6 (m, 4H); 2,45 (t, 2H, J = 7,5); 2,4 til 2,1 (ms, 2H); 2,1 til 1,85 (ms, 3H); 1,6 til 1,4 (m, 2H); 1,4 til 1,05 (ms, 2H)
Eksempel 5: 1 -(4-{2-[4-(3-trifluormetylfeny)piperazin-1 -yljetyl}cykloheksyliden)propan-2-on
'RF F
\ N
Til en løsning av 114 mg (0,25 mmol) /V-metoksy-/V-metyl-2-(4-{2-[4-(3trifluormetylfeny)piperazin-1-yl]etyl}-cykloheksyliden)acetamid i 5 ml tørrtetrahydrofuran avkjølt til 0°C blir satt 0,2 ml (0,50 mmol) av en 22% metylmagnesiumklorid-løsning i tetrahydrofuran. Blandingen blir oppvarmetopptil 5°C og omrørt i 90 minutter. Hydrolyse blir utført ved langsom tilsetning av 3 ml vann. Produktet blir ekstrahert 3 ganger med etylacetat. De organiske
fasene blir samlet, tørket over magnesiumsulfat, filtrert og konsentrert under redusert trykk. Det oppnådde residuet blir renset over 5 g silikagel (elueringsmiddel diklormetan/metanol 95/5), hvilket gir 43 mg (44%) av 1-(4-{2[4-(3-trifluormetylfeny)piperazin-1 -yl]etyl}cykloheksyliden)propan-2-on som enolje.
1H NMR: 7,35 (t, 1H, J = 7,5); 7,2 til 7,0 (ms, 3H); 6,0 (s, 1H); 3,7 (m, 1H); 3,25 (m, 4H); 2,6 (m, 4H); 2,45 (m, 4H); 2,25 (m, 2H); 2,2 (s, 3H); 1,95 (m, 3H);
1,7 til 1,4 (ms, 1H); 1,35 til 1,0 (ms, 2H)
Eksempel 6: 1 -(4-{2-[4-(3-trifluormetylfeny)piperazin-1 -yl]etyl}cykloheksyl)propan-2-on, hydroklorid
V r~F F
I N
HCI
En løsning av 33 mg (0,08 mmol) 1-(4-{2-[4-(3-trifluor-metylfeny)piperazin1-yl]etyl}cykloheksyliden)propan-2-on blir avkjølt og spylt med argon. Ettertilsetning av 5 mg 10% palladium på aktivert karbon blir blandingen hydrogener! ved romtemperatur og atmosfærisk trykk natten over. Suspensjonen blir filtrert over et sjikt av celite og filtratet blir konsentrert under redusert trykk. Residuet blir oppløst i acetonitril, surgjort med en mettet saltsyre-etylacetat-løsning, filtrertog tørket under redusert trykk, hvilket gir 29 mg (85%) av 1 -(4-{2-[4-(3trifluormetylfeny)piperazin-1-yl]etyl}cykloheksyl)propan-2-on, hydroklorid som ethvitt, fast stoff.
Smeltepunkt: 160°C
1H NMR: 7,35 (t, 1H, J = 7,5); 7,2 til 7,0 (ms, 3H); 3,5 (bred s, 1H); 3,25 (m, 4H); 2,6 (m, 4H); 2,5 til 2,3 (ms, 4H); 2,2 (s, 3H); 1,9 til 1,65 (ms, 4H); 1,65 til 1,15 (ms, 6H); 1,0 (m, 2H)
Eksempel 7: /V-(4-{2-[4-(3-acetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid trans/cis 80/20
f N
trans/cis 80/20
N
En løsning av 44 mg (0,35 mmol) oksalylklorid i 1 ml diklormetan blir spylt med argon og avkjølt til en temperatur nær -70°C. En løsning av 66 mg(0,8 mmol) dimetylsulfoksid i 1 ml diklormetan blir tilsatt. Omrøring blir holdt ved en temperatur nær -70°C i 15 minutter og en løsning av 120 mg (0,3 mmol) 2cyano-/V-[4-(2-{4-[3-(1-hydroksyetyl)fenyl]piperazin-1-yl}etyl)cykloheksyljacetamid trans/cis 80/20 i 4 ml diklormetan blir tilsatt. Etter en ytterligere omrøring i 15 minutter ved en temperatur nær -70°C, blir 110 mg(1,08 mmol) trietylamin tilsatt. Blandingen får oppvarmes til romtemperatur og blir deretter omrørt natten over ved romtemperatur. Blandingen blir hellet i vann og ekstrahert to ganger med etylacetat. De organiske fasene blir samlet, vasket med vann, deretter saltvann, tørket over magnesiumsulfat, filtrert og konsentrert under redusert trykk. Det oljeaktige residuet blir renset over 5 g silikagel (elueringsmiddel diklormetan/metanol 98/2 deretter 95/5), hvilket gir 25 mg (21 %) av /V-(4-{2-[4-(3-acetylfenyl)piperazin-1 -yl]etyl}cykloheksyl)-2cyanoacetamid trans/cis 80/20 som et hvitt, fast stoff.
Smeltepunkt 160°C
1H NMR: 7,5 (s, 1H); 7,45 (d, 1H, J = 7,5); 7,35 (t, 1H, J = 7,5); 7,1 (d, 1H; J = 7,5); 6,15 (bred d, 0,2 H); 5,9 (bred d, 0,8H); 4,05 (m, 0,2H); 3,8 (m, 0,8H); 3,4 (s, 0,4H); 3,35 (s, 1,6H); 3,2 (m, 4H); 2,65 (m, 4H); 2,6 (s, 3H); 2,45 (m, 2H); 2,05 (m, 2H); 1,85 (m, 2H); 1,8 til 1,4 (ms, 4H); 1,4 til 1,0 (ms, 3H)
Den følgende tabell oppsummerer noen ytterligere eksempler og metoden ved hvilken de kan oppnås
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
'A'0vN'^ cih
। 0
4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}piperidin-1 -karboksylsyretert-butylester, hydroklorid
IIIB
C|H
cih
o F
1-(4-{2-[4-(2-fluorfenyl)piperazin1 -yl]etyl}pi perid in-1 -yl)propan-2on, dihydroklorid
IIIB
CIH X 1 F
CIH
0 F
C^oA^-J
(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)eddiksyreterf-butylester, dihydroklorid
IIIB
CIH f j]
CIH
0 F
u
1-fenyl-2-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}piperid in-1 -yl)etanon,dihydroklorid
IIIB
pnXI^ o ^y""F
cih
1-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}piperid in-1 -yl)butan-1,2dion, hydroklorid
HIA
r-N^l^
o F
^nCJ
3,3-dimetyl-1-(4-{2-[4-(3
trifluormetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)butan-2-on
IIIB
pnXX^f
o nA f
Ar/J
H å
/V-[2-okso-2-(4-{2-[4-(3
trifluormetylfenyl)piperazin-1
yl]etyl}piperidin-1 -yl)etyl]acetamid
HIA
cih
r Tf
3-okso-3-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propannitril,hydroklorid
HIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
0IH
2-metoksy-1-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}piperid in-1 -yl)etanon,hydroklorid
HIA
CIH pN-Oy;
F
/-o-y-n-J
2-etoksy-1-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}piperid in-1 -yl)etanon,hydroklorid
HIA
cih
I Y-f
yyy-^N-^y1 F
N^ o
5-okso-5-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)pentannitril,hydroklorid
HIA
- X
0 yy^N-> F
3-(4-{2-[1-(2-oksopropyl)piperidin-4
y IJety l}piperazin-1 -y I )-5trifluormetylbenzonitril, dihydroklorid
IIIB
en [f^l]
CIH
/yy\/N. J Cl o y
yA^/N^J
1 -(4-{2-[4-(2-metoksy
fenyl)piperazin-1 -yl]etyl}piperidin
1-yl)propan-2-on, dihydroklorid
IIIB
y-N-^yAio yy-NJ ClyA^N^J
1-(4-{2-[4-(2,3
diklorfenyl)piperazin-1
yl]etyl}piperidin-1-yl)propan-2-on
IIIB
cih A
cih y-yiO yyNJ ili A^nJ n
2-metyl-6-(4-{2-[1-(2oksopropyl)piperidin-4yl]etyl}piperazin-1 -yl)benzonitril,dihydroklorid
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
cih i 11 CIH
o F
2-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)acetamid,dihydroklorid
IIIB
CIH CIH | |1
o 01
1-(4-{2-[4-(2-klorfenyl)-piperazin1 -yl]etyl}pi perid in-1 -yl)propan-2on, dihydroklorid
IIIB
CIH CIH f jl
o
3-(4-{2-[1-(2
oksopropyl)piperidin-4
yl]etyl}piperazin-1-yl)benzonitril,
dihydroklorid
IIIB
GIH CIH 1 1 p
o F
/-crVN'-J
(4-{2-[4-(3-trifluormetylfenyl)piperazin-1 -yl]etyl}piperidin1 -yl)eddiksyre-etylester,
dihydroklorid
IIIB
F cm " rA
1-(4-{2-[4-(3,5-difluorfenyl)piperazin-1 -yl]etyl}piperid in-1 yl)propan-2-on, dihydroklorid
IIIB
,.-O.
9 r f cih
CIH
1 -(4-{2-[4-(2,3-dimetylfenyl)piperazin-1 -yl]etyl}piperid in-1 yl)propan-2-on, dihydroklorid
IIIB
£1
|-^N'^^"CI
0 yy—
1-(4-{2-[4-(3-klorfenyl)-piperazin1 -yl]etyl}pi perid in-1 -yl)propan-2on
IIIB
r-9
CIH CIH
1 -{4-[2-(4-o-tolylpiperazin-1 -yl)thyl]piperidin-1-yl}propan-2-on,dihydroklorid
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
T 1
CIH CIH
1-(4-{2-[4-(2-klor-5metylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
Tl
0 Q—
CIH CIH
1-(4-{2-[4-(5-fluor-2metylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
Qi-Xl^
o F
HCI HCI
1-(3,4-difluorfenyl)-2-(4-{2-[4-(3
trifluormetylfenyl)-piperazin-1
yl]etyl}piperid in-1 -yl)etanon
IIIB
F'sx'F
cA o f
aJU hci
1-(4-{2-[4-(3,5-bistrifluormetylfenyl)piperazin-1 -y l]ety I}piperid in-1 -yl)propan-2-on
IIIB
0 F
JCM HCI HCI
1 -(4-{2-[4-(2,3-difluorfenyl)piperazin-1 -yl]etyl}piperid in-1 yl)propan-2-on
IIIB
« A
o
1 -{4-[2-(4-naftalen-1 -ylpiperazin1 -yl )etyl] piperid in-1 -yl}propan-2on
IIIB
qXA o f
ryA-UU H
(4-{2-[4-(3-trifluormetyl
fenyl)piperazin-1
yl]etyl}cykloheksyl)karbaminsyrebenzyl ester
HA
ruXA;
o nA f
FyA
2,2,2-trifluor-/V-(4-{2-[4-(3
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)acetamid
HA
cA ,w.. ’
H
(4-{2-[4-(3-trifluormetyl
fenyl)piperazin-1-yl]etyl}cyklo
heksyl)karbaminsyre-metylester
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
£1 p
o F
Tetrahydrofuran-2-karboksylsyre(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
HA
£1 p
o F
^o^An.-LJ
H
2-metoksy-/V-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
CIH X. Å F
i N r~F
0 F
.o^AN.kJ
H
2-metoksy-/V-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid, hydroklorid
IIA
HCI jX
HCI i^N^Y
0 !Y^n£ A
1 -(4-{2-[4-(2-isopropylfenyl)piperazin-1 -yl]etyl}piperid in-1 yl)propan-2-on
IIIB
<.yA’
A... '
F H
2,2-difluor-/V-(4-{2-[4-(3
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)acetamid
IIA
Pn-O^;
0 £0 F
h
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(3-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)amid
IIA
r^N^X;
o f
HO--X"-X""""-^ CIH
H
2-hydroksy-/V-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid, hydroklorid
IIA
A^XFp
H
3-metoksy-/V-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
£IF
. JUO ' '
H
/V-(4-{2-[4-(2,4-difluorfenyl)
piperazin-1 -yl]etyl}cykloheksyl)-2metoksyacetamid
HA
..a . ojua.".'!
H
A/-(4-{2-[4-(2-cyano-3metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2metoksyacetamid
HA
-w.".1'
H
A/-(4-{2-[4-(2-fluorfenyl)
piperazin-1-yl]etyl}cykloheksyl)-2
metoksyacetamid
IIA
Yl F
cih
° F
H
2-etoksy-/V-(4-{2-[4-(3
trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid, hydroklorid
IIA
<tV3...' '
VJ H
Cyklopent-3-enkarboksylsyre-(4
{2-[4-(3-trifluormetylfenyl)
piperazin-1-yl]etyl}cykloheksyl)amid
IIA
£1 r
o f
cY0
Cykloheks-1 -enkarboksylsyre-(4{2-[4-(3-trifluormetylfenyl)piperazin-1-yl]etyl}cykloheksyl)amid
IIA
n,Q
..iW.. J
H
A/-(4-{2-[4-(2-cyano-3
metylfenyl)-3,6-dihydro-2/-/pyridin-1 -yl]etyl}cykloheksyl)-2metoksyacetamid
IIA
t.n
-w..J
H
A/-(4-{2-[4-(2-cyano-3metylfenyl)piperidin-1 yl]etyl}cykloheksyl)-2metoksyacetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
r-P
.-JX'...' ’
H
2-etoksy-/V-(4-{2-[4-(2
fluorfenyl)piperazin-1
yl]etyl}cykloheksyl)acetamid
HA
r-J?
..J '
Tetrahydrofuran-2-karboksylsyre(4-{2-[4-(2-fluorfenyl)piperazin-1yl]etyl}cykloheksyl)amid
HA
,...9
,».w...'1
H
/V-(4-{2-[4-(2-cyanofenyl)
piperazin-1-yl]etyl}cykloheksyl)-2metoksyacetamid
IIA
H
2-metoksy-/V-(4-{2-[4-(3trifluormetylfenyl)-3,6-dihydro2/-/-pyridin-1 yl]etyl}cykloheksyl)acetamid trans/cis 95/5
IIA
o p,. N-P
H
2-metoksy-/V-{4-[2-(4fenylpiperazin-1 -yl )ety I]cykloheksyljacetamid
IIA
pXlp
F F
H
2-metoksy-/V-(4-{2-[4-(3
trifl uormetylfenyl)piperid in-1 yl]etyl}cykloheksyl)acetamid trans/cis 95/5
IIA
Q-Op
0 F
U "
2-fenoksy-/V-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
pN£\<FF
.".1 '
H
3,3,3-trifluor-/V-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
IIA
r-N-Op
0 F
,<\PPJ
H
4-metoksy-/V-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
....'
VJ H
Cyklopent-3-enkarboksylsyre {4[2-(4-py rid in-2-yl piperazin-1 yl)etyl]cykloheksyl}amid
HA
,...0
0 O'"sn
Cykloheks-1-enkarboksylsyre {4[2-(4-fenylpiperazin-1 yl)etyl]cykloheksyl}amid trans/cis 90/10
HA
r..9
o <Y^nJ f O'lP
Cykloheks-1 -enkarboksylsyre-(4{2-[4-(2-fluorfenyl)-piperazin-1yl]etyl}cykloheksyl)-amid
IIA
,..9
o F
\_J H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(2-fluorfenyl)-piperazin-1yl]etyl}-cykloheksyl)amid
IIA
,..9
\ H
A/-(4-{2-[4-(2-fluorfenyl)
piperazin-1-yl]etyl}cykloheksyl)-2
metoksypropanamid
IIA
r»9 ow.. '
VJ H
Cyklopent-3-enkarboksylsyre-(4{2-[4-(2-fluorfenyl)-piperazin-1yl]etyl}-cykloheksyl)amid trans/cis95/5
IIA
rrF
o ry F
rip
Cykloheks-1 -enkarboksylsyre-(4{2-[4-(2,4-difluorfenyl)-piperazin1 -yl]etyl}-cykloheksyl)amid
IIA
yyCl
å w
VJ H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(2-cyano-3-metylfenyl)-3,6d ihydro-2/-/-pyrid in-1 yl]etyl}cykloheksyl)-amid
IIA
„ ?.oV
H
/V-(4-{2-[4-(2-cyanofenyl)
piperazin-1-yl]etyl}cykloheksyl)-2etoksyacetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
r»-?
0 ill
jfll N
VJ H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(2-cyanofenyl)-piperazin-1yl]etyl}cykloheksyl)-amid
HA
rZ vz..' '
A/-(4-{2-[4-(2-fluorfenyl)
piperazin-1-yl]etyl}cykloheksyl)-2
metoksypropanamid
HA
cz
^-Zr9O'''''^N'J F
H
A/-(4-{2-[4-(2-fluorfenyl)
piperazin-1-yl]etyl}cykloheksyl)-4
metoksybutanamid
IIA
r-N^X^Fo n'"^1 F zW
2-metoksy-2-metyl-/V-(4-{2-[4-(3
trifluormetylfenyl)-piperazin-1
yl]etyl}cykloheksyl)-propanamid
IIA
n o^]...^nGN^Sn
H
/V-(4-{2-[4-(3-cyanofenyl)
piperazin-1-yl]etyl}cykloheksyl)-2
etoksyacetamid trans/cis 75/25
IIA
rZ .vo.'
H
2-cyano-/V-(4-{2-[4-(2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
rN-Oy;
o F
H
2-metylsulfanyl-/V-(4-{2-[4-(3
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)acetamid
IIA
rZOZ o y^CZ^Z
H
4-metoksy-/V-(4-{2-[4-(3trifluormetylfenyl)-3,6-dihydro2/7-pyridin-1 yl]etyl}cykloheksyl)butanamid
IIA
/GXf
on^...^nCj Xf
H
2-etoksy-/V-(4-{2-[4-(3
trifluormetylfenyl)-3,6-dihydro
2/7-pyridin-1
yl]etyl}cykloheksyl)acetamid
trans/cis 95/5
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
° F
H
2-etoksy-/V-(4-{2-[4-(3
trifl uormetylfenyl)piperid in-1 yl]etyl}cykloheksyl)acetamid
HA
0 Q-Xr
H
4-metoksy-/V-(4-{2-[4-(3trifl uormetylfenyl)piperid in-1 yl]etyl}cykloheksyl)butanamid
HA
CIH X. JI ,F
2-(2-metoksyetoksy)-/V-(4-{2-[4(3-trifluormetylfenyl)-piperazin-1yl]etyl}cykloheksyl)-acetamid,hydroklorid trans/cis 75/25
IIA
n oXX^"^0 N
H
/V-(4-{2-[4-(3cyanofenyl)piperazin-1 yl]etyl}cykloheksyl)-2metoksyacetamid
IIA
,..-9
.UA.J '
F H
3,3,3-trifluor-/V-(4-{2-[4-(2
fluorfenyl)piperazin-1
yl]etyl}cykloheksyl)propanamid
IIA
aQ
o f
q0 tX
A/-(4-{2-[4-(2-fluorfenyl)
piperazin-1-yl]etyl}cykloheksyl)-2fenoksyacetamid
IIA
r»9
•VX1..' ’
0 H
A/-(4-{2-[4-(2-fluorfenyl)
piperazin-1-yl]etyl}cykloheksyl)-2oksobutanamid
IIA
X
o N-%^Ck .J\_J
H
2-cyano-/V-(4-{2-[4-(3cyanofenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid trans/cis 75/25
IIA
X
0 p^NX F
H
A/-(4-{2-[4-(2,3-difluorfenyl)
piperazin-1 -yl]etyl}cykloheksyl)-2metoksyacetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
0 F
H
2-cyano-/V-(4-{2-[4-(3
trifluormetylfenyl)-3,6-dihydro
2/-/-pyridin-1
yl]etyl}cykloheksyl)acetamid
HA
oy:
o f
H
4-metoksy-/V-(4-{2-[4-(2,3,4,5tetrafluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butyramid
HA
Gin |l
0 .F
H
2-okso-/V-(4-{2-[4-(3
trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid, hydroklorid trans/cis 70/30
IIA
cih xl f
r^^^r-F■yUT... '
fi H
2-okso-/V-(4-{2-[4-(3
trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid, hydroklorid trans/cis 70/30
IIA
pN-Xly
,N. J F
। ? o
H
2-dimetylamino-/V-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
,.y
o pv—ny F
T H
/V-(4-{2-[4-(2-fluorfenyl)
piperazin-1-yl]etyl}cykloheksyl)-2
isopropoksyacetamid
IIA
A
"At XA"^ F
H
4-cyano-/V-(4-{2-[4-(2,3,4,5tetrafluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butyramid
IIA
A
H
4-metoksy-/V-{4-[2-(4
fenylpiperazin-1
yl)etyl]cykloheksyl}butanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
'^T H
2-isopropoksy-/V-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid trans/cis 80/20
HA
o ill F
N
H
A/-(4-{2-[4-(2-cyano-3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2isopropoksyacetamid
HA
o j, F
N
H
A/-(4-{2-[4-(2-cyano-3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2etoksyacetamid
IIA
Q^Qyf
0 ill F
N^\^A N
H
2-cyano-/V-(4-{2-[4-(2-cyano-3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
cih J-L J
f N ..
H
2-cyano-/V-{4-[2-(4-fenyl
piperazin-1-yl)etyl]cykloheksyl}
acetamid, hydroklorid
IIA
H H I 1 y.AAJ
2-acetylamino-/V-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
hci ^""Tr1^
HCI „ k IL
. rT.OT*1
2-klor-6-fluor-3-(4-{2-[1-(2
oksopropyl)piperidin-4
yl]etyl}piperazin-1-yl)benzonitril
IIIB
F'-CF
A f
^''N^
J F
"kW ..
H
A/-(4-{2-[4-(3,5-bistrifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)-2cyanoacetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
H
/V-(4-{2-[4-(3,5
bistrifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)-2
etoksyacetamid
HA
jf! p
0 0 F
H
3-okso-/V-(4-{2-[4-(3
trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid trans/cis 70/30
HA
.oN
F o n.^ox
F H
/V-{4-[2-(6-cyano-3,4-dihydro-1/-/isokinolin-2-yl)etyl]cykloheksyl}3,3,3-trifluorpropanamid
IIA
r^N
'•.W..1
H
2-cyano-/V-(4-{2-[4-(2,6-di-terfbutylpyrimidin-4-yl)piperazin-1 yl]etyl}cykloheksyl)acetamid trans/cis 65/35
IIA
£1
£.£3"''^^ F
H
/V-(4-{2-[4-(2,3-difluorfenyl)
piperazin-1 -yl]etyl}cykloheksyl)-2etoksyacetamid
IIA
jC1
0 Y>'^N^ F
H
2-cyano-/V-(4-{2-[4-(2,3difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
r-Y-K.W.".’ !
H
2-cyano-/V-(4-{2-[4-(2-cyano-3metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
,.Y
4 w.1 !
F H
A/-(4-{2-[4-(2-cyano-3metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-3,3,3trifluorpropanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
fjL
"«-W.1
H
2-cyano-/V-(4-{2-[4-(5,6,7,8tetrahydronaftalen-1-yl)piperazin1 -yl]etyl}cykloheksyl)acetamid
HA
£1
...w..1 ■ H
2-etoksy-/V-(4-{2-[4-(5,6,7,8tetrahydronaftalen-1-yl)piperazin1 -yl]etyl}-cykloheksyl)acetamid
HA
..■£
H
A/-(4-{2-[4-(3,5bistrifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)-2metoksyacetamid
IIA
.j n.-1 ’
H
A/-(4-{2-[4-(2-cyano-3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2metoksyacetamid
IIA
H
2-cyano-/V-{4-[2-(4-pyridin-4ylpiperazin-1
yl)etyl]cykloheksyl}acetamid trans/cis 65/35
IIA
H
A/-(4-{2-[4-(2,6-di-tørfbutylpyrimidin-4-yl)piperazin-1 yl]etyl}cykloheksyl)-2etoksyacetamid
IIA
r£""N
-W.''"'j
H
A/-(4-{2-[4-(2,6-di-tørfbutylpyrimidin-4-yl)piperazin-1 yl]etyl}cykloheksyl)-2metoksyacetamid
IIA
r-'Q
.-juo..' °
H
2-etoksy-/V-(4-{2-[4-(2metoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
-.w.1 °
H
2-cyano-/V-(4-{2-[4-(2metoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
,..J?
..J
H
2-metoksy-/V-(4-{2-[4-(2metoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
C|H
o F
H
2-cyano-/V-(4-{2-[4-(2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid, hydroklorid
IIA
■«.W'.CrJ?l
H
2-cyano-/V-(4-{2-[4-(2-fluorfenyl)
3,6-d ihyd ro-2/-/-pyrid in-1 yl]etyl}cykloheksyl)-acetamidtrans/cis 90/10
IIA
rNX)
H ? O
S H
2-acetylamino-/V-{4-[2-(4
fenylpiperazin-1
yl)etyl]cykloheksyl}acetamid
IIA
,...9
.10
H
A/-(4-{2-[4-(2-klorfenyl)-piperazin1 -yl]etyl}cy kloheksyl )-2metoksyacetamid
IIA
£1
0 M
H
2-metoksy-/V-(4-{2-[4-(5,6,7,8tetrahydronaftalen-1-yl)piperazin1 -yl]etyl}cykloheksyl)acetamid
IIA
,.«9
'•-W.".1 0
H
A/-(4-{2-[4-(2-klorfenyl)-piperazin1 -yl]etyl}cy kloheksyl )-2cyanoacetamid
IIA
r.9
...1 °
H
A/-(4-{2-[4-(2-klorfenyl)-piperazin1 -yl]etyl}cy kloheksyl )-2etoksyacetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
.J
H
2-cyano-/V-(4-{2-[4-(3-fluorfenylpiperazin-1
yl]etyl}cykloheksyl)acetamid
HA
,..Q
•avo..1'
0 H
2-acetylamino-/V-(4-{2-[4-(2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
rN£\<;
2-terf-butoksy-/V-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid trans/cis 95/5
IIA
(^N-X^C!
"*.vo..1
H
/V-(4-{2-[4-(3-klor-2metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
IIA
pjOki
H
/V-(4-{2-[4-(3-klor-2metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2etoksyacetamid
IIA
fa<f
£1
o n.
H
2-cyano-/V-(4-{2-[4-(3-cyano-5
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)acetamid
IIA
FCF
£1 oJLnX)-0 N
H
/V-(4-{2-[4-(3-cyano-5trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2metoksyacetamid
IIA
£££^n°^N
H
/V-(4-{2-[4-(3-cyano-5trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2etoksyacetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
i.o
.SJO..
H
2-cyano-/V-{4-[2-(4-fenyl-3,6d ihydro-2/-/-pyrid in-1 yl)etyl]cykloheksyl}acetamid
HA
..•JQO.-J‘-J "
H
A/-(4-{2-[4-(2,3-diklorfenyl)
piperazin-1 -yl]etyl}cykloheksyl)-2metoksyacetamid
HA
£1
.' "
H
2-cyano-/V-(4-{2-[4-(2,3diklorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
£1
^N'^Y^'ci
£nj£'^n'^j Cl
H
A/-(4-{2-[4-(2,3-diklorfenyl)
piperazin-1 -yl]etyl}cykloheksyl)-2etoksyacetamid
IIA
£1
\ _-N ., J F
h ff n W-N-U
J H
2-acetylamino-/V-(4-{2-[4-(2,3difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
£1
CIH ^N-^Y^F
r.W-'"-1 '
/V-(4-{2-[4-(2,3-difluorfenyl)
piperazin-1 -yl]etyl}cykloheksyl)2
isopropoksyacetamid, hydroklorid
IIA
hoi /°'Y;r£
HCI J«s.JL
< N — Cl
1-(4-{2-[4-(5-klor-2metoksyfenyl)piperazin-1 yl]etyl}piperidin-1-yl)propan-2-on
IIIB
XI
o y£.-^n^Jn<Y^£ XX
H
2-cyano-/V-(4-{2-[4-(3,5dimetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
£1
,N. £ n^£L j£"
H
2-cyano-/V-(4-{2-[4-(3etylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
£1
£^n'^/Xn''
XX
H
2-cyano-/V-(4-{2-[4-(3dimetylaminofenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
Cl
fjl
H
2-cyano-/V-(4-{2-[4-(3,5diklorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
Yl
-.W.1
H
2-cyano-/V-(4-{2-[4-(2,5dimetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
qXY;
0 f
nC/"
1-acetylpiperidin-4karboksylsyre-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
IIA
o f
J H
N-(4-{2-[4-(3-trifluormetyl
fenyl)piperazin-1
yl]etyl}cykloheksyl)succinamid trans/cis 65/35
IIA
Ti
kW...'
H
/V-(4-{2-[4-(5-klor-2metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
IIA
£1
YUO..1
H
A/-(4-{2-[4-(3-klorfenyl)-piperazin1 -yl]etyl}cy kloheksyl )-2cyanoacetamid
IIA
AY
O x\,
H
2-cyano-/V-(4-{2-[4-(3
trifluormetoksyfenyl)piperazin-1
yl]etyl}cykloheksyl)acetamid
IIA
jfl p
0 Yl f f
H
2-cyano-/V-(4-{2-[4-(2-fluor-3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
F
-.f/D...'
H
2-cyano-/V-(4-{2-[4-(3,5difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid trans/cis 95/5
HA
/l p
0 F
H
2-cyano-/V-(4-{2-[4-(3-metoksy-5trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
r,~^VF
0 F
H
4-cyano-/V-(4-{2-[4-(3
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)butanamid
IIA
rrF
-.V3.*■" ’
H
2-cyano-/V-(4-{2-[4-(2,4difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
cih /\ /L JL, Å
Y N O ^'
O r'''"'"-!
H
2-cyano-/V-(4-{2-[4-(3isopropoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid, hydroklorid
IIA
CIH Xj-Å,
Y N 0
-.v:r..
H
2-cyano-/V-(4-{2-[4-(3metoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid, hydroklorid
IIA
'°T^L ff
.. ^ ,N, J F
n^å X)'
H
2-cyano-/V-(4-{2-[4-(2-metoksy-5trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
£1
Y^N'^/^'
X._J
H
2-cyano-/V-{4-[2-(4-mtolylpiperazin-1 yl)etyl]cykloheksyl}acetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
-Jt I) ''^N^ F
3 a
3-dietylamino-/V-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid trans/cis 85/15
HA
c|h pnXX^;
° F
3-cyano-/V-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid, hydroklorid
HA
£1
,.\ Æ J ।
"KÅ n
H
A/-(4-{2-[4-(3-tørtbutylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
IIA
£1
o <"""-,
H
2-cyano-/V-(4-{2-[4-(3etoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
F£1
-.MJ.".'
H
/V-(4-{2-[4-(5-klor-2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
IIA
p-N-OVfNx^^£3'F F
H
4-cyano-/V-(4-{2-[4-(2-fluor-3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
£l££
0 ,.^N-J
N^£
H
2-cyano-/V-(4-{2-[4-(6
trifluormetylbenzo[b]tiofen-3
yl)piperazin-1
yl]etyl}cykloheksyl)acetamid
IA
Fn f
0 F
H
2-cyano-/V-(4-{2-[4-(2-fluor-5trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
■KÅ/y..
H
2-cyano-/V-(4-{2-[4-(3hydroksyfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid, hydroklorid
HA
1.1
-.W...1
H
/V-(4-{2-[4-(5-klor-2metoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
HA
N^N
o F
H
A/-(4-{2-[4-(2-tørf-butyl-6
trifluormetylpyrimidin-4
yl)piperazin-1
yl]etyl}cykloheksyl)-2
cyanoacetamid trans/cis 85/15
IIA
£1 p
0 1 F
H
2-cyano-/V-(4-{2-[4-(2-metyl-3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
Cl
,.£
y.w.1
H
/V-(4-{2-[4-(5-klor-2metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-3,3,3trifluorpropanamid
IIA
(.,£
■•..w.".'
H
2-cyano-/V-(4-{2-[4-(3,5dimetoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
F
fjl ^N-^^CI
'•.W...'
H
/V-(4-{2-[4-(3-klor-5fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
IIA
£1
^N'^/XS'x'
xW..J
H
2-cyano-/V-(4-{2-[4-(3metylsulfanylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
n
'K.W . U
H
2-cyano-/V-{4-[2-(4-naftalen-1 ylpiperazin-1yl)etyl]cykloheksyl}acetamid
HA
A
/V-(4-{2-[4-(3,5
bistrifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)-4
cyanobutanamid
HA
fl
XJVO...J ’
H
/V-(4-{2-[4-(3-klor-2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
IIA
r,Q .u:j..1'
S H
A/-(4-{2-[4-(2-fluorfenyl)piperazin
1-yl]etyl}cykloheksyl)succinamid
IIA
nj3
,VA-O.°
S H
/V-{4-[2-(4-fenylpiperazin-1
yl)etyl]cykloheksyl}succinamid
IIA
A
f o 1
fA å å j
H
3,3,3-trifluor-/V-{4-[2-(4
fenylpiperazin-1
yl)etyl]cykloheksyl}propanamid
IIA
CnXA; nAA —1 F
H
/V-(4-{2-[4-(2-klor-5
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)-2
cyanoacetamid
IIA
A
o '^•n'A
O H
/V-(4-{2-[4-(5-klor-2
metylfenyl)piperazin-1
yl]etyl}cykloheksyl)succinamid
IIA
rNXA
O F
H
4-okso-pentansyre-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
Fn
o
H
2-cyano-/V-(4-{2-[4-(2-fluor-5metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
1Å
"‘..W.
H
/V-(4-{2-[4-(2-klor-5metoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
HA
,..9
--.W.".J ■'
H
2-cyano-/V-(4-{2-[4-(2metylsulfanylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
T |
-.W.".'
H
2-cyano-/V-(4-{2-[4-(2-metoksy-5metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
'XX
"KÅ/O. ’
H
2-cyano-/V-(4-{2-[4-(5-fluor-2metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
^°X1
-JQC'..
H
A/-(4-{2-[4-(5-tørf-butyl-2metoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
IIA
XI
"«JX>.
H
2-cyano-/V-(4-{2-[4-(5-metoksy-2metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
F<:F
rXYF
J FF
H
/V-(4-{2-[4-(3,5
bistrifluormetylfenyl)-3,6-dihydro
2/-/-pyridin-1 -yl]etyl}cykloheksyl)
2-cyanoacetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
rTÅYF
J FF
JUO H
/V-(4-{2-[4-(3,5-bis
trifl uormetylfenyl)piperid in-1
yl]etyl}cykloheksyl)-2
cyanoacetamid
HA
HCI
HCI ___ Jk
rYr3
o ci
1-(4-{2-[4-(2,3-diklorfenyl)-3,6
d ihydro-2/-/-pyrid in-1
yl]etyl}piperidin-1-yl)propan-2-on
IIIB
o o F
H
5-okso-heksansyre-(4-{2-[4-(3
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)amid
HA
CIH X,JL /
N
J
X)'
H
4-cyano-/V-(4-{2-[4-(3etylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid, hydroklorid trans/cis 85/15
IIA
,.?
--.vo.J'
H
4-cyano-/V-(4-{2-[4-(2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
f-^NkXi
O Y""r F
H
/V-(4-{2-[4-(3-klor-2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-4cyanobutanamid
IIA
j^nX^cAt
o
4-cyano-/V-(4-{2-[4-(3
trifluormetoksyfenyl)piperazin-1
yl]etyl}cykloheksyl)butanamid
IIA
Xll-F
O F
n^-^anXJ
H
4-cyano-/V-(4-{2-[4-(2-fluor-5trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
pnXXf 0 pfvY II N
H
2-cyano-/V-(4-{2-[4-(2-cyano-3fluorfenyl-piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
H
4-cyano-/V-(4-{2-[4-(5,6,7,8tetrahydronaftalen-1-yl)piperazin1 -yl]etyl}cykloheksyl)butanamid
HA
£1
o Cl
H
4-cyano-/V-(4-{2-[4-(2,3diklorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
HA
r,æ
-juo...'
H
2-cyano-/V-(4-{2-[4-(5,6,7,8tetrahydronaftalen-2-yl)piperazin1 -yl]etyl}cykloheksyl)acetamid
IIA
£X>
-•..w.■.1
H
2-cyano-/V-{4-[2-(4-indan-5
ylpiperazin-1
yl)etyl]cykloheksyl}acetamid
IIA
X
o f
A/-(4-{2-[4-(3,5bistrifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)-3cyanopropanamid
IIA
° f f
3-cyano-/V-(4-{2-[4-(2-fluor-3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid trans/cis 95/5
IIA
n ^N'^Y^'ci XJUO.°
H
/V-(4-{2-[4-(3-klor-2metoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
IIA
£1
...\ .hk J J\
H
/V-(4-{2-[4-(3-benzylfenyl)
piperazin-1-yl]etyl}cykloheksyl)-2cyanoacetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
Xjl å
f N N O"'^
O H
[3-(4-{2-[4-(2cyanoacetylamino)cykloheksyl]et yl}piperazin-1
yl)fenyl]karbaminsyre-etylester
HA
- F F
H
2-cyano-/V-(4-{2-[4-(3
trifl uormetylfenyl)piperid in-1 yl]etyl}cykloheksyl)acetamid
HA
,.a
-*.æ...1
H
2-cyano-/V-(4-{2-[4-(2,3dimetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
,..0
.
H
2-cyano-/V-{4-[2-(4-otolylpiperazin-1 yl)etyl]cykloheksyl}acetamid
IIA
^°X1
n^å X)'
H
2-cyano-/V-(4-{2-[4-(2,5dimetoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
cA
4-oksopentansyre-(4-{2-[4-(3,5bis-trifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)amid
IIA
qXa
? ry F
H
4-dimetylamino-/V-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
r^^A;
2-(4-fluorfenoksy)-/V-(4-{2-[4-(3
trifluormetylfenyl)-piperazin-1
yl]etyl}cykloheksyl)-acetamid
IIA
CIH
-.w.
H
2-cyano-/V-(4-{2-[4-(2trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid, hydroklorid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
r:n,
-JXi..J
H
2-cyano-/V-(4-{2-[4-(2,5difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
I
"...W..'
H
/V-(4-{2-[4-(2-klor-5metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
HA
T 1
.".J
H
2-cyano-/V-(4-{2-[4-(2,5diklorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
p^N'^^'CI
H
A/-(4-{2-[4-(3-klorfenyl)-piperazin1 -yl]etyl}cy kloheksyl )-4cyanobutanamid
IIA
nk^JX1' '
H
4-cyano-/V-(4-{2-[4-(2-metyl-3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
r.N^?vF
° F F
H
4-oksopentansyre-(4-{2-[4-(2
fluor-3-trifluormetyl
fenyl)piperazin-1
yl]etyl}cykloheksyl)amid
IIA
II
0 rV^N.J
H
2-cyano-/V-(4-{2-[4-(3,5-di-terfbutylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
0 C!
IJ\^J
H
A/-(4-{2-[4-(2-klorfenyl)piperazin1 -yl]etyl}cy kloheksyl )-4cyanobutanamid
IIA
rNXl
H
4-cyano-/V-{4-[2-(4-mtolylpiperazin-1 yl)etyl]cykloheksyl}butanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
n
F 0
3,3,3-trifluor-/V-{4-[2-(4-m
tolylpiperazin-1
yl)etyl]cykloheksyl}propanamid
HA
--.vo..
H
4-cyano-/V-(4-{2-[4-(2metylsulfanylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
HA
oVi .W"-".
H
2-cyano-/V-{4-[2-(4-kinolin-8ylpiperazin-1 -yl)etyl]cykloheksyljacetamid
IIA
£1
V ] 1
H
4-cyano-/V-(4-{2-[4-(3metylsulfanylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
vÅ£r°
H
2-cyano-/V-{4-[2-(4-kinolin-5
ylpiperazin-1
yl)etyl]cykloheksyl}acetamid
IIA
Xl°s°
o oH N^\^
H
2-cyano-/V-(4-{2-[4-(3metansulfonylaminofenyl)piperazi n-1-yl]etyl}cykloheksyl)-acetamid
IIA
rf
.W...1
H
2-cyano-/V-(4-{2-[4-(4-fluor
fenyl)piperazin-1
yl]etyl}cykloheksyl)acetamid
IIA
ff
o n£< å J-. j
H
2-cyano-/V-{4-[2-(4-ptolylpiperazin-1 yl)etyl]cykloheksyl}acetamid
IIA
r-PvW...‘ °
H
2-cyano-/V-(4-{2-[4-(2etoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
N^N
o F
A/-(4-{2-[4-(2-tørf-butyl-6
trifluormetylpyrimidin-4
yl)piperazin-1
yl]etyl}cykloheksyl)-3
cyanopropanamid trans/cis 80/20
HA
cr9
-.W.. °'O
H
2-cyano-/V-(4-{2-[4-(2fenoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
Pn-C^ci
o II
n
H
/V-(4-{2-[4-(3-klor-2cyanofenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
IIA
r--?
-.UD..'
H
2-cyano-/V-(4-{2-[4-(2etylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
9^'N^^^'CI
O X^-^x-N^xxl
H
/V-(4-{2-[4-(5-klor-2metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-4cyanobutanamid
IIA
XI
O XX- \x-N\x^
H
4-cyano-/V-(4-{2-[4-(3,5dimetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
£1
F 0 P>-'-xNU
F H
/V-(4-{2-[4-(3-etylfenyl)-piperazin1 -yl]etyl}cy kloheksyl )-3,3,3trifluorpropanamid
IIA
£1 ° i/O' ''^^N'^
3-cyano-/V-(4-{2-[4-(3etylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
HCI '""""^"""1'1
HCI ,
f N 0
0 Py—
1 -(4-{2-[4-(5-metoksy-2metylfenyl)piperazin-1 yl]etyl}piperidin-1-yl)propan-2-on
IIIB
xx54f
4-cyano-/V-(4-{2-[4-(6
trifluormetylbenzo[b]tiofen-3
yl)piperazin-1
yl]etyl}cykloheksyl)butanamid
IA
fjl
H r
H
4-cyano-/V-(4-{2-[4-(3,5difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
HA
. n.oT
II ] 1
H
2-cyano-/V-(4-{2-[4-(2,4d ietylfenyl )piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
£1 p
F 0 F F
F H
3,3,3-trifluor-/V-(4-{2-[4-(2-fluor-3
trifluormetylfenyl)-piperazin-1
yl]etyl}cykloheksyl)-propanamid
IIA
X1 0 py^^1
/V-(4-{2-[4-(5-klor-2metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-3cyanopropanamid
IIA
O x\,. 1
H f J
H
/V-(4-{2-[4-(3-klor-2metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-4cyanobutanamid
IIA
^N-^^CI
N<. U / j
H
/V-(4-{2-[4-(3-klor-5fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-4cyanobutanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
0 ' F F
H
/V-(4-{2-[4-(2-fluor-3
trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2metoksyacetamid
HA
Cl
o r-''T
H trans/cis98/2
4-cyano-/V-(4-{2-[4-(3,5diklorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid trans/cis 98/2
HA
£1
O 1A
H f J
H
4-cyano-/V-{4-[2-(4-kinolin-8
ylpiperazin-1
yl)etyl]cykloheksyl}butanamid
IIA
HCI l48^
HCI z\/KJk
_J
1-(4-{2-[4-(2,3-dimetylfenyl)-3,6d ihydro-2/-/-pyrid in-1 yl]etyl}piperidin-1-yl)propan-2-on
IIIB
£ £/> r"''N>^'N
o
1 -{4-[2-(4-benzotiazol-5ylpiperazin-1 -y I )ety I] piperid i n-1 yl}propan-2-on
IIIB
PjnAy;
o '""\^NxA f f£-A£J
F H
4,4,4-trifluor-/V-(4-{2-[4-(3
trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
r.£
o F
3-cyano-/V-(4-{2-[4-(2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
IIA
F-X)0 ।
I 1 J
H
2-cyano-/V-(4-{2-[4-(2,6dimetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
p„XAoh
0 A.~»J
NX £ 1 J
H
2-cyano-/V-(4-{2-[4-(3hydroksymetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
3-cyano-/V-(4-{2-[4-(3metylsulfanylfenyl)piperazin-1 yl]etyl}cykloheksyl)-propanamid
HA
ii f J
H
2-cyano-/V-(4-{2-[4-(3metoksymetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
rNXl_
II f J
H
2-cyano-/V-(4-{2-[4-(3propylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
^\^C|
£ I
hK jf ] J
H
2-cyano-/V-(4-{2-[4-(3,4diklorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
£1
0 oh
hk II
trans/cis 80/20
H
2-cyano-/V-[4-(2-{4-[3-(1hydroksyetyl)fenyl]piperazin-1 yl}etyl)cykloheksyl]acetamid trans/cis 80/20
IIA
F j£JfF
o r-V'^N-k
N^ II ] 1
H
2-cyano-/V-(4-{2-[4-(4trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
^\/C| r j
o r^..~N-/J
hK J 1 1
H
/V-(4-{2-[4-(4-klorfenyl)piperazin1 -yl]etyl}cy kloheksyl )-2cyanoacetamid
IIA
n
o x\."'\xn\£ ££
N<. u fj
H
/V-{4-[2-(4-bifenyl-3-yl-piperazin
1 -yl )etyl]cy kloheksyl}-2cyanoacetamid
IIA
r^Ok
o F
N^ II 1 J
H
2-cyano-/V-(4-{2-[4-(4-fluor-3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
Yl
3-cyano-/V-(4-{2-[4-(5-fluor-2metylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
HA
Yl
II f J
H
4-cyano-/V-(4-{2-[4-(5-fluor-2metylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
HA
/.Yl
p N Br
r-j/ ji I I
h
/V-(4-{2-[4-(3bromfenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
IIA
Yl
0 F
nyji. J\J
Pj trans/cis 90/10
2-cyano-/V-[4-(2-{4-[3-(1,1
difluoretyl)fenyl]piperazin-1 yl}etyl)cykloheksyl]acetamid trans/cis 90/10
IIA
fjl f
^n'^/Y<f
0 F
ny 1 J. J
z\ H
2-cyano-2,2-dimetyl-/V-(4-{2-[4(3-trifluormetylfenyl)-piperazin-1yl]etyl}cykloheksyl)-acetamid
IIA
Y1F
O .-"\/N/Y
M/ || f J
H
4-cyano-/V-(4-{2-[4-(4fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
rrF
f o
fY^n^-1
3,3,3-trifluor-/V-(4-{2-[4-(4fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
IIA
YY
o .
N/ il | 1
H
2-cyano-/V-(4-{2-[4-(4etylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
r-P
0 //•■■•/■N.J k
N/ || 1 1
H
4-cyano-/V-(4-{2-[4-(2etylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
CIH pn-P
F
1-(4-{2-[4-(2-fluorfenyl)-piperazin
1 -yl]etyl}cy klo
heksyliden)propan-2-on,
hydroklorid
226-8
IIC
cih pn-JQ
F
1-(4-{2-[4-(2-fluorfenyl)-piperazin
1 -yl]etyl}cykloheksyl)propan-2on, hydroklorid trans/cis 80/20
IIC
o f
/ZVJ cih
1 -(1,3-dihydroisoindol-2-yl)-2-(4{2-[4-(3-trifluormetylfenyl)piperazin-1 -y IJety l}cy kloheksyliden)etanon, hydroklorid
IIC
CIH r-N-Cl^;
o F
1 -(1,3-dihydroisoindol-2-yl)-2-(4{2-[4-(3
trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)etanon, hydroklorid 60/40 blanding av isomerer
IIC
PyXly; øJvU
1 -pyrrol id in-1 -yl-2-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyliden) etanon
IIC
£1 p o r'f'^ F
/V,/V-dimetyl-2-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyliden) acetamid
IIC
fN^YFF
o F
/V,/V-dimetyl-2-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid trans/cis 80/20
IIC
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
O F
øAjJ
1 -pyrrol id in-1 -yl-2-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)etanon
IIC
rX^;
o F
H
/V-metyl-2-(4-{2-[4-(3
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)acetamid
cis/trans 50/50
IIC
q-X;
/V-(2-metoksyetyl)-2-(4-{2-[4-(3
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)acetamid
IIC
qXIy
x 0 N
/V-(2-metoksyetyl)-2-(4-{2-[4-(3
trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyliden) acetamid
IIC
cih
/V-(2-metoksyetyl)-2-(4-{2-[4-(3
trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid, hydroklorid
IIC
,..9
0 F
H
2-(4-{2-[4-(2-fluorfenyl)piperazin
1 -yl]etyl}cy kloheksyl iden)-/Vmetylacetamid
IIC
r-9
o F
H
2-(4-{2-[4-(2-fluorfenyl)-piperazin
1 -yl]etyl}cy kloheksyl )-Nmetylacetamid
IIC
,.Q
0 ppYzJ F
2-(4-{2-[4-(2-fluorfenyl)-piperazin
1 -yl]etyl}cy kloheksyl iden)-1 pyrrolidin-1-yletanon
IIC
r..9
o ry"^^ F
2-(4-{2-[4-(2-fluorfenyl)-piperazin1 -yl]etyl}cy kloheksyl )-1 -pyrrol id in1-yletanon
92-93
IIC
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
o Py— F
h I H
2-(4-{2-[4-(2-fluorfenyl)-piperazin
1 -yl]etyl}cy klo-heksyl iden)-N(2,2,2-trifluoretyl)acetamid
IIC
rX8
o F
h 1 H
2-(4-{2-[4-(2-fluorfenyl)piperazin
1-yl]etyl}cykloheksyl)-A/-(2,2,2trifl uoretyl )acetam id
158-9
IIC
aQ
o pp- F
H
2-(4-{2-[4-(2-fluorfenyl)piperazin
1 -yl]etyl}cy kloheksyl iden)-/Vpropylacetamid
IIC
r-90 py^N^ F
H
2-(4-{2-[4-(2-fluorfenyl)-piperazin
1 -yl]etyl}cy kloheksyl )-Npropylacetamid
IIC
rX3
o F
ns;:" h
A/-cyanometyl-2-(4-{2-[4-(2fluorfenyl)piperazin-1 yl]etyl}cykloheksyliden) acetamid
IIC
o py'^ F
A/-cyanometyl-2-(4-{2-[4-(2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid trans/cis 90/10
IIC
cih f
CIH
FJJ
1 -(4-fluorfenyl)-2-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}piperid in-1 -yl)etanon,dihydroklorid
IIIB
,..0"
o pp— N—1
1 -{4-[2-(4-p-tolylpiperazin-1 yl)etyl]piperidin-1-yl}propan-2-on
IIIB
Cl
pN-^i^CIo p^-NJ
1-(4-{2-[4-(3,5-diklorfenyl)piperazin-1 -yl]etyl}piperid in-1 yl)propan-2-on
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
rXu
4-cyano-/V-(4-{2-[4-(3propylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
HA
r-^
H
2-cyano-/V-(4-{2-[4-(3-fluor-2metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
nv^JnjQ'''~^ F F
H
4-cyano-/V-[4-(2-{4-[3-(1,1
difluoretyl)fenyl]piperazin-1
yl}etyl)cykloheksyl]butanamid
IIA
XT>
o r''"""! ■'
H
/y-{4-[2-(4-benzo[1,3]dioksol-5
ylpiperazin-1 -yl)etyl]cykloheksyl}
2-cyanoacetamid
IIA
f N 0
.w
H
2-cyano-/V-(4-{2-[4-(2,3dihydrobenzo[1,4]dioksin-6yl)piperazin-1
yl]etyl}cykloheksyl)acetamid
IIA
cih if^i
CIH
o
1-(4-{2-[4-(5,6,7,8
tetrahydronaftalen-1-yl)piperazin
1 -yl]etyl}pi perid in-1 -yl)propan-2
on
IIIB
cih fT^i
CIH
o r-Y^N—J F F F
1-(4-{2-[4-(2-fluor-3trifluormetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
CIH
Q < y
1-(4-{2-[4-(2-metyl-3trifluormetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
£1
,UX>...1
F H
3,3,3-trifluor-/V-{4-[2-(4-kinol in-5ylpiperazin-1
yl)etyl]cykloheksyl}propanami-de
HA
£1
0 m
4-cyano-/V-{4-[2-(4-kinolin-5
ylpiperazin-1
yl)etyl]cykloheksyl}butanamid
HA
r.XX
H
2-cyano-/V-(4-{2-[4-(4-fluor-3metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
CIH 1 1 r
C|H
o pynJ f
1-(4-{2-[4-(3-trifluormetylfenyl)
3,6-d ihyd ro-2/-/-pyrid in-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
0 f F
N^< £ Å J
>-7"" X
V H
2-cyano
cyklopropankarboksylsyre-(4-{2
[4-(3-trifluormetylfenyl)piperazin
1 -yl]etyl}cykloheksyl)amid
IIA
£XF
-.X
H
2-cyano-/V-(4-{2-[4-(3,4difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
£1
o
H
2-cyano-/V-(4-{2-[4-(3-etylfenyl)
3,6-d ihyd ro-2/-/-pyrid in-1 yl]etyl}cykloheksyl)-acetamid
IIA
^£æ
YXt XJ
H
4-cyano-/V-(4-{2-[4-(3-etylfenyl)
3,6-d ihyd ro-2/-/-pyrid in-1 yl]etyl}cykloheksyl)butanamid
IIA
£1
O
nx^x
H
2-cyano-/V-(4-{2-[4-(3etylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
cih X X CIH
o
1-(4-{2-[4-(3-etylfenyl)-piperazin1 -yl]etyl}pi perid in-1 -yl)propan-2on, dihydroklorid
IIIB
ghh XX Å f
CIH
0 F
5-(4-{2-[4-(3-trifluormetyl
fenyl)piperazin-1 -yl]etyl}piperidin
1-yl)pentan-2-on, dihydroklorid
IIIB
CIH X
CIH ^N^^y^CI
o F
XX^-N^X
1-(4-{2-[4-(3-klor-2fluorfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
CIH X;X-....,
CIH I
o
XX/^kX
1 -{4-[2-(4-m-tolylpiperazin-1 yl)etyl]piperidin-1 -yl}propan-2-on,dihydroklorid
IIIB
cih Al
CIH pN>y<F
o
1-(4-{2-[4-(3-fluor-2metylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
qAA;
o o F
,^/J
H
2-metansulfinyl-/V-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
Ai
Y'n'^^X/
"»..W..1
H
2-cyano-/V-(4-{2-[4-(3isopropylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
X
o
N^ jl 1 1
H
2-cyano-/V-(4-{2-[4-(3,5dimetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
^nAX;
° ° o ya’^nX f
Js^AnA^
H
2-metansulfonyl-/V-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
C|H ||
cih i^n ifn
1 -{4-[2-(4-Kinol in-8-yl piperazin-1 yl)etyl]piperidin-1 -yl}propan-2-on,dihydroklorid
IIIB
jOC
Jl
H
2-cyano-/V-(4-{2-[4-(3-fluor-4metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
r/X n<kÅ X)
H
2-cyano-/V-(4-{2-[4-(3,4dimetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
F
Af
■*.I-O.
H
2-cyano-/V-(4-{2-[4-(3,4,5trifl uorfenyl )piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
o n.^NCir> N;xX'
H
2-cyano-/V-(4-{2-[4-(2-fluor-3trifluormetylfenyl)-3,6-dihydro2/-/-pyridin-1 yl]etyl}cykloheksyl)acetamid
IIA
r.04, /\ . \ ,-N., JvJL JO
H
2-cyano-/V-(4-{2-[4-(3trifluormetylsulfanylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid
IIA
" r.A
0 pp-NJ
1-(4-{2-[4-(3,5dimetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,
dihydroklorid
IIIB
CIH XX
cm . L Jl ,
f N 0
0 r-Y^N—JXX^N\X
1-(4-{2-[4-(3metoksyfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
" ,.
ro.".’4
2-(4-{2-[1-(2
oksopropyl)piperidin-4
yl]etyl}piperazin-1-yl)benzonitril,
dihydroklorid
IIIB
CIH
C|H k 1
f N
o ro—
1-(4-{2-[4-(3-propylfenyl)piperazin-1 -yl]etyl}piperid in-1 yl)propan-2-on, dihydroklorid
IIIB
CIH F
CIH /- AÅ X^n-^^cOVt
o
AX-n--A
1 -(4-{2-[4-(3-trifluormetoksyfenyl)piperazin-1 -yl]etyl}piperidin1-yl)propan-2-on, dihydroklorid
IIIB
»
1-(4-{2-[4-(2-etylfenyl)-piperazin1 -yl]etyl}pi perid in-1 -yl)propan-2on, dihydroklorid
IIIB
CIH
cih rV" □ rr-O U
X^n\A
1 -{4-[2-(4-kinol in-5-yl piperazin-1 yl)etyl]piperidin-1 -yl}propan-2-on,dihydroklorid
IIIB
r-XX
o rv—NO 0 0 N\A AJ
H
2-cyano-/V-(4-{2-[4-(3metansulfonylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
cih A JL f
CIH k N Y-F
'nA f
Y^—-'n-A
4-(4-{2-[4-(3-trifluormetyl
fenyl)piperazin-1 -yl]etyl}piperidin
1-yl)butan-2-on, dihydroklorid
IIIB
CIH f 1
CIH A \ /
o ptnJ
/A^-N a
1 -{4-[2-(4-lndan-4-ylpiperazin-1 yl)etyl]piperidin-1 -yl}propan-2-on,dihydroklorid
IIIB
pXf o rr.■■■'■'—-n--A f
n^tY J\J
H
2-cyano-/V-(4-{2-[4-(3
difluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)acetamid
HA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
f JJ J PF
4-cyano-/V-(4-{2-[4-(2-fluor-3trifluormetylfenyl)-3,6-dihydro2/-/-pyridin-1 yl]etyl}cykloheksyl)butanamid
HA
XJ
H
4-cyano-/V-(4-{2-[4-(3-fluor-2metylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
HA
rNxx
o
H
4-cyano-/V-(4-{2-[4-(3,4difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
rNxr
H
4-cyano-/V-(4-{2-[4-(4-fluor-3metylfenyl)piperazin-1 yl]etyl}cykloheksylbutanamid
IIA
,.Xr
vW'-".J
H
/V-(4-{2-[4-(4-klor-2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
IIA
ruXly;
NX<^X
H
/V-(4-{2-[4-(4-klor-3
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)-2
cyanoacetamid
IIA
r>XrF
H
2-cyano-/V-(4-{2-[4-(4-fluorfenyl)
3,6-d ihyd ro-2/-/-pyrid in-1 yl]etyl}cykloheksyl)-acetamid
IIA
/UU
xJt Xi"
H
A/-(4-{2-[4-(4-klorfenyl)-3,6d ihydro-2/-/-pyrid in-1 yl]etyl}cykloheksyl)-2cyanoacetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
4-cyano-/V-(4-{2-[4-(3trifluormetylsulfanylfenyl)piperazin-1
yl]etyl}cykloheksyl)butanamid
HA
4-cyano-/V-(4-{2-[4-(3
difluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)butanamid
HA
£ 1 >
o
/y-{4-[2-(4-benzo[1,3]dioksol-5
ylpiperazin-1 -yl)etyl]cykloheksyl}
4-cyanobutanamid
IIA
rj»££ o ZVk^'N'-zJ f fil f J
4-cyano-/V-(4-{2-[4-(2-fluor-3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
nxx
cih
H
4-cyano-/V-(4-{2-[4-(4-fluor-3metylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid, hydroklorid
IIIB
^v'Cl
p^N'><::;:>^'Cl
H
4-cyano-/V-(4-{2-[4-(3,4diklorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
IT
N'^\£- rX/J
H
/V-(4-{2-[4-(3-klor-4metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
IIA
>>N
XX
o r''"'""!
N^A XX
H
2-cyano-/V-(4-{2-[4-(4cyanofenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
Cl'>^>
nv^x<xx^NvJ
H
4-cyano-/V-(4-{2-[4-(2,5diklorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
r-"-P,7W.°
VJ H
Cyklopent-3-enkarboksylsyre-(4
{2-[4-(2-metoksyfenyl)piperazin
1 -yl]etyl}cykloheksyl)amid
HA
H
2-cyklopent-2-enyl-/V-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
H
4-cyano-/V-(4-{2-[4-(3,4,5trifl uorfenyl )piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
r^-^CV
/y-(4-{2-[4-(3-acetylfenyl)
piperazin-1-yl]etylcykloheksyl)-4
cyanobutanamid
IIA
,...o
"K-W.. !
H
2-cyano-/V-(4-{2-[4-(2cyanofenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
r-?
H
4-cyano-/V-(4-{2-[4-(2cyanofenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
rNxx,
h
Cyklopent-3-enkarboksylsyre-(4{2-[4-(3-etylfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
IIA
n aW.'
VJ H
Cyklopent-3-enkarboksylsyre {4[2-(4-m-tolylpiperazin-1 yl)etyl]cykloheksyl}
IIA
n
\___J H
Cyklopent-1-enkarboksylsyre {4[2-(4-m-tolylpiperazin-1 yl)etyl]cykloheksyl} amid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
H
/V-(4-{2-[4-(3-klor-4metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-4cyanobutanamid
HA
H
4-cyano-/V-(4-{2-[4-(2metoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
HA
qX1^
0 F
N^\X
H
2-cyano-/V-(4-{2-[4-(2-metyl-5trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
£IF
0 Pj—F /pX^N^XX \_] H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(2,4-difluorfenyl)-piperazin1 -yl]etyl}cykloheksyl)amid
IIA
xrF X'N"X/'
o F
XX
FO H
/V-(4-{2-[4-(2,4difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-2-(4fluorfenoksy)acetamid
IIA
rrF
H
/V-(4-{2-[4-(2,4
difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-3,3,3trifluorpropanamid
IIA
,.Q
<x W J '
H
2-cyklopent-3-enyl-/V-(4-{2-[4-(2fluorfenylpiperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
Nx_ÅX)
4-cyano-/V-(4-{2-[4-(2-metyl-5trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butyramid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
T I
-.M2i..'
H
N-(4-{2-[4-(2-klor-4-fluor-5metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
HA
rXX X)
H
/V-(4-{2-[4-(2-klor-4-fluor-5metylfenylpiperazin-1 yl]etyl}cykloheksyl)-4cyanobutanamid
HA
Yl o rY-^,N.J
4-cyano-/V-(4-{2-[4-(5-metoksy-2metylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
o'' A. ~k^YjY"^n^
4-cyano-/V-(4-{2-[4-(3,5dimetoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
n^^nJ2j ~NA |||
H
/V-(4-{2-[4-(3-klor-2cyanofenyl)piperazin-1 yl]etyl}cykloheksyl)-4cyanobutanamid
IIA
11 1^'N'^^'F
o
Cr’Y
Cykloheks-1 -enkarboksylsyre-(4{2-[4-(3-fluorfenyl)-piperazin-1yl]etyl}cyklo-heksylamid
IIA
£1 X^N'^/*XF A X NiK/Y A'
H
4-cyano-/V-(4-{2-[4-(3fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
£1
X"N
o
r-AA
U "
A/-(4-{2-[4-(3-fluorfenyl)piperazin1 -yl]etyl}cy kloheksyl )-2fenoksyacetamid
IIA
A
S H
A/-(4-{2-[4-(3-fluorfenyl)
piperazin-1-yl]etyl}cykloheksyl)succinamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
£1
o
S H
A/-(4-{2-[4-(3-fluorfenyl)
piperazin-1-yl]etyl}cykloheksyl)succinamid
HA
r.xk
.VO.H
2-cyano-/V-(4-{2-[4-(3,5dimetylfenyl)-3,6-dihydro-2/-/pyridin-1 -yl]etyl}cy kloheksyl)acetamid
HA
£1
VJ H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(3-fluorfenyl)-piperazin-1yl]etyl}cykloheksyl)amid
IIA
££
i j£'"—' F
H
4-cyano-/V-(4-{2-[4-(2,4difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
HCI £^£ hci X. Å
o ‘
1-(4-{2-[4-(3,5-di-tertbutylfenyl)piperazin-1 yl]etyl}piperidin-1-yl)propan-2-on
IIIB
xyF
3-cyano-/V-(4-{2-[4-(2,4difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
IIA
pX!^
N-p_^^X XX
/V-(4-{2-[4-(2-klor-5
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)-4
cyanobutanamid
IIA
pXX^;
XX
4-cyano-/V-(4-{2-[4-(2-metoksy-5
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)butanamid
IIA
<X1
H
4-cyano-/V-(4-{2-[4-(3,5dimetylfenyl)-3,6-dihydro-2/-/pyridin-1 -yl]etyl}cy kloheksyl)butanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
°
U-J H
1 /-/-lnden-2-karboksylsyre-(4-{2[4-(3-fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
HA
r.,o,
.
VJ H
Cyklopent-3-enkarboksylsyre-(4
{2-[4-(3-fluorfenyl)-piperazin-1yl]etyl}cykloheksyl)amid
HA
rNxx
F o ry"^^
F H
3,3,3-trifluor-/V-(4-{2-[4-(3fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
IIA
H
2-cyano-/V-(4-{2-[4-(4-fluorfenyl)
3,6-d ihyd ro-2/-/-pyrid in-1 yl]etyl}cykloheksyl)-acetamid
IIA
£1
° rr"^
J H
3-dietylamino-/V-(4-{2-[4-(3fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
IIA
£1
3-cyano-/V-(4-{2-[4-(3fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
IIA
££
-'
H
4-cyano-/V-(4-{2-[4-(2,5dimetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
FX1
H
/V-(4-{2-[4-(5-klor-2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-4cyanobutanamid
IIA
^.O-^X
XI nv/^nXT^n""j
H
/V-(4-{2-[4-(5-klor-2metoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)-4cyanobutanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
4-cyano-/V-(4-{2-[4-(3metoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
HA
£1
Y__J H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(3-metoksyfenyl)-piperazin1 -yl]etyl}cykloheksyl)amid
HA
° jr'r~^N'J
3-cyano-/V-(4-{2-[4-(3metoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
IIA
£1
o
H
A/-(4-{2-[4-(3-fluorfenyl)piperazin1 -yl]etyl}cy kloheksyl )-4metoksybutanamid
IIA
rX£ C£å££"^n^
H
2-cyklopent-2-enyl-/V-(4-{2-[4-(3fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
O'' rNZ£F o f
4-cyano-/V-(4-{2-[4-(3-metoksy-5
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)butanamid
IIA
,.9
F 0 k
F-J 11 1 1
H
A/-(4-{2-[4-(2-etylfenyl)piperazin1 -yl]etyl}cy kloheksyl )-3,3,3trifluorpropanamid
IIA
CIYY>Y/CI
r-yO-fS
n Y^Y,..-\x-ny£ f
N^A |*I*Y_Y
H
2-cyano-/V-(4-{2-[4-(2,4-diklor-5trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
CI\Y\zCl r^; n z-"', ''yn-£ f
N^y/\y£ xC.y'
4-cyano-/V-(4-{2-[4-(2,4-diklor-5
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)butanamid
IIA
£1
P^n-^yy^yY
O rY'£ ''\yNyy-I°£An£J
H
/V-(4-{2-[4-(3-etylfenyl)-piperazin1 -yl]etyl}cy kloheksyl )-2metansulfonylacetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
£1
0 0 0 F
H
/V-(4-{2-[4-(2,3-difluorfenyl)
piperazin-1 -yl]etyl}cykloheksyl)-2
metansulfonylacetamid
HA
^\/cl
r j
XAnÅJ
H
A/-(4-{2-[4-(4-klorfenyl)-piperazin1 -yl]etyl}cy kloheksyl )-2metansulfonylacetamid
HA
a?
H
4-cyano-/V-{4-[2-(4-otolylpiperazin-1 yl)etyl]cykloheksyl}butanamid
IIA
H
4-cyano-/V-(4-{2-[4-(2,3dimetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
0 f
r<\/
4-cyano-/V-(4-{2-[4-(4-fluor-3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
r.O’
V-J H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(4-fluorfenyl)-piperazin-1yl]etyl}cykloheksyl)amid
IIA
N
..A
4-cyano-/V-(4-{2-[4-(3-cyano-5
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)butanamid
IIA
C|H r ¥
CIH pN'^
o r-Y^N^J
1-(4-{2-[4-(2-klor-4-fluor-5metylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
Cl
cih ri
CIH
o r-Y--N-J
1-(4-{2-[4-(3-klor-5metylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
o
H
4-cyano-/V-{4-[2-(4-fenyl-3,6dihydro-2H-pyridin-1 yl)etyl]cykloheksyl}butanamid
HA
å£T—'fA
H
4-cyano-/V-(4-{2-[4-(2trifluormetylfenyl)piperazin-1 yl]etylcykloheksyl)butanamid, hydroklorid
HA
Cl
rA
--W.'
H
/V-(4-{2-[4-(3-klor-5metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
IIA
Cl
A
H
/V-(4-{2-[4-(3-klor-5metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-4cyanobutanamid
IIA
rA
0 0^.
H
4-cyano-/V-(4-{2-[4-(2etoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
Frx
H
4-cyano-/V-(4-{2-[4-(2-fluor-5metylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
Fxi
\_] H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(2,5-difluorfenyl)-piperazin1 -yl]etyl}cykloheksyl)amid
IIA
r:xx N!vX<nX'"'^n'^J
H
4-cyano-/V-(4-{2-[4-(2,5difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
ZnAAf
ZZ ’ ’
F H
2,2-difluor-/V-(4-{2-[4-(2-fluor-3
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)acetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
HCI L II f
o f
1-(4-{2-[4-(4-metyl-3
trifluormetylfenyl)piperazin-1
yl]etyl}piperidin-1-yl)propan-2-on
IIIB
fjl
J F
X)''
H
4-cyano-/V-(4-{2-[4-(2,3difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
HA
,.Y,
F H
/V-(4-{2-[4-(2,3
difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-3,3,3trifluorpropanamid
HA
£1
Y Y.. '
\_] H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(2,3-difluorfenyl)-piperazin1 -yl]etyl}cykloheksyl)amid
IIA
Xjl
0 YY~O^N nY U f J
4-cyano-/V-(4-{2-[4-(3cyanofenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
£1 £^n'^Y|Y^C| Nx^£tNj£ °
H
/V-(4-{2-[4-(3-klor-2metoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)-4cyanobutanamid
IIA
j££ p^N'^y^'F 0 Y'~N^ F nY^£
H
2-cyano-/V-(4-{2-[4-(2,3,4trifl uorfenyl )piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
rj^C nx_^£ j£ f
H
4-cyano-/V-(4-{2-[4-(2,3,4trifl uorfenyl )piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
rN-C£f£å£3 ° °
H
3,3,3-trifluor-/V-(4-{2-[4-(3
metansulfonylfenyl)piperazin-1 yl]etyl}cykloheksyl)-propanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
cih r i
CIH
o
1-(4-{2-[4-(3-fluorfenyl)piperazin1 -yl]etyl}pi perid in-1 -yl)propan-2on, dihydroklorid
IIIB
Gin f [1
CIH
o rr—
1-(4-{2-[4-(3etoksyfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
cih AX
CIH i^N-^Y
o pynJ f
1-(4-{2-[4-(2,4difluorfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
oX
nY^X
H
2-cyano-/V-{4-[2-(4-indan-4
ylpiperazin-1
yl)etyl]cykloheksyl}acetamid
IIIB
n^GNJ?> å jG'
H
4-cyano-/V-{4-[2-(4-indan-4
ylpiperazin-1
yl)etyl]cykloheksyl}butanamid
HA
yAA;
cr1 h
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(2-fluor-3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
HA
Q-AVfo YT' '’"'/n"-G f f
/V-(4-{2-[4-(2-fluor-3
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)succinamid
IIA
qXA o Y>'',','x-xN'G f f
4-cyano-2,2-difluor-/V-(4-{2-[4-(2
fluor-3-trifluormetyl
fenyl)piperazin-1
yl]etyl}cykloheksyl)butanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
o o'°
v/j
2,2,2-trifluor-/V-(4-{2-[4-(3metansulfonylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
[Pl
A/-{4-[2-(4-bifenyl-3-ylpiperazin-1
yl)etyl]cykloheksyl}-4
cyanobutanamid
HA
F
Jp
..1
\_j H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(3,4,5trifl uorfenyl )piperazin-1 yl]etyl}cykloheksyl)amid
IIA
rr
o
PP-N-P
2-metyl-5-(4-{2-[1-(2
oksopropyl)piperidin-4
yl]etyl}piperazin-1 -yl)benzonitril
IIIB
..å:
H
2-etoksy-/V-(4-{2-[4-(3,4,5trifl uorfenyl )piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
F p aW.~.'
VJ H
Cyklopent-3-enkarboksylsyre-(4{2-[4-(3,4,5
trifl uorfenyl )piperazin-1
yl]etyl}cykloheksyl)amid
IIA
IT
-'
H
4-cyano-/V-{4-[2-(4-ptolylpiperazin-1 yl)etyl]cykloheksyl}butanamid
IIA
o'"
HCI
HCI I 1 F
o F
PPnyP
1 -(4-{2-[4-(3-metoksy-5trifluormetylfenyl)piperazin-1 yl]etyl}piperidin-1-yl)propan-2-on
IIIB
£1
°P'^N'J 00
'P'A H
4,4,4-trifluor-N-(4-{2-[4-(3metansulfonylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
/V-(4-{2-[4-(2-fluor-3
trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)-4metoksybutanamid
HA
Nx^jtNxy'^N""J F
H
/V-(4-{2-[4-(4-klor-2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-4cyanobutanamid
HA
FnF
nkJL XJ
H
2-cyano-/V-(4-{2-[4-(2,4,5trifl uorfenyl )piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
FnF i ri"~—'
H
4-cyano-/V-(4-{2-[4-(2,4,5trifl uorfenyl )piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
CX
H
2-etoksy-/V-{4-[2-(4-ptolylpiperazin-1 yl)etyl]cykloheksyl}acetamid
IIA
CX
°
V-J H
Cyklopent-1-enkarboksylsyre {4[2-(4-p-tolylpiperazin-1 yl)etyl]cykloheksyl} amid
IIA
r^^Qr;
fyP
5,6-dihydro-4/-/-pyran-3karboksylsyre-(4-{2-[4-(2-fluor-3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl amid
IIA
£1
F 0 py OH
3,3,3-trifluor-/V-[4-(2-{4-[3-(1hydroksyetyl)fenyl]piperazin-1 yl}etyl)cykloheksyl]propanamid
IIA
^■'Qvf
££D F F
H
2-etoksy-/V-(4-{2-[4-(2-fluor-3
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)acetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
H
A/-(4-{2-[4-(4-klorfenyl)piperazin1 -yl]etyl}cy kloheksyl )-4cyanobutanamid
HA
^ -XCI
£ J
f F 0
H
A/-(4-{2-[4-(4-klorfenyl)-piperazin1 -yl]etyl}cy kloheksyl )-3,3,3trifluorpropanamid
HA
cih jTycl Clhl
o F
1-(4-{2-[4-(4-klor-2
fluorfenyl)piperazin-1
yl]etyl}piperidin-1-yl)propan-2-on
IIIB
XT P’N'P/j
o F
£P-n-P
1-(4-{2-[4-(2-fluor-4metylfenyl)piperazin-1 yl]etyl}piperidin-1-yl)propan-2-on
IIIB
rNXl
NV^JtNX^
H
4-cyano-/V-(4-{2-[4-(2-metoksy-5metylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
rP
o f
N^Yix Jl
H
2-cyano-/V-(4-{2-[4-(2-fluor-4metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
Ci
J F
? rj
H
4-cyano-/V-(4-{2-[4-(2-fluor-4metylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
r i Yn’^/4x'c|
V¥ H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(3,4-diklorfenyl)piperazin-1yl]etyl}cykloheksyl)amid
IIA
,<<\XCI
£ 1
Y'N'^/ix'CI
H
A/-(4-{2-[4-(3,4diklorfenyl)piperazin-1 yl]etyl}cykloheksyl)-2etoksyacetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
£ J
o
\___J H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(4-klorfenyl)-piperazin-1 yl]etyl}cykloheksyl)amid
HA
" ,.-Q4’
0 F
1-(4-{2-[4-(2-fluor-4
trifluormetylfenyl)piperazin-1
yl]etyl}piperidin-1-yl)propan-2-on
IIIB
cih £ jl.
o
H
/V-(4-{2-[4-(3-klor-4metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2etoksyacetamid
HA
rr p^N-^^CI
\£ H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(3-klor-4metylfenyl)piperazin-1 -yl]etyljcy kloheksyl )am id
IIA
^N-^^CI
F 0
F H
/V-(4-{2-[4-(3-klor-4metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-3,3,3trifluorpropanamid
IIA
IT
F 0 fA££££
F H
3,3,3-trifluor-/V-{4-[2-(4-ptolylpiperazin-1 yl)etyl]cykloheksyl}propanamid
IIA
,;rvo.’.1'
VJ H
Cyklopent-3-enkarboksylsyre-(4{2-[4-(2,4-difluorfenyl)-piperazin1 -yl]etyl}cykloheksyl)amid
IIA
r i
o pp-^££-n-~£
1-(4-{2-[4-(3,4-diklorfenyl)piperazin-1 -yl]etyl}piperid in-1 yl)propan-2-on
IIIB
CIH \ Il
CIH pNAJ
o
1-(4-{2-[4-(4-fluorfenyl)-piperazin
1 -yl]etyl}pi perid in-1 -yl)propan-2on
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
° f f
o\2jr^' h
4,5-dihydrofuran-3karboksylsyre-(4-{2-[4-(2-fluor-3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
HA
<-vXJo Cf
H
A/-(4-{2-[4-(4-klorfenyl)-3,6d ihydro-2/-/-pyrid in-1 yl]etyl}cykloheksyl)-2etoksyacetamid
HA
^ff
^Iff^
H
A/-(4-{2-[4-(4-klorfenyl)-3,6dihydro-2H-pyridin-1 yl]etyl}cykloheksyl)-4cyanobutanamid
IIA
rvCiF
N I
H
4-cyano-/V-(4-{2-[4-(4-fluorfenyl)
3,6-d ihyd ro-2/-/-pyrid in-1 yl]etyl}cykloheksyl)-butanamid
IIA
F F åV°
Pyrrolidin-2-karboksylsyre-(4-{2[4-(2-fluor-3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
IIA
^^-C1
XX
0 ^^NX
/°\^^X^kXX
H
/V-(4-{2-[4-(3,4
diklorfenyl)piperazin-1 yl]etyl}cykloheksyl)-4metoksybutanamid
IIA
° F
H
/V-(4-{2-[4-(2,4
difluorfenyl)piperazin-1
yl]etyl}cykloheksyl)-2
etoksyacetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
o F
H
/V-(4-{2-[4-(2,4
difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-4metoksybutanamid
HA
£T v^Xr''—‘
H
4-cyano-/V-(4-{2-[4-(3,4dimetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
HA
£T
o
H
/V-(4-{2-[4-(3,4
dimetylfenyl)piperazin-1 yl]etyl}cykloheksyl)-4metoksybutanamid
IIA
£Y
° r'7""'^NvJ
VJ H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(3,4-dimetylfenyl)-piperazin1 -yl]etyl}cykloheksyl)amid
IIA
ZT
H
/V-(4-{2-[4-(3,4
dimetylfenyl)piperazin-1
yl]etyl}cykloheksyl)-2
etoksyacetamid
IIA
ZT f f o ry^N'J
H
/V-(4-{2-[4-(3,4-dimetylfenyl)
piperazin-1-yl]etyl}cykloheksyl)
3,3,3-trifluorpropanamid
IIA
zz
N^ZZZ'—1
4-cyano-/V-(4-{2-[4-(5,6,7,8tetrahydronaftalen-2-yl)piperazin1 -yl]etyl}cykloheksyl)butanamid
IIA
Z1
F F O nN
H
/V-(4-{2-[4-(3cyanofenyl)piperazin-1 yl]etyl}cykloheksyl)-3,3,3trifluorpropanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
V-J H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(3-cyanofenyl)-piperazin-1yl]etyl}cykloheksyl)amid
HA
£1
/V-(4-{2-[4-(3-cyanofenyl)
piperazin-1-yl]etyl}cykloheksyl)-4
metoksybutanamid
HA
.F
H
2-etoksy-/V-(4-{2-[4-(2-fluor-5
trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
rNXJ
° r/3'
H
A/-(4-{2-[4-(4-klor-fenyl)piperazin
1 -yl]etyl}-cy kloheksy I )-2etoksyacetamid
IIA
0 f f
/V-(4-{2-[4-(2-fluor-3
trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2propoksyacetamid
IIA
YY--CI
r j
0 pv''-- F
X_J H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(4-klor-2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
IIA
XT
0 F
X_J H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(2-fluor-4metylfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
IIA
,..9:
-•.w...J'
H
2-cyano-/V-(4-{2-[4-(3,4-diklor-2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
£ X X'N'£/^'Cl 0 F
H
4-cyano-/V-(4-{2-[4-(3,4-diklor-2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
T 1
° X1
H
A/-(4-{2-[4-(2,5-diklorfenyl)
piperazin-1 -yl]etyl}cykloheksyl)-2etoksyacetamid
HA
o .I
N-§k II 1 J N
H
4-cyano-/V-(4-{2-[4-(2-cyano-3fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
HA
FrrF rtÅX>..‘
VJ H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(2,4,5
trifl uorfenyl )piperazin-1
yl]etyl}cykloheksyl)amid
IIA
° n^oX1"N
O\X H
4,5-dihydrofuran-3karboksylsyre-(4-{2-[4-(3cyanofenyl)piperazin-1 yl]etyl}cykloheksyl)amid
IIA
Fxi Xn'^/<'ci
\_] H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(5-klor-2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
IIA
r^j
4-cyano-/V-(4-{2-[4-(3-oksazol-2
ylfenyl)piperazin-1
yl]etyl}cykloheksyl)butanamid
IIA
£rF
0 F
oXX
4,5-dihydrofuran-3karboksylsyre-(4-{2-[4-(2,4difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
IIA
Cl
Zn-^X
O ZZ Z/N^J F
N'$\X
H
/V-(4-{2-[4-(3-klor-5
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)-2
cyanoacetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
Cl
/V-(4-{2-[4-(3-klor-5
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)-4
cyanobutanamid
HA
n^jl X)'
H
2-cyano-/V-(4-{2-[4-(3-oksazol-2
ylfenyl)piperazin-1
yl]etyl}cykloheksyl)acetamid
HA
rvCTF
ON^...^NrJ
H
2-etoksy-/V-(4-{2-[4-(4-fluorfenyl)
3,6-d ihyd ro-2/-/-pyrid in-1 yl]etyl}cykloheksyl)-acetamid
IIA
o,y%XJ
4,5-dihydrofuran-3karboksylsyre(4-{2-[4-(3-oksazol2-ylfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
IIA
0 /-oA^hkJ
(4-{2-[4-(2,3
dimetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)eddiksyreetylester
IIIB
Fn
° jXi'"'"^^
X_J H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(2-fluor-5metylfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
IIA
Xji
4-cyano-/V-(4-{2-[4-(3etoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
,-jO1
° rr^
VJ H
Cyklopent-1-enkarboksylsyre {4[2-(4-fenyl-3,6-dihydro-2Hpyridin-1 -yl)etyl]cy kloheksyl}amid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
rxc
VJ H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(3-fluor-4metylfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
HA
£T
H
4-cyano-/V-(4-{2-[4-(3-fluor-4metylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
HA
r„xxF
H
2-etoksy-/V-(4-{2-[4-(3-fluor-4
metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
£1
0 OH
4-cyano-/V-[4-(2-{4-[3-(1
hydroksypropyl)fenyl]piperazin-1
yl}etyl)cykloheksyl]butanamid
IIA
o
A CIH
O H CIH
Pyrrolidin-2-karboksylsyre-(4-{2[4-(3-cyanofenyl)piperazin-1 yl]etyl}cykloheksyl)amid, dihydroklorid
IIA
F
Xt
H
2-metoksy-/V-(4-{2-[4-(3,4,5trifl uorfenyl )piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
nF
0 F
h
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(2,3,4-trifluorfenylpiperazin1 -yl]etyl}cykloheksyl)amid
IIA
zA
0 r--''"r "■""-^-N"ANZ^-\A rXX
4-cyano-/V-(4-{2-[4-(4
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)butanamid
IIA
Clx<<x
1 1
° X3
H
/V-(4-{2-[4-(2,5
diklorfenyl)piperazin-1
yl]etyl}cykloheksyl)-2
etoksyacetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
O '\^N F
A-KÅJ cih
O H CIH
Pyrrolidin-2-karboksylsyre-(4-{2[4-(2-fluor-5trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
HA
PnX^ci
0 1
H
/V-(4-{2-[4-(3-klor-2metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-4metoksybutanamid
HA
XX
o
A^n-A cihCIH
1 -(4-{2-[4-(3,4-dimetylfenyl)piperazin-1 -yl]etyl}piperid in-1 yl)propan-2-on
IIIB
XT 0 YY^NvJ f JL-nU cih/ x/ C|H
1-(4-{2-[4-(3,4-diklor-2
fluorfenyl)piperazin-1
yl]etyl}piperidin-1-yl)propan-2-on
IIIB
XTF
a..aX3 c|h
[ ] H CIH
Pyrrolidin-2-karboksylsyre-(4-{2[4-(2,4-difluorfenyl)-piperazin-1yl]etyl}cykloheksyl)amid, dihydroklorid
IIA
£IF
YnA^01 n^åY"^n^ f H
/V-(4-{2-[4-(3-klor-2,4difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
IIA
fYF P^n^^Y'01 0 A..^nJ F i-XXH
/V-(4-{2-[4-(3-klor-2,4difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-4cyanobutanamid
IIA
CIH F'V<X
CIH ynA^t-f
o f
XX/-n\X
1-(4-{2-[4-(2-fluor-5trifluormetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
- nf N Y Cl
o 'N^
1-(4-{2-[4-(3-klor-2metoksyfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
/UCA
o
N^\A
H
2-cyano-/V-(4-{2-[4-(4
trifluormetylfenyl)-3,6-dihydro
2/-/-pyridin-1
yl]etyl}cykloheksyl)acetamid
HA
r-9
YJ H
Cyklopent-1-enkarboksylsyre {4[2-(4-o-tolylpiperazin-1 yl)etyl]cykloheksyl} amid
HA
o9
H
2-etoksy-/V-{4-[2-(4-otolylpiperazin-1 yletyl]cykloheksyl}acetamid
IIA
-^N
Pl
H
4-cyano-/V-{4-[2-(6-cyano-3,4dihydro-1 H-isokinol in-2yl)etyl]cykloheksyl}butanamid
IIA
PN
J-LA
■‘JW
H
2-cyano-/V-{4-[2-(6-cyano-3,4dihydro-1 H-isokinol in-2yl)etyl]cykloheksyl}acetamid
IIA
nXX,
/V-(4-{2-[4-(3-etylfenyl)piperazin1 -yl]etyl}cy kloheksyl )-4metoksybutanamid
IIA
rNXA
CiP
5,6-dihydro-4/-/-pyran-2karboksylsyre-(4-{2-[4-(3etylfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
5,6-dihydro-4/-/-pyran-2karboksylsyre-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
HA
£1
H
2-etoksy-/V-(4-{2-[4-(3etylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
ruXl^;
O XX ■'\/N\-''1 F
vJ H
4,5-dihydrofuran-3karboksylsyre-(4-{2-[4-(3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
IIA
rrF
o F
p'Pp^N’Z'^
L° H
5,6-dihydro-4/-/-pyran-2karboksylsyre-(4-{2-[4-(2,4difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
IIA
£1
.-\.n. _£ 6h
n=k£ XJ
H
2-cyano-/V-[4-(2-{4-[3-(1
hydroksypropyl)fenyl]piperazin-1
yl}etyl)cykloheksyl]acetamid
IIA
o £rJXXX
_1 H
Cyklopent-1 -enkarboksylsyre-(4
{2-[4-(2,4-difluorfenyl)-3,6
d ihydro-2/-/-pyrid in-1 yl]etyl}cykloheksyl)amid
IIA
Af
H
4-metoksy-/V-(4-{2-[4-(3,4,5trifl uorfenyl )piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
cih
CIH
o r-Y^N'-J
1 -{4-[2-(4-lndan-5-ylpiperazin-1 yl)etyl]piperidin-1 -yl}propan-2-on,dihydroklorid
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
o
4-cyano-/V-(4-{2-[4-(4
trifluormetylfenyl)-3,6-dihydro
2/-/-pyridin-1
yl]etyl}cykloheksyl)butanamid
HA
jd'0''
o
VJ H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(4-metoksyfenyl)-piperazin1 -yl]etyl}cykloheksyl)amid
HA
rNXI
JL Z)'^N^
H
2-etoksy-/V-(4-{2-[4-(4metoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
rXT
H
2-cyano-/V-(4-{2-[4-(4metoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
XjI^f
H
2-cyano-/V-(4-{2-[4-(3,5-difluor-4trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
£11
n ° y£ 0H
H
2-cyano-/V-[4-(2-{4-[3-(1hydroksy-2metylpropyl)fenyl]piperazin-1 yl}etyl)cykloheksyl]acetamid
IIA
£l£
1 -(4-{2-[4-(5,6,7,8-tetrahydronaftalen-2-yl)piperazin-1 yl]etyl}piperidin-1-yl)propan-2-on
IIIB
Cl rA
H
/V-(4-{2-[4-(3-klor-5metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2etoksyacetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
Cl
Xjl
H
/V-(4-{2-[4-(3-klor-5metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-4metoksybutanamid
HA
rNXX
H
/V-(4-{2-[4-(2-klor-4-fluor-5metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2etoksyacetamid
HA
C|^^,F
XX
H
/V-(4-{2-[4-(2-klor-4-fluor-5metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-4metoksybutanamid
IIA
X ^N-^^CI
1-(4-{2-[4-(3-klor-5
fluorfenyl)piperazin-1
yl]etyl}piperidin-1-yl)propan-2-on
IIIB
n0"
N^y_^^X XX
4-cyano-/V-(4-{2-[4-(4metoksyfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
CIH yN-Q"0o pyNJ °^J XX-N-X
1 -(4-{2-[4-(3,4-dihydro-2Hbenzo[b][1,4]dioxepin-6yl)piperazin-1 -yl]etyl}piperid in-1 yl)propan-2-on, dihydroklorid
IIIB
£1 >
O
XXn-X
1 -{4-[2-(4-benzo[1,3]dioksol-5ylpiperazin-1 -y I )ety I] piperid i n-1 yl}propan-2-on
IIIB
<X)
o nxn
\_j H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(2-fluorfenyl)-3,6-dihydro2/-/-pyridin-1 yl]etyl}cykloheksyl)amid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
O F
_!l X J
H
2-cyano-/V-(4-{2-[4-(2-fluor-5trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
F
1-(4-{2-[4-(4
trifluormetylfenyl)piperazin-1
yl]etyl}piperidin-1-yl)propan-2-on
IIIB
rAJ,
1- (4-{2-[4-(3trifluormetylsulfanylfenyl)piperazi n-1 -yl]etyl}piperid in-1 -yl)propan
2- on
IIIB
HCI
HCI
0 F
1-[4-(2-{4-[3-(1,1
d ifluoretyl)fenyl]piperazin-1 yl}etyl)piperidin-1 -yl]propan-2-on,dihydroklorid
IIIB
HCI
HCI Pn'^XYf
o F
1-(4-{2-[4-(3-difluormetyl
fenyl)piperazin-1 -yl]etyl}piperidin
1-yl)propan-2-on, dihydroklorid
IIIB
HC| jQ
HCI f^N^y^o
J O~^ o ।
1 -{4-[2-(4-benzo[1,3]dioksol-4ylpiperazin-1 -y I )ety I] piperid i n-1 yl}propan-2-on, dihydroklorid
IIIB
zxF o (^[^nA
1-(4-{2-[4-(3-klor-4
fluorfenyl)piperazin-1
yl]etyl}piperidin-1-yl)propan-2-on
IIIB
r-XV
^.-^nCJ rn«k å
4-cyano-/V-(4-{2-[4-(3
trifluormetylfenyl)-3,6-dihydro
2/-/-pyridin-1
yl]etyl}cykloheksyl)butanamid
HA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
rrF
II | 1
H
/V-(4-{2-[4-(3-klor-4fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
HA
o rr^J
1-(4-{2-[4-(4-klorfenyl)-3,6
d ihydro-2/-/-pyrid in-1
yl]etyl}piperidin-1-yl)propan-2-on
IIIB
HCI
HCI AsJI
< N
o
4-(4-{2-[1-(2
oksopropyl)piperidin-4
yl]etyl}piperazin-1-yl)-benzonitril,
dihydroklorid
IIIB
HCI Hr il
HCI Jk
o
^Jl^N.,_J
1-(4-{2-[4-(2-fluor-5metylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
XX"
[I 1 1
H
/V-(4-{2-[4-(3-klor-4fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-4cyanobutanamid
HA
. ,.,.Ou
N<. II f 'l
H
/V-(4-{2-[4-(2-klor-5cyanofenyl)piperazin-1 yl]etyl}cykloheksyl)-2cyanoacetamid
IIA
hci X'"
HCI N^N
0 r-T—N—1
1-(4-{2-[4-(2,6-di-ferfbutylpyrimidin-4-yl)piperazin-1 yl]etyl}piperidin-1-yl)propan-2-on,dihydroklorid
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
T 1
H f J
/V-(4-{2-[4-(2-klor-5cyanofenyl)piperazin-1 yl]etyl}cykloheksyl)-4cyanobutanamid
HA
XX PN^Y^Ci
0 f
0 H
/V-(4-{2-[4-(3-klor-2,4
difluorfenyl)piperazin-1
yl]etyl}cykloheksyl)succinamid
HA
fjl
^N... J 0
o x y
1-(4-{2-[4-(3-acetylfenyl)piperazin-1 -yl]etyl}piperid in-1 yl)propan-2-on
IIIB
XX
o 0
1-[3-(4-{2-[1-(2
oksopropyl)piperidin-4
yl]etyl}piperazin-1
yl)fenyl]propan-1-on
IIIB
HC| X^Xi i
HCI X 1 1
N '[f
o yy^n^ 0
XX/N^X
2-metyl-1-[3-(4-{2-[1-(2oksopropyl)piperidin-4-yl]etyl}piperazin-1 -yl)fenyl]propan-1 -on,dihydroklorid
IIIB
XI
/\/\^-N.X OH
o x y
XX^-N-Y
1-[4-(2-{4-[3-(1hydroksyetyl)fenyl]piperazin-1 yl}etyl)piperidin-1-yl]propan-2-on
IIIB
XI
Y"n'^^y/x^
0 oh
XY-n-Y
1-[4-(2-{4-[3-(1
hydroksypropyl)fenyl]piperazin-1
yl}etyl)piperidin-1-yl]propan-2-on
IIIB
II1
0 oh
XYn-Y
1 -[4-(2-{4-[3-(1 -hydroksy-2metylpropyl)fenyl]piperazin-1 yl}etyl)piperidin-1-yl]propan-2-on
IIIB
HCI rXA
y^y^x^-N-Y
/\ JM. X yY
3-{4-[2-(4-lndan-4-ylpiperazin1
yl)etyl]piperid in-1 -yl}-3oksopropannitril, hydroklorid
HIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
HCI II5!
1 -{4-[2-(4-lndan-4-ylpiperazin-1 yl)etyl]piperid in-1 -yl}propan-1,2dion, hydroklorid
HIA
HCI jC-X
0 Cl
1-(4-{2-[4-(2,3diklorfenyl)piperazin-1 yl]etyl}piperid in-1 -yl)propan-1,2dion, hydroklorid
HIA
fjl
HCI ^N'^y/^CI
Cl
^N .- J
3-(4-{2-[4-(2,3diklorfenyl)piperazin-1 yljetyljpiperid in-1 -yl )-3oksopropannitril, hydroklorid
HIA
rr^F
N<. il f J
H
2-cyano-/V-(4-{2-[4-(4trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
HCI f^il
HCI p N
o °>
1-(4-{2-[4-(2etoksyfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
<vO"
0 .X^X^N._J
1 -(4-{2-[4-(4-fluorfenyl)-3,6dihydro-2H-pyridin-1 yl]etyl}piperidin-1-yl)propan-2-on
IIIB
ryO^; 0 nJ\^','''''^N'^ F
/V-(4-{2-[4-(2-fluor-5
trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)-4metoksybutanamid
IIA
Ox^x
Hd Y |l
HCI [^nAAc,
O r^\-^X/NxX^_J
1-(4-{2-[4-(2,5diklorfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
IX
o
1-(4-{2-[4-(3-klor-4metylfenyl)piperazin-1 yl]etyl}piperidin-1-yl)propan-2-on
IIIB
hci r5ii
HC| zxAA
1-{4-[2-(4-lndan-4-yl-3,6-dihydro2/-/-pyridin-1 -yl)etyl]piperid in-1 yl}propan-2-on, dihydroklorid
IIIB
hci X. Å
o L-V
X ,N, J
h2n
4-{4-[2-(4-indan-4-ylpiperazin-1
yl)etyl]piperid in-1 -yl}-4oksobutanamid
HIA
HCI X 1
f N yX
o W
■^X^y-N-X
1 -{4-[2-(4-indan-4-ylpiperazin-1 y)etyl] piperid in-1 -ylbutan-1,2dion, hydroklorid
HIA
hci XX
HCI
0 0 0
XX-N-xX
1-(4-{2-[4-(3metansulfonylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
XX O xz^vx^^Nx^ F XX^xX
1-(4-{2-[4-(3-klor-2,4
difluorfenyl)piperazin-1
yl]etyl}piperidin-1-yl)propan-2-on
IIIB
^xo
0 XX^xX
1-{4-[2-(4-fenyl-3,6-dihydro-2Hpyrid in-1 -yl)etyl]piperid in-1 yl}propan-2-on
IIIB
nei X^ii
N^x< XX
H
2-cyano-/V-(4-{2-[4-(3,5dimetylfenyl)-3,6-dihydro-2/-/pyridin-1 yl]etyl}cykloheksyl)acetamid, hydroklorid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
HCI 1 1
HCI
o
1-(4-{2-[4-(3-fluor-4metylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
CIH
CIH
2-{2-[1-(2-oksopropyl)piperidin-4yl]etyl}-1,2,3,4
tetrahydroisokinolin-6-karbonitril,dihydroklorid
IIIB
CIH r^Y'CI
CIH X 1 F
J F F
0 < y
1-(4-{2-[4-(4-klor-3trifluormetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
GHH
CIH
o r-Y--N-J M
1 -{4-[2-(4-bifenyl-3-ylpiperazin-1 yl)etyl]piperidin-1 -yl}propan-2-on,dihydroklorid
IIIB
cih xyF CIH
0 1
1-(4-{2-[4-(4-fluor-2metylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
øXX^
o f
Vy-AÅJ
/V-(4-{2-[4-(2-fluor-5
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)succinamid
HA
HG! A I
HCI '/''NzJ'''A'qz
1-(4-{2-[4-(2,5dimetoksyfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
" .oA
1 -{4-[2-(4-l ndan-4-ylpiperid in-1 yl)etyl]piperidin-1 -yl}propan-2-on,dihydroklorid
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
HCI fs!:!fV’''F
HCI
o
1-(4-{2-[4-(4-fluorfenyl)piperidin1 -yl]etyl}pi perid in-1 -yl)pi"opan-2on, dihydroklorid
IIIB
HCI 1 1 F
HCI
0 NX F
1 -(4-{2-[4-(2-metoksy-5trifluormetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
HCI f j]
HCI
o L-7
1 -{4-[2-(4-lndan-4-ylpiperazin-1 yl)etyl]piperidin-1 -yl}pentan-2-on,dihydroklorid
IIIB
rrF
HCI 1 1 F
HCI |-^'N'^-^Xcf
o NX f
1-(4-{2-[4-(4-fluor-3trifluormetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
hci ^0
HCI
o p-pXX 1
1-(4-{2-[4-(2,6dimetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,
dihydroklorid
IIIB
hci X X
HCI Y''n^'^o/
0 yy—NX
1-(4-{2-[4-(2-klor-5metoksyfenylpiperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
yNXjLoH o yy-^X
1-(4-{2-[4-(3
hydroksymetylfenyl)piperazin-1
yl]etyl}piperidin-1-yl)propan-2-on
IIIB
Hd r H
HCI r^N'T\
o
XX/n-~^X
1-(4-{2-[4-(6,7,8,9-tetrahydro-5Hbenzocyklohepten-1-yl)piperazin1 -yl]etyl}pi perid in-1 -yl)pi"opan-2on, dihydroklorid
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
XjO
o
1-(4-{2-[4-(6,7,8,9-tetrahydro-5Hbenzocyklohepten-2-yl)piperazin1 -yl]etyl}piperid in-1 -yl)propan-2on
IIIB
/A
o
3-cyano-/V-(4-{2-[4-(4trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
HA
£1
0 n~° N
3-cyano-/V-(4-{2-[4-(3cyanofenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
HA
(.
O f
M;. II f J
H
2-cyano-/V-(4-{2-[4-(2-fluor-4trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
II f J
4-cyano-/V-(4-{2-[4-(2-fluor-4trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)-butanamid
IIA
HCI r H
HCI o
_J
1 -(4-{2-[4-(2-metoksy-5metylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihyroklorid
IIIB
HCI Cl
Hd yA
y^-Ar
o F
AA/N^A
1-(4-{2-[4-(3-klor-5trifluormetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihyroklorid
IIIB
0^
Yy^~^n'-A —
N<>. । |
4-{4-[2-(4-lndan-4-ylpiperazin-1yl)etyl]piperid in-1 -yl}-4-oksobutanonitril
HIA
Hd ]
Hd yA
pN-VlyPp
o y-y^^ F
Ay-n\A
1-(4-{2-[4-(3-fluor-5
trifluormetylfenyl)piperazin-1
yl]etyl}piperidin-1-yl)propan-2-on
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
HCI
HCI
o r^U r
1-(4-{2-[4-(2-fluor-5trifluormetylfenyl)-3,6-dihydro2/-/-pyridin-1 -yl]etyl}piperid in-1 yl)propan-2-on, dihyroklorid
IIIB
£IF
0 F
H
4-metoksy-/V-(4-{2-[4-(2,3,4trifl uorfenyl )piperazin-1 yl]etyl}cykloheksyl)butanamid
HA
£1
.æ.° ’
F H
/V-(4-{2-[4-(3
cyanofenyl)piperazin-1
yl]etyl}cykloheksyl)-4,4,4
trifluorbutanamid
HA
£1
o n.
^o''~'A^nAA
H
/V-(4-{2-[4-(3cyanofenyl)piperazin-1 yl]etyl}cykloheksyl)-3metoksypropanamid
IIA
rAA o .^nCj r
il f J
H
2-cyano-/V-(4-{2-[4-(2-fluor-5trifluormetylfenyl)-3,6-dihydro2/-/-pyridin-1 yl]etyl}cykloheksyl)acetamid
IIA
XX o N^ F
1-(4-{2-[4-(2,3,4
trifl uorfenyl )piperazin-1
yl]etyl}piperidin-1-yl)propan-2-on
IIIB
HCI fl ff
HCI
o
1-(4-{2-[4-(3fenoksyfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihyroklorid
IIIB
HCI £1 i
HCI Pn-^^cA
O Py—A
1-(4-{2-[4-(3isopropoksyfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihyroklorid
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
£IF
o
2-fluor-5-(4-{2-[1-(2
oksopropyl)piperidin-4
yl]etyl}piperazin-1-yl)benzonitril
IIIB
°,.r.O«'.
H f 'l
H
2-cyano-/V-(4-{2-[4-(3-cyano-4fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
. n xcA
/V-(4-{2-[4-(3-cyano-4fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-4metoksybutanamid
HA
rf
„ ^..xxO^
M^x II f J
4-cyano-/V-(4-{2-[4-(3-cyano-4fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
Fxi
1-(4-{2-[4-(2,5
difluorfenyl)piperazin-1
yl]etyl}piperidin-1-yl)propan-2-on
IIIB
gA;
N^ II f 'I
H
2-cyano-/V-(4-{2-[4-(3-fluor-5trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
rA;
n X"'-, ■"''x.x-N-x/J F
NX 11 f 1
'<x^-~x^x^N<rx^x
4-cyano-/V-(4-{2-[4-(3-fluor-5trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
HCI f "il
HCI
0 ^A^-hix^J
1-(4-{2-[4-(3-tørfbutylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
HC| A
HCI Xn^V
o
X^XxNx/
1-(4-{2-[4-(2trifluormetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
rXl,;
o F
3-cyano-/V-(4-{2-[4-(2-fluor-5trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
HA
HCI 'l^il
° F
/V-(4-{2-[4-(2-fluor-5
trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2propoksyacetamid, hydroklorid
HA
F O F
fPAX7
3,3,3-trifluor-/V-(4-{2-[4-(2-fluor-5
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)propanamid
IIA
rXlp
0 o F
/V-(4-{2-[4-(2-fluor-5
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)-malonamid
IIA
HCI
HCI X A
\ N
9 A]
1-(4-{2-[4-(3benzylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
rXc
Ux II f J
H
2-cyano-/V-(4-{2-[4-(5-etyl-2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
Yl
l''"N'^’""-/,’''-/
o
N-p 11 ] 1
4-cyano-/V-(4-{2-[4-(5-etyl-2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
Yl
o
Æ-pp
H
4-metoksy-/V-{4-[2-(4-mtolylpiperazin-1 yl)etyl]cykloheksyl}butanamid
IIA
HCI \ T
hoi pNAAF
o pp-'Y
1-(4-{2-[4-(3,4difluorfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
HC| r iT
HCI
0 /^s/N\Z
1-(4-{2-[4-(4-klorfenyl)piperazin1 -yl]etyl}pi perid in-1 -yl)propan-2on, dihydroklorid
IIIB
hci
HCI p N-VV
0 f-y-- N~y '
1-(4-{2-[4-(3isopropylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
XI
HCI
'L—/
Y
5-{4-[2-(4-lndan-4-ylpiperazin-1yl)etyl]piperid in-1 -yl}-5-oksopentannitril, hydroklorid
HIA
XI
HCI
yyx^^Nx^J 11— o^ynX
2-etoksy-1 -{4-[2-(4-indan-4ylpiperazin-1 -y I )ety I] piperid i n-1 yljetanon, hydroklorid
HIA
0 yXr^ kk/NxX
3-(1-{2-[1-(2
oksopropyl)piperidin-4-yl]etyl}
1,2,3,6-tetrahydropyridin-4yl)benzonitril
IIIB
xxXK
x. .XxnCX^"
II f J
H
2-cyano-/V-(4-{2-[4-(3
cyanofenyl)-3,6-dihydro-2/-/
pyridin-1 -yljetyl}cykloheksyl)acetamid
IIA
xxJCX
°
/V-(4-{2-[4-(3-cyanofenyl)-3,6dihydro-2H-pyridin-1 yl]etyl}cykloheksyl)-4metoksybutanamid
IIA
xssyx-01
£ T
Cl
0 ^.^NX F
H
A/-(4-{2-[4-(3,4-diklor-2-fluor
fenyl)piperazin-1yl]etyl}cykloheksyl)-4metoksybutanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
HCI FxT!!S?,Sil
HCI __
N Cl
1-(4-{2-[4-(5-klor-2fluorfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
£1 o pv—N~y
1 -(4-{2-[4-(3-metylsulfanylfenyl)piperazin-1 -y l]ety I}piperid in-1 -yl)propan-2-on
IIIB
IX o ,-,XnXnII f 'J
H
2-cyano-/V-(4-{2-[4-(3-cyano-2,4difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
v_jn.0?
4-cyano-/V-(4-{2-[4-(3-cyano-2,4difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
HA
PnX^-f
0 1
H
/V-(4-{2-[4-(3-fluor-2metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-4metoksybutanamid
IIA
xxF
0 r-y—O F "N
2,6-d ifluor-3-(4-{2-[1 -(2-oksopropyl)piperidin-4yl]etyl}piperazin-1-yl)benzonitril
IIIB
Cl
X
o
^o^YnAJ
H
/V-(4-{2-[4-(3,5diklorfenyl)piperazin-1 yl]etyl}cykloheksyl)-4metoksybutanamid
IIA
xxF
0 yXX
A/-(4-{2-[4-(3-cyano-2,4difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-4metoksybutanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
4-(4-{2-[4-(3-fluor-5trifluormetylfenyl)piperazin-1 yl]etyl}piperid in-1 -yl )-4oksobutanonitril
HIA
hci
HCI
o
1-(4-{2-[4-(3metoksymetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
0 f
_J
1-(4-{2-[4-(2,3,4,5tetrafluorfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
HCI CI'Y^
HCI L II F
Yn^^Y-f
o f
1-(4-{2-[4-(2-klor-5trifluormetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
F j^YF
1-(4-{2-[4-(3,4,5-trifluorfenyl)piperazin-1 -yl]etyl}piperid in-1 yl)propan-2-on
IIIB
rNXl 0
AA
H
A/-(4-{2-[4-(4-klorfenyl)-piperazin1 -yl]etyl}cy kloheksyl )-4metoksybutanamid
HA
" ,.A
O
1-(4-{2-[4-(3,5-difluor-4
trifluormetylfenyl)piperazin-1
yl]etyl}piperidin-1-yl)propan-2-on
IIIB
Hd \y
HCI Å
HCI An
rnAIy;
o F
1-(4-{2-[4-(2-tørf-butyl-6
trifluormetylpyrimidin-4yl)piperazin-1 -yl]etyl}piperid in-1 yl)propan-2-on, trihydroklorid
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
o F
H
/V-(4-{2-[4-(2-fluor-5
trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2metoksyacetamid
HA
HCI
HCI k J
rz^,iJ>T
O Cl
1-(4-{2-[4-(2,4diklorfenyl)piperazin-1 yl]etyl}piperidin-1 yl)propan-2-on,dihydroklorid
IIIB
HCI V/'
HC| JL. X
fX^N'^!lX^CI
0 "Z
1-(4-{2-[4-(2,4,5
tri klorfeny l)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
Cl
HCl rXi
4-(4-{2-[4-(3-klor-5trifluormetylfenyl)piperazin-1 yl]etyl}piperid in-1 -yl )-4oksobutanonitril, hydroklorid
HIA
øXl^;
O rX\-"\x-N^XJ F
H
Cyklopent-1 -enkarboksylsyre-(4{2-[4-(2-fluor-5trifluormetylfenylpiperazin-1 yl]etyl}cykloheksyl)amid
IIA
QiXl^
o Z^i '''\^N'-X F
XanZJ
H
/V-(4-{2-[4-(2-fluor-5
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)-2
metansulfonylacetamid
IIA
£T
o F
H
/V-(4-{2-[4-(2-fluor-4metylfenyl)piperazin-1 yl]etyl}cykloheksyl)-4metoksybutanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
,..4:
o f
Il 1 J
H
2-cyano-/V-(4-{2-[4-(2,3,4,5tetrafluorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
^Cl
r j
0 Cl
U 1 J
H
2-cyano-/V-(4-{2-[4-(2,4diklorfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
HC|
HCI o
1-(4-{2-[4-(5-klor-2metylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
f N 0
o
1-(4-{2-[4-(2,3
dihydrobenzo[1,4]dioksin-6yl)piperazin-1 -yl]etyl}piperid in-1 yl)propan-2-on
IIIB
o r
4-cyano-/V-(4-{2-[4-(2-fluor-5trifluormetylfenyl)-3,6-dihydro2/-/-pyridin-1 yl]etyl}cykloheksyl)butanamid
IIA
o " F
/V-(4-{2-[4-(2-fluor-5
trifluormetylfenyl)-3,6-dihydro
2/-/-pyridin-1 -yl]etyl}cykloheksyl)
4-metoksybutanamid
IIA
HCI
HCI X
< N
o
_J
1 -(4-{2-[4-(2,5-dimetylfenyl)piperazin-1 -yl]etyl}piperid in-1 yl)propan-2-on, dihydroklorid
IIIB
rA
o
H
/V-(4-{2-[4-(3,5-dimetylfenyl)
piperazin-1-yl]etyl}cykloheksyl)-4
metoksybutanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
A
3-cyano-/V-(4-{2-[4-(3,5dimetylfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
HA
ck^\,ci
T £
...x ,N. J
i JT7
H
2-cyano-/V-(4-{2-[4-(2,4,5tri klorfeny I )piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
F
HCI
HCI \ il
1-(4-{2-[4-(3-fluor-5metylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
AI
0 r—NA F xO^AnAJ
H
A/-(4-{2-[4-(3,4-diklor-2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-2metoksyacetamid
IIIB
^\^CI
£ 1
|/"'N'>’"''|/J''CI
0 f
3-cyano-/V-(4-{2-[4-(3,4-diklor-2fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)propanamid
IIIB
F
HCI Xx
HCI
o r^U Tf Ax/N-A
1-(4-{2-[4-(3-fluor-5trifluormetylfenyl)-3,6-dihydro2/-/-pyridin-1 -yl]etyl}piperid in-1 yl)propan-2-on, dihydroklorid
IIIB
hci <-vXX<f
f f n-K^^nA
4-(4-{2-[4-(2-fluor-5
trifluormetylfenyl)-3,6-dihydro
2/-/-pyridin-1 -yl]etyl}piperid in-1 yl)-4-oksobutanonitril, hydroklorid
HIA
xAv
o ^^nCT r Nx, II f J
H
2-cyano-/V-(4-{2-[4-(3-fluor-5trifluormetylfenyl)-3,6-dihydro2/-/-pyridin-1 yl]etyl}cykloheksyl)acetamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
F F
II f J
4-cyano-/V-(4-{2-[4-(3-fluor-5trifluormetylfenyl)-3,6-dihydro2/-/-pyridin-1 yl]etyl}cykloheksyl)butanamid
HA
F
A
o .
Å Å J
H
2-cyano-/V-(4-{2-[4-(3-fluor-5metylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
HA
rsK X 1 J
H
4-cyano-/V-(4-{2-[4-(3-fluor-5metylfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
HOI (^V01
HCI A Å
0 Cl
1-(4-{2-[4-(2,3,4
tri klorfeny I )piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
hci r5!5?'V'F
Hd L II
1-(4-{2-[4-(4-fluor-3metylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
^^.Gl r x
X'N^’""-X’"CI
0 Cl
A J. J
H
2-cyano-/V-(4-{2-[4-(2,3,4tri klorfeny I )piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
F
HCI F>A'Y''F
HCI A Å
X'n'yXf
0 F
1 -{4-[2-(4-Pentafluorfenylpiperazin-1 -yl)etyl]piperid in-1 yl}propan-2-on, dihydroklorid
IIIB
XA;
o Pj— n-X F
N
N H
5-cyano-pentansyre-(4-{2-[4-(2
fluor-5-trifluormetyl
fenyl)piperazin-1
yletyl}cykloheksyl)amid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
( N y Cl
o f
/V-(4-{2-[4-(3-klor-2,4difluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-3cyanopropanamid
HA
4-(4-{2-[4-(2,3diklorfenyl)piperazin-1 yl]etyl}piperid in-1 -yl )-4oksobutanonitril
HIA
o X\|''\/N\xxl 1 F
H
2-metoksy-/V-(4-{2-[4-(2-metyl-3trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid
IIA
0 F
4-metoksy-/V-(4-{2-[4-(2-metyl-3
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)butanamid
IIA
rA,
o F
4,4,4-trifluor-/V-(4-{2-[4-(2-fluor-5
trifluormetyl-fenyl)piperazin-1
yl]etyl}cykloheksyl)butanamid
IIA
Pn-^Y^cio yy^^ Cl
1-(4-{2-[4-(2,3diklorfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
F,/F
.■A
o o r1~ F
H.N-KYXJ
A/-(4-{2-[4-(3,5-bistrifluormetyl
fenyl)piperazin-1
yl]etyl}cykloheksyl)malonamid
IIA
: rTxr°
1-(4-{2-[4-(2-etylfenyl)-3,6
d ihydro-2/-/-pyrid in-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
o
H
/V-(4-{2-[4-(3-klor-5fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-4metoksybutanamid
HA
A/-(4-{2-[4-(3,5-bistrifluormetylfenyl)piperazin-1yl]etyl}cykloheksyl)-4metoksybutanamid
HA
A ^N-^^CIo <Y^»J
H
/V-(4-{2-[4-(3-klor-5fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-2metoksyacetamid
IIA
A
/V-(4-{2-[4-(3-klor-5fluorfenyl)piperazin-1 yl]etyl}cykloheksyl)-3cyanopropanamid
IIA
FxxF [^N'x^551^F _J
1-(4-{2-[4-(2,4,5-trifluorfenyl)piperazin-1 -yl]etyl}piperid in-1 yl)propan-2-on
IIIB
o F
5-cyano-pentansyre-(4-{2-[4-(3
trifluormetylfenyl)-piperazin-1
yl]etyl}cykloheksyl)amid
IIA
7 ,tA FV/J
4,4,4-trifluor-1-{4-[2-(4-indan-4ylpiperazin-1 -y I )ety I] piperid i n-1 yl}butan-1-on, hydroklorid
HIA
" .cA
F 0
3,3,3-trifluor-1-{4-[2-(4-indan-4ylpiperazin-1 -yl )ety I] piperid i n-1 yl}propan-1-on, hydroklorid
HIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
o
N^. A J
H
2-cyano-/V-(4-{2-[4-(2-etylfenyl)
3,6-d ihyd ro-2/-/-pyrid in-1 yl]etyl}cykloheksyl)acetamid
HA
o n..^OA jf I I
H
4-cyano-/V-(4-{2-[4-(2-etylfenyl)
3,6-d ihyd ro-2/-/-pyrid in-1 yl]etyl}cykloheksyl)-butanamid
HA
0 n.^NCjA N-^k A -Å J
H
2-cyano-/V-{4-[2-(4-o-tolyl-3,6
dihydro-2H-pyridin-1
yl)etyl]cykloheksyl}acetamid
IIA
r-A3o rY^U f N^k å A J
H
4-cyano-/V-{4-[2-(4-o-tolyl-3,6
dihydro-2H-pyridin-1
yl)etyl]cykloheksyl}butanamid
IIA
HCI f5^
HCI
0 ^^nCTT
1-{4-[2-(4-o-tolyl-3,6-dihydro-2Hpyridin-1 -yl)etyl]piperid in-1 yl}propan-2-on, dihydroklorid
IIIB
r~A
0 f
N^ II ] I
H
2-cyano-/V-{4-[2-(4pentafluorfenylpiperazin-1 yl)etyl]cykloheksyl}acetamid
IIA
ynAA
0 <~>""'\-'N'A f
/O^AnAA
/V-(4-{2-[4-(4-fluor-3
trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)-4metoksybutanamid
IIA
Y-y-C!
rNXA;
0 <^>''''''^--N'A f
zOx/A-nAJ
/V-(4-{2-[4-(4-klor-3
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)-4
metoksybutanamid
IIA
Yy-ciynAA n /'VXzNy1 f
fsK LI A J
/V-(4-{2-[4-(4-klor-3
trifluormetylfenyl)piperazin-1
yl]etyl}cykloheksyl)-4
cyanobutanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
/V-(4-{2-[4-(3-fluor-5trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)-4metoksybutanamid
HA
hci jO
HCI
1-(4-{2-[4-(2isobutylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
HCI fil
HCI
o 'A'
/A/n-A
1-(4-{2-[4-(3-isobutylfenyl)piperazin-1 -yl]etyl}piperid in-1 yl)propan-2-on, dihydroklorid
IIIB
o F
H
/V-(4-{2-[4-(4-fluor-3
trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)-2metoksyacetamid
HA
rj
0 Cl
H
/V-(4-{2-[4-(2,4
diklorfenyl)piperazin-1 yl]etyl}cykloheksyl)-4metoksybutanamid
IIA
rA NX_Å JØ.~N-J Cl
H
4-cyano-/V-(4-{2-[4-(2,4diklorfenyl)piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
rA;
o f
2-cyano
cyklopropankarboksylsyre-(4-{2
[4-(2-fluor-5
trifluormetylfenyl)piperazin-1 yl]etyl}cykloheksyl)amid
IIA
XX p^N'^^'Cl
Nv^x. x2y'^NvJ
H
4-cyano-/V-(4-{2-[4-(2,4,5tri klorfeny I )piperazin-1 yl]etyl}cykloheksyl)butanamid
IIA
Eks
Struktur
Navn
SM.P.
(°C)
Synteserute
^^,CI r ¥
Cl
H
4-cyano-/V-(4-{2-[4-(2,3,4tri klorfeny 1 )piperazin-1 yl]etyl}cykloheksyl)butanamid
HA
o n.^cx
H
A/-(4-{2-[4-(4-fluorfenyl)-3,6d ihydro-2/-/-pyrid in-1 yl]etyl}cykloheksyl)-4metoksybutanamid
HA
HCI r*55^
HCI J
1-(4-{2-[4-(2metylsulfanylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
O n...-NCjX^N
H
/V-(4-{2-[4-(3-cyanofenyl)-3,6d ihydro-2/-/-pyrid in-1 yl]etyl}cykloheksyl)-2metoksyacetamid
IIA
vn^'"
F H
/V-(4-{2-[4-(3-cyanofenyl)-3,6d ihydro-2/-/-pyrid in-1 yl]etyl}cykloheksyl)-4,4,4trifluorbutanamid
IIA
hc! /--Olo <V-nJ ,
AxCr n
2-klor-6-(4-{2-[1-(2
oksopropyl)piperidin-4
yl]etyl}piperazin-1-yl)benzonitril,
dihydroklorid
IIIB
HCI
HC! r 1
1-(4-{2-[4-(4,5-diklor-2
fluorfenyl)piperazin-1
yl]etyl}piperidin-1-yl)propan-2-on
309 (dek.)
IIIB
s r/X
/^XxNxx^
1-(4-{2-[4-(3-klor-2metylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)propan-2-on,dihydroklorid
IIIB
Ytterligere karakterisering ved 1H NMR av noen representative eksempler er gitt i den følgende tabell:
Eks.
Struktur
1H NMR
0 F
7,3 (t, 1H, J = 7,5); 7,15 til 7,0 (ms, 3H); 3,35 (s, 2H); 3,25 (m, 4H); 2,9 (m, 2H); 2,6 (m, 4H); 2,45 (m, 2H); 2,0 (m, 2H); 1,8 til 1,55 (ms, 2H); 1,55 til 1,2 (ms, 5H); 1,15 (s, 9H)
0 f
|l 1 H
7,45 til 7,25 (ms, 6H); 7,2 til 7,0 (ms, 3H); 5,1 (s, 2H); 4,6 (bred d, 1H); 3,45 (m, 1H); 3,25 (m, 4H);
2,6 (m, 4H); 2,4 (m, 2H); 2,05 (m, 2H); 1,8 (m, 2H); 1,7 til 1,0 (ms, 7H)
n p
CIH
H
7,5 (t, 1H, J = 7,5); 7,4 til 7,25 (ms, 3H); 4,05 (s, 2H); 4,0 til 3,8 (ms, 2H); 3,8 til 3,5 (ms, 3H); 3,35 til 3,05 (ms, 6H); 1,95 til 1,5 (ms, 7H); 1,5 til 1,0 (ms, 4H) (D2O)
ryOv;
H
7,7 til 7,35 (ms, 4H); 6,35 (bred d, 1H); 6,15 (s, 1H); 3,9 (s, 2H); 3,8 (m, 1H); 3,4 (s, 3H); 3,2 (m, 2H); 2,7 (m, 2H); 2,6 (m, 2H); 2,5 (m, 2H); 2,0 (m, 2H); 1,8 (m, 2H); 1,75 til 1,4 (ms, 2H); 1,4 til 1,0 (ms, 5H)
F
U H
7,45 til 7,25 (ms, 4H); 7,2 til 7,0 (ms, 3H); 7,0 til 6,85 (ms, 2H); 6,4 (bred d, 1H); 4,45 (s, 2H); 3,85 (m, 1H); 3,3 (m, 4H); 2,65 (m, 4H); 2,45 (m, 2H);
2,0 (m, 2H); 1,9 til 1,4 (ms, 4H); 1,4 til 1,0 (ms, 5H)
r--1?
-.w-"-J'
H
7,15 til 6,85 (ms, 4H); 5,85 (bred d, 1H); 3,75 (m, 1H); 3,4 (s, 2H); 3,15 (m, 4H); 2,65 (m, 4H); 2,45 (m, 2H); 2,0 (m, 2H); 1,85 (m, 2H); 1,8 til 1,4 (ms, 3H); 1,4 til 1,0 (ms, 4H)
Eks.
Struktur
1H NMR
CIH
pF
11,2 (bred s, 1H); 7,55 til 7,35 (ms, 2H); 7,3 (d, 1H, J = 5); 7,25 (s, 1H); 7,15 (d, 1H, J = 5); 4,0 til 3,7 (ms, 5H); 3,7 til 3,4 (ms, 4H); 3,4 til 2,95 (ms, 9H); 1,85 til 1,85 (ms, 13) (DMSO De)
ghh f 7l
..'
10,8 (bred s, 1H); 8,4 (d, 1H, J = 7,5); 7,35 til 7,2 (ms, 2H); 7,15 (d, 1H, J = 7,5); 3,9 (m, 2H); 3,5 (m, 2H); 3,4 til 3,05 (ms, 7H); 2,9 (q, 2H, J = 7,5); 1,85 til 1,55 (ms, 5H); 1,55 til 1,15 (ms, 4H); 1,15 til 1,85 (ms, 5H) (DMSO De)
cih ri f
y"Xr. '
0 H
11,05 (bred s, 1H); 8,35 (d, 1H, J = 7,5); 7,4 (t, 1H, J = 7,5); 7,35 til 7,2 (ms, 2H); 7,1 (d, 1H, J = 7,5); 3,9 (m, 2H); 3,75 til 3,4 (ms, 3H); 3,4 til 2,9 (ms, 6H); 2,3 (s, 3H); 1,9 til 1,15 (ms, 9H); 1,15 til 0,85 (ms, 2H) (DMSO De)
pN-Oy;
xW.. '
H
7,35 (t, 1H, J = 7,5); 7,15 til 7,0 (ms, 3H); 6,95 (bred d, 1H); 3,75 (m, 1H); 3,25 (m, 4H); 2,9 (s, 2H); 2,65 (m, 4H); 2,45 (m, 2H); 2,25 (s, 6H); 2,0 (m, 2H); 1,8 (m, 2H); 1,5 (m, 2H); 1,4 til 1,0 (ms, 5H)
yXly f
7,35 (t, 1H, J = 7,5); 7,2 til 7,0 (ms, 3H); 6,4 (bred d, 1H); 3,9 (s, 2H); 3,8 (m, 1H); 3,65 (m, 1H); 3,25 (m, 4H); 2,6 (m, 4H); 2,45 (m, 2H); 2,05 (m, 2H); 1,85 (m, 2H); 1,7 (m, 1H); 1,5 (m, 2H); 1,4 til 1,0 (ms, 10H)
F<1F
H
7,35 til 7,2 (ms, 2H); 5,85 (bred d, 1H); 3,75 (m, 1H); 3,4 (s, 2H); 3,3 (m, 4H); 2,6 (m, 4H); 2,45 (m, 2H); 2,05 (m, 2H); 1,85 (m, 2H); 1,6 (m, 1H);
1,5 (m, 2H); 1,4 til 1,0 (ms, 4H)
Eks.
Struktur
1H NMR
£1 F
o o F
H
7,35 (t, 1H, J = 7,5); 7,2 til 7,0 (ms, 3H); 6,75 (bred d, 1H); 3,7 (m, 1H); 3,4 (s, 2H); 3,25 (m, 4H); 2,6 (m, 4H); 2,45 (m, 2H); 2,3 (s, 3H); 2,05 (m, 2H); 1,85 (m, 2H);1,75 til 1,4 (ms, 3H); 1,4 til 1,0 (ms, 4H)
.a°
H
8,25 (d, 2H, J = 7,5); 6,65 (d, 2H, J = 7,5); 6,45 (bred s, 1H); 4,0 (0,35H equatorial); 3,7 (0,65H axial); 3,35 til 3,25 (ms, 6H); 2,55 (m, 4H); 2,4 (m, 2H); 2,3 (1,7H); 2,0 (m, 1,4H); 1,8 (m, 1,4H); 1,75 til 0,9 (ms, 7,5H)
r.o
*.«./r
H
7,5 til 7,15 (ms, 5H); 6,1 (m, 1H); 5,85 (bred d, 1H); 3,75 (m, 1H); 3,35 (s, 2H); 3,2 (m, 2H); 2,7 (m, 2H); 2,6 (m, 2H); 2,5 (m, 2H); 2,05 (m, 2H);
1,9 (m, 2H); 1,5 (m, 2H); 1,4 til 1,0 (ms, 5H)
.
H
7,25 (t, 1H, J = 7,5); 6,85 til 6,65 (ms, 3H); 5,85 (bred d, 1H); 3,75 (m, 1H); 3,35 (s, 2H); 3,2 (m, 4H); 2,7 til 2,5 (ms, 6H); 2,4 (m, 2H); 2,05 (m, 2H); 1,85 (m, 2H); 1,45 (m, 2H); 1,4 til 1,0 (ms, 7H)
o f
".«y^N-U
5 H
7,35 (t, 1H, J = 7,5 ); 7,2 til 7,0 (ms, 3H); 6,05 (bred s, 1H); 5,65 (bred d, 1H); 5,35 (bred s, 1H);
4,0 (m, 0,35H equatorial); 3,7 (m, 0,65H axial);
3,25 (m, 4H); 2,7 til 2,45 (ms, 8H); 2,4 (m, 2H);
2,0 (m, 2H); 1,8 (m, 2H); 1,55 (m, 1H); 2,5 (m, 2H); 2,4 til 1,0 (ms, 4H)
y-N^Qy;nv^JnjQ'"'^n^ f f
H
7,25 til 7,05 (ms, 3H); 5,3 (bred d, 1H); 3,7 (m, 1H); 3,15 (m, 4H); 2,65 (m, 4H); 2,55 til 2,4 (ms, 4H); 2,3 (t, 2H, J = 7,5); 2,0 (m, 4H); 1,8 (m, 2H);
1,45 (m, 2H); 1,4 til 1,0 (ms, 5H)
Eks.
Struktur
1H NMR
.u:r.. H
10.4 (bred s, 1H); 8,2 (d, 1H, J = 7,5); 7,0 (t, 1H, J = 7,5); 6,4 (d, 1H, J = 7,5); 6,35 (s, 1H); 6,25 (d, 1H, J = 7,5); 3,7 (m, 2H); 3,65 (s, 2H); 3,6 til 3,3 (ms, 3H); 3,2 til 2,9 (ms, 6H); 1,9 til 1,5 (ms, 6H);
1.4 til 0,9 (ms, 5H) (DMSO De)
CIH
o F
10,3 (bred s, 1H); 7,4 (t, 1H, J = 7,5); 7,4 til 7,0 (ms, 7H); 4,8 (s, 2H); 4,6 (s, 2H); 3,9 (m, 2H); 3,5 (m, 2H); 3,3 til 2,8 (ms, 7H); 2,3 (d, 0,8H, J = 7,5);
2,2 (d, 1,21-1, J = 7,5); 1,9 til 0,8 (ms, 11H)trans/cis 60/40 (DMSO De)
r-N-O^;
0 F
I
7,35 (t, 1H, J = 7,5); 7,2 til 7,0 (m, 3H); 3,25 (m, 4H); 3,2 (s, 3H); 2,95 (s, 3H); 2,45 (m, 4H); 2,2 (t, 2H, J = 7,5); 2,2 (d, 2H, J = 7,5); 1,9 til 1,6 (ms, 4H); 1,6 til 1,15 (ms, 5H); 1,15 til 0,75 (ms, 3H)
7,35 (t, 1H, J = 7,5); 7,15 til 7,0 (ms, 3H); 5,8 (bred t, 1H); 3,45 (m, 4H); 3,35 (s, 3H); 3,25 (m, 4H); 2,6 (m, 4H); 2,41 (t, 2H, J = 7,5); 2,05 (d, 2H, J = 7,5); 1,9 til 1,7 (ms, 5H); 1,6 til 1,1 (ms, 4H); 1,1 til 0,8 (ms, 3H)
W-O%F
7,35 (t, 1H); 7,15 til 7,0 (ms, 3H); 5,75 (bred t, 1H); 5,25 (s, 1H); 3,75 (m, 1H); 3,45 (m, 4H); 3,35 (s, 3H); 3,25 (m, 4H); 3,6 (m, 4H); 2,45 (t, 2H, J = 7,5); 2,3 til 1,85 (ms, 5H); 1,6 til 1,4 (ms, 2H); 1,3 til 1,0 (ms, 3H)
HCI -X- X F
HCI p N
7,5 (t, 1H, J = 7,5); 7,4 til 7,2 (ms, 3H); 4,75 (2H);
3,9 (m, 2H); 3,7 (m, 2H); 3,55 (m, 2H); 3,45 til 3,05 (ms, 10H); 2,95 (m, 2H); 2,2 (s, 3H); 2,0 (m, 2H); 1,9 til 1,6 (3H); 1,5 (m, 2H) (D2O)
Eks.
Struktur
1H NMR
nxx
Nx 0 CX'''
H
13,4 (bred s, 1H); 7,75 til 7,5 (ms, 2H); 7,1 (t, 1H, J = 7,5); 5,85 (d, 1H); 4,55 (m, 2H); 4,3 til 3,95 (ms, 3H); 3,7 (m, 4H); 3,15 (m, 2H); 2,6 til 2,15 (ms, 7H); 2,1 til 1,05 (ms, 13H)
HCI f5855^^13
HCI
_J
7,35 til 7,2 (ms, 2H); 7,05 (t, 1H, J = 7,5); 4,85 (s, 2H); 4,25 (s, 2H); 3,65 (m, 2H); 3,5 (m, 2H); 3,35 til 2,85 (ms, 7H); 2,2 (s, 3H); 2,15 til 1,9 (ms, 6H); 1,9 til 1,5 (ms, 5H)
£1
7,15 (t, 1H, J = 7,5); 6,95 (d, 1H, J = 7,5); 6,75 (d, 1H, J = 7,5); 4,6 (m, 1H); 3,75 (m, 1H); 3,25 til 3,0 (ms, 5H); 2,9 (t, 2H, J = 7,5); 2,85 (t, 2H, J = 7,5);
2.8 til 2,5 (ms, 7H); 2,45 (m, 2H); 2,05 (m, 2H);
1.8 (m, 2H); 1,7 til 1,45 (ms, 5H); 2,15 (m, 2H)
cA
6,9 (s, s, 1H); 6,8 til 6,6 (m; 2H); 4,6 (m, 1H); 3,8 (m, 1H); 3,25 (m, 4H); 3,05 (m, 2H); 2,75 til 2,65 (ms, 3H); 2,5 til 2,35 (ms, 5H); 2,45 (m, 2H); 1,8 (m, 2H); 1,7 til 1,4 (ms, 3H); 1,2 (m, 2H)
.UT-0 ’
H
6,9 til 6,75 (ms, 3H); 5,45 (d, 1H, J = 7,5); 3,75 (m, 1H); 3,45 (t, 1H, J = 7,5); 3,4 (s, 3H); 3,1 (m, 4H); 2,65 (m, 4H); 2,45 (m, 2H); 2,3 (s, 3H); 2,25 (t, 2H, J = 7,5); 2,1 til 1,7 (ms, 6H); 1,45 (m, 2H); 1,35 til 1,0 (ms, 5H)
F
HCI FVii<F
HO L II
0 F
4,75 (s, 2H); 4,2 (s, 2H); 3,65 til 3,1 (ms, 12H); 3,0 (m, 2H); 2,2 (s, 3H); 2,0 (m, 2H); 1,85 til 1,4 (ms, 5H) (D2O)
Eksempel 771 1 -(4-{2-[4-(2,3-diklorfenyl)piperazin-1 -yljetylpiperidin-1 yl)butan-2-on
n y N. J Cl
0 r
Trinn a: 1 -(4-{2-[4-(2,3-diklorfenyl)piperazin-1 -yl]etyl}piperidin-1 -yl)butan-2ol
r^N'\^CI rt J ci
OH r Å
En suspensjon av 0,41 g (1 mmol) 1-(2,3-diklorfenyl)-4-(2-piperidin-4yletyl)piperazin, dihydroklorid i 25 ml isopropanol og 0,29 g (2,1 mmol) kaliumkarbonat blir omrørt i 30 minutter og deretter blir 0,08 g (1,1 mmol av 2etyloksiran tilsatt. Suspensjonen blir omrørt under tilbakeløp natten over. Fellingen blir filtrert og løsningen blir konsentrert under redusert trykk. Residuet blir oppløst i etylacetat, vasket med vann og med saltvann, tørket over magnesiumsulfat, filtrert og konsentrert under redusert trykk. Residuet blir renset over 10 g silikagel (diklormetan/metanol 90/10), hvilket gir 0,2 g (50%) av 1-(4{2-[4-(2,3-diklorfenyl)piperazin-1 -yl]etyl}piperidin-1 -yl)butan-2-ol som en olje somkrystalliserer ved henstand.
Smeltepunkt: 94°C
1H NMR: 7,2 til 7,05 (ms, 2H); 7,0 til 6,9 (m, 1H); 3,7 (m, 1H); 3,1 (m, 6H); 2,9 (m, 2H); 2,65 (m, 4H); 2,55 til 2,2 (ms, 4H); 2,05 (m, 1H); 1,7 (m, 2H); 1,65 til 1,25 (ms, 7H); 1,0 (t, 3H, J = 7,5)
Trinn b: 1 -(4-{2-[4-(2,3-diklorfenyl)piperazin-1 -yljetylpiperidin-1 -yl)butan-2on
N Y Cl
l\k J Cl
o r Å
1 -(4-{2-[4-(2,3-diklorfenyl)piperazin-1 -yljetylpiperidin-1 -yl)butan-2-onet bliroppnådd ved Swern-oksidasjon av 1-(4-{2-[4-(2,3-diklorfenyl)piperazin-1yl]etyl}piperidin-1 -yl)butan-2-ol i henhold til metoden beskrevet i eksempel 7.
Smeltepunkt: 68°C
1H NMR: 7,2 til 7,1 (m, 2H); 6,95 (m, 1H); 3,2 (s, 2H); 3,15 (m, 4H); 2,85 (m, 2H); 2,7 (m, 4H); 2,6 til 2,4 (ms, 4H); 2,05 (m, 2H); 1,7 (m, 2H); 1,65 til 1,2 (ms, 5H); 1,1 (t, 3H, J = 7,5)
Eksempel 772: 2-(4-{2-[4-(2,3-dimetylfenyl)piperazin-1 -yl]etyl}piperidin1 -yl)-/V-metoksy-/V-metylacetamid
■N. )
0 r
O^nA/N.
Trinn a: (4-{2-[4-(2,3-dimetylfenyl)piperazin-1 -yl]etyl}piperidin-1 yl)eddiksyre
|^N
.l\k J
0 f
Å .N.
HO'
(4-{2-[4-(2,3-dimetylfenyl)piperazin-1 -yl]etyl}piperidin-1 -yl)eddiksyre blirfremstilt fra (4-{2-[4-(2,3-dimetylfenyl)piperazin-1 -yl]etyl}piperidin-1 -yl)eddiksyreetylester ved anvendelse av metoden beskrevet i fremstilling F, trinn 1.
Trinn b: 2-(4-{2-[4-(2,3-dimetylfenyl)piperazin-1 -yl]etyl}piperidin-1 -yl)-/Vm eto ksy-/V-m ety I aceta m id
0 f o,n^n
I
2-(4-{2-[4-(2,3-dimetylfenyl)piperazin-1-yl]etyl}piperidin-1-yl)-/V-metoksy-/Vmetylacetamid blir fremstilt fra 4-{2-[4-(2,3-dimetylfenyl)piperazin-1yl]etyl}piperidin-1 -yl)eddiksyre ved anvendelse av metoden beskrevet ifremstilling F, trinn 2.
Smeltepunkt: 66°C
1H NMR: 7,1 (t, 1H, J = 7,5); 7,0 til 6,85 (ms, 2H); 3,7 (s, 3H); 3,35 (s, 2H); 3,3 til 2,6 (ms, 17H); 2,4 til 2,15 (ms, 8H); 1,9 til 1,65 (ms, 3H), 1,65 til 1,35 (ms, 2H)
Eksempel 773 1 -(4-{2-[4-(2,3-dimetylfenyl)piperazin-1 -yl]etyl}piperidin1 -yl)-3-metylbutan-2-on, hydroklorid
F J .hk J ।
HCI
° r
Å .N.
1 -(4-{2-[4-(2,3-dimetylfenyl)piperazin-1 -yl]etyl}piperid in-1 -yl)-3-metyl-butan2-on, hydrokloridet blir fremstilt ved tilsetning av en løsning avisopropylmagnesiumbromid på 2-(4-{2-[4-(2,3-dimetylfenyl)piperazin-1 yl]etyl}piperidin-1-yl)-/V-metoksy-/V-metylacetamid ved anvendelse av metodenbeskrevet i fremstilling F, trinn 3.
Smeltepunkt: 182°C
1H NMR: 7,1 (t, 1H, J = 7,5); 7,0 til 6,85 (ms, 2H); 6,4 (bred s, 1H); 3,0 til 2,7 (ms, 8H); 2,7 til 2,5 (ms, 4H); 2,45 (m, 2H); 2,3 (s, 3H); 2,25 (s, 3H); 2,2 til 2,0 (ms, 3H); 1,7 (m, 2H); 1,5 (m, 2H); 1,4 til 1,1 (ms, 3H); 1,0 (d, 3H); 0,85 (d, 3H, J = 7,5)
Eksempel 774 1 -(4-{2-[4-(2,3-dimetylfenyl)piperazin-1 -yl]etyl}piperidin1-yl)butan-2-on, dihydroklorid
HCI
HCI
I N i\k )
0 r
1 -(4-{2-[4-(2,3-dimetylfenyl)piperazin-1 -yl]etyl}piperid in-1 -yl)butan-2-on,dihydrokloridet blir fremstilt ved tilsetning av en løsning av etylmagnesiumbromid på 2-(4-{2-[4-(2,3-dimetylfenyl)piperazin-1 -yl]etyl}piperidin-1 -yl)-/V-metoksy-/Vmetylacetamid ved anvendelse av metoden beskrevet i fremstilling F, trinn 3.
Smeltepunkt: 315°C
Eksempel 775 1 -(4-{2-[4-(2,3-dimetylfenyl)piperazin-1 -yl]etyl}piperidin1-yl)pentan-2-on
f N
•ISk J
0 (
1 -(4-{2-[4-(2,3-dimetylfenyl)piperazin-1 -yl]etyl}piperidin-1 -yl) pentan-2-onetblir fremstilt ved tilsetning av en løsning av propylmagnesiumbromid på 2-(4-{2[4-(2,3-dimetylfenyl)piperazin-1-yl]etyl}piperidin-1-yl)-/V-metoksy-/Vmetylacetamid ved anvendelse av metoden beskrevet i fremstilling F, trinn 3.
Smeltepunkt: 47°C
Eksempel 776: 3-(4-{2-[4-(4
metoksybutanoylamino)cykloheksyl]etyl}piperazin-1-yl)benzamid
nh2
f N
En blanding av 85 mg (0,2 mmol) A/-(4-{2-[4-(3-cyanofenyl)piperazin-1yl]etyl}cykloheksyl)-4-metoksybutanamid, 2 ml dimetylsulfoksid, 16,5 mgkaliumkarbonat og 0,12 ml av en vandig 30% hydrogenperoksid-løsning bliromrørt i 2 timer ved romtemperatur. Suspensjonen blir hellet i 50 ml vann. Det faste stoffet blir filtrert, vasket med vann, tørket under redusert trykk, hvilket gir 15 mg (17%) av 3-(4-{2-[4-(4-metoksybutanylamino)cykloheksyl]etyl}piperazin-1yl)benzamid som et hvitt, fast stoff.
Smeltepunkt: 202°C
1H NMR (DMSO De): 7,85 (s, 1H); 7,6 (d, 1H, J = 7,5); 7,35 (s, 1H); 7,3 til 7,15 (ms, 3H); 7,05 (m, 1H); 3,4 (m, 1H); 3,25 (t, 2H, J = 7,5); 3,2 (s, 3H); 3,15 (m, 4H); 2,45 (m, 4H); 2,3 (m, 2H); 2,05 (m, 2H); 1,8 til 1,55 (ms, 6H); 1,35 (m, 2H); 1,25 til 0,8 (ms, 5H)
Eksempel 777: [3-(4-{2-[1 -(2-oksopropyl)piperidin-4-yl]etyl}piperazin-1 yl)fenyl]karbaminsyre-etylester
N O’
H
p N N. J
Trinn a: 1 -(4-{2-[4-(3-aminofenyl)piperazin-1 -yl]etyl}piperidin-1 -yl)propan-2on
f N hk J
1 -(4-{2-[4-(3-aminofenyl)piperazin-1 -yl]etyl}piperidin-1 -yl)propan-2-onet blirfremstilt fra 1 -(4-{2-[4-(3-nitrofenyl)piperazin-1 -yl]etyl}piperidin-1 -yl)propan-2-onved anvendelse av metoden beskrevet i fremstilling D, trinn 2, hvilket gir tittelforbindelsen i 49% urenset utbytte, anvendt uten ytterligere rensning.
Trinn b: [3-(4-{2-[1 -(2-oksopropyl)piperidin-4-yl]etyl}piperazin-1 yl)fenyl]karbaminsyre-etylester
n o
H
I N hk
0 f
Til en avkjølt løsning av 0,1 g (0,3 mmol) 1 -(4-{2-[4-(3aminofenyl)piperazin-1-yl]etyl}piperidin-1-yl)propan-2-on i 5 ml diklormetan og0,03 g (0,3 mmol) trietylamin, blir langsomt satt 0,032 g (0,3 mmol) etylklorformiat. Blandingen bliromrørt natten over ved romtemperatur og deretter konsentrert under redusert trykk. Produktet blir oppløst i etylacetat, vasket to ganger med vann, tørket over magnesiumsulfat, filtrert og konsentrert under redusert trykk. Det oljeaktige residuet blir renset over 10 g silikagel (elueringsmiddel diklormetan/metanol 95/5), hvilket gir 0,025 g (20%) av [3-(4{2-[1-(2-oksopropyl)piperidin-4-yl]etyl}piperazin-1-yl)fenyl]karbaminsyre-etylestersom et fast stoff.
Smeltepunkt: 118°C
1H NMR: 7,25 til 7,1 (ms, 2H); 6,75 (d, 1H, J = 7,5); 6,65 (d, 1H, J = 7,5); 6,55 (s, 1H); 4,25 (q, 2H, J = 7,5); 3,25 (m, 4H); 3,15 (s, 2H); 2,85 (m, 2H); 2,6 (m, 4H); 2,45 (m, 2H); 2,2 (s, 3H); 2,05 (m, 2H); 1,8 til 1,2 (ms, 10H)
Eksempel 778: 3-okso-4-(4-{2[4-(3-trifluomnetylfenyl)piperazin-1 yl]etyl}piperidin-1 -yl)butannitril, dihydroklorid
HCI
HCI
PF F
I N
0 r
Å .N
En løsning av 0,77 ml (1,3 mmol) kalium-terf-pentoksid-løsning (1,7M itoluen) blir satt dråpevis ved romtemperatur til en omrørt løsning av 52 mg (1,27 mmol) acetonitril i 2,5 ml tetrahydrofuran fulgt av dråpevis tilsetning av 0,19 g (0,44 mmol) (4-{2-[4-(3-trifluormetylfenyl)piperazin-1 -yl]etyl}piperidin-1 yl)eddiksyre-etylester i 1 ml tetrahydrofuran. Etter 30 minutter vedromtemperatur blir reaksjonsblandingen fortynnet med 10 ml av en vandig 0,2N vandig saltsyreløsning og 50 ml etylacetat som danner en emulsjon. Blandingen blir konsentrert under redusert trykk og produktet blir renset over 10 g silikagel (elueringsmiddel diklormetan/metanol 95/5). Det oljeaktige produktet blir oppløst i 2 ml dietyleter og surgjort med en saltsyre-dietyleter-løsning. Fellingen blirfiltrert, vasket med dietyleter og tørket under redusert trykk, hvilket gir 30 mg (14%) av 3-okso-4-(4-{2[4-(3-trifluormetylfenyl)piperazin-1 -yIJetyIJpiperidin-1 yl)butannitril, dihydroklorid.
Smeltepunkt: 160°C
1H NMR (DMSO De): 11,2 (bred s, 1H); 10,2 (bred s, 1H); 7,45 (t, 1H, J = 7,5); 7,3 (d, 1H, J = 7,5); 7,25 (s, 1H); 7,1 (d, 1H, J = 7,5); 4,35 (s, 2H); 4,2 (s, 2H); 3,95 (m, 2H); 2,55 (m, 2H); 2,45 til 2,9 (ms, 10H); 2,0 til 2,45 (ms, 7H)
Eksempel 779: A/-(4-{2-[4-(3-acetylfenyl)piperazin-1 -yIJetyl}cykloheksyI)3,3,3-trifluorpropanamid
p N N. J
/V-(4-{2-[4-(3-acetylfenyl)piperazin-1-yl]etyl}cykloheksyl)-3,3,3-trifluorpropanamid blir fremstilt ved oksidasjon av 3,3,3-trifluor-/V-[4-(2-{4-[3-(1hydroksyetyl)fenyl]piperazin-1 -yl}etyl)cykloheksyl]propanamid (eksempel 477)ved anvendelse av metoden beskrevet i eksempel 7, hvilket gir tittelforbindelsen.
Smeltepunkt 165°C.
Eksempel 780: 2-cyano-/V-(4-{2-[4-(3-propanoylfenyl)piperazin-1yl]etyl}cykloheksyl)acetamid
N
2-cyano-/V-(4-{2-[4-(3-propanoylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid blir fremstilt ved oksidasjon av 2-cyano-/V-[4-(2-{4-[3-(1 hydroksypropyl)-fenyl]piperazin-1 -yl}etyl)cykloheksyl]acetamid (eksempel 566)ved anvendelse av metoden beskrevet i eksempel 7, hvilket gir tittelforbindelsen.
Smeltepunkt 178°C.
Eksempel 781: 4-cyano-/V-(4-{2-[4-(3-propanoylfenyl)piperazin-1yl]etyl}cykloheksyl)butanamid
f N
4-cyano-/V-(4-{2-[4-(3-propanoylfenyl)piperazin-1-yl]etyl}cykloheksyl)butanamidet blir fremstilt ved oksidasjon av 4-cyano-/V-[4-(2-{4-[3-(1-hydroksypropyl)fenyl]piperazin-1-yl}etyl)cykloheksyl]butanamid (eksempel 540) vedanvendelse av metoden beskrevet i eksempel 7, hvilket gir tittelforbindelsen.
Smeltepunkt 158°C.
Eksempel 782: 2-cyano-/V-(4-{2-[4-(3-isobutanylfenyl)piperazin-1 yl]etyl}cykloheksyl)acetamid, dihydroklorid
f N
HCI
2-cyano-/V-(4-{2-[4-(3-isobutanylfenyl)piperazin-1-yl]etyl}cykloheksyl)acetamid,dihydrokloridet blir fremstilt ved oksidasjon av 2-cyano-/V-[4-(2-{4-[3(1-hydroksy-2-metylpropyl)fenyl]piperazin-1-yl}etyl)cykloheksyl]acetamid(eksempel 575) ved anvendelse av metoden beskrevet i eksempel 7, hvilket gir tittelforbindelsen.
Smeltepunkt 185°C.
Affinitet av forbindelser for den humane Ds reseptor kan bestemmes ved [3H] spiperon binding
CHO-celler blir transfektert av cDNA som koder for den humane Dsreseptor (hDs). [3H]Spiperon (0,5 å 2 nM) binding blir utført i nærvær av 2,5 til 5 pg av membran-proteiner i et medium inneholdende 120 mM NaCI, 5 mM KCIog 50 mM Tris HCI pH 7,4; inkubering i 60 minutter ved romtemperatur blir utført. Uspesifikk binding blir beregnet i nærvær av 10 pM haloperidol. Ikketransfekterte celler mangler noen spesifikk binding.
Eksemplifiserte forbindelser viser alle en hemningskonstant under 1 pM, mesteparten av dem under 50nM.
Affiniteter for den humane Ds reseptor av noen representative eksempler og referanseforbindelser er gitt i den følgende tabell (ref angir referanseforbindelser):
Eks
Struktur
Ki (nM)
2 ref
o F
CIH
6,6
15 ref
CIK
r Tf
F
,N, )
15,1
36 ref
»
o
1,32
54 ref
oxi
-,w."J 4
H
18,3
65 ref
N N
(TW.
VJ H
31,6
r.„o
.MO
å H
3,9
291 ref
qXI^
o F
4,4
Eks
Struktur
Ki (nM)
14 ref
H S
15,1
ref
C|H f
CIH
XX/N^J
9,5
o
HO--X"--X’""-X CIH
H
12,0
61 ref
pX)
H
8,5
ref
f o yy-CCfX-X--nX-...X
f H
10,6
288 ref
CIH PnX F
2,1
° jn"""^^
3,5
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81556306P | 2006-06-22 | 2006-06-22 | |
EP06291027A EP1870405A1 (en) | 2006-06-22 | 2006-06-22 | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
PCT/IB2007/001673 WO2007148208A2 (en) | 2006-06-22 | 2007-06-21 | Carbonylated (aza) cyclohexanes as dopamine d3 receptor ligands |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20085288L NO20085288L (no) | 2009-01-16 |
NO342105B1 true NO342105B1 (no) | 2018-03-26 |
Family
ID=37192657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20085288A NO342105B1 (no) | 2006-06-22 | 2008-12-18 | Karbonylerte (aza)cykloheksaner, fremgangsmåte for fremstilling av slike forbindelser, farmasøytiske preparater omfattende slike forbindelser samt anvendelse av slike forbindelser for behandling |
Country Status (28)
Country | Link |
---|---|
US (1) | US8802678B2 (no) |
EP (2) | EP1870405A1 (no) |
KR (1) | KR101432112B1 (no) |
CN (1) | CN101511805B (no) |
AP (1) | AP2730A (no) |
AU (1) | AU2007262426B2 (no) |
BR (1) | BRPI0712631B8 (no) |
CA (1) | CA2655654C (no) |
CY (1) | CY1117143T1 (no) |
DK (1) | DK2038268T3 (no) |
EA (1) | EA020305B1 (no) |
EC (1) | ECSP088989A (no) |
ES (1) | ES2561425T3 (no) |
HR (1) | HRP20090235B1 (no) |
HU (1) | HUE028391T2 (no) |
IL (1) | IL196001A (no) |
MA (1) | MA30950B1 (no) |
MX (1) | MX2008016574A (no) |
NO (1) | NO342105B1 (no) |
NZ (1) | NZ573832A (no) |
PL (1) | PL2038268T3 (no) |
PT (1) | PT2038268E (no) |
RS (1) | RS57871B1 (no) |
SI (1) | SI2038268T1 (no) |
TN (1) | TNSN08513A1 (no) |
UA (1) | UA101797C2 (no) |
WO (1) | WO2007148208A2 (no) |
ZA (1) | ZA200810670B (no) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0700269A2 (en) * | 2007-04-11 | 2009-04-28 | Richter Gedeon Nyrt | Pyrimidinyl-piperazines useful as d3/d2 receptor ligands, pharmaceutical compositions containing them and their use |
CA2730002A1 (en) * | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Pyridinylpiperazin derivatives useful as modulators of dopamine d3 receptors |
CN102164927A (zh) | 2008-09-23 | 2011-08-24 | 弗·哈夫曼-拉罗切有限公司 | 用作多巴胺d3受体调节剂的异唑并[4,5]吡啶-3-基-哌嗪衍生物 |
JP2010184889A (ja) * | 2009-02-12 | 2010-08-26 | Nihon Univ | 高血圧症予防治療薬 |
US8586579B2 (en) * | 2010-06-21 | 2013-11-19 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
US8470828B2 (en) * | 2010-07-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
US8877778B2 (en) | 2010-12-15 | 2014-11-04 | Hoffmann-La Roche Inc. | Benzofurane compounds |
US8598357B2 (en) * | 2011-03-03 | 2013-12-03 | Hoffmann-La Roche Inc. | Benzodioxole piperidine compounds |
US8921397B2 (en) | 2011-05-04 | 2014-12-30 | Hoffmann-La Roche Inc. | Benzofurane-piperidine compounds |
US9376396B2 (en) * | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
WO2014086098A1 (zh) * | 2012-12-03 | 2014-06-12 | 江苏恒谊药业有限公司 | 环己烷胺类化合物及其作为抗精神分裂症药物的应用 |
AR095264A1 (es) | 2013-03-15 | 2015-09-30 | Abbvie Deutschland | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
UY35420A (es) * | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
CN104140421B (zh) * | 2013-05-08 | 2017-04-05 | 上海医药工业研究院 | 苯并异噻唑类化合物及在制备抗精神分裂症药物中的应用 |
EP3087080B1 (en) * | 2013-12-24 | 2018-11-28 | President and Fellows of Harvard College | Cortistatin analogues and syntheses and uses thereof |
SG11201708007VA (en) * | 2015-05-21 | 2017-12-28 | Pulmocide Ltd | Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1 -yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)- 3-methylphenyl)piperazin-1 -yl )-n -(2-h yd roxycyc lo h exyl) b e nzam i d e, or a pharmaceutically acceptable salt thereof. |
CN106518841B (zh) * | 2015-09-15 | 2019-03-05 | 浙江京新药业股份有限公司 | 环己烷衍生物或其立体异构体或盐及其制备与应用 |
WO2017045599A1 (zh) * | 2015-09-15 | 2017-03-23 | 浙江京新药业股份有限公司 | 环己烷衍生物或其立体异构体或盐及其制备与应用 |
CN105330616B (zh) * | 2015-12-09 | 2017-09-26 | 苏州明锐医药科技有限公司 | 卡利拉嗪的制备方法 |
US10870660B2 (en) | 2016-07-28 | 2020-12-22 | Shionogi & Co., Ltd. | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect |
CN107793408B (zh) * | 2016-09-05 | 2020-12-08 | 上海医药工业研究院 | 哌啶氨基衍生物及其治疗精神分裂症的应用 |
CN107793350B (zh) * | 2016-09-05 | 2021-06-04 | 上海医药工业研究院 | 芳乙基哌啶基衍生物及其治疗精神分裂症的应用 |
WO2019146740A1 (ja) | 2018-01-26 | 2019-08-01 | 塩野義製薬株式会社 | ドーパミンd3受容体拮抗作用を有する環式化合物 |
CN111801330B (zh) | 2018-01-26 | 2024-04-05 | 盐野义制药株式会社 | 具有多巴胺d3受体拮抗作用的稠环化合物 |
RU2677268C9 (ru) * | 2018-06-15 | 2019-07-23 | Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар", (ООО "НИИ ХимРар") | Частичный агонист допаминовых D2/D3 рецепторов - метиламид 4-{ 2-[4-(2,3-дихлорфенил)-пиперазин-1-ил]-этил} -пиперидин-1-карбоновой кислоты, способы его получения (варианты) и применения |
CN110872272A (zh) * | 2018-08-30 | 2020-03-10 | 浙江京新药业股份有限公司 | 一种环己烷衍生物的盐 |
CN112047848B (zh) * | 2019-06-05 | 2023-05-02 | 中国科学院分子细胞科学卓越创新中心 | 多巴胺d2受体选择性激动剂及其应用 |
CN110372557B (zh) * | 2019-08-06 | 2021-05-18 | 上海勋和医药科技有限公司 | 环己烷胺类d3/d2受体部分激动剂 |
CN111533756A (zh) * | 2020-04-28 | 2020-08-14 | 华东理工大学 | 来源于植物病原真菌的螺缩酮类化合物及制备方法与应用 |
LT3906927T (lt) * | 2020-05-04 | 2022-08-10 | Bioprojet Pharma | Dalinių dopamino d3 agonistų naudojimas centrinės nervų sistemos sutrikimams gydyti |
CN113754580B (zh) * | 2020-06-05 | 2023-04-25 | 上海中泽医药科技有限公司 | 一种吡啶吗啉类化合物、其制备方法及其应用 |
WO2024072930A1 (en) * | 2022-09-30 | 2024-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5047406A (en) * | 1989-12-06 | 1991-09-10 | Warner-Lambert Co. | Substituted cyclohexanols as central nervous system agents |
WO1998050364A1 (en) * | 1997-05-03 | 1998-11-12 | Smithkline Beecham Plc | Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors |
WO2005012266A1 (en) * | 2003-08-04 | 2005-02-10 | Richter Gedeon Vegyészeti Gyár Rt. | (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5395835A (en) * | 1994-03-24 | 1995-03-07 | Warner-Lambert Company | Naphthalamides as central nervous system agents |
CN1092627C (zh) * | 1997-01-17 | 2002-10-16 | 住友化学工业株式会社 | 制备4-叔丁基环己醇和乙酸4-叔丁基环己酯的方法 |
EP1246817B1 (en) * | 1999-12-30 | 2004-06-23 | H. Lundbeck A/S | 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives |
CN1156425C (zh) * | 2001-04-18 | 2004-07-07 | 中国石油化工股份有限公司 | 环己醇脱氢制环己酮的方法 |
HU227543B1 (en) * | 2001-09-28 | 2011-08-29 | Richter Gedeon Nyrt | N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them |
FR2878524B1 (fr) * | 2004-12-01 | 2007-01-19 | Bioprojet Soc Civ Ile | Nouveaux derives d'arylpiperazine |
HUP0500170A3 (en) * | 2005-02-03 | 2007-11-28 | Richter Gedeon Nyrt | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
US7875610B2 (en) * | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
-
2006
- 2006-06-22 EP EP06291027A patent/EP1870405A1/en not_active Withdrawn
-
2007
- 2007-05-14 MX MX2008016574A patent/MX2008016574A/es active IP Right Grant
- 2007-06-21 US US12/306,044 patent/US8802678B2/en active Active
- 2007-06-21 KR KR1020097001325A patent/KR101432112B1/ko active IP Right Grant
- 2007-06-21 PL PL07766572T patent/PL2038268T3/pl unknown
- 2007-06-21 CN CN2007800309649A patent/CN101511805B/zh active Active
- 2007-06-21 BR BRPI0712631A patent/BRPI0712631B8/pt active IP Right Grant
- 2007-06-21 NZ NZ573832A patent/NZ573832A/xx unknown
- 2007-06-21 AU AU2007262426A patent/AU2007262426B2/en active Active
- 2007-06-21 UA UAA200814733A patent/UA101797C2/ru unknown
- 2007-06-21 DK DK07766572.7T patent/DK2038268T3/en active
- 2007-06-21 EP EP07766572.7A patent/EP2038268B1/en active Active
- 2007-06-21 AP AP2008004727A patent/AP2730A/xx active
- 2007-06-21 CA CA2655654A patent/CA2655654C/en active Active
- 2007-06-21 PT PT77665727T patent/PT2038268E/pt unknown
- 2007-06-21 WO PCT/IB2007/001673 patent/WO2007148208A2/en active Application Filing
- 2007-06-21 RS RS20090187A patent/RS57871B1/sr unknown
- 2007-06-21 EA EA200900048A patent/EA020305B1/ru not_active IP Right Cessation
- 2007-06-21 ES ES07766572.7T patent/ES2561425T3/es active Active
- 2007-06-21 HU HUE07766572A patent/HUE028391T2/en unknown
- 2007-06-21 SI SI200731742T patent/SI2038268T1/sl unknown
-
2008
- 2008-12-11 TN TNP2008000513A patent/TNSN08513A1/en unknown
- 2008-12-17 IL IL196001A patent/IL196001A/en active IP Right Grant
- 2008-12-18 EC EC2008008989A patent/ECSP088989A/es unknown
- 2008-12-18 ZA ZA2008/10670A patent/ZA200810670B/en unknown
- 2008-12-18 MA MA31486A patent/MA30950B1/fr unknown
- 2008-12-18 NO NO20085288A patent/NO342105B1/no unknown
-
2009
- 2009-04-22 HR HRP20090235AA patent/HRP20090235B1/hr active IP Right Grant
-
2016
- 2016-01-20 CY CY20161100063T patent/CY1117143T1/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5047406A (en) * | 1989-12-06 | 1991-09-10 | Warner-Lambert Co. | Substituted cyclohexanols as central nervous system agents |
WO1998050364A1 (en) * | 1997-05-03 | 1998-11-12 | Smithkline Beecham Plc | Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors |
WO2005012266A1 (en) * | 2003-08-04 | 2005-02-10 | Richter Gedeon Vegyészeti Gyár Rt. | (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists |
Non-Patent Citations (2)
Title |
---|
THOMAS R. BELLIOTTI ET AL., "Novel cyclohexyl amides as potent and selective D3 dopamine receptor ligands", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (1997), vol. 7, no. 18, page 2403-2408,, Dated: 01.01.0001 * |
WUSTROW D ET AL, "Aminopyrimidines with High Affinity for Both Serotonin and Dopamine Receptors", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, (19980206), vol. 41, no. 5, ISSN 0022-2623, pages 760 - 771, Dated: 01.01.0001 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO342105B1 (no) | Karbonylerte (aza)cykloheksaner, fremgangsmåte for fremstilling av slike forbindelser, farmasøytiske preparater omfattende slike forbindelser samt anvendelse av slike forbindelser for behandling | |
JP6382403B2 (ja) | Lsd1阻害剤としての(ヘテロ)アリールシクロプロピルアミン化合物 | |
AU701452B2 (en) | Benzylpiperidines and piperazines as muscarinic antagonists | |
US20070066584A1 (en) | Amido compounds and their use as pharmaceuticals | |
NZ720444A (en) | Prodrugs of pyridone amides useful as modulators of sodium channels | |
WO2002055496A1 (en) | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | |
SK2242004A3 (en) | Quinoline compound | |
JPWO2013129622A1 (ja) | 複素環化合物およびその用途 | |
US20040204453A1 (en) | 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors | |
EP4168406A1 (en) | Arylsulfonyl derivatives and their use as muscarinic acetylcholine receptor m5 inhibitors | |
DE602005006018T2 (de) | Arylpiperazinderivate und deren verwendung als für den dopamin-d3-rezeptor selektive liganden | |
TW201032803A (en) | Piperidine derivatives | |
TWI332499B (en) | Chemical compounds | |
JP2007500758A (ja) | ケモカイン受容体活性のモジュレーターとしてのn−ウレイドアルキル−ピペリジン | |
HRP920778A2 (en) | Novel 1-oxa-2-oxo-8-azaspiro74,5/ decane derivatives, pharmaceutical preparations containing them and process for the preparation thereof | |
HRP930475A2 (en) | Process for the preparation of novel 1-(cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives | |
JP2001335579A (ja) | フロイソキノリン誘導体、その製造法および用途 | |
NZ710293B2 (en) | Amides as modulators of sodium channels |